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INTRODUCTION
Since the beginning of interventional cardiology, coronary angiography has been the 
reference tool for assessing the severity of coronary lesions and guide stent implanta-
tion. With growing knowledge about the pathophysiology of atherothrombosis and 
stent failure it became of interest to visualise in vivo different processes taking place 
at the level of the coronary vessel wall for the purpose of improving cardiovascular 
outcomes. 1, 2 Intracoronary imaging techniques overcome the lumenographic limita-
tions of angiography by enabling a histology-like cross-sectional view of the vessel wall 
and implanted devices. Although intravascular ultrasound (IVUS) has provided valuable 
insights into the dynamic nature of atherosclerosis and the causes of stent failure, the 
technology has a limited axial resolution (100-250 µm) and poor ability to differentiate 
between various tissue components. 3, 4 Intracoronary optical coherence tomography 
(OCT) has opened the door to a new world in interventional cardiology. With a near-
histological resolution of 10-20 µm, this near-infrared light-based technology offers a 
significantly improved visualisation of plaque and stent-related features. 5, 6 However, 
only after its introduction did we realise how much the technology differs from IVUS 
beyond the level of resolution: in terms of aspects related to the use of light rather than 
sound, affecting tissue and stent characterisation and resulting in a unique array of 
artefacts; but also as a consequence of the significantly increased amount of data and 
its hierarchical nature requiring an adjustment of the qualitative-, quantitative- and sta-
tistical methods for an appropriate utilisation of the technology. This thesis will provide 
an insight into the development of these methods and their clinical application.
The first chapter reviews the history, principles and limitations of the OCT technology, 
and evaluates the consequence of the need to flush the vessel during image acquisition 
in terms of the clinical feasibility and safety. For successfully utilising OCT in research 
and clinics, it is necessary to understand the OCT image in order to recognise a variety 
of phenomena that can distort it and mimic pathology: these will be reviewed and 
discussed in detail.
The main part of this thesis relates to the application of OCT in the imaging of coronary 
devices – ultimately, for the prevention of stent thrombosis. Chapter 2 describes the 
characterisation with OCT of strut apposition and coverage within conventional metallic 
stents, specifically illustrating how the methods have developed over time to allow the 
assessment of morphological features previously unseen by IVUS and histology, while 
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at the same time taking into account the inability of OCT to depict the entire metallic 
strut thickness.
In chapter 3, we evaluate vascular healing following coronary intervention with drug-
eluting stents (DES). The newly defined protruding struts and specifically the associated 
coronary evaginations are investigated with respect to their occurrence, predictors and 
mechanisms. Whether these can induce flow disturbances in the respective lesions is 
also tested. Whilst coronary evaginations can be seen at follow-up, edge dissections 
represent vascular injury at baseline – in some studies related to early stent thrombosis. 
Due to their dramatic appearance by OCT, even when angiographically not flow-limiting, 
we have revisited the natural history and clinical impact of these lesions.
Although DES have effectively reduced the rates of restenosis 7, 8, they are associated 
with drawbacks that need yet to be addressed. In addition to late/very late stent throm-
bosis and the potential disposition of the metallic and polymeric material to induce 
chronic inflammatory reactions 9, 10; the “caging” effect related to the permanent nature 
of the metallic stents interferes with normal vascular physiology. 11 Everolimus-eluting 
bioresorbable vascular scaffolds (BVS) have been introduced as a promising alternative 
to metallic DES. Being composed primarily of poly-L-lactide which is slowly degraded 
by hydrolysis, the goal of this device is to provide a temporary scaffold which allows 
restoration of physiological, pharmacological and biological vascular functions once the 
polymer is resorbed. When imaged with OCT and compared with metallic stents, the 
BVS presents important differences related to the optical translucent polymeric struts, 
necessitating a different analysis methodology. 12 
Chapter 4 describes how OCT can be used to evaluate BVS in scaffold-overlap regions, 
and the nature of “white dots”, as well as the relationship between OCT and histology for 
quantitative measurements.
In chapter 5, we assess with serial OCT the vascular healing processes following im-
plantation of BVS, and compare measureable changes within the scaffold itself between 
OCT, IVUS and IVUS-virtual histology. Additionally, we discuss the potential role of the 
neointima not only as a temporary protection for the scaffold, but also as a plaque shield 
once the scaffold is resorbed.
Finally, in chapter 6, the goal to comprehensively review how OCT visualises athero-
sclerosis is used as a starting point for discussing important physical differences and 
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terminological confusions between OCT, histology and IVUS, as well as the limitations 
of OCT for tissue characterisation and how these can be overcome using multimodality 
imaging.
In conclusion, the aims of this thesis are:
•  To demonstrate the systematic interpretation of OCT findings related to metallic 
stent implantation and atherosclerotic plaques, with consideration of important 
artefacts and fundamental differences between OCT and histology;
•  To illustrate the development and application of methods to evaluate the acute ef-
fects of stent implantation and the vascular responses taking place thereafter; and
•  To specifically assess the occurrence, predictors, mechanisms and haemodynamic 
effects of coronary evaginations; the natural history of edge dissections; and various 
aspects of vascular healing following BVS implantation.
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INTRODUCTIE
Coronair angiografie is van af het begin van de interventie cardiologie de referentie 
techniek voor het vaststellen van de ernst en uitgebreidheid van coronaire laesies 
en voor het begeleiden van stent implantatie. Met de toenemende kennis van de 
pathofysiologie van atherosclerose en stent disfunctie werd het ook interessant om 
verschillende in vivo pathofysiologische processen te bestuderen die plaats vinden in 
de vaatwand, met als doel de cardiovasculaire prognose te verbeteren. 1, 2 Intra coro-
naire beeldvormende technieken zoals intravasculair ultrageluid (IVUS) of optische 
coherentie tomografie (OCT) kennen niet de beperkingen van de lumenografie van 
coronair angiografie doordat zij in staat zijn een op pathologie/histogie gelijkende 
dwarsdoorsnede van de vaatwand en van de ge-implanteerde stents of “scaffolds “ te 
genereren. IVUS heeft waardevolle inzichten in de dynamiek van atherosclerose en de 
oorzaken van stent disfunctie gegeven, echter de techniek is beperkt door de beperkte 
axiale resolutie (100-250 µm) en de geringe mogelijkheid om verschillende weefsel 
componenten te onderscheiden. 3, 4 OCT heeft de deur geopend naar een nieuwe wereld 
in de interventie cardiologie. Deze op bijna infrarood licht gebaseerde techniek met een 
resolutie van 10-20µm die bijna de histologie benaderd, is in staat om een significante 
verbetering  te geven van de  coronaire plaque en stent karakteristieken. 5, 6 Maar, pas 
na de introductie van deze techniek begonnen we ons te realiseren dat OCT zeer grote 
verschillen toont met IVUS, niet alleen wat betreft de resolutie maar bovenal het gebruik 
van licht in plaats van geluid. Licht genereert andere weefsel en stent eigenschappen, 
inclusief nieuwe artefacten, terwijl de enorme toename van data samenhangend met 
hierarchische aspecten anpassing vereist van kwalitatieve, kwantitatieve en statistische 
methoden  voor een correct gebruik van de technologie. Dit proefschrift verschaft 
inzicht in de ontwikkeling van deze methoden en van de klinische toepassing.
Het eerste hoofdstuk geeft een overzicht van de geschiedenis, principes en beperkin-
gen van de OCT technologie en bespreekt de consequentie van de noodzaak om het 
vat bloedvrij te maken door het schoon te spoelen gedurende de beeld acquisitie in 
termen van uitvoerbaarheid en veiligheid. Om OCT goed te kunnen begrijpen is het 
noodzakelijk dat men de beelden correct kan interpreteren en dat men de verschillende 
fenomenen kan herkennen die de beeldvorming verstoren en zelfs op pathologie kun-
nen lijken: dit alles wordt uitgebreid opnieuw bekeken en in detail besproken.
Het belangrijkste deel van dit proefschrift betreft de toepassing van OCT voor het af-
beelden van coronaire stents en “scaffolds” met het ultieme doel de preventie van stent 
trombose. In hoofdstuk 2 wordt beschreven hoe we stent appositie en de bekleding 
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van metalen stents met OCT moeten beoordelen. Specifiek wordt ingegaan hoe deze 
methodes zich in de tijd hebben ontwikkeld, met de nadruk op het detecteren van 
morfologische kenmerken die niet mogelijk waren met IVUS of histologie. Ook worden 
de tekortkomingen van OCT besproken met betrekking tot het afbeelden van complete 
metalen stents met name van de stent “strut” dikte.
In hoofdstuk 3 evalueren we het vasculaire genezings proces na coronaire interventie 
met “drug-eluting stents“ (DES). We introduceren een specfiek fenomeen: “protruding 
struts” en de daarmee samenhangende “coronary evaginations” (uitstulpingen). De 
frequentie, de voorspelling en ontstaanswijze worden besproken. De mogelijkheid dat 
deze uitstulpingen bloedstroom storingen kunnen veroorzaken wordt getest. Coronaire 
uitstulpingen worden gezien bij vervolg onderzoek en stentrand dissecties onmiddel-
lijk na implantatie ten gevolge van vasculaire beschadiging; deze worden in sommige 
studies gerelateerd met vroege stent trombose. Omdat deze laesies er zo dramatisch 
uit zien, zelfs indien ze niet stroom belemmerend zijn, was voor ons de reden om het 
natuurlijke beloop en klinische gevolgen te bestuderen.
DES zijn effectief in het reduceren van re-stenosen 7, 8, maar ze hebben ook nadelen, 
die ook bespreking behoeven zoals late en zeer late trombose, chronische ontsteking 
9, 10, het “kooi” effect ten gevolge van de blijvende aard van de metalen stent daarmee 
de normale fysiologie van de vaatwand verstorend. 11 “Everolimus-eluting bioresorb-
able vascular scaffolds” (BVS) zijn een veelbelovend alternatief voor de metalen stent. 
Ze zijn samengesteld uit poly-l-lactide, dat langzaam degradeert door hydrolyse. Het 
doel van deze tijdelijke “scaffold” is dat na resorptie van de “scaffold” er een herstel van 
de fysiologische, farmacologische en biologische vaatwand functies kan optreden. OCT 
van de BVS is duidelijk verschillend van DES door de optische doorlaatbaar-heid van de 
BVS. Dit maakt een andere analyse noodzakelijk. 12
In hoofdstuk 4 wordt beschreven hoe OCT kan worden gebruikt voor de evaluatie van 
de BVS daar waar de “struts” overlappen, voor de bestudering van de “white dots” en de 
relatie van de kwantitatieve metingen tussen OCT en histologie.
In hoofdstuk 5 onderzoeken we middels serieel OCT het vasculaire genees proces na 
implantatie van een BVS en de vergelijking van de meetbare veranderingen binnen de 
“scaffold” tussen OCT, IVUS en IVUS-VH (virtuele histologie). Bovendien bespreken we de 
potentiele rol van de neointima die niet allen kan dienen als een tijdelijke bescherming 
van de BVS maar ook kan fungeren als een plaque schild nadat de BVS is geresorbeerd.
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In hoofdstuk 6 wordt uitgebreid behandeld hoe OCT atherosclerose afbeeld en we 
bespreken belangrijke fysische verschillen en verwarrende terminologie zoals dit kan 
optreden tussen OCT, histologie en IVUS. De beperkingen van OCT voor weefsel clas-
sificatie worden belicht en ook hoe dit kan worden ondervangen met het gebruik van 
meerdere afbeeld technieken.
Concluderend, de doelen van dit proefschrift zijn:
•  De demonstratie van een systematische interpretatie van OCT van metalen stents, 
en atherosclerotische plaques, rekening houdend met de fundamentele verschillen 
tussen OCT en histologie;
•  De illustratie van de ontwikkelingen en toepassing van methodes om de acute ef-
fecten van stent implantatie en de daarmee samenhangende vaatwand reactie te 
bestuderen; en
•  De specifieke vaststelling van de frequentie, voorspellers en ontstaanswijze en 
hemodynamische effecten van “coronary evaginations”, het natuurlijk beloop van 
stentrand dissecties, en de verschillende aspecten van het vasculaire genees proces 
na BVS implantatie.
20 Introduction
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ABSTRACT
Aim: We assessed the feasibility and the procedural and long-term safety of Intracoro-
nary (i.c) imaging for documentary purposes with optical coherence tomography (OCT) 
and intravascular ultrasound (IVUS) in patients with acute ST-elevation myocardial 
infarction (STEMI) undergoing primary PCI in the setting of IBIS-4 study.
Methods and Results: IBIS4 (NCT00962416) is a prospective cohort study conducted at 
five European centers including 103 STEMI patients who underwent serial three-vessel 
coronary imaging during primary PCI and at 13 months. The feasibility parameter was 
successful imaging, defined as the number of pullbacks suitable for analysis. Safety 
parameters included the frequency of peri-procedural complications, and major adverse 
cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI) and 
any clinically-indicated revascularization at 2 years. Clinical outcomes were compared 
with the results from a cohort of 485 STEMI patients undergoing primary PCI without 
additional imaging. Imaging of the infarct-related artery at baseline (and follow-up) 
was successful in 92.2% (96.6%) of patients using OCT and in 93.2% (95.5%) using IVUS. 
Imaging of the non-infarct-related vessels was successful in 88.7% (95.6%) using OCT 
and in 90.5% (93.3%) using IVUS. Periprocedural complications occurred less than 2.0% 
of OCT and none during IVUS. There were no differences throughout 2 years between 
the imaging and control group in terms of MACE (16.7% vs 13.3%, adjusted HR1.40, 
95%CI0.77-2.52, p=0.27). 
Conclusions: Multi-modality three-vessel i.c. imaging in STEMI patients undergoing 
primary PCI is consistent a high degree of success and can be performed safely without 
impact on cardiovascular events at long-term follow-up. 
KEYWORDS
Optical coherence tomography, intravascular ultrasound, ST-segment elevation myocar-
dial infarction
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ABBREVIATIONS AND ACRONYMS
ARC = Academic Research Consortium
CI = Confidence interval
DES = Drug-eluting stent
MACE = Major adverse cardiac event 
MI = Myocardial infarction
ST = Stent thrombosis
TLF = Target lesion failure
TLR = Target lesion revascularization
IVUS = Intravascular ultrasound
IVUS-VH = IVUS-virtual histology
OCT = Optical coherence tomography
PCI = Percutaneous coronary intervention
STEMI = ST-elevation myocardial infarction 
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INTRODUCTION
Multimodality intracoronary (i.c.) imaging using optical coherence tomography (OCT), 
grayscale intravascular ultrasound (IVUS), and IVUS-virtual histology (IVUS-VH) provides 
means to characterize coronary atherosclerosis and optimize stent implantation in 
a comprehensive manner. Based on near-infrared light, OCT visualizes in great detail 
the vascular luminal integrity, thrombus, and characteristics of plaque vulnerability 
and facilitates the detection of geographical miss, stent strut malapposition and edge 
dissections following stent implantation.1 Although the resolution of IVUS is an order 
of magnitude lower than OCT, the technology provides a greater penetration depth 
and therefore the ability to assess plaque volume.2 IVUS-VH is based on radiofrequency 
analysis and has been proposed as a method to assist the evaluation of plaque compo-
sition, particularly necrotic core.3 The combined use of these sound- and light-based 
modalities theoretically increases the accuracy to detect “vulnerable” plaques 4,5  and 
may thus provide a complete platform to exploit future treatment targets. Additionally, 
these technologies have the potential to improve cardiovascular outcomes by optimiz-
ing percutaneous coronary intervention (PCI), particularly in STEMI patients..6 
Nevertheless, the use of intracoronary imaging catheters may be accompanied by 
procedural complications including injury of the endothelium, which may increase the 
risk of short- and long-term events. Despite an increasing use of intracoronary imaging 
in daily practice, there is insufficient data on the feasibility and safety of multimodality 
imaging. We therefore aimed to analyse the feasibility and short- and long-term safety 
of patients enrolled in the IBIS-4 imaging study, a prospective, observational multicenter 
study with the objective to assess the arterial healing after biolimus-eluting stent 
implantation versus bare metal stent implantation and to investigate the changes in 
atherosclerosis on the background of a high intensity statin therapy in the two non-
infarct related arteries. 7
METHODS
Study population
IBIS 4 (NCT00962416) is a prospective cohort study nested into the COMFORTABLE-AMI, 
a trial comparing the safety and efficacy of a biolimus-eluting stent with a bare metal 
stent in 1161 STEMI patients undergoing primary PCI at 11 international centers.8 A total 
of 103 patients were enrolled in this imaging study using OCT, IVUS and IVUS-VH to as-
sess the arterial healing response following stent implantation and to quantify changes 
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in atherosclerotic plaque characteristics in non-infarct related arteries in the presence of 
high dose statin therapy (rosuvastatin 40mg daily).
Patients enrolled in the COMFORTABLE-AMI trial were eligible for participating in 
the IBIS 4 study when the following criteria were met: age< 90 years, haemodynamic 
stability allowing the administration of nitroglycerine, preserved renal function (GFR 
>30ml/min), >TIMI II flow of the infarct-related artery at the end of the intervention, 
and a coronary anatomy considered suitable for intracoronary imaging (e.g. absence of 
vessel tortuosity).
Following PCI, multimodality imaging with OCT followed by IVUS/IVUS-VH was per-
formed, first addressing the treated culprit lesion, and then the two non-infarct related 
arteries. Care was taken to maintain an activated clotting time >250 seconds, and prior 
to each pullback, i.c. nitroglycerine (200mg) was administered to achieve maximal va-
sodilatation. After complete acquisition, imaging pullbacks were analyzed offline by 
an independent CoreLab (Cardialysis B.V., Rotterdam). Operators were strongly recom-
mended not to optimize the treatment result based on the post-procedural i.c. imaging 
result.
All patients were scheduled for repeat angiography and the same three vessel multi-
modality imaging protocol at 13 months. In total, they were followed up to 2 years, and 
events were recorded at 30 days, 1 year, and 2 years. Per protocol, all patients received 
rosuvastatin 40mg once daily throughout the 13 month follow-up period. 
The control group of the present study consisted of 485 patients who were simultane-
ously enrolled in the COMFORTABLE-AMI study at the five imaging centers, but who 
did not undergo imaging although they formally fulfilled the inclusion criteria for the 
imaging sub-study. All patients provided written informed consent for the participation 
in both the COMFORTABLE-AMI study and IBIS 4. 
OCT
OCT images were acquired using the frequency domain (FD) C7 console system (Light-
lab, St. Jude, Westford, MA) and the Dragonfly catheter at a pullback speed of 20mm/
sec. Blood clearance was achieved using the non-obstructive technique with a power 
injector applying flushing rates of 3-6 ml/sec depending on vessel size. The regions of 
interest included in the culprit vessel: at least 5mm of the proximal and distal reference 
vessel segments; and as much as possible of the proximal non-infarct-related arteries, 
though a minimum of 40mm as measured from the respective ostia.
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IVUS
IVUS-images were acquired with the Volcano s5 system (Volcano Corp., Rancho Cordova, 
CA) and the 2.9 French Eagle Eye catheter, which uses a 20 MHz transducer, at a pullback 
rate of 0.5mm/sec. The regions of interest were the same as for OCT, as were the storage 
of pullbacks and transfer to Corelab for further offline analysis.
Antithrombotic therapy regimen
All patients were loaded with aspirin (≥250 mg) prior to the procedure. In centers where 
prasugrel was available, an initial dose of 60 mg (including patients preloaded with 
clopidogrel) was given followed by a daily maintenance dose of 10 mg. If prasugrel was 
not available or contraindicated, clopidogrel was administered at a loading dose of 600 
mg, followed by 75mg twice daily for seven days, followed by a maintenance dose of 75 
mg daily. Dual antiplatelet therapy was prescribed for the duration of 13 months. 
Feasibility parameters
Feasibility was defined as the acquisition of a pullback with sufficient image quality for 
independent CoreLab analysis, e.g. allowing the acquisition of >70% of the region of 
interest and satisfactory blood clearing with visibility of >3 quadrants in >70% of the 
pullback length.
Safety parameters
The following procedural complications (directly related to the imaging or within 24 
hours of the procedure) were prospectively collected: coronary artery dissection (an-
giographic) or vessel perforation, ventricular fibrillation, symptomatic brady- or tachyar-
rythmia, thrombus formation, spasm and air embolism. 
The primary clinical safety endpoint was a composite of cardiac death, myocardial 
infarction and any clinically indicated revascularization. Secondary safety endpoints 
included death, cardiac death, myocardial infarction, Academic research consortium 
(ARC-)-defined definite- and definite or probable stent thrombosis and major bleeding 
events according to the Bleeding-ARC (BARC) definition.  All definitions of endpoints 
used in this study have been previously reported.9 Any revascularization refers to all 
revascularizations (target-lesion revascularization (TLR), target-vessel revascularization 
(TVR), and non-TVR). Acute renal failure was defined as an absolute increase in serum 
creatinine of >1.5 fold from baseline or a glomerular filtration rate decrease of >25% 
within 72 hours. 
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Data management 
Independent study monitors verified source data according to a prespecified monitor-
ing plan. Data were stored in a central online database. Follow-up appointments were 
scheduled at 30 days, 1 year and 2 years, and patients were questioned about the oc-
currence of angina, any adverse events. All events were independently adjudicated by a 
clinical event committee. 
Statistical analysis 
Categorical variables are presented as counts with percentages and compared using 
chi-square or Fisher’s tests, and continuous variables as means with standard deviations 
or medians and interquartile ranges, and compared using the Student t-test and Mann-
Whitney U-test, respectively. Lesion-level data were analyzed using general or general-
ized linear mixed models, nesting lesions within patient identifiers, wherever applicable. 
Time-to-first event or composite events were analyzed using Cox’s regression analysis 
comparing the Imaging group and the control group (at 30 days, 1 year and 2 years 
of follow-up), both crude (presented with Kaplan-Meier graphs), and adjusted (using 
inverse-probability of treatment weighting (IPTW), where the treatment is the imaging 
performed). IPTW was calculated using the following baseline variables: age, gender, 
body mass index, diabetes, hypertension, hypercholesterolemia, current smoker, renal 
insufficiency, anemia, pain onset within 6h, Killip II, resuscitation, left ventricular ejection 
fraction, treatment of a bifurcation lesion, small vessel ≤2.5mm diameter, long lesion 
≥20mm length, SYNTAX score, TIMI flow pre-procedure, after 20 times multiple imputa-
tion of missing data using chained equations (IPTW Adjusted Cox’s Regressions weight 
the patients by their IPTW and are based on 20 imputed data-sets). Sensitivity crude 
and IPTW adjusted Cox’s regression analyses were conducted on the primary outcome, 
stratifying patients according to whether they received clopidogrel loading or prasug-
rel/double loading during the index procedure. Similarly, event rates at discharge were 
analysed using Crude or IPTW Adjusted Poisson Regressions with robust error variances 
and reported as Risk Ratios RR with 95% confidence intervals (95%CI). P-values from 
Fisher’s tests are reported in case of zero events. All statistical analyses were performed 
with Stata 12.1 (StataCorp, Texas, USA) and differences were considered significant at 
α=0.05.
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RESULTS
A total of 103 STEMI patients undergoing primary PCI were included at 5 European 
centers into the IBIS 4 imaging study between September 2009 and January 2011. 
Feasibility of multimodality intracoronary imaging
The feasibility of OCT, grayscale IVUS, and IVUS-VH at baseline and follow-up imaging is 
shown in Table 1. Imaging of the infarct-related artery at baseline (and follow-up) was 
successful in 92.2% (96.6%) patients using OCT, 93.2% (95.5%) patients using grayscale 
IVUS and 88.3% (94.3%) patients using IVUS-VH. Imaging of the non-infarct related 
artery at baseline (and follow-up) was successful in 88.7% (95.6%) patients using OCT, 
90.5% (93.3%) patients using grayscale IVUS and 83.1% (92.6%) patients using IVUS-VH, 
respectively. Failure of OCT imaging was mainly related to insufficient image quality due 
to incomplete vessel flushing but also due to difficulties to advance the OCT catheter in 
the non-infarct related artery. IVUS-VH imaging failure was mainly caused by technical 
problems with the ECG transmission for gating of the acquisition, and by the use of 
manual- instead of automatic pullback. 
Procedural complications
In the setting of primary PCI, 2 out of 103 (1.9%) OCT pullback acquisitions resulted in 
a complication at baseline, and 1 out of 91 (1.1%) at follow-up. Specifically, a dissection 
at the proximal stent edge was caused by the tip of the OCT imaging catheter in one 
of the cases at baseline; whereas the other two complications (one at baseline, one at 
follow-up) consisted of ventricular fibrillation induced by vessel flushing with contrast. 
Complications were managed by additional stent implantation in the former case, and 
successful defibrillation in the other cases, without further sequelae. IVUS imaging was 
performed without complications; and there were no cases of i.c. related thrombus 
formation, perforation, air embolism, or mechanical device failure or spasm. 
Safety analysis
A total of 103 imaging patients were compared to a cohort of 485 control patients.
Baseline clinical characteristics of the two groups are shown in Table 3. Imaging pa-
tients were younger, more frequently male, had a higher BMI and were less likely to 
have hypercholesterolemia compared to patients not undergoing i.c. imaging. Imaging 
patients were more often resuscitated prior to hospital admission. Prognostically impor-
tant characteristics like diabetes, Killip classification and left ventricular function were 
similar. Procedural characteristics are shown in Table 4. Other than a lower maximal 
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balloon pressure and a higher amount of contrast used, there were no significant differ-
ences between groups. Antithrombotic medication prior or during the procedure and 
at hospital discharge is shown in Table 5. Imaging patients more frequently (58.3% vs. 
32.7%, p<0.001) received a concomitant loading dose of prasugrel in addition to clopi-
dogrel and were more frequently discharged with prasugrel as compared with control 
patients (77.5% vs. 52.1%, p<0.001), the proportion of patients on double antiplatelet 
therapy at discharge, however, was similar.
Table 1 Feasibility of OCT, IVUS, and IVUS-VH at baseline and 13 months follow-up
Infarct-related vessel Non-infarct-related vessel
OCT IVUS IVUS-VH OCT IVUS IVUS-VH
Baseline 
   Number of patients    103 103
   Number of vessels available for imaging 103 103 103 204 201 201
   Successful imaging 95 (92.2) 96 (93.2) 91 (88.3) 181 (88.7) 181 (90.5) 172 (83.1)
   Unsuccessful imaging 8 (7.8) 7 (6.8) 12 (11.7) 23 (11.3) 20 (9.5) 29 (14.4)
      Failure to cross lesion 1 (1.0) 3 (2.9) 3 (2.9) 11 (5.4) 9 (4.5) 9 (4.5)
      Technical problem§ 0 1 (1.0) 6 (5.8) 0 3 (1.5) 12 (6.0)
      Insufficient quality for analysis 6 (5.8) 2 (1.9) 2 (1.9) 10 (4.9) 6 (3.0) 6 (3.0)
      Patient compliance ǁ 1 (1.0) 1 (1.0) 1 (1.0) 2 (1.0) 2 (1.0) 2 (1.0)
Follow-up
   Number of patients 91 91
    Total number of vessels available for imaging 91 91 91 185 183 183
   Not obtained as at baseline# 2 2 2 25 20 20
   Successful imaging* 86 (96.6) 85 (95.5) 84 (94.3) 153 (95.6) 152 (93.3) 150 (92.6)
   Unsuccessful imaging 3 (3.4) 4 (3.4) 5 (5.6) 7 (4.4) 9 (5.5) 11 (7.3) 
      Failure to cross lesion 2 (2.2) 2 (2.2) 2 (2.2) 0 1 (0.6) 1 (0.6)
      Technical problem§ 0 2 (1.1) 3 (3.4) 1 (0.6) 5 (3.1) 7 (4.3)
      Insufficient quality for analysis 1 (1.1) 0 0 3 (1.9) 1 (0.6) 1 (0.6)
      Patient compliance ǁ 0 0 0 3 (1.9) 2 (1.2) 2 (1.2)
Values are number (%) or mean ± SD.  
OCT, optical coherence tomography; IVUS, intravascular ultrasound; VH, virtual histology; 
#Not investigated at follow-up as no baseline was available 
*The success rate at follow-up = successful imaging /(total number of vessel available  –  number of not obtained 
as at baseline)
§Technical problem is defined as manual pullback or DVD defect or ECG trigger missing. 
ǁPatient compliance is defined as preterm termination of the imaging procedure due to patient discomfort in 
view of the prolonged catheterization time.
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Short and long term outcomes of patients undergoing intracoronary imaging 
Table 6 presents clinical outcomes at 30 days, 1 year and 2 years. The primary endpoint 
MACE was similar for patients undergoing i.c. imaging and controls at 2 years (16.7% vs 
13.3%, adjusted HR=1.4, 95%CI 0.77–2.52, p=0.27) (Figure 1). Similarly, no differences in 
the individual endpoints including death, myocardial infarction and any revasculariza-
tion were observed at two years. Two recurrent myocardial infarctions were noted in 
the imaging group within 30 days. One event was related to an early stent thrombosis 
four days after stent implantation in a calcified ostial RCA lesion due to stent underex-
pansion. The second event occurred in a patient who was readmitted with cardiogenic 
shock due to ischemic mitral regurgitation with documentation of stent thrombosis. 
There was no significant difference in the rate of acute renal failure at 30 days between 
2 groups (1% vs. 1.9%, adjusted HR=0.68, 95%CI 0.09-5.37, p=0.72). Revascularization 
of non-infarct related arteries (clinically indicated non-TVR) is an important surrogate 
for lesion progression potentially related to i.c. imaging. Non-TVR occurred at a similar 
frequency in the imaging (9.0%) and control group (4.8%, HR=1.70, 95%CI 0.76-3.81, 
p=0.20). Similarly, there was no difference in the frequency of any clinically indicated 
revascularization (Table 6). 
To investigate whether the observed differences in the use of P2Y12 inhibitors were 
responsible similar MACE rates, we performed a sensitivity analysis for the primary 
endpoint MACE. We found hazards to be consistent for both groups at any time point 
of follow-up when separately comparing patients receiving a clopidogrel loading dose 
(imaging vs. control group, adjusted 2 year HR 1.18, 95%CI 0.39-3.61, p=0.77) and those 
receiving either prasugrel or a double loading dose separately  (adjusted 2 year HR 1.67 
95%CI 0.81-3.43, p=0.16) (Appendix Table S1).  
Table 2 Complications related to imaging procedure (per patient)
Baseline Follow-up
OCT
N=103
IVUS
N=103
OCT
N=91
IVUS
N=91
Dissection 1 (1.0) 0 0 0
Ventricular fibrillation 1 (1.0) 0 1 (1.1 ) 0
Symptomatic brady- or tachyarrhythmia 0 0 0 0
Thrombus formation 0 0 0 0
Perforation 0 0 0 0
Air embolism 0 0 0 0
Total 2 (1.9) 0 1 (1.1) 0
Values are number (%). OCT, optical coherence tomography; IVUS, intravascular ultrasonography.
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DISCUSSION
This is the first report on the feasibility and safety of multimodality three-vessel intra-
coronary imaging in the setting of a prospective observational study in STEMI patients 
undergoing primary PCI. Less extensive intracoronary imaging may be used in daily 
clinical routine, a situation for which our findings are also applicable.
The following major findings apply to this study:
Table 3 Baseline clinical characteristics
Imaging group
(n=103)
Control group
(n=485)
P value
Age (yrs ) 58.2 ± 10.5 61.5 ± 12.2 0.012
Male gender 93 (90.3) 385 (79.4) 0.008
BMI – kg/m2 27.8 ± 4.2 26.8 ± 4.0 0.019
Cardiovascular risk factors
   Diabetes 13 (12.6) 65 (13.4) 1.00
   Hypertension 48 (46.6) 212 (43.7) 0.66
   Hypercholesterolemia 42 (40.8) 259 (53.7) 0.022
   Current smoker 48 (46.6) 242 (50.4) 0.52
   Family history of CAD 31 (31.0) 130 (27.3) 0.46
   Renal failure 1 (1.0) 13 (2.7) 0.48
   Previous MI 2 (1.9) 26 (5.4) 0.20
   Previous CABG 0 (0.0) 13 (2.7) 0.14
Peak CK 1847 (1045-3494) 1652 (800-2814) 0.20
Peak CK-MB 187 (107-319) 160 (72-300) 0.20
Clinical presentation 
   Time from symptom onset to balloon inflation, min 258 (170-472) 244 (164-422) 0.72
   Time from arrival at hospital to balloon inflation, min 40 (30-56) 42 (30-63) 0.18
   Killip class II, III, or IV 8 (7.8) 34 (7.0) 0.83
   Resuscitation before hospital arrival 5 (4.9) 7 (1.4) 0.042
   LVEF (%) 47.8 ± 9.4 48.6 ± 10.1 0.52
Values are expressed as mean ± SD or number (%). 
BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; 
CABG, coronary artery bypass graft; CK, creatine kinase;  LVEF, left ventricular ejection fraction.
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Table 4 Baseline procedural characteristics
Imaging group
(n=103)
Control group
(n=485)
P value
No of lesions treated in infarct vessel 121 542
Infarct vessel location 0.24*
  Left main coronary artery 1 (1.0) 1 (0.2)
  Left anterior descending artery 46 (44.7) 184 (38.0)
  Left circumflex artery 18 (17.5) 68 (14.0)
  Right coronary artery 38 (36.9) 229 (47.3)
Baseline TIMI flow 0.51*
   0 or 1 73 (60.8) 351 (65.0)
   2 17 (14.2) 67 (12.4)
   3 30 (25.0) 122 (22.6)
Lesion complexity
   Bifurcation lesion,no. 14 (13.6) 44 (9.1) 0.20*
   Small vessel 14 (13.6) 67 (13.9) 1.00*
   Long lesion 31 (30.1) 149 (31.0) 0.91*
   SYNTAX MI Score 14.7 ± 6.7 14.5 ± 8.3 0.82*
Primary PCI procedure
   No. of stents per lesion 1.22 ± 0.51 1.30 ± 0.67 0.28*
Type of stent 
     Biolimus-eluting stent 64 (52.9) 268 (49.8) 0.60*
     Bare metal stent 57 (47.1) 274 (50.9) 0.57*
Stent length per lesion, mm 22.1 ± 10.5 24.1 ± 13.2 0.16*
Stent diameter, mm 3.25 ± 0.49 3.2 ± 0.7 0.36*
Direct stenting 24 (19.8) 127 (23.6) 0.31*
Maximal balloon pressure, atm 13.7 ± 2.9 14.9 ± 3.4 <0.001*
Thrombus aspiration performed 70 (68.0) 288 (59.5) 0.12
Intravenous vasopressors 2 (1.9) 14 (2.9) 1.00
TIMI flow post-procedure 0.76
   0 or 1 0 (0.0) 3 (0.6)
   2 2 (1.7) 22 (4.1)
   3 119 (98.3) 516 (95.4)
Total amount of contrast used during primary PCI, ml
   BL 268.3 ± 109.8 197.9 ± 88.8 <0.001
Total amount of contrast used for imaging, ml
   BL 174 ± 72 n.a.
   FUP 169 ± 83 n.a.
Total time for primary PCI intervention, min 34.3 ± 18.5 36.2 ± 20.1 0.39
Total time used for imaging, min 44 ± 22 n.a.
Data are expressed as number (%) unless otherwise specified. 
* Mixed model p-value accounting for lesions nested within patient
IQR, interquartile range; SD, standard deviation; PCI, percutaneous coronary intervention; QCA, quantitative 
coronary angiography; 
TIMI, thrombolysis in myocardial infarction; BL, baseline; FUP, follow-up; MI, myocardial infarction, n.a. not 
applicable
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1) Multimodality three-vessel i.c. imaging was consistent with high degree of success, 
confirming the feasibility even in the acute setting of primary PCI at centers with 
various level of expertise in i.c. imaging.
2) Periprocedural complications were rare (1.9 % per patient at baseline, 1.1% at follow-
up), solely related to the imaging with OCT, and resolved without sequelae in all cases.
3) Rates of death and myocardial infarction at 30 days were similar between patients 
undergoing i.c. imaging and controls attesting to the procedural safety of three-
vessel multimodality imaging.
4) Rates of MACE up to 2 years were low and similar for both groups indicating that 
diagnostic serial multimodality i.c. imaging is not associated with harm. 
Feasibility
The present study demonstrates an overall high feasibility of both OCT and IVUS for im-
aging the infarct vessel, which did not differ between the baseline acute setting and the 
planned follow-up investigation at 13 months, suggesting that the acute presentation 
does not limit the success rate of i.c. imaging except in cases of hemodynamic instability 
or poor PCI result. As opposed to the infarct-related vessels, the success rates for evalu-
ating non-infarct related arteries were lower. The principal reason for this was the caliber 
Table 5 Medication during the procedure and at discharge
Imaging group
(n=103)
Control 
group
(n=485)
P value
Periprocedural medication
   Unfractionated heparin 101 (98.1) 478 (98.6) 0.66
   Bivalirudin 6 (5.8) 29 (6.0) 1.00
   Glycoprotein IIb/IIIa antagonists 54 (52.4) 241 (49.7) 0.67
Loading dose of clopidogrel and prasugrel
   Clopidogrel only (600mg) 26 (25.2) 251 (52.0) <0.001
   Prasugrel only (60mg) 17 (16.5) 68 (14.1) 0.54
   Both 60 (58.3) 158 (32.7) <0.001
   No loading dose clopidogrel and prasugrel 0 (0.0) 6 (1.2) 0.60
Medication at discharge
   Aspirin 102 (100.0) 481 (99.8) 1.00
   Clopidogrel 23 (22.5) 230 (47.7) <0.001
   Prasugrel 79 (77.5) 251 (52.1) <0.001
   Any dual antiplatelet therapy 102 (100.0) 480 (99.6) 1.00
Values are n (%).  
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of some of the arteries, vessel tortuosity, and an untreated stenosis. This is however, 
not surprising since these features typically make part of the exclusion criteria in OCT 
studies. Nevertheless, as we aimed at a three-vessel evaluation in an already diseased 
patient population, with as few exclusion criteria as possible to minimize selection bias, 
these vessels were included yet still contribute to an overall high success rate. Studies 
investigating the feasibility of multimodality three-vessel i.c. imaging in STEMI patients 
undergoing primary PCI are lacking. Up until now, few studies performed three vessel 
(single modality) imaging with either OCT 10 or IVUS 11, however, these reports did not 
disclose the number of excluded patients related to imaging failures, thus only reported 
Figure 1. Cumulative incidence curve for MACE (cardiac death, MI and any clinically indicated revasculariza-
tion) throughout 2 years. Continuous line indicates imaging group, dotted line indicates control group not 
undergoing imaging.
Figure 2. Cumulative incidence curve for the composite of cardiac death or MI throughout 2 years.
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the number of pullbacks excluded due to insufficient imaging quality and safety data is 
not available.
Periprocedural complications
Peri-procedural complications were rare and solely related to the use of OCT. In two out 
of 309 OCT pullbacks (0.6%), ventricular fibrillation occurred due to prolonged flush-
ing with contrast media. Given the overall low frequency of ventricular fibrillation in 
this patient group presenting for primary PCI, and in view of the prompt restoration of 
sinus rhythm following defibrillation, OCT can be considered as a safe diagnostic tool. 
Nonetheless, physicians using this technology need to be aware about the potential of 
inducing ventricular fibrillation. The single dissection recorded at a proximal stent edge 
was related to the short monorail of the previous version of the dragonfly OCT catheter, 
which was difficult to advance in a vessel curvature. 
The largest study with time-domain (TD-) OCT where peri-procedural complica-
tions were reported included 468 mainly stable coronary artery disease patients, and 
observed ventricular fibrillation in 1.1% of patients, air embolism in 0.6% and vessel dis-
section in 0.2% of patients. Only few data is available on the safety of FD-OCT 12, 13, which 
acquires images at frame rates at least 10 times faster than TD-OCT and results in an 
improved imaging quality. The marked simplification of the acquisition procedures and 
reduction in the required contrast volume has decreased the imaging procedure time 
and increased the imaging quality.11 The absence of complications with the use of IVUS 
confirms the already known high degree of safety of this technique, and may be the 
result of device adaptations since the introduction of the technique in the early 1990s 
and the high degree of experience with its use. Conversely, OCT has been introduced 
only 15 years later. In our study, two participating study centers initiated the use of OCT 
only with the occasion of this study, which increases the applicability of the study results 
to a broader spectrum of centers performing i.c. imaging.
Short and long-term safety
We did not limit our analysis to peri-procedural complications and compared clinical 
outcome measures of safety between imaging patients and a control group. At 30 days, 
the composite endpoint cardiac death or MI occurred at a similar rate in imaging and 
non-imaging patients, further supporting the procedural and long-term safety of multi-
modality imaging for documentary purpose. Similarly, no difference in cardiac death or 
MI was noted at 1 and 2 years of follow-up.
Safety concerns related to imaging procedures in native coronary arteries are not 
limited to peri-procedural complications occurring during the first 30 days after imaging 
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but also apply to a hypothetical acceleration of atherosclerosis during long-term follow-
up 14,15,16 Hypothetically, the introduction of imaging catheters solely for diagnostic pur-
poses (IVUS: 2.9 French, OCT 2.7 French) may induce clinically silent endothelial injury 
as previously demonstrated in an experimental model17. The iatrogenic damage may 
trigger atherosclerotic disease progression by initiating clinically silent plaque ruptures 
with subsequent progression18. As non-infarct related arteries of STEMI patients are 
known to accommodate vulnerable plaques, and as they are potentially more sensitive 
to catheter-induced rupture than other lesions, we extended our evaluation to a long-
term monitoring with a particular focus on repeat revascularization events in untreated 
segments.11,10 Indicators of a disease progression in untreated vessel segments are the 
frequency of target vessel revascularizations (TVR) and the revascularizations occurring 
in the untreated vessels (non-target lesion revascularization, non-TVR). Throughout 
2 years, TVR and non-TVR occurred in a similar frequency when comparing the imag-
ing with the control group. Similar to our findings, the “Avasimibe and progression of 
coronary lesions assessed by IVUS” (A-PLUS trial) investigating i.c. imaging related ath-
erosclerosis progression, found no evidence by quantitative coronary analysis of disease 
progression 24 months following IVUS investigation, as compared to control arteries of 
the same patients.15 
OCT and IVUS require the placement of an i.c. guidewire and therefore, radiation expo-
sure and contrast agents are important safety considerations. While we did not record 
the incremental radiation dosage required for three-vessel i.c. imaging, we did assess 
the amount of contrast agents used. OCT requires complete blood removal achieved by 
a proper contrast injection. In our study, the contrast use per pullback ranged between 
15 and 30 ml per pullback and we used injection rates between 3.5 and 6 ml/sec. A 
total of 174 ml of contrast media was injected at baseline and 164 ml at follow-up. This 
relatively high number has to be interpreted in light of our IBIS-4 study protocol, which 
required the placement of a guidewire in two non-intervened vessels, the placement 
and documentation of the image wire for matching purpose, the acquisition of OCT 
pullbacks in three vessels and a documentary final angiography after both IVUS and OCT 
to confirm the absence of harm. Despite the higher contrast use in imaging patients, 
the risk of developing renal failure after primary PCI was low and similar for patients in 
the imaging and control group (1.0% vs. 1.9%, p=0.72). In addition, no difference was 
observed in the creatinine increase from admission to peak during the index hospitaliza-
tion (7.2±9.2 µmol/L vs. 8.8±15.2 µmol/L, p=0.16).
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Limitation 
This study has some limitations. First of all, there is to date no clinical indication for the 
performance of multi-modality three vessel imaging during primary PCI. However, the 
results observed in the setting of a maximal i.c. imaging approach can be translated to 
less extensive imaging procedures in daily clinical routine, attesting to their feasibility 
and safety. 
Despite the attempt to select a comparable control group, the decision to perform 
i.c. imaging was not random introducing some selection bias and probably including 
a lower risk population in the imaging study. Repeated manipulation with the infarct 
related artery could potentially lead to an increasing risk for micro-embolization. Whilst 
myocardial blush grade was not recorded, no difference in final TIMI-flow between the 
two groups were recorded. Although the presence of a myocardial infarction at baseline 
hypothetically masks the occurrence of a imaging induced peri-procedural myocardial 
infarction, we did not observe an increased risk at follow-up under stable conditions.
In addition, we did not assess the radiation dose in both groups. Nevertheless, the 
total radiation time inevitably increases as positioning of the coronary wire and imaging 
catheter has to be documented with both OCT and IVUS. The total number of patients 
investigated is limited considering the presence of a complex imaging protocol. 
CONCLUSIONS
Multi-modality three-vessel i.c. imaging in the acute setting of STEMI and performed 
for documentary purposes is consistent with a high degree of success and can be 
performed safely without impact on cardiovascular events at long-term follow-up. This 
data provides reassurance on the feasibility and safety of intravascular imaging in daily 
routine, where a less extensive approach may be used.
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Appendix Table 1 Clinical outcomes at discharge, 30 days, 1 year, and 2 years of follow-up separated for 
clopidogrel loading and prasugrel loading/double loading 
Crude IPTW adjusted
Imaging 
group
Control 
group
Hazard Ratio(95% 
CI)
P 
value
Hazard Ratio(95% 
CI)
P 
value
Clopidogrel loading
Number of patient treated 26 251
   MACE at discharge 1 (3.8) 5 (2.0) 1.93 (0.23-15.97) 0.54 2.84 (0.35-23.13) 0.33
   MACE at 30 days 2 (7.7) 11 (4.4) 1.80 (0.40-8.12) 0.44 2.15 (0.46-10.00) 0.33
   MACE at 1 year 3 (11.5) 21 (8.5) 1.40 (0.42-4.68) 0.59 1.39 (0.38-5.12) 0.62
   MACE at 2 years 4 (15.4) 33 (13.5) 1.18 (0.42-3.32) 0.76 1.18 (0.39-3.61) 0.77
  
Prasugrel loading or 
double loading
Number of patient treated 77 226
   MACE at discharge 0 (0.0) 1 (0.4) 1.46 (0.13-15.88) 1.00
   MACE at 30 days 1 (1.3) 4 (1.8) 0.73 (0.08-6.56) 0.78 1.38 (0.16-12.13) 0.77
   MACE at 1 year 4 (5.2) 15 (6.7) 0.77 (0.26-2.33) 0.65 0.78 (0.23-2.67) 0.70
   MACE at 2 years 13 (17.3) 27 (12.3) 1.43 (0.74-2.77) 0.29 1.67 (0.81-3.43) 0.16
Values are % (n/N). MACE, major adverse cardiac event.
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Abstract
Aims: To describe different patterns of stent strut apposition, as visualised with optical coherence
tomography.
Methods and results: Strut thicknesses were reconstructed according to the manufacturers’ specifications.
The stent area (SA) was measured by connecting the reconstructed abluminal surfaces of struts with
a trace line, and the vessel wall area (VWA) was estimated from the abluminal strut surfaces, as well as
from the lumen border, in cases of struts that were separated from the vessel wall by flush. Strut apposition
was evaluated by comparing the SA- and VWA traces. We observed four patterns of strut apposition. Based
on these, stent struts could be classified as: (I) apposed struts, (II) struts overlying the ostium of a side
branch, (III) malapposed struts that were clearly separated from the vessel wall by flush, and (IV)
pseudoapposed struts that were not separated from the vessel wall by visual estimate, but were
malapposed in the sense that SA<VWA. Pseudoapposed struts were found in frames with “flower-shaped”
lumen contours, and were often surrounded by structures of a lower signal intensity than the rest of the
vessel wall.
Conclusions: For a detailed analysis of strut apposition with OCT, we reconstructed strut thicknesses and
estimated stent- and vessel wall areas. With this method, we found four types of strut apposition, where
pseudoapposed struts constitute a type of struts not previously described. The clinical importance of
pseudoapposed struts remains to be settled.
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Introduction
The importance of refining stent implantation in coronary artery
lesions was previously demonstrated using intravascular ultrasound
(IVUS).1 Accordingly, it became customary to deploy coronary
stents at high pressure, since this improves stent expansion and
apposition to the vessel wall.2 Although IVUS- and histopathological
reports have related stent strut malapposition to late thrombosis of
drug-eluting stents (DES)3,4, other studies have shown that
malapposition may occur in up to 10% of DES without any clinical
consequence.5,6 The importance of strut malapposition therefore
remains controversial.
Optical coherence tomography (OCT) is an infrared light-based
imaging technique with a resolution of 10 μm, which is ten times
higher than that of IVUS.7 As a sensitive tool, OCT detects strut
malapposition and thin strut coverages more often than IVUS.8
Consequently, intracoronary OCT examination of stented areas
might contribute to evaluate the clinical importance of strut
malapposition.
At present, there is no consensus regarding the classification of
strut apposition as visualised with OCT. It was recently suggested
that strut apposition on OCT may be classified into three grades;
embedded, protruding, and malapposed9, where embedded and
protruding struts are different degrees of apposed struts. In our
work with OCT, we have encountered various morphological
configurations of the stent/vessel wall complex that seem to be
related to strut apposition. The objectives of this study were
therefore (1) to describe the different morphological appearances of
the stent/vessel wall complex at the frame level, and (2) to analyse
whether these, by means of various quantitative parameters, are
related to apposition at the strut level.
Methods
Patient population
The study included data from patients with coronary stents
implanted at least two months prior to the OCT examinations. These
were performed either as part of an elective diagnostic- or routine
control angiography, or in connection with an angiography
performed subacutely as part of the diagnostic program in acute
coronary syndrome (ACS). Only examinations with a good image
quality, defined as an adequate displacement of blood and
visualisation of >70% of the vessel wall circumference, were
included.
OCT image acquisition
The M2 OCT system (LightLab Imaging Inc., Westford, MA, USA)
used in this study has been described previously.10 We used
occlusive or non-occlusive techniques to obtain blood displacement
during OCT imaging. In brief, after crossing the stent with an
angioplasty wire, an over-the-wire OCT occlusion balloon catheter
(Helios™) or a Renegade™ catheter (Boston Scientific, Natick, MA,
USA) was advanced distal to the stented segment, and the coronary
wire was exchanged with the OCT image wire (ImageWire™). For
the occlusive method, the OCT catheter was retracted proximally to
the stented segment and the balloon was inflated at 0.5-
0.7 atmospheres. For the non-occlusive method, the Renegade
catheter was retracted into the guiding catheter. During image
acquisition, coronary blood was displaced by manual infusion of
saline or Visipaque (Iodixanol 320, GE Healthcare, Ireland) for the
occlusive and non-occlusive set-up, respectively. Although the non-
occlusive technique may imply a slightly higher intracoronary
pressure during image acquisition compared to the occlusive
technique, the potential change in areas of relevance for this study,
is likely to be proportional for the different areas. We therefore
assumed it unlikely that the choice of technique would influence
strut apposition. Cross-sectional images were acquired at
15.4 frames/s, and we used an automated pullback system at 1.0
or 2.0 mm/s. Image acquisition was performed for a maximum of
40 seconds under careful monitoring of heart rhythm and
haemodynamics.
OCT image analysis
Frames within the stented segment were examined at 1 mm
intervals to identify recurring morphological patterns in the
stent/vessel wall complex at the frame level. Because OCT visualises
only the endoluminal surfaces of struts, strut thicknesses are
underestimated by visual estimate.11 To compensate for this, we
reconstructed all strut thicknesses according to the manufacturers’
specifications (Table 1) before evaluating strut apposition (Figure 1).
Aspects influencing the appearance of struts on OCT, and thus the
reconstruction of strut thicknesses, are considered in the online
appendix (www.eurointervention.org).
The stent area (SA) was measured planimetrically by fitting a
smooth curve through the trace points of the reconstructed
abluminal strut surfaces (Figure 1A). If the lumen contour on visual
estimation was located inside the stent area, the stent at this cross-
sectional point was considered apposed. Thus, the best possible
estimation of the vessel wall area (VWA) in contact with the stent,
then equalled the SA. In cases of stent malapposition, the VWA was
traced along points in the lumen contour located outside the stent
contour (Figure 1B).
Table 1. Actual and reconstructed strut thicknesses of the stents
analysed.
Stent Metal Polymer Total Reconstructed 
strut thickness strut thickness
Cypher Select 140 7 154 160
Taxus Liberté/Express 97 15 127 130
Endeavor Sprint 91 8 * 107 110
NIR, Palmaz-Schatz 102 - 102 100
Micro-Driver 91 - 91 90
CoStar 89 - 89 90
Multilink Vision 81 - 81 80
All values are in µm. *Average thickness of uneven endo- and abluminal
polymers. Cypher Select/Palmaz-Schatz (Cordis Corp., Johnson & Johnson,
Warren, NJ, USA); Taxus Liberté/Express (Boston Scientific Corp., Natick,
MA, USA); Endeavor Sprint/Micro-Driver (Medtronic Vascular, Santa Rosa,
CA, USA); NIR (Medinol, Boston Scientific, Tel Aviv, Israel); CoStar (Conor
Medsystems, Menlo Park, CA, USA); Multilink Vision (Abbott Vascular,
Redwood City, CA, USA).
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Apposition to the vessel wall was evaluated for every strut by
comparing the location of the reconstructed abluminal strut surface
with the VWA trace line (Figure 1). A strut was defined as apposed if
the abluminal strut surface was located outside the lumen contour
and was tangent to the estimated VWA trace. In cases of
malapposed struts, the distance between the abluminal strut
surface and the VWA trace, interspace distance (ISD), was
additionally measured (Figure 1B).
Statistical analysis
Statistical analysis was performed with SAS statistical package,
version 9.2 (SAS Institute Inc., Cary, NC, USA), and the R
statistical environment, version 2.10.0. Continuous data 
are presented as mean ± standard deviation or median and
interquartile range (IQR), and categorical variables as
percentages. Normality of the data was assessed by visual
estimation of residual plots. Frequencies were compared with
Fisher’s exact test.
Given the hierarchical structure of the data (stent struts nested
within frames nested within lesions), a multilevel model was applied
to compare the interspace distance between relevant apposition
classes, with variance components for “struts within frames” and
“frames within lesions”, using only strut apposition as a fixed factor.
In order to have a good fit of the normal distribution, analysis was
performed on a logarithmic scale.
Intra-observer reproducibility of the classification of strut
apposition was assessed by calculating the Kappa coefficient.
A two-tailed p-value of ≤0.05 was considered statistically significant
for all analyses.
Results
Clinical-, stent- and procedural characteristics
at OCT examination
Thirty-one patients with 31 lesions (37 stents) were included in the
study. Clinical-, stent-, and procedural characteristics are shown in
Table 2. The majority (87.1%) of stents were DES, and the median
duration from implantation was 20 months (range 2-125 months).
Eight patients had acute coronary syndrome (ACS) at the time of
OCT examination, while the remaining 23 patients were examined
in a stable clinical setting.
The non-occlusive technique was used in 13 patients, of which one
developed ventricular fibrillation during image acquisition of a stent
in the right coronary artery. Sinus rhythm was immediately restored
after defibrillation. Otherwise there were no haemodynamic
instabilities, arrhythmias, coronary dissections, subsequent
myocardial infarctions, or deaths with any of the two methods used.
Qualitative assessment of the stent /vessel wall
morphology
A total of 596 frames were analysed. We identified four
morphological patterns of the stent/vessel wall complex, each of
which were accompanied by distinct features of strut apposition.
Figure 2A shows a frame where the lumen contour is regular,
circular, and located inside the SA. The VWA is estimated as
VWA=SA, and we conclude that every single strut is well apposed to
the vessel wall. This pattern of the stent/vessel wall complex was
seen in 506 frames from all 31 lesions.
As an example of the second morphological pattern, Figure 2B
shows three struts where the abluminal strut surfaces are not in
touch with the vessel wall. Analysis of consecutive frames shows
that the vessel wall “opens up” and “closes” (not shown) again
behind these struts, indicating that struts are overlying the ostium of
a side branch. This pattern was seen in 15 frames from 10 lesions.
In Figure 2C1 we see two struts that are clearly separated from the
vessel wall by lumen extending behind them. Analysis of
consecutive frames showed no signs suggestive of a side branch
(not shown). Estimation of SA and VWA shows that VWA exceeds
SA, and that abluminal strut surfaces at 10 o’clock are located
Figure 1. Schematic drawing of the methodology used for the OCT
analysis. Yellow boxes represent the endoluminal surfaces of struts, as
visualised by OCT. Actual strut thicknesses were reconstructed by
drawing a trace line for every strut from the strongest endoluminal
surface reflection a certain distance (exaggerated in the figure) in the
abluminal direction (green traces), as specified by the stent
manufacturer. White dotted lines represent the stent area (SA). Blue
traces represent the best possible estimation of the vessel wall area
(VWA), estimated from the SA in cases of apposed struts (panel A), or
from the lumen contour in cases of clearly malapposed struts (panel
B). For the purpose of clear visualisation, the VWA in panel A is
depicted slightly outside the SA. Comparison of the abluminal strut
surfaces with the VWA trace for every strut yields that struts are
apposed in panel A, and malapposed at 1 and 3 o’clock in panel B.
The interspace distance (red trace) for the malapposed struts was
measured from the abluminal strut surface to the VWA trace.
OCT visualisation of strut apposition
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inside the VWA trace (Figure 2C2), indicating that struts are
malapposed. This pattern was present focally in seven lesions
(23 frames), predominantly at the edges, but also at the mid
portions of the stents. The stents in question included an Endeavor
stent (12 months after implantation), one Taxus Express stent
(40 months after implantation), one NIR stent (100 months after
implantation), and four Cypher stents (12, 15, 20 and 29 months
after implantation).
In the last type of stent/vessel wall configuration, lumen contour is
irregular and flower-shaped (Figure 2D). On first impression, struts
look apposed to the vessel wall. After reconstruction of strut
thicknesses and estimation of SA it appears that the lumen contour
at several points exceeds the SA trace. Planimetrical estimation of
Table 2. Clinical-, stent- and procedural characteristics.
n=31 patients/lesions n (%)
Patient characteristics
Age (years) 65.3±8.8*
Male gender 22 (71.0)
Hypertension 22 (71.0)
Statin treatment 31 (100.0)
Diabetes mellitus 10 (32.3)
Smoker (current/former) 25 (80.6)
Family history of IHD 12 (38.7)
Clinical setting at OCT
CAG control 6 (19.4)
Clinical indication 25 (80.6)
Stable angina 17 (54.8)
ACS presentation 8 (25.8)
Stent characteristics
Average stent number per lesion 1.2±0.5
Duration from implantation (months) 20 (9–34)**
Stent type
BMS 4 (12.9)
DES 27 (87.1)
Stent type, specified
Cypher Select 13 (41.9)
Taxus Liberté 6 (19.4)
Taxus Express 2 (6.5)
Endeavor 5 (16.1)
CoStar 1 (3.2)
Micro-Driver 1 (3.2)
Multilink Vision 1 (3.2)
Palmaz-Schatz 1 (3.2)
NIR 1 (3.2)
Average stent diameter (mm) 2.9±0.4
Total stented length 20 (13–33)*
Lesion location
Target vessel
LAD 8 (25.8)
LCX 6 (19.4)
RCA 16 (51.6)
VG 1 (3.2)
Location
Proximal 6 (19.4)
Mid 21 (67.7)
Distal 3 (9.7)
VG 1 (3.2)
* Mean ± standard deviation; ** Median (interquartile range); IHD: ischaemic
heart disease; CAG: coronary angiography; ACS: acute coronary syndrome;
BMS: bare metal stent; DES: drug-eluting stent; LAD: left anterior descending
artery; LCX: left circumflex artery; RCA: right coronary artery; VG: vein graft
the VWA from these outer points shows that SA is smaller than VWA,
suggesting that the stent in this frame is malapposed although struts
are not clearly separated from the vessel wall. Comparison of the
location of the abluminal strut surfaces with the VWA trace suggests
the presence of malapposed struts from 6 to 3 o’clock. Further, the
regions in immediate approximation of these types of struts often
displayed a lower signal brightness than the rest of the vessel wall
(Figures 2D and 3A). The pattern where the VWA exceeds the SA,
but where struts are not clearly separated from the vessel wall, was
present to varying extents in 89 frames from 11 lesions,
predominantly at the mid portions of the stents. The stents involved,
and the time points from implantation were: Endeavor (three and
12 months), Taxus Express (40 and 51 months), Cypher (12, 15, 20,
29 and 41 months), Taxus Liberté (21 months), and NIR
(100 months).
Based on these four patterns of stent/vessel wall morphology, strut
apposition can be divided in four classes: (I) apposed struts, in
frames where SA=VWA; (II) struts overlying the ostium of a side
branch (SA=VWA); (III) malapposed struts, that are clearly
separated from the vessel wall where SA<VWA; and (IV) struts that
are not clearly separated from the vessel wall, but where SA<VWA.
For the latter, we suggest the term “pseudoapposed” struts.
Quantitative assessment of strut apposition in
relation to vessel wall and stent parameters
A total of 5,966 struts were analysed and classified according to the
definition above. 5,592 struts were apposed, 20 were overlying the
ostium of a side branch, 52 were malapposed, and 302 were
pseudoapposed.
At the strut level, the interspace distance was 2.85 times higher for
malapposed- compared to pseudoapposed struts (95% confidence
limits [CI]: 2.29–3.56, p<0.0001), with a (geometrical) mean [95%CI]
ISD of 101.1 μm [80.2–127.5] and 288.4 μm [213.4–389.9] for
pseudo- and malapposed struts, respectively.
The overall intra-observer agreement in classification of strut
apposition was very good (Kappa coefficient [95% CI]=0.94
[0.92–0.96]). Further, the absolute difference in ISD between two
observations by the same observer was 0 μm, within ±10 μm and
±20 μm for 17%, 44% and 60% of paired observations, respectively.
The clinical importance of mal- and
pseudoapposed struts
In total, mal- and pseudoapposed struts were present in 35% of patients
(11 out of 31). Mal- and pseudoapposed struts were found in bare metal
stents as well as DES, and were often present together in the same
lesions (seven out of 11 lesions with pseudo- and/or malapposed struts).
Patients with ACS had more frequently mal- and pseudoapposed struts
than patients examined in a stable clinical setting (fraction [95% CI]:
75% [35–97] vs. 22% [7–44], respectively [p=0.012]).
Discussion
The main finding of the present study is the identification with OCT
of a type of stent strut apposition not previously described. These
struts were found in frames where the stent/vessel wall complex was
irregular, tending to have a flower-shaped appearance. Estimation of
- 89 -
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SA and VWA suggested they were malapposed, although not clearly
separated from the vessel wall. Further, the region adjacent to these
struts often displayed a lower signal brightness than the rest of the
vessel wall. We propose that this category of struts be classified as
“pseudoapposed” – a designation that refers to their lack of
apparent separation from the vessel wall, as well as their
malapposed appearance by closer examination. Since the detection
of pseudoapposed struts is based on a methodology that estimates
the location of the vessel wall, we find it relevant to comment on this
methodology and how it relates to current approaches.
Reconstruction of strut thicknesses and
estimation of stent and vessel wall areas
The underestimation of strut thicknesses on OCT may be addressed
in different ways. One approach is to measure the distance from the
endoluminal strut surface to the visible lumen- or vessel wall contour,
and compare it with the actual strut thickness.9,12 We addressed this
issue by reconstructing the actual strut thickness for every strut,
which allowed us to locate the abluminal surfaces of struts, and use
them for estimation of other parameters. Compared to the method
used by Tanigawa et al, our approach does not distinguish between
apposed struts that are “protruding” from- and apposed struts that
are “embedded” into the vessel wall. Importantly, a consistent use of
this grading, requires a clear definition of the reference structure that
is being referred to, which in turn requires consideration of the time
point at which OCT is performed and the presence or not of a strut
coverage. In the present study, we assumed apposed struts to be of
the protruding type, in order not to overestimate apposition. In this
way, it is unlikely that a protruding strut which is covered, will be
mixed up with a pseudoapposed strut surrounded by material.
With other methodologies, the stent area is assessed from the
leading endoluminal strut surface. We chose to estimate the SA from
the reconstructed abluminal surfaces of struts because strut
apposition refers to a contact between the vessel wall and the strut
surface orienting towards it. In this way, the abluminal strut surfaces
were used to estimate the dimensions of the vessel wall in contact
with the stent (in cases of apposed struts), and in combination with
the lumen contour, the vessel wall that was not in contact with the
stent (in cases of malapposed struts), expressed as the VWA. Since
the detection of pseudoapposed struts is dependent on the
estimation of the abluminal SA and the VWA, these struts cannot be
identified with the current approaches, because they do not estimate
a parameter that is equivalent to the VWA used in this study. Until the
importance of pseudoapposed struts is clarified, we find it relevant to
reconstruct strut thicknesses when evaluating strut apposition,
particularly in frames with an irregular lumen contour.
It should be emphasised that the VWA as we have estimated it with
OCT, is different from that measured with IVUS at stent implantation
and generally referred to as the “external elastic membrane (EEM)
area”. The EEM area refers to the border between the media and
adventitia, and is used for the study of vessel remodeling behind the
stent.13 Due to a limited tissue penetration, OCT is rarely able to
visualise the EEM when the vessel is significantly diseased. What the
VWA with OCT actually represents depends on the strut apposition at
stent implantation, and the occurrence or not of late vessel
remodelling and stent recoil. Due to the lack of post-implantation
OCT, this was not possible to evaluate in our study. Nevertheless, as
with IVUS, serial estimation of the SA and the VWA with OCT may
allow us to monitor changes in the stent and vessel wall over time,
including the luminal part of vessel remodelling and stent recoil.
Figure 2. Morphological patterns of the stent/vessel wall complex. Green lines depict the reconstructed strut thicknesses, blue lines represent the
vessel wall area (VWA) trace, and the white lines the stent area (SA) trace (A-D). In panels A2 and B2, the white lines are hidden behind the blue
lines. Panel A shows apposed struts. In panel B, struts are overlying the ostium of a side branch at 4 to 6 o'clock. Panel C shows malapposed
struts at 10 o'clock. In panel D, lumen is flower-shaped and struts are pseudoapposed at 6 to 3 o'clock. The regions in the vicinity of struts at 6
and 9 o'clock have a lower signal intensity than the rest of the vessel wall. Stent types and time points from implantation are: A: Cypher (41
months), B: Cypher (22 months), C and D: Cypher (15 months).
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Strut malapposition with different imaging
modalities and potential explanation of
pseudoapposed struts
With IVUS, strut malapposition, also referred to as incomplete stent
apposition, has been defined as a lack of contact between stent struts
and the underlying vessel wall not overlying a side branch, with blood
speckle between struts and the vessel wall.13,14 With other OCT
approaches, as well as with the one described here, struts were
considered malapposed when the distance from its endoluminal
surface to the vessel wall was greater than the actual thickness of the
strut, indirectly including a separation of struts from the vessel wall by
flush. Although no clear histopathological criteria have been defined
for strut malapposition, histological images reveal that struts can be
separated from the original vessel wall by material such as fibrin. In
these cases the authors conclude that struts are malapposed.4,15
Considering this, it is interesting to speculate whether these struts
would have appeared malapposed or apposed, had they been
examined with IVUS or OCT in vivo; and inversely, whether there is a
risk that some struts on IVUS and OCT visualised in vivo can be
classified as apposed, although they are in reality malapposed.
Although difficult to objectify, analysis of tissue texture is a novel and
interesting aspect in the evaluation of coronary stents.16,17 In the
present study, we noticed that the structures in the vicinity of
pseudoapposed struts often displayed a lower signal brightness than
the rest of the vessel wall (Figures 2D and 3A). Considering that the
variation in signal intensity on OCT is related to variations in
backscatter- and attenuation coefficients between tissue
components18, the differences in signal brightness might indicate
that the regions containing these struts are composed of various
materials. On previously published histology images, it is not only
evident that struts can be separated from the vessel wall by fibrin,
but also that these fibrin deposits have a morphological shape that
resembles that of the low-signal areas on OCT (Figure 3).4,15
Moreover, some of these histological cross-sections exhibit a “flower-
shaped” appearance of the lumen contour, reminding of the one
observed with OCT in this study (Figure 4A1 and 4B1). Considering
the proposed link between persistent fibrin deposition around struts
and late stent thrombosis, it would be remarkable if OCT could
visualise this in vivo. Whether the low-signal structures adjacent to
some of the pseudoapposed struts on OCT may represent fibrin
overlying components of the initial vessel wall; and whether
pseudoapposed struts in some cases could actually be malapposed,
would be interesting to investigate in comparison with histology.
It should be stressed that the flower-shaped appearance of the
stent/vessel wall configuration in frames with pseudoapposed struts
should not be mixed up with a similar pattern seen in both OCT
images and histological sections, where the outer portion of the
“petals” are created by stent struts rather than the vessel wall
(Figure 4).19 This phenomenon is probably a consequence of stent
implantation at high pressure, stretching the vessel wall between struts.
We would also like to mention that struts overlying side branch ostia
were included as part of the classification, as to describe their
existence. Since the mechanism of non-apposition, as well as the
potential consequence hereof is pathophysiologically different from
Figure 3. Area of low signal brightness around a strut on OCT
morphologically resembling fibrin deposition from a histology image of
late stent thrombosis. Panel A shows an OCT image from a Cypher
stent, 12 months after implantation. The pseudoapposed strut at one
o’clock (estimated SA and VWA not shown) is separated from the
vessel wall by material that has a lower signal brightness than the rest
of the vessel wall. Panel B shows a histology section from a Cypher
stent with thrombosis 24 months after implantation (stained with
Movat’s pentachrome). Struts at 6 and 8 o’clock are separated from
the vessel wall by fibrin. In panels A2 and B2, the morphological
shapes of the low-signal area by OCT and fibrin deposit by histology,
respectively, are marked. (B. from Finn et al; Circulation 2007.
Reproduced with permission from Wolters Kluwer Health.)
that of malapposed struts, they cannot be compared. Struts
overlying side branch ostia are therefore often excluded from
studies involving analysis of strut apposition.9
Relevance of detecting pseudo- and malapposed
struts with OCT
Although our study population was highly heterogeneous, it
demonstrates that pseudoapposed struts can be found in many
different stent types, at varying time points after implantation. In the
present study, pseudoapposed struts were considerably more
common than malapposed struts, and were frequently found in
frames and lesions also containing malapposed struts. Both types of
stent struts were found in stable as well as unstable clinical settings,
albeit more frequently in ACS. Whether this could be related to mal-
and pseudoapposed struts is difficult to evaluate from our small
population, and requires larger, serial studies with OCT.
Strut malapposition has been related to late stent thrombosis,
although the frequency of malapposed struts has varied between
autopsy- and IVUS studies.3,4 With histology, focus has mainly been
on stent healing, where a lack of neointimal stent coverage and a
persistent deposition of fibrin around struts has been associated
with late stent thrombosis.15 However, the importance of strut
apposition for stent healing is not known, which may partly be
related to the insufficient resolution of IVUS, precluding the
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visualisation of very thin strut coverages and thus the study of the
relationship between strut healing and apposition. Thus far, OCT
studies have indicated that malapposed struts were more frequently
uncovered than struts that were apposed.20,21 It is yet to be clarified
whether the same is true for pseudoapposed struts.
Limitations
This study was a retrospective observational analysis. Due to the lack
of post-implantation OCT data, it was not possible to evaluate whether
mal- or pseudoapposition was present immediately after implantation
or was acquired. Moreover, our study population was very
heterogeneous and limited to a small number of cases, wherefore it
was not possible to estimate the prevalence of pseudoapposed struts
in different stent types, and at different time points after implantation.
Conclusion
For a detailed analysis of strut apposition with OCT, we used a
methodology involving the reconstruction of strut thicknesses and
estimation of stent- and vessel wall areas. With this method, we
found four types of strut apposition, where pseudoapposed struts
constitute a type of struts not previously described. These struts
were found in frames with flower-shaped lumen contours, and were
surrounded by structures of different signal intensities on OCT. The
clinical importance of pseudoapposed struts remains to be settled.
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Introduction
ate coronar stent alapposition as een reporte ater are
etalstentasellasruelutinstentiplantation,
usinintravascularultrasoun.1,2ltoustentalappo
sitionaseenrelatetolatestenttroosis3,4,teresults
o oter stuies suestalapposition to occur in up to 10o
iplanteitout an clinical conseuence at late ollo
up.5,6eiportanceolatestentalappositiontereorereains
controversial.
pticalcoerencetoorapisaninrarelitase
iaintecniuetatproviesetaileinorationaouttecor
onar vessel all, strut apposition an tissue coverae  .7
itaresolutiono10,etectsstrutalappositionan
strutcoveraeoreeicientltan.8
eaverecentlsuesteteolloinaseclassiica
tionostrutappositionapposestruts,strutsoverlinte
ostiuoasieranc,alapposestruts,anpseuoap
poseprotruinstruts(Figure 1).9rotruinstrutsereounin
raesitcorruateluencontours,anerecaracterise
 inin tat pits in te luencontour eteneeon te
stentarea traceelineate rote reconstructealuinal strut
suraces,altoustrutsappearetoeellapposetotevessel
all. rotruin struts ere oten present in raes an lesions
containinalapposestruts,anerereuentlsurroune
structures isplain a loer sinalintensit tan te rest o te
vesselall.enatureotesestructuresisnotnon,utor
poloicall te resele irin eposits tat separate alap
posestrutsrotevesselall,asseeninpreviouslpulise
istoloiaes.9,10
eoectivesotisstuere1toanalseterelationsip
eteentetpeostrutappositionatolloupanclinicalan
proceuralcaracteristicsatstentiplantation,an2toeaine
strutcoveraeasasurroateorstentealin, inrelationtostrut
apposition at olloup. e potesise tat protruin struts
roaioloicalpointovieaveoresiilarititalap
posestrutstanitapposestruts.
Methods
PATIENT POPULATION AND LESION CHARACTERISTICS AT 
STENT IMPLANTATION
eteenepteer2007anepteer2008, 35patientsere
eaine it  ater stent iplantation at our institution.
oseitiualitacuisitions,eineasanaeuate
visualisationo70otevesselallcircuerencetrouout
te stente area,ere selecte or tis stu. atientsit 
ereeclue.
Figure 1.








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mopolooalionatalinaiom
t oona anioam. a on t poti tat tain
lionaatitiatalinmainlnttappoitionin
t ot ano lontm,  it t olloin lion
aatitialiiation,onitotalolion3mont,
tom,nttotalolion3mont,iia2
m,itotoitananlation90.11minoi
tion,notnailiilontanioam,oinonn
tion it mot oona alloon ilatation12,  oni
anioapiall iil ition a iniiant13, an
potitattolinlntalinotl
all in t tnt an n a an impat on tnt tt
appoition. nioam  anal inpnntl  to
pinopatoolintotlinialpnta
tion. n t a o iamnt, a onn ianoi a
otainpatain.
OCT IMAGE ACQUISITION
 ima  ai it t2  tm ita
mainn.,to,,.pnntonlanatom,
oliononolitnitoiplaloo
inimain.tointtntitananioplati,
an oti  olion alloon att lio o a
na att oton intii, ati, ,  a
aanitalltottntmnt,antoonaia
anittmai.otolimto,
talloonattatatpoimalltottntmnt
antalloonainlatat0.5to0.7atmopinl.
otnonolimto,tnaattatat
into t i att. in ima aiition, oona loo
aiplamanalinionoalinoiipaoianol
320alta,inami,otolian
nonoli tp, ptil. otional ima 
aiat15.4am,inatomatpllaat1o2mm.
maaiitionapomnamonamimonitoin.
ltotnonoli tnimaimplalitli
intaoona p tan t oli tni, t potntial
anintimnionotlallantntalilto
popotional.  to am tat t oi o tni
olnotinlnttappoition.
OCT IMAGE ANALYSIS
otionitinttntmntanal1mm
 an pin o, o a lin to t linial an
anioapiaatiti.toanntimationotatal
tinotmtaltttinalit,allttti
nonttinamtointl9.a
on appoition, tt  ii into o la  appo
ttttolintotimoaianmalap
pottanpotintt,antli(Fig-
ure 1).9matialointtaaaoatotnt
alin, an t minimm tin a ma manall o
tt.
Statistical analysis
tatitialanaliapomittota,ion
15.0n.,iao,,.omalitotantitati
ataaaialtimationoialplot.ontino
ataapnttimiananintatilan,
anatoialaialapnta.iananni
ompaittannitnttaniat
tt,ptil.
planntoompaitpnoanotto
a,aniittinottoa,tni
ntttappoitionallaatpoolinttinoopan
atin o onon lat to tnt alin, naml tim
om tnt implantation to ollop14,15, linial pntation at
implantation118,iatmllit19,20,tnttp21,22,liontp17,18,
pipoal aatiti, tt tin an tnt in.23
totompliaialttooatatnttt
ntitinamntitinlion,tionanali
i a mltill mol. o, t itition o 
olnottanomtonomalit,ananonpaamtii
alnttatanatolantoaiat,inotaailal.nta,
mianotaiottappoitionaltpitin
paatlionitmalappoanopotinttal
lat,antinompaitailoonin
antt,paiattlionll.
otompaiononionotttn
appoitionaltp,aloitimltillionanalianot
poiltotomplatatt,ominitala
tilinmooaiatanatonotpopla
tion.o,pnttnionottp
tt appoitional tp. tail ain tt olin i
anotiaaaloon,tintapatopioloi
allintomotnonappottmalappoano
potintt,tlomtanali.
ntaopoiilitotlaiiationottappo
itionannonottaaallat
intappaoiint.totailpal0.05aoni
tatitialliniiantoallanal.
Results
STRUT APPOSITION AT FOLLOW-UP OCT IN RELATION TO 
CHARACTERISTICS AT STENT IMPLANTATION
ntit lion 32 tnt om 28 patint  anal.
itlionloatintltantioninat,iin
t lt imlat, an14 in t it oonaat.
tnt amin  ot  p 43, a it
21,naopint18,anapanlti
liniion,ota,ioi,analmaat3.a.
totalo507amontainin5,159ttanal.
4,907appott,20ttolinianotia,1malap
pott,an21potintt.inmalappoanpo
tinttotnointamlion,anolto
not  anal paatl, lion ii into to op
toitot op 1, n20, an toit op 2, n8 t
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ssisssis
 i i ss i  sis  s
sssisiiiii
ssiiis
ssi
 ii  isis   i s
ii s iTable 1is i
i isis  ii si isis
 ii  s  sis
iiisisisisisis
 i ss      siii
i     s   s
iiiisi s ss
siissi
sisisiss
ssiiiiississ
i  sisisss s
i sissis  ii  
iissiiii
is iissiii
ssiiiisiiissisi
iisiiiii
sissisii
  i   sissis   i
s

STRUT COVERAGE IN RELATION TO STRUT APPOSITION
Table 2ssisss
siiiissisisi
issss
        i s
Table 1. Clinical and procedural characteristics.
Lesions without malapposed 
and/or protruding struts
n = 20
%
Lesions with malapposed 
and/or protruding struts
n = 8
%
p-value
Patient characteristics
Age (years) 65 (60 to 73)* 64 (57 to 74)* 0.78
Male gender 75 50 0.37
Hypertension 75 63 0.65
Statin therapy 100 100 –
Diabetes mellitus 35 25 1.00
Smoker (current/former) 85 63 0.31
Family history of IHD 40 25 0.67
Clinical presentation
Patients with ACS 25 75 0.03
Angiographic lesion characteristics
Calcification 15 25 0.60
Chronic total occlusion (>3 months) 10 13 1.00
Thrombus 10 25 0.56
Recent total occlusion (<3 months) 15 25 0.60
Diffuse disease (>20 mm) 30 25 1.00
Excessive tortuosity/angulation >90º 5 0 1.00
Procedural and stent characteristics
Predilatation 85 100 0.54
Angiographic dissection 20 75 0.01
Implantation of DES 85 100 0.54
Stent struts >110 μm 65 75 1.00
Stent length (mm) 19 (12-31)* 22  (16-31)* 0.67
Stent overlap 10 0 1.00
Postdilatation 40 38 1.00
Maximal balloon diameter (mm) 3.0 (2.5-3.0)* 3.0 (3.0-3.5)* 0.20
Maximal balloon inflation pressure (atm) 16 (15-18)* 15 (14-17)* 0.50
* Median (IQR); IHD: ischaemic heart disease; ACS: acute coronary syndrome; PCI: percutaneous coronary intervention; DES: drug-eluting stent
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.
         

..

.
      

(Table 3).

..
.         
....
CLINICAL OUTCOMES
        

..

.


.


    
.
Discussion
        
 
       
      .  
     

.
       
   .   
      
.
EVALUATION AND IMPORTANCE OF STRUT APPOSITION 
FOR STENT HEALING
   
.

Table 2. Frequencies of uncovered struts and the thickness of strut coverage per strut type for lesions without- as compared to lesions 
with -malapposed and/or protruding struts.
Lesions without malapposed and/or protruding struts
n=20
Lesions with malapposed and/or protruding struts
n=8
N total struts
N (%) uncovered 
struts
TSC N total struts
N (%) uncovered 
struts
TSC, µm
Strut apposition
Apposed struts 3,442 16 (0.5) 160 (80-310) 1,465 98 (6.7) 110 (40-180)
SB struts 15   1 (6.7) 50 (20-90) 5 4 (80.0) –
Malapposed struts – 16 2 (12.5) 35 (15-50)
Protruding struts – 216 54 (25.0) 20 (5-30)
TSC: thickness of strut coverage (median [IQR]); SB struts: struts overlying side branch ostia
Table 3. Number of struts per strut type, and the thickness of the strut coverage (TSC) in lesions containing malapposed and/or protruding struts.
Lesion N
app
TSC
app
N
mal
TSC
mal
N
protr
TSC
protr
p-value for Mann-Whitney U-test
App vs. mal App vs. protr Mal vs. protr
61,2 91 210 (140-260) 1 50 1 20 
71 132 105 (45-170) 2 25 (20-30) 0.08
111,3 86 30 (20-50) 7 50 (20-60) 81 20 (0-30) 0.28 0.06 0.04
121,3 190 70 (40-110) 17 10 (0-20) <0.001
131,3 208 35 (20-80) 1 10 44 20 (10-30) <0.001
243 141 10 (0-30) 7 30 (0-40) 48 10 (0-20) 1.00 0.24 0.43
251,3 205 170 (70-270) 6 75 (20-130) 0.03
272,3 412 160 (130-200) 17 120 (100-130) <0.001
N
app
: number of apposed struts; app: well-apposed struts; mal: malapposed struts; protr: protruding struts; 1 denotes the presence of acute coronary syndrome; 2 denotes that the patient was 
diabetic; 3 denotes the occurrence of an angiographically visible dissection. The multiple comparison Mann-Whitney U-test was performed with a Bonferroni correction. The TSC shown is the 
median (IQR). In lesions where there was only one single strut per appositional type, this was excluded from the pair-wise analysis, because one single strut was not considered representative 
for a whole appositional group within the respective lesion. The type of stent and time point from implantation was: Lesion 6: Endeavor Sprint, 12 months; Lesion 7: Taxus Express, 51 months; 
Lesion 11: Cypher Select, 12 months; Lesion 12: Endeavor Sprint, 3 months; Lesion 13: Cypher Select, 20 months; Lesion 24: Cypher Select, 15 months; Lesion 25: Taxus Liberté , 21 months; 
Lesion 27: Cypher, 41 months.
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oossussylsso.10
soluoos,o,suoo
lllls,sso10.sololsuy
u sus    oo uo sus  oss
soyoooo.
ssololly,uosussuslo
ool ssuoosllul,soo
uslllsolllls.uso
oo ssu  us uo.24lou su o
oussy,soullyo
ullysusollyo,lou
ssussosslol
uyosys.25uoouosus
osssoous.u,
soulosololoouosuss
o,susososoo,sso
oosssoss.10osyluso
oouosusossso,us
oouoluso,lu1u
osusossso,soss
ousuyoouo23,10susossso2
uoosssos lu lyss
ouoslusoosssoss3
ooslooosssosousuy,sloss
sosullysy1osuo33oss
sos  s, s y sooloy, ylly 35
osssossslool,,sl
s.u lyss o su o soul
ouo.
ssuysoyoslssoou
suoolosousus,so
oossus.lousoloysus o
luosoooooysssl
sus,slyssoosuol
o o oso os o s o   o 
ously.4,17,18,2633ssyoloy,slollos
s ,    oso o  ou
sus.slyloylls,sus
ulysoouslllso.sou
 ooly  oll ,  osus 
oooo.14susso
sslll,soouslllsyoloou
o,lyoossus,
ssuy,oulyuoo
ossus.ools
o,loosoosslllys
suslyls.
CLINICAL AND ANGIOGRAPHIC LESION CHARACTERISTICS 
AT STENT IMPLANTATION
u s s sus   o ssos
ysosolosoususollo
u. l os  ly oos  l  l
sloso17,18,34,35,o,sso
ously  so o ou sus.  sl
osollousuy,soosslo
lu  los  ou sus 
uoss.  oo,ossl
ssoul  ossloso o
oso o sus o  ssl ll u o  s o
oooosllusouo
uso oososl susu
ososusssllluoloo
uulosoosolo
ss(Figure 2A)ooulosossoluo
oousslo.2
s   uy o  s lo 
slosousus
o, sooy  o
s o ous. s y  l y   
slloyuloolly,oo
lololusos.
oooulssosssososo
los  ou sus, ossl ss oul
ololosoososslll
sossososslososuol
loy oso sus  sslll o
uoususooulossus
ossslolluolousy
oouosslllsosuo
sso,usssllloos,
sulousoo(Figure 2B).ou
susylsssosoos
sususslolloyolos.
lsoosouslysussoll
susolsloso2,5,36,37.o,soluo
osolysuoslyousus,us
slulsusul
lsluoousoly1009,
ssoluoo.
THE FREQUENCY OF MALAPPOSITION COMPARED TO 
PREVIOUS STUDIES
 uy olos sus s o
slyousos,loyo
sus.uosu,olyouo
 u o ss  los sus.17,18,2630,33 o
ollusoull31ysslu
lsolossuosl
o.    o  os ollo lo,
olols75olsoss
loyol o25o lsos s
 usl  o sl     ls o
lossulooou.
lly,uolouysloo55s24
31ly looyss
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Strut apposition and healing by OCT    ■
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aaesaaasesrserere
ree  e are  Sr.  a e
raeessaeaseaasesrereaser
asees.3a33s.r
aSreseey.eresesyesss
ayeaasesrsa9essaasear
rrsrsaaea8ss
eesea.areerera
eaesreayerrsrsere
reree Sare S.33Tesesrser
eereayreesesreerease
y e  s aery srs a rre  e
ereaeaasress.sasare
eeraareSTLTrasesa
38essrseeraSsayesesrsa
year .38 eereess e rae  aaser
rsrs rerese yes erease
saaere eseesrerara
arerses.
CLINICAL IMPORTANCE OF MALAPPOSED AND PROTRUDING 
STRUTS
esererreeserssaaeaer
Teaa.eer  r aesere resre
aaaeeerayrse.areeeaaayss
ae se aas eaae y S as assae 
LST.39easeaasaes
LST as se    aes rey eae a e
sseaasaa
years.3e3aesLSTyeasreae
asrareaeeeeerere
reseerr.Seeraaserersesre
erreeLSTaersaaaee eray
rararras ssaas.
eeseresSeeesrerae
reaseasaseesseeaaeae
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Strut apposition and healing by OCT    ■
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CHAPTER 3 THE APPLICATION OF OPTICAL 
COHERENCE TOMOGRAPHY 
IN THE CLINICAL EVALUATION 
OF THE ACUTE EFFECTS AND 
VASCULAR REACTIONS TO 
METALLIC STENT IMPLANTATION
3.1 Coronary evaginations are 
associated with positive vessel 
remodelling and are nearly absent 
following implantation of newer-
generation drug-eluting stents: An 
optical coherence tomography and 
intravascular ultrasound study. 
Radu MD*, Räber L*, Kalesan B, Muramatsu T, 
Kelbæk H, Heo J, Jørgensen E, Helqvist S, Farooq V, 
Brugaletta S, Garcia-Garcia HM, Jüni P, Saunamäki 
K, Windecker W, Serruys PW. 
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Coronaryevaginations areassociatedwithpositive
vessel remodelling and are nearly absent following
implantation of newer-generation drug-eluting
stents: an optical coherence tomography and
intravascular ultrasound study
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Objectives The purpose of this study was to assess the occurrence, predictors, and mechanisms of optical coherence tomography
(OCT)-detected coronary evaginations following drug-eluting stent (DES) implantation.
Background Angiographic ectasias and aneurysms in stented segments have been associatedwith a risk of late stent thrombosis. Using
OCT, some stented segments show coronary evaginations reminiscent of ectasias.
Methods Evaginations were defined as outward bulges in the luminal contour between struts. They were considered major eva-
ginations (MEs) when extending≥3 mm along the vessel length, with a depth≥10% of the stent diameter. A total of 228
patientswhohad sirolimus (SES)-, paclitaxel-, biolimus-, everolimus (EES)-, or zotarolimus (ZES)-eluting stents implanted
in 254 lesions, were analysed after 1, 2, or 5 years; and serial assessment using OCT and intravascular ultrasound (IVUS)
was performed post-intervention and after 1 year in 42 patients.
Results Major evaginations occurred frequently at all time points in SES (�26%) and were rarely seen in EES (3%) and ZES (2%,
P ¼ 0.003). Sirolimus-eluting stent implantation was the strongest independent predictor of ME [adjusted OR (95% CI)
9.1 (1.1–77.4), P ¼ 0.008]. Malapposed and uncovered struts weremore common in lesions with vs. without ME (77 vs.
25%, P, 0.001 and 95 vs. 20%, P, 0.001, respectively) as was thrombus [49 vs. 14%, OR 7.3 (95% CI: 1.7–31.2),
P ¼ 0.007]. Post-intervention intra-stent dissection and protrusion of the vessel wall into the lumen were associated
with an increased risk of evagination at follow-up [OR (95% CI): 2.9 (1.8–4.9), P, 0.001 and 3.3 (1.6–6.9),
P ¼ 0.001, respectively]. In paired IVUS analyses, lesions with ME showed a larger increase in the external elastic
membrane area (20% area change) compared with lesions without ME (5% area change, P, 0.001).
Conclusion Optical coherence tomography-detected MEs are a specific morphological footprint of early-generation SES and are
nearly absent in newer-generation ZES and EES. Evaginations appear to be related to vessel injury at baseline; are asso-
ciated with positive vessel remodelling; and correlate with uncoverage, malapposition, and thrombus at follow-up.
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78  Chapter 3.1
Introduction
Early-generation drug-eluting stents (DESs) have been associated
with an increased risk of very late stent thrombosis (ST) due to
delayed arterial healing with evidence of prolonged inflammation,
resulting in incomplete endothelialization and acquired malapposi-
tion.1,2 Owing to an ultrahigh resolution (10 mm), optical coherence
tomography (OCT) allows an in vivo histology-like evaluation of
coronary arteries and implanted devices, including the identification
of uncovered and malapposed struts.3,4 Using OCT, it has been
observed that some stented segments show outward vessel
bulging—‘coronary evaginations’—of the luminal contour between
struts during the follow-up.5,6 Three-dimensional (3D) visualization of
these segments suggests an ectatic appearance of the vessel wall rem-
iniscent of that seen in angiographic ectasias and aneurysms, which
were previously shown to be associated with cardiovascular adverse
events.7,8 Although both drugs and polymers of DES have been sus-
pected as culprits for these changes, the specific mechanisms of the
luminal enlargement remain unknown and can only be determined
with serial invasive assessment. At present, there are no data on the
occurrence, predictors, and mechanisms of OCT-detected coronary
evaginations following implantation of early- and newer-generation
DES. The objectives of the present study were therefore to assess
evaginations using OCT at follow-up in a large cohort of patients; and
to investigate the underlying mechanism by serial investigations with
OCT and intravascular ultrasound (IVUS) in a subset of patients.
Methods
Study population
The pooled analysis included OCT acquisitions from the LEADERS-,
RESOLUTE-, and SIRTAX-LATE OCT substudies, and from the Copen-
hagen OCT registry, employing the following stents: Cypher Selectw
(Cordis, Johnson and Johnson, Warren, NJ, USA); Taxus Expressw
(Boston Scientific, Natick, MA, USA); Endeavor Resolutew (Medtronic,
Inc., Santa Rosa, CA, USA); Xience Vw (Abbott Vascular, Santa Clara,
CA, USA); and Biomatrixw (Biosensors, Inc., Newport Beach, CA, USA).
Thedesign andeligibility criteria forLEADERS-, RESOLUTE-, andSIRTAX-
LATEOCT substudies are described in detail elsewhere.6,9,10 TheCopen-
hagen OCT registry was a single-centre prospective non-randomized
evaluation of strut coverage and apposition at 12-month follow-up in rela-
tion to apposition at baseline, using the Cypher Selectw, Taxus Expressw,
and Endeavor Resolutew stents. Patients were eligible if they had ≥1
lesionwith.50% diameter stenosis in a native coronary artery, with a ref-
erence vessel diameter between 2.25 and 4.0 mm. Exclusion criteria were
ST-segment elevation myocardial infarction (MI), left ventricular ejection
fraction ,30%, renal insufficiency (creatinine .133 mmol/L), and lesion
location in the left main stem or bypass graft. Optical coherence tomog-
raphy and IVUS were performed after a satisfactory angiographic result,
defined as a residual diameter stenosis ,20% and thrombus in MI flow
grade3, and imagingwithbothmodalitieswas repeatedat 1-year follow-up.
A total of 56 consecutive patients were included at baseline out of which
eight withdrew consent for follow-up, and two were excluded due to
system failure or insufficient quality for analysis. Figure 1 shows an overview
of the number of patients, lesions, and stent types included in each cohort,
and the time point of OCT acquisition.
Out of the 46 patients with 48 lesions from the Copenhagen OCT
registry, 43 patients with 45 lesions were available with complete serial
OCT assessment at baseline and follow-up. Out of these, 40 patients
with 42 lesions had a serial IVUS assessment. All studies were conducted
in accordance with the Declaration of Helsinki and approved by the
ethical committees of the involved centres. All patients provided
written informed consent prior to the enrolment.
Optical coherence tomography and
intravascular ultrasound acquisitions
Optical coherence tomography-images were acquired with commercially
available time-domainM2andM3 systems; and the frequency-domainC7
system from LightLab/St Jude (Westford, MA, USA) at a frame rate of
15.6, 20, and 100 frames/s; and a pullback speed of 1, 3, and 10 mm/s;
with the M2, M3, and C7, respectively. Acquisition with occlusive (M2)
and non-occlusive (M3 and C7) techniques was described previously.11
Intravascular ultrasound images were acquired with the Atlantis SR Pro
40 MHz catheter and iLab system (Boston Scientific, Natick, MA, USA)
at a frame rate of 30 frames/s and pullback speed of 0.5 mm/s, according
Figure 1 Overview of the optical coherence tomography data used for the pooled analysis. FUP, follow-up; SES, sirolimus-eluting stent; PES,
paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent.
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to accepted standards. As for serial investigations, the same imaging
systems were used at baseline and follow-up.
Optical coherence tomography image analysis
The region of interest included the stented segments which were ana-
lysed systematically at 1 mm intervals according to corelab standards
(Cardialysis, BV, Rotterdam, The Netherlands). The methodology is
shown in Figure2A. The lumen- and stent areawere assessed aspreviously
reported.12 Malapposition was considered to be present when the
distance from the endoluminal strut border to the lumen contour
was larger than the sum of strut metal + polymer thickness, resulting
in cut-offs of ≥160 mm for Cypher, ≥160 mm for Taxus Express, ≥100
mm for Endeavor Resolute, ≥90 mm for Xience V, and ≥130 mm for
the Biomatrix stent.10,12,13 In case of malapposition, the incomplete
Figure 2 Overview of optical coherence tomography image analysis. (A) Frame-level analysis included the assessment of the stent area (blue-
broken trace) and lumen area (white trace). Evaginations were defined as bulges in the luminal contour between struts with a maximum depth
(white double-headed arrow) exceeding the actual strut thickness. Evagination areas were delineated by the stent contour towards the centre
of the lumen and the lumen contour in the opposite direction (broken trace along the luminal contour at 11 o’clock). Struts projecting into the
lumen without separation from the vessel wall were defined as protruding when the distance (yellow double-headed arrow) from the stent area
trace to a ‘lumen help line’ (yellow trace extrapolated between deepest point of evaginations and lumen contour) exceeded the actual strut thick-
ness. (B) A three-dimensional reconstruction of an evagination. Evaginations were considered major when extending ≥3 mm longitudinally, with a
depth≥10%of the stent diameter. Prolapse (C )wasdefined as convex-shaped tissue projecting into the lumenbetween strutswithout disruptionof
the luminal continuity, and registered only when the distance from the stent area trace (white-dotted line) to the maximum point of prolapse was
≥150 mm. Intra-stent dissections (D) were defined as disruptions of the luminal vessel contour within the stented segment, whereas tissue protru-
sion (E)wasdefinedas amasswith an irregular surface attached to the vesselwall or struts andprotruding into the lumen.Various features at baseline
(i.e. prolapse, intra-stent dissection, tissue protrusion, and malapposed struts) were cross-correlated with the presence of evaginations in matched
cross-sections at follow-up (F ).
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stent apposition (ISA) area was measured. Struts projecting into the
lumenwithout obvious separation from the vesselwall were labelled pro-
truding when the distance from the strut marker to a ‘lumen help line’
exceeded that of the actual strut thickness, using the same cut-offs as
for malapposition.5,6 The ‘lumen help line’ was drawn by extrapolating
a trace line between the deepest points in evagination/s and the luminal
vessel contour laterally. Struts within overlapped segments and those
overlying side branch ostia were excluded from the analysis. Struts
were considered uncovered if any part of the strut was visibly exposed
to the lumen, and covered if a layer of tissue was identified above the
struts.3
A coronary evagination (Figure 2A) was defined as the presence of an
outward bulge in the luminal vessel contour between apposed struts
with a maximum depth of the bulge exceeding that of the actual strut
thickness, as measured semi-automatically from the deepest point in
the bulge to the stent area trace using the thickness-ruler function.6
The same cut-offs as for malapposition were used. For each evagin-
ation, we assessed the evagination area defined as the area limited by
the stent contour towards the centre of the lumen and the lumen
contour in the opposite direction. Imaging of evaginations with both
time- and Fourier-domain OCT systems was performed in a few
cases, excluding any influence of OCT system on the appearance of
evaginations.
Evaginationsmay extend over several consecutive cross-sections, giving
the vessel an ectatic appearance by 3D reconstruction (Figure 2B). Thus,
evaginations can be characterized both at the 2D cross-sectional level,
and along the length of the stented segment. We assessed the presence
ofmajor evagination (ME), defined as theoccurrenceof cross-sectional eva-
gination in ≥3 adjacent frames (i.e. minimum 3 mm of length) with a
minimal evagination depth of 10% of the nominal stent diameter. Evagin-
ation areasof the various cross-sections belonging to aMEwere assumed
to be constant 0.5 mm proximal and distal to the analysed cross-section
in order to calculate evagination volumes for each 1 mm segment. If
evaginations were present in adjacent cross-sections, they were assumed
to be in a continuum, and their volumes were summed up to calculate
the totalevagination volume. In addition,weassessed thepresenceof throm-
bus defined as a mass ≥100 mm in diameter with an irregular surface
attached to the vessel wall or struts and protruding into the lumen.
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Table1 Baselinedemographics andbaselinepatient and lesion level predictorsofmajorevaginationsadjusted for time to
follow-up
Characteristics Entire cohort Major evagination at
follow-up
Crude OR (95% CI) P-value Adj OR (95% CI) P-value
n (%) Yes, n (%) No, n (%)
No. of patients 228 31 197
Age 60.0+10.4 59.2+11.0 60.2+10.3 1.00 (0.96–1.04) 1.00 1.00 (0.96–1.05) 0.89
Male gender 179 (78.5) 24 (77.2) 155 (78.7) 0.88 (0.35–2.26) 0.78 0.89 (0.33–2.41) 0.82
Hypertension 127 (55.7) 15 (48.4) 112 (56.9) 0.77 (0.35–1.69) 0.52
Hyperlipidaemia 153 (67.1) 20 (64.5) 133 (67.5) 0.87 (0.38–2.00) 0.74
Diabetes mellitus 44 (19.3) 4 (12.9) 40 (20.3) 0.58 (0.19–1.80) 0.35
Current/previous smoker 87 (38.2) 11 (35.5) 76 (38.6) 0.75 (0.33–1.71) 0.49
Previous MI 58 (25.7) 6 (19.4) 52 (26.7) 0.68 (0.26–1.82) 0.45
LVEF ≤50 42 (18.4) 12 (38.7) 30 (15.2) 3.20 (1.32–7.72) 0.01 2.71 (1.03–7.16) 0.044
STEMI 48 (21.1) 9 (29.0) 39 (19.8) 1.89 (0.74–4.82) 0.19 1.48 (0.49–4.44) 0.48
Stent type 0.0055 0.0084
EES (reference) 27 (11.8) 1 (3.2) 26 (13.2) Reference Reference
PES 55 (24.1) 4 (12.9) 51 (25.9) 2.06 (0.19–22.48) 1.96 (0.17–22.53)
BES 18 (7.9) 2 (6.5) 16 (8.1) 3.26 (0.27–39.38) 3.80 (0.31–46.61)
ZES 37 (16.2) 1 (3.2) 36 (18.3) 0.72 (0.04–12.08) 0.83 (0.05–14.01)
SES 91 (40.0) 23 (74.2) 68 (34.5) 8.84 (1.07–72.97) 9.05 (1.06–77.35)
Multivessel disease 23 (13.4) 3 (10.3) 20 (14.0) 0.61 (0.15–2.57) 0.51
No. of lesions 254 33 221
Target vessel 0.15
Left main (reference) 3 (1.2) 1 (3.1) 2 (0.9) Reference
LAD 101 (40.0) 7 (21.9) 94 (43.1) 0.16 (0.01–2.45) 0.19
Circumflex 57 (22.8) 7 (21.9) 50 (22.9) 0.20 (0.01–3.26) 0.26
RCA 88 (35.2) 17 (53.1) 71 (32.6) 0.47 (0.03–6.93) 0.58
Graft 1 (0.4) 0 (0) 1 (0.5) 0.16 (0.01–2.45) 0.19
Stent diametera 3.0+0.4 3.1+0.4 3.0+0.4 7.05 (0.42–119.3) 0.18
Total stented lengtha 21.6+13.9 22.6+10.4 21.4+14.3 1.00 (0.91–1.11) 0.96
Stents per lesiona 1.4+0.7 1.4+0.8 1.4+0.7 0.91 (0.07–11.12) 0.94
aExpressed as means+ SD.
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The Copenhagen OCT registry included OCT examinations at base-
line and 1-year follow-up. Cross-sections at baseline and follow-up
were matched on the basis of distance from stent borders and the pres-
ence of anatomical landmarks such as side branches. This allowed the fol-
lowing serial assessments at the cross-sectional level (Figure 2C–E):
At baseline, we assessed the presence of tissue prolapse, intra-stent
dissection and tissue protrusion. Tissue prolapse was defined as convex-
shaped tissue with a regular surface protruding into the lumen
between adjacent struts without disruption of the continuity of the
luminal vessel surface.14 The tissue was considered prolapsing only
when thedistance fromthe stent area trace to themaximumpointof pro-
lapse was ≥150 mm, chosen arbitrarily since some degree of prolapse
can be seen in most cross-sections. Intra-stent dissections were defined
as disruptions of the luminal vessel contour within the stented
segment, whereas tissue protrusionwas defined as amass with an irregular
surface attached to the vessel wall or struts and protruding into the
lumen. These features as well as the presence of ≥1 malapposed strut
were then correlated with the presence of evagination at the time of
serial follow-up, in matched cross-sections (Figure 2F).
Intravascular ultrasound image analysis
Intravascular ultrasoundpullbackswere analysedoff-line using theQCU-
CMS software (Medis, Leiden, TheNetherlands) at standard 1 mm inter-
vals, in the same region of interest as forOCT, following the international
consensus.15 Accordingly, we measured the lumen-, stent-, and external
elastic membrane area, the latter referred to as vessel area. The plaque
and media (P&M) area was calculated as (vessel area – stent area –
lumen area outside the stent), and the plaque burden as (P&M area/
vessel area) × 100. Positive vessel remodellingwasdefined as an increase
in the vessel area from baseline to follow-up.
Statistical analysis
We used Bayesian hierarchical random-effects model based on Markov
chain Monte–Carlo simulation methods16 with non-informative priors,
to compare OCT features such as strut malapposition, protrusion, and
coverage between lesions with ME and lesions without. The model
included random-effects at the level of cross-sections and lesions,
accounting for the correlation of characteristics of cross-sections
within lesions, and assigning analytical weights to each lesion depending
on the number of struts or cross-sections observed per lesion. Continu-
ous characteristicsof lesions suchas lumenareaand stent areawerecom-
pared between lesions with vs. without ME using frequentist mixed
maximum-likelihood regression models with study cohort, type of
stent, patient, and/or lesion as random intercepts. Means and standard
deviations were estimated from predicted values. To determine the
association of characteristics of lesions and patients at baseline with the
presence or absence of ME at follow-up, we usedmixedmaximum logis-
tic regressionmodels adjusted for time to follow-up (1, 2, or 5 years)with
study cohort, type of stent and lesion specified as random intercepts. The
same model was used to analyse stent and lumen area over time as
assessed with OCT and IVUS in the Copenhagen OCT registry. Mixed
maximum logistic regression models with type of stent, patient, and
lesion as random intercepts were used to assess the association of the
baseline cross-sectionalOCT features intra-stentdissection, strutmalap-
position, tissue protrusion, and prolapsewith cross-sectional evagination
at follow-up,with univariable andmultivariablemutual adjustments for all
four features. Statistical analyses were performed using WinBUGS
version 1.4.3 (Imperial College and MRC, UK) and Stata, version 11.0
(StataCorp, College Station, TX, USA).
Results
Incidence and extent of evaginations
A total of 228 patients with 254 lesions containing 5843 frames with
58 967 struts were included in the analysis (Figure 1). Overall, 75.8%
of patients were male and 19.3% had diabetes (Table 1). The clinical
setting at stent implantation was STEMI in 21.1% of cases, and 40.0%
ofpatients receivedaSES.Overall, amedian (IQR)of19(15–26)cross-
sections and 183 (140–273) struts were analysed per lesion. Out of
254 lesions, 152 (59.8%) had at least one cross-section with evagin-
ation, and 33 (13.0%) lesions contained at least one ME. Out of the
33 lesions with ME, 23 had a SES implanted, four a PES, four a BES,
one a ZES, and one an EES. The frequency of cross-sectional and ME
according to stent type and time point of implantation are shown in
Table 2. Both ‘any’ cross-sectional and ME were more frequent in
the SES group when compared with the PES-, ZES-, and EES-groups.
The frequency of MEwas low for lesions treated with ZES and EES at
1 year, and PES at 5 years.
Table 3 shows themean evagination- and ISAvolumes per lesion in
lesions with any cross-sectional evagination and lesions with ME
according to stent type and time since implantation. Evagination
volumes were consistently larger for the SES group when compared
with the other stents. Incomplete stent apposition volumes were
similarly larger in SES at 2 and 5 years. Evaluating SES alone, there
was a trend for an increase in ISA volumes from 1 to 2 to 5 years
(all lesions: P ¼ 0.024; lesions with any cross-sectional evagination:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Occurrence of cross-sectional and major evaginations stratified by stent type and time to follow-up
Lesions SES PES BES ZES EES P-value
No. of lesions with any evagination/total no. of lesions (%)
Year 1 22 /31 (71) 4 /8 (50) 25 /43 (58) 13 /35 (37) 0.045
Year 2 16/22 (73) 15 /27 (56) 0.25
Year 5 29 /41 (71) 28/47 (60) 0.37
No. of lesions with major evagination/total no. of lesions (%)
Year 1 8/31 (26) 1 /8 (13) 1 /43 (2) 1 /35 (3) 0.003
Year 2 4/22 (18) 4 /27 (15) 1.00
Year 5 11/41 (27) 3/47 (6) 0.02
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P ¼ 0.016; lesions with ME: P ¼ 0.14). The average depths and
lengths of cross-sectional and ME are presented in the appendix.
Predictors of major evaginations
Table 1 presents patient and lesion characteristics and their associ-
ation with ME. The indication for stent implantation was STEMI in
29.0% of patients with and 19.8% of patients without ME (P ¼
0.19). Left ventricular ejection fraction ≤50% was more frequent in
patients with compared with those without ME, and the use of SES
emerged as an independent predictor for the presence of ME.
Pooled optical coherence tomography
analysis
The quantitative results of the OCT analysis at the time of follow-up
are shown inTable 4.Minimal and average lumen and stent areaswere
larger in lesions with when compared with those without ME.
Malapposed, protruding, and uncovered struts were more
common in lesions with than without ME, and found in 77.2 vs.
24.9% (P, 0.001), 97.0 vs. 82.1% (P, 0.001), and 94.6 vs. 20.1%
(P, 0.001) lesions, respectively. Similarly, the proportion of
lesionswith≥10%malapposed and uncovered strutswas significant-
ly larger in the ME group. The average (means+ SD) thickness of
strut coverage was smaller in lesions with MEs compared with
those without this feature [0.11+0.29 vs. 0.14+ 0.23 mm; differ-
ence (95%CI):20.03 (20.06 to20.004)mm,P ¼ 0.022].At follow-
up, thrombus was more frequent in lesions with ‘any’ evagination
[28.0 vs. 5.9%, OR (95% CI): 6.1 (2.0–17.1), P ¼ 0.001] as well as
ME [48.5 vs. 14.0%, OR (95% CI): 7.3 (1.7–31.5), P ¼ 0.007].
Serial optical coherence tomography
and intravascular ultrasound analyses
Quantitative serial OCT results are shown in Table 5. All lesions with
ME were implanted with SES. The stent and lumen areas were larger
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table3 Evaginationand incomplete stentapposition volumes at the lesion level in lesionwith anyandmajorevaginations
by stent type and time to follow-up
SES PES BES ZES EES P-value
At Year 1
Lesions with any evagination
EV 2.24+1.68 (22) 0.50+0.72 (4) 0.38+1.79 (25) 0.42+1.29 (13) 0.002
ISAV 0.20+2.12 (22) 3.00+0.90 (4) 0.76+2.25 (25) 2.20+1.63 (13) 0.30
Lesions with ME
EV 24.20+1.77 (8) 5.31+0.59 (1) 4.42+0.59 (1) 10.28+0.59 (1) 0.39
ISAV 0.54+1.64 (8) 12.10+0.58 (1) 0.26+0.58 (1) 6.23+0.58 (1) ,0.001
All lesions
ISAV 0.14+1.80 (31) 1.51+0.92 (8) 0.57+2.12 (43) 0.92+1.92 (35) 0.17
At Year 2
Lesions with any evagination
EV 2.47+2.52 (16) 0.57+2.44 (15) 0.03
ISAV 1.54+3.32 (16) 0.19+3.21 (15) 0.24
Lesions with ME
EV 30.40+1.30 (4) 4.08+1.19 (4) 0.01
ISAV 5.22+5.15 (4) 0.79+5.15 (4) 0.21
All lesions
ISAV 1.34+2.69 (22) 0.12+2.98 (27) 0.12
At Year 5
Lesions with any evagination
EV 2.54+1.58 (29) 0.72+1.55 (28) ,0.001
ISAV 3.81+6.69 (29) 1.42+6.57 (28) 0.10
Lesions with ME
EV 11.80+0.59 (11) 4.40+0.25 (3) 0.008
ISAV 7.47+13.52 (11) 1.91+7.06 (3) 0.41
All lesions
ISAV 2.72+5.49 (41) 1.04+5.88 (47) 0.09
ME, major evagination; EV, evagination volume; ISAV, incomplete stent apposition volume. Volumes are expressed as means+ SD (no. of lesions) mm3 and predicted from
maximum-likelihood models.
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in lesions with when compared with those without ME at both
baseline and follow-up, with a significant change in the lumen area
at follow-up in both groups [increase in the lumen area in lesions
with ME (P ¼ 0.01), and decrease in the lumen area in lesions
without ME (P, 0.001)]. The change in the stent area from baseline
to follow-up within the ME group was not significant (P ¼ 0.15).
Table 6 shows the association of OCT characteristics recorded at
baseline with cross-sectional evagination at follow-up in matched
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Table 4 Results of follow-up optical coherence tomography analysis
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Lesions analysed, n 33 221
Frames analysed, n 804 5039
Struts analysed, n 8385 50,582
Lumen area, mm2a 8.34+5.90 6.44+2.50 1.90 (1.08–2.72) ,0.001
Minimal lumen area, mm2a 5.99+5.60 4.88+2.20 1.12 (0.34–1.89) 0.005
Stent area, mm2a 8.50+6.10 7.37+3.00 1.13 (0.33–1.93) 0.006
Minimal stent area, mm2a 6.71+6.40 5.88+3.70 0.83 (0.03–1.62) 0.04
Strut type, % (95% CrI)
Malapposed strutsb
Malapposed struts per lesion 1.07 (0.41–2.62) 0.11 (0.06–0.17) 0.96 (0.31–2.52) ,0.001
Lesions with ≥1 77.20 (52.80–92.80) 24.9 (15.40–34.90) 51.80 (25.40–72.60) ,0.001
Lesions with ≥10% 5.53 (0.86–19.30) 0.18 (0.02–1.19) 5.24 (0.70–18.90) 0.001
Protruding strutsb
Protruding struts per lesion 3.04 (1.52–5.87) 0.11 (0.06–0.17) 2.92 (1.42–5.77) ,0.001
Lesions with ≥1 97.00 (86.70–99.60) 82.1 (72.30–89.60) 14.30 (4.04–23.80) 0.01
Lesions with ≥10% 9.34 (2.03–27.10) 4.93 (1.93–10.80) 4.09 (-3.42–21.20) 0.37
Uncovered strutsb
Uncovered struts per lesion 3.82 (2.12–6.82) 1.39 (1.06–1.79) 2.43 (0.70–5.46) 0.002
Lesions with ≥1 94.60 (81.00–99.10) 20.10 (11.40–30.00) 74.00 (56.00–85.80) ,0.001
Lesions with ≥10% 5.59 (0.85–19.30) ,0.01 (,0.01–0.16) 5.57 (0.84–19.30) ,0.001
Lumen and stent areas are expressed as means+ SD.
CrI, credibility interval.
aUsing traditional mixed maximum-likelihood model.
bUsing Bayesian hierarchical 2-level logistic regression model.
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Table 5 Quantitative serial optical coherence tomography results of the stented segment
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Patients analysed, n 8 35
Lesions analysed, n 8 37
Frames analysed, n 154 705
SA BL, mm2 8.60+1.42 7.14+1.22 1.84 (0.32–3.37) 0.02
SA FUP, mm2 9.21+1.59 7.33+1.36 2.28 (0.57–3.98) 0.009
SA change, mm2 0.61+0.29 0.20+0.24 0.43 (-0.02–0.88) 0.06
LA BL, mm2 8.85+1.11 7.30+0.92 1.89 (0.45–3.33) 0.01
LA FUP, mm2 9.03+1.22 6.29+1.01 2.89 (1.27–4.52) ,0.001
LA change, mm2 0.17+0.66 21.00+0.59 0.99 (0.29–1.69) 0.006
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; BL, baseline; FUP, follow-up.
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cross-sections. In both uni- andmultivariable analyses, intra-stent dis-
sections, and tissue protrusions at baseline were associated with
cross-sectional evagination at follow-up: the odds of evagination at
follow-up were increased by about three in the presence of either
dissection or tissue protrusion at baseline.
The corresponding serial IVUS analyses are summarized in Table 7.
At baseline, the vessel area was larger among lesions with ME. Serial
IVUS analysis showed a larger increase in the vessel area and positive
remodelling in lesions with ME when compared with those without
(21.1 vs. 4.6%, P, 0.001), mainly driven by an increase in the P&M
area and accompanied by an increase in the lumen area. Again, the
stent area appeared to increase between baseline and follow-up in
lesions with ME (P ¼ 0.84), but not in lesions without [difference in
change between groups (95% CI): 0.43 (0.01–0.85) mm2, P ¼ 0.04].
Discussion
The present study shows that OCT-detected MEs are specifically
related to early-generation SES, and much smaller and in general
less frequent in newer-generation DES. The mechanism underlying
the pathogenesis of ME was suggestively a positive remodelling.
Signs of injury documented immediately after stent implantation
were associated with an increased risk of evagination at follow-up.
Positive remodelling as acauseof coronary
evagination
Coronary artery ectasias and aneurysms following DES implantation
have generated great interest owing to their associationwith ST.7,8,17
These vessel distensions have often been accompanied by ISA, sug-
gesting positive remodelling as the underlying pathomechanism,
since regional vessel remodelling was previously identified as a cause
of late acquired stent malapposition (LASM).7,17,18 In the present
study, we took advantage of information obtained by OCT on depth,
cross-sectional area, and longitudinal extent, to assess evaginations in
three dimensions. The association between positive remodelling and
ME suggests that positive remodelling is the mechanism underlying
the pathogenesis of evaginations.
We observed that ME in general occurred more frequently and
appeared to be larger in SES, suggesting these to be a specific
morphological footprint of these early-generation DES. Conversely,
MEs were less frequent in PES compared with SES at 5 years—a dif-
ferencewhich is confirmatory of the SIRTAX-LATEOCT study. At 1
year, MEs were less frequent in PES compared with SES but were
almost absent in newer-generation ZES and EES. No difference,
however, was observed between SES and BES at 2 years—something
that needs to be interpreted in light of a relatively low sample size of
only 18 SES and 18 BES patients at 2 years of follow-up. (Accordingly,
it cannot be excluded that this finding could bedue to chance.Never-
theless, assessment of evagination volumes showed that these were
significantly larger for SES compared with BES, thus being in line with
the findings in the other subgroups, particularly the SES vs. ZES and
EES, where the sample size was also relatively low.) In a meta-analysis,
Hassan et al.19 reported similar findings in terms of IVUS-detected
LASM, which were also accompanied by positive vessel remodelling,
with the highest incidence in SES followed by PES, and newer-
generationZESandEES.These similarities, togetherwith theobserved
association of MEwith malapposed, protruding, and uncovered struts,
suggest that these features may be part of the same disease entity.
Pre-clinical and human autopsy studies previously demonstrated
that the inflammatory response following DES implantation strongly
relates to the type of stent: SES typically induces granulomatous
inflammation with macrophages, giant cells, lymphocytes, and eosi-
nophils; PES exhibits extensive fibrin deposition and medial smooth
muscle cell necrosis; ZES and EES show only low levels of inflam-
mation and fibrin deposition.1,20–22 In addition, SES has been asso-
ciated with marked adventitial inflammation and fibrosis—findings
associated with positive remodelling.20,23 These results are in line
with observations of aneurysmal vessel dilation, stent malapposition,
and generalized eosinophilic vasculitis in a case of late ST in a patient
with SES.24 Similarly, the extent of vascular remodelling predomin-
antly after SES implantation correlated with the number of eosino-
phils harvested from thrombus aspirates in patients with very late
ST,25 supporting the notion that OCT-detected ME represent a
pathological vascular reaction particularly related to this stent.
If evaginations and protruding struts are precursors of ISA, a
stretch in the P&M may occur during the vessel expansion before
complete detachment from the stent. Interestingly, we observed a
trend towards a decrease in the size of ME from 1 and 2 to 5-year
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Assessment of the correlation of baseline optical coherence tomography features and evaginations, inmatched
cross-sections
Evagination at
follow-up
Crude OR (95% CI) P-value Multivariable OR (95% CI) P-value
Yes No
No. of frames at follow-up 128 713
Characteristics of cross-section at baseline
Intra-stent dissection, n (%) 60 (46.9) 159 (21.8) 3.01 (1.81–5.00) ,0.001 2.93 (1.75–4.89) ,0.001
Malapposed strut, n (%) 12 (9.4) 35 (4.8) 1.76 (0.77–4.03) 0.18 1.69 (0.72–3.99) 0.23
Tissue protrusions, n (%) 27 (21.1) 73 (10.0) 3.27 (1.59–6.70) 0.001 3.34 (1.61–6.93) 0.001
Prolapse, n (%) 26 (20.3) 162 (22.2) 1.04 (0.57–1.90) 0.90 1.06 (0.57–1.99) 0.85
Using mixed logistic regression with stent type, patient, and lesion as random intercept.
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follow-up among SES-stented segments, while there was a trend
towards an increase in ISA volume, suggesting that evaginations
may transition into ISA. Regarding the large ISA volumes at 1 year
in the two cases of PES and ZES with ME; the ISA in the PES repre-
sented persistent malapposition, whereas the ISA in ZES was
located in the proximity of a large bifurcation and thus likely
present at baseline.
The unexpected finding of a larger stent area only in lesions with
ME, which was consistent across the pooled analysis as well as
the serial independent evaluation with OCT and IVUS, may either
be related to the vessel expansion before detachment or due to
chance. It is unlikely that a more intense use of nitroglycerine or po-
tentially higher flush rate during OCT acquisition at follow-up when
compared with baseline could have induced these findings only in
lesions with ME.
Mechanisms of vessel remodelling
The SES-specific remodelling pattern may be triggered by the
polymer rather than the drug. Evidence in favour of this hypothesis
is thepresenceof a focal giant cell reaction surroundingpolymer rem-
nants separated from the stent struts,24 together with observations
that durable-polymer SES when compared with polymer-free SES
and bare-metal stents are associated with a larger external elastic
membrane area.23 Considering that 80% of sirolimus is released
from durable-polymer SES within the first 4 weeks, it seems unlikely
that sirolimus itself induces long-term alterations of the vessel wall
such as the ME detected up to 5 years in the present study.
The specific mechanisms by which polymers may induce positive
remodelling in casesof coronaryaneurysms andLASMremain specu-
lative. In relation to SES, it is known that methacrylate may exert a
toxic effect on endothelial cells and leucocytes, and can modulate
pro-coagulant activities of monocytes.26 Exposure to the poly-n-
butyl-methacrylate polymer can furthermore cause delayed (type
IV) hypersensitivity reactions mediated at least in part by accumu-
lated CD4 T-helper cells secreting interleukin (IL)-4 and IL-13.24
Ofnote, IL-13wasassociatedwith increased smoothmuscle cell con-
tractility in asthma,27 andcan inducealveolar remodelling andemphy-
sema inmice via induction of matrixmetalloproteinase (MMP)-9 and
MMP-12.28 Both these MMPs were identified as important factors in
the development of abdominal aortic aneurysms in humans by deg-
radation of elastin.29 At the same time, MMP-12 has been found to
be amediatorof the accumulationofmacrophages and eosinophils.28
Similar pathwaysmay be responsible for the remodelling and eosino-
philia observed in SES-treated coronary arteries. However, then
remains the question why not all patients develop this finding.
To further address this, we compared OCT findings following
stent implantation with the presence of evaginations at follow-up in
corresponding cross-sections. Accordingly, our study demonstrated
that cross-sections exhibiting intra-stent dissections and tissue pro-
trusions at baseline—both representing markers of injury—were
associated with an increased risk of evagination at the time of OCT
follow-up. (Of note, tissue protrusionswere defined as tissue projec-
tions with irregular lumen contour and thereby suggestive of either
thrombus or tissue disruptions other than intra-stent dissections,
whereas tissue prolapses were characterized by an intact lumen
contour, suggestive of prolapsing plaque.) This relationship is sup-
ported by previous observations relating OCT-detected evagina-
tions and coronary artery aneurysms with vessel wall dissections
and deep arterial injury caused by oversized balloons, stents,
and atherectomy.5,30,31 Nevertheless, considering that intra-stent
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Table 7 Quantitative serial intravascular ultrasound results of the stented segment
Major evagination at follow-up Diff (95% CI) P-value
Yes No
SA BL, mm2 8.67+1.94 7.61+1.62 1.31 (20.43 to 3.05) 0.14
SA FUP, mm2 9.18+2.03 7.67+1.68 1.76 (20.09 to 3.60) 0.06
SA change, mm2 0.50+0.31 0.06+0.24 0.43 (0.01 to 0.85) 0.04
LA BL, mm2 8.67+1.92 7.59+1.61 1.33 (20.39 to 3.06) 0.13
LA FUP, mm2 9.28+2.00 7.37+1.63 2.10 (0.24 to 3.97) 0.03
LA change, mm2 0.59+0.40 20.22+0.33 0.75 (0.22 to 1.28) 0.006
VA BL, mm2 16.53+2.63 13.78+1.99 3.44 (0.62 to 6.25) 0.02
VA FUP, mm2 20.06+3.44 14.41+2.76 6.29 (3.00 to 9.59) ,0.001
VA change, mm2 3.51+1.19 0.63+1.00 2.84 (1.71 to 3.98) ,0.001
P&M area BL, mm2 7.86+1.79 6.14+1.56 2.11 (0.52 to 3.70) 0.009
P&M area FUP, mm2 10.78+2.36 7.02+2.06 4.17 (2.08 to 6.27) ,0.001
P&M area change, mm2 2.89+0.92 0.87+0.76 2.06 (1.11 to 3.00) ,0.001
PB BL, % 46.82+4.02 44.36+2.95 3.02 (22.65 to 8.70) 0.30
PB FUP, % 52.78+4.36 48.46+3.15 5.26 (20.93 to 11.46) 0.10
PB change, % 5.90+1.98 3.95+1.72 2.21 (20.08 to 4.49) 0.06
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; VA, vessel area; P&M, plaque and media; PB, plaque burden; BL, baseline; FUP, follow-up.
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dissections were present in 27%, 15%, and 31% of cross-sections in
SES, PES and ZES, respectively, it may be argued that the influence
of stent type, as compared to that of vessel injury, is relatively
greater on the development of ME, which in the serially studied
lesions were all present in segments implanted with SES. Although
the depth of intra-stent dissections could not be systematically
assessed due to the limited tissue penetration of OCT, we did
observe 12 cases of evaginations following intra-stent dissections
extending into the media and adventitia (Figure 3).
Potential clinical relevance of coronary
evaginations
Features associated with very late ST include uncovered struts, late
malapposition, positive remodelling, chronic inflammation as well
as ectasias and aneurysms.1,2,7,8,17,25,32We found nearly all these fea-
tures to bemore common in lesionswithME, suggesting thatMEmay
be part of the same pathophysiological entity commonly recognized
as inappropriatehealing followingDES implantation, proposing apos-
sible linkwith late ST.Moreover, our finding of a greater frequency of
thrombus in lesions with ‘any’ andMEsmay be an expression of a po-
tential thrombogenicity of these lesions compared with those
without evaginations. Although our pooled study sample included
one of the largest OCT cohorts to date, it was too small for a mean-
ingful evaluation of such a relationship, however, two of the patients
withME fromtheSIRTAX-LATEcohort experiencedvery lateSTat5
and 12 months following 5-year OCT follow-up. Both of these oc-
curred in SES which had some of the most extensive evagination-
and ISA volumes in the entire cohort.6 Along the same line,
Alfonso et al.7 described that among patients with angiographic
Figure 3 Co-location of intra-stent dissections post-PCI and evaginations at follow-up. (A–C) Three cross-sections obtained at corresponding
sites before (A1–C1), immediately after (A2–C2), and at 1 year (A3–C3) following stent implantation. The large side-branch (*) in (A1)–(A3) confirms
a goodmatching, as does the pericardial space (†) and evidence of trilaminar vessel structure (i, intima;m,media; a, adventitia) in (B1)–(B3) and (C1)–
(C3). In (B2) and (C2), a large intra-stent dissection extends from 10 to 1 o’clock (white arrows), exposing the underlying adventitia, and a small dis-
section is seen at 6 o’clock (white arrow). Of note, evaginations (e) are clearly seen at the corresponding sites at follow-up in (B3) and (C3). The upper
middlepanel showsa schematicoverviewof the locationof intra-stentdissectionatbaselineandevaginationat follow-upwithinmatched frames. (D)An
endoscopic three-dimensional view of the vessel in question, where evaginations (e) create an irregular luminal surface. The optical coherence tom-
ography-catheter (Cx) is located to the leftof the ‘pointof view’. (E)Aperpendicular viewof theevagination in (B3) and (C3) at 10o’clock (whitee in (E)),
which in the three-dimensional reconstruction is separated fromanother evagination (black e in (E)) along the vessel segment by a strut (white arrow).
The evagination at 12 o’clock in (C3) is hidden behind the optical coherence tomography-catheter (Cx) in (E).
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coronary artery aneurysms, subsequent ST correlated with a larger
vessel and lumen volume by IVUS at the time of imaging. Similarly,
Imai et al.8 observed an increased risk of ST and target lesion revascu-
larization in SES with ectasias measuring ≥20% of the stent diameter
and extending longitudinally at least the length of the stent diameter,
corresponding to an ectasia depth and length of 0.6 mm and 3 mm in
a 3 mm stent, respectively—a similar length but twice the depth of
the ME definition used in our study. These data suggest that the
extent of evagination matters and that clarification of the natural
history of evaginations as well as the relationship between the
degree of evagination and clinical events merits consideration.
Although first-generation SES are no longer manufactured, they
have been implanted in a considerable number of patients world-
wide. Recent data from a registry of .12 000 patients, and a
meta-analysis including 49 trials, suggest that treatment with newer-
generation EES is associated with a lower risk of very late ST when
compared with early-generation SES and PES,33,34 which are add-
itionally associated with a continued risk of very late ST when com-
pared with EES. In this context, it is interesting that the occurrence
of evaginations, malapposition, and uncoverage by OCT in the
present study, aswell as the incidenceof IVUS-detectedLASM inpre-
vious studies,19 follow a similar pattern. Our findings therefore
suggest that evaginations detected with high-resolution OCT may
be predictors of late ST particularly in SES, and alongside malapposi-
tion and uncoverage provide a possible explanation for differences
in late adverse ischaemic events in early- compared with newer-
generation DES. Conversely, PES when compared with SES
showed fewer ME and only a modest increase when compared
with newer-generation DES. Although clinical rates of ST have
been comparable between SES and PES, the trigger leading to throm-
bosis appears to differ21 in view of substantial differences in the fre-
quency of evaginations. Studies assessing clinical outcomes with
OCT and IVUS—particularly with serial imaging—are demanding
to perform due to the relatively complex and costly set-ups and
the large number of patients required. In view of this, the present
study, although relatively small with the 254 imaged lesions, provides
important new insights into the utility of OCT for assessing vascular
reactions following stent implantation, and suggests that this technol-
ogy can identify features specific for different stents, which may be
useful for improving the prediction of events in the future.
Limitations
The following shortcomings must be considered when interpreting
the results of the present study. First, we pooled data from four sep-
arate cohortswith different time to follow-up, outofwhichone came
from a non-randomized registry. Efforts were made to adjust for
these issuesby using frequentist andBayesianmixedmodels account-
ing for the clustered nature of data. Secondly, we did not assess the
type of malapposition at follow-up primarily as our focus was on eva-
ginations, and since the relationship between acquiredmalapposition
and positive remodelling has already been shown.18 Considering that
positive remodelling is a common denominator of evaginations and
LASM, it seems reasonable to assume that the majority of malap-
posed struts at follow-up within lesions with ME were late acquired,
particularly since there was no correlation between malapposed
struts at baseline and ME at follow-up. Thirdly, we extrapolated
cross-sectional evagination areas 0.5 mm proximal and distal to the
frame of interest to estimate the volume of ME, which may both
over- and underestimate the size. Separate evaluation of cross-
sectional and ME does however not affect the results of the relative
occurrence and predictors of evaginations. Whether this is also
true for the mechanisms is unknown since serial IVUSwas only avail-
able for one of the cohorts. In this regard, it cannot be discarded that
evaginations at 2 and 5 years may be caused by mechanisms other
than remodelling as observed at 1 year. Furthermore, OCT cross-
sections were analysed at 1 mm intervals, although the highest sam-
pling density with commercially available new-generation OCT is
0.2 mm. This could potentially give inaccurate estimates of the occur-
rence and size of cross-sectional and ME. Considering that gold-
standard histology typically evaluates entire lesions based on three to
five cross-sections—remarkably lower compared with the average
19 cross-sections per lesion assessed in our study—we chose to
accept this level of accuracy, as well as the potential imprecision in
the selection of corresponding cross-sections at baseline and
follow-up, which is inevitably present whenever serial evaluations are
performed. Also, although care was taken to obtain as accurate mea-
surements of evagination- and ISA-volumes as possible, the inherent
risk of multiplication of small measurement errors cannot be excluded.
Finally, even though this study is one of the largest OCT studies
to date, the small number of lesions with MEs, especially in the
ZES and EES groups at 1 year, nonetheless limits the power of
the study.
Conclusion
Optical coherence tomography-detected MEs are a specific mor-
phological footprint of early-generation SES and are nearly absent
in newer-generation ZES and EES. Optical coherence tomography
detected intra-stent dissections and tissue protrusions at baseline
are associated with an increased risk of evaginations at follow-up.
The mechanism underlying the pathogenesis of ME is suggestively a
positive remodelling.
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Appendix
Addendum to the methodology
and results
Optical coherence tomography and
intravascular ultrasound image analysis
The lumen area (LA) was measured using the automatic area trace
function. Stent struts were defined as signal-intense spots with
dorsal shadowing and a marker was placed at the endoluminal
leading edge of the strut, in the mid-point of its axis. The stent area
(SA) was measured by connecting the strut markers with a trace
line. Strut appositionwas assessed for each strut by measuring the dis-
tance fromthe strutmarker to the lumencontour semi-automatically
using the thickness-ruler function.
For the LEADERS and RESOLUTE trials, lumen and stent area
measurements, strut apposition, and strut coverage were assessed
by corelab analysts (Cardialysis) blinded to stent type andclinical out-
comes. The OCT analyses of the SIRTAX-LATE OCT substudy, the
Copenhagen OCT registry, and the assessment of evaginations and
protruding struts in all studies were performed by two observers.
In case of disagreement, a referee was consulted to a final decision.
The time-consuming assessment of evaginations in the LEADERS,
RESOLUTE, and Copenhagen cohorts were performed un-blinded,
as blinding would have implied a detailed assessment of evaginations
using the cut-off of the thinnest stent (Xience, 90 mm or Resolute,
100 mm), and thus the assessment of a large number of bulges in
the thicker stents which would, following un-blinding, not fulfil the
definition of evagination. Assessments of OCT cross-sections at
baseline and follow-up were performed independently, without
knowledge of the characteristics of matched cross-sections. The
same methodology was used throughout all four OCT studies.
Intravascular ultrasound analyses were performed by two obser-
vers, and in case of disagreement a referee was consulted to reach
a final decision. Baseline IVUS assessment was performed independ-
ently of the follow-up evaluation, and without knowledge of the
results of the OCT analysis.
Details of the Bayesian approach
The proportions of malapposed, protruding, and uncovered struts
per lesion were analysed using a model with Bernoulli distribution,
while the proportions of lesions with ≥1 and ≥10% malapposed,
protruding, and uncovered struts were analysed using Bayesian hier-
archical random-effectsmodelwith logit distribution. Estimateswere
derived fromthemedianof theposterior distributionof the50 001 to
150 000 iteration, with the initial 50 000 iterations discarded as
‘burn-in’. We derived 95% credibility intervals (95% CrI) from the
2.5th and 97.5th percentiles of the posterior distribution, also calcu-
lating two-sidedP-values fromtheposteriordistribution. 95%CrI and
P-values from posterior distributions can be interpreted similarly to
conventional 95% confidence intervals and P-values.
Additional details on the evagination size
The average depths and lengths of cross-sectional and ME are pre-
sented in the appendix table 1 and 2.
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Appendix table 1 Specification of the volume, depth and number of cross-sections spanned for “any” cross-sectional
evaginations, by stent type and time to FUP
SES PES BES ZES EES p
At Year 1
Lesions with any evagination N 22 4 25 13
EV 2.24+1.68 0.50+0.72 0.38+1.79 0.42+1.29 0.002
Max depth 0.36+0.45 0.33+0.19 0.23+0.48 0.25+0.34 0.005
N CS/lesion* 4.02 (2.90–6.68) 2.56 (2.09–3.67) 3.01 (2.34–4.16) 2.26 (1.94–2.88) 0.46
At Year 2
Lesions with any evagination N 16 15
EV 2.47+2.52 0.57+2.44 0.03
Max depth 0.32+0.63 0.26+0.61 0.15
N CS/lesion* 4.41 (3.57–10.96) 2.32 (1.74–8.49) 0.13
At Year 5
Lesions with any evagination N 29 28
EV 2.54+1.58 0.72+1.55 ,0.001
Max depth 0.36+0.80 0.30+0.56 0.13
N CS/lesion* 4.44 (3.99–5.92) 2.25 (1.96–2.73) ,0.001
N CS/lesions refers to the number of CSs per lesion with any evagination. Values are presented as means+ SD unless otherwise specified.
EV, evagination volume; CS, cross-section.
*Expressed as median (IQR). Volumes are expressed in mm3, and depths in mm.
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stent type and time to FUP
SES PES BES ZES EES p
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*Expressed as median (IQR). Volumes are expressed in mm3, and depths in mm.
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Abstract
Aims: Angiographic ectasias and aneurysms in stented segments have been associated with late stent throm-
bosis. Using optical coherence tomography (OCT), some stented segments show coronary evaginations remi-
niscent of ectasias. The purpose of this study was to explore, using computational fluid-dynamic (CFD) 
simulations, whether OCT-detected coronary evaginations can induce local changes in blood flow.
Methods and results: OCT-detected evaginations are defined as outward bulges in the luminal vessel con-
tour between struts, with the depth of the bulge exceeding the actual strut thickness. Evaginations can be 
characterised cross-sectionally by depth and along the stented segment by total length. Assuming an ellipsoid 
shape, we modelled 3-D evaginations with different sizes by varying the depth from 0.2-1.0 mm, and the 
length from 1-9 mm. For the flow simulation we used average flow velocity data from non-diseased coronary 
arteries. The change in flow with varying evagination sizes was assessed using a particle tracing test where 
the particle transit time within the segment with evagination was compared with that of a control vessel. The 
presence of the evagination caused a delayed particle transit time which increased with the evagination size. 
The change in flow consisted locally of recirculation within the evagination, as well as flow deceleration due 
to a larger lumen – seen as a deflection of flow towards the evagination.
Conclusions: CFD simulation of 3-D evaginations and blood flow suggests that evaginations affect flow 
locally, with a flow disturbance that increases with increasing evagination size.
KEYWORDS
• computational 
fluid-dynamic 
simulation
• coronary 
evaginations
• flow disturbance
• optical coherence 
tomography
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Introduction
Drug-eluting stent (DES) implantation has revolutionised the treat-
ment of coronary artery disease by dramatically reducing the rates 
of target lesion revascularisation, as compared to bare metal stent 
implantation. However, shortly after the introduction of DES, late 
stent thrombosis (LST) emerged as a major concern related to their 
use. Subsequent autopsy reports and in vivo imaging studies have 
suggested a number of mechanisms, including incomplete endothe-
lialisation/uncovered struts, chronic inflammation, and stent malap-
position, possibly triggered by the antiproliferative drugs and 
durable polymers1-4. Although newer-generation DES have signifi-
cantly reduced the rate of LST, concern still exists for the patients 
who received a first-generation DES, not least as emerging data 
indicate a continued risk of LST over time with these devices5,6. 
Identification of reliable predictors that can be assessed with an 
accurate imaging technology is therefore needed.
Intravascular optical coherence tomography (OCT) has an ultra-high 
resolution of 10 µm allowing an in vivo histology-like evaluation of 
intracoronary stents including strut coverage and apposition, as previ-
ously validated7. Although the presence of uncovered and malapposed 
struts has been associated with LST8, OCT relatively often demon-
strates the presence of these features even in lesions from asympto-
matic patients at up to very long-term follow-up9. This suggests that 
additional mechanisms may be involved in causing these adverse 
events and, indeed, neoatherosclerosis was recently proposed as an 
additional potential cause of LST10,11. Using OCT in DES at follow-up 
after implantation, we have observed that some stented segments show 
outward bulging – “coronary evaginations” – of the luminal contour 
between struts (Figure 1A)9,12. Previous in vivo and computer-simulated 
haemodynamic studies have demonstrated that severe arterial dilations, 
such as aneurysms of the aorta, cerebral vessels and coronary arteries, 
are accompanied by changes in blood flow and shear stresses13-15. It has 
also been proposed that these features may be responsible for adverse 
events related hereto, namely ischaemia due to thrombosis and/or dis-
section14,15. Although the evaginations observed by OCT in DES are 
smaller than the aneurysms encountered in, e.g., Kawasaki’s coronary 
vasculitis with luminal diameters up to 28 mm13, it may be hypothe-
sised that these evaginations – analogous to other vessel dilations – may 
cause disturbances in coronary haemodynamics, which may in turn pro-
mote local thrombogenicity. The purpose of this study was therefore to 
explore, using computational fluid-dynamic (CFD) simulations, whether 
OCT-detected coronary evaginations can induce local changes in blood 
flow and, if so, whether this varies for different evagination sizes.
Methods
The study was set up in two steps beginning with the CFD simula-
tion of a three-dimensional (3-D) reconstructed evagination 
obtained in vivo from a patient (referred to as “actual” evagination), 
yielding results which motivated additional flow simulations in 
modelled evaginations of varying sizes.
Figure 1. OCT-detected evagination. A) shows a cross-section of a stent where struts are visualised as bright spots with dorsal shadowing. 
The stent area is demarcated by the white dashed line connecting the endoluminal surfaces of struts. At 11 o’clock, the luminal contour (white 
trace line) creates an outward bulge in the vessel wall between struts. Since the maximum depth of the bulge (white double-headed arrow) is 
greater than the actual strut thickness, it is termed a coronary evagination. B) shows a 3-D reconstruction of a vessel segment with two 
evaginations (crosses) separated by a strut (black arrow). CA: OCT catheter. C and D show a 3-D reconstructed evagination before (C) and 
after (D) compensation for catheter rotation. In E, the evagination in D has been merged with a cylindrical vessel.
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DEFINITION AND 3-D RECONSTRUCTION OF AN ACTUAL 
EVAGINATION
OCT-detected evaginations are defined in the cross-sectional view 
as outward bulges in the luminal vessel contour between struts, 
where the maximum depth of the bulge exceeds the actual thickness 
of the strut (Figure 1A). Accordingly, evaginations can be character-
ised quantitatively by a depth and an area. Evaluation of entire OCT 
pullbacks shows that evaginations are often present over several 
consecutive frames – something appearing as focal outward bulges 
on 3-D reconstructions (Figure 1B). In order to define how to com-
puter-model evaginations, we selected an actual evagination repre-
senting a typical geometry as observed in ~300 previously studied 
evaginations, and reconstructed the 3-D geometry from a set of 
consecutive OCT slices. Each slice was expressed in a cylindrical 
coordinate system taking the centre of the stent as origin. The lumi-
nal vessel contour including the luminal evagination contour was 
given coordinates derived from a series of radii measured at one 
degree increments along the circumference of the vessel. The rota-
tion of the vessel relative to the OCT catheter during pullback, 
mainly related to cardiac motion, was compensated for by first 
determining in each slice the vector pointing from the lumen centre 
to the evagination centroid, and, secondly, aligning the vectors 
throughout the slices using MATLAB® (MathWorks, Natick, MA, 
USA). In this way, we obtained a surface of the evagination, which 
was converted into a volume using Geomagic Studio® (Geomagic 
Solutions, Morrisville, NC, USA) and finally merged in Unigraphics 
NX (Siemens PLM Software, Plano, TX, USA) with a cylindrical 
vessel 3.55 mm in diameter according to the size of the original 
vessel. Figure 1C and Figure 1D show this 3-D reconstruction before 
and after compensation for catheter rotation, and Figure 1E shows 
the final result after merging with the cylindrical vessel.
COMPUTER MODELLING OF EVAGINATIONS
From this 3-D reconstruction and for simplicity, it is reasonable to 
assume an ellipsoid 3-D shape for the subsequent assessment of local 
flow changes in evaginations of varying sizes. These ellipsoids were 
modelled to protrude with no offset from a straight cylindrical vessel, 
meaning that the distance between the centreline of the vessel and 
the horizontal centreline of the evagination equals the vessel radius. 
The ellipsoid evaginations were inserted right at the inlet of the 
cylindrical vessel using SolidWorks (Dassault Systèmes SolidWorks 
Corporation, Waltham, MA, USA) (Figure 2A), and the obtained 
geometries were imported into COMSOL Multiphysics (COMSOL® 
Inc., Stockholm, Sweden) for the CFD simulations. For all simula-
tions, the length of the vessel segment was 10 mm and the diameter 
3 mm. For the evaluation of the effect of different evagination sizes 
on blood flow, we varied for each simulation the principal axes of 
the ellipsoids as follows: the depth was varied at 0.1 mm increments 
beginning from 0.2 mm up to 1 mm, with the width always equal-
ling twice the depth of the evagination (Figure 2B). The length of the 
evagination was varied from 1 mm up to 9 mm, at 1 mm increments. 
The rationale for using these values and increments was based on the 
range of depths and lengths of ~300 studied evaginations (Figure 3). 
In order to compensate for the sharp edge between the cylinder and 
the ellipsoid which does not occur in vivo and which may lead to 
unwanted artefacts in CFD, we introduced a smoothing fillet with an 
Figure 2. Modelling of evaginations and flow velocity. A) and B) show an example of a modelled elliptic evagination used in the simulations. 
The geometry is characterised by a length (A), a depth and a width (B). The sharp edge between the ellipsoid and the cylindrical vessel was 
compensated for by the insertion of a smoothing fillet (B). C) shows the flow velocity curve used in the simulations.
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arbitrary radius amounting to 10% of the evagination depth (Figure 
2B). Considering the symmetry of the evagination and vessel, the 
simulation was performed for half of the geometry only.
Assessment of haemodynamics in evaginations
MODELLING OF BLOOD FLOW
We used an average flow velocity curve (Figure 2C) attained by 
superimposition of coronary flow data from 23 patients assessed 
at steady state (without adenosine infusion) in non-diseased left 
anterior descending arteries. The flow velocity curves included 
the entire cardiac cycle with an average duration of 0.84 sec, cor-
responding to a heart rate ~71 beats/min. The average peak flow 
velocity amounted to 33 cm/sec. Doppler signals were meas-
ured using ComboWire® guidewires (Volcano Corp., San Diego, 
CA, USA) equipped with a miniaturised Doppler probe located 
at the tip and connected to a ComboMap® interface (Volcano 
Corp.) able to visualise and route incoming Doppler signals. The 
Doppler-derived instantaneous peak velocity signals were digit-
ised at a sample frequency of 500 Hz using a NI cDAQ-9172 sys-
tem equipped with a NI 9206 A/D-converter module (National 
Instruments, Austin, TX, USA). Signal averaging was performed 
using MATLAB (MathWorks). All recordings were obtained in 
the setting of another study, and were previously approved by the 
local ethics committee.
COMPUTATIONAL FLUID-DYNAMIC SIMULATION CONDITIONS
In the actual evagination, the Reynolds number at peak forward 
flow did not exceed 355 (Reynolds number based on blood den-
sity=1,060 kg/m3; blood viscosity=3.5 mPa·s; vessel diame-
ter=3.55 mm; peak flow velocity=33 cm/sec), and therefore the 
flow was treated as laminar and computed using the Navier-Stokes 
equations for incompressible flow. The frequency spectrum of 
the flow curve shown in Figure 2C exhibits a strong peak at the 
fundamental frequency of the heartbeat, i.e., 1.19 Hz, and two other 
peaks of negligible amplitude at the second and third harmonic fre-
quency. Using the Womersley theory16, we concluded that viscous 
effects dominate and that a Poiseuille flow can safely be assumed at 
the inlet of the vessel. A fully developed parabolic velocity profile 
was therefore set as inlet boundary condition. A zero-pressure zero-
viscous-stress boundary condition was defined at the outlet. No-slip 
and slip boundary conditions were imposed at the vessel wall and 
the symmetry plane, respectively. The geometry was discretised 
with an automatically generated tetrahedral mesh comprising two 
boundary layers at the vessel wall (sweeping of a cross-sectional 
mesh along the vessel was not possible due to the presence of the 
evagination). A smooth initialisation of the time-dependent simula-
tion was achieved by computing initial values for the flow in the 
vessel for a stationary situation with an inlet velocity of 18.5 cm/sec 
(Figure 2C, time=0 sec). Both the stationary and time-dependent 
computations used a PARDISO direct solver.
PARTICLE TRACING
Since the change in flow (pattern and velocity) with varying 
evagination dimensions cannot be quantified numerically using 
computational models, we performed a “particle tracing” test. This 
test model consists of simulating the release of a certain number of 
passive tracer particles (zero mass) at the inlet of the vessel and 
subsequently collecting them at the outlet. The passage of each 
particle can be characterised by the transit time, defined as the time 
elapsed from the moment a particle is released at the inlet until the 
particle has reached the outlet. Subsequently, one can derive the 
number and percentage of “delayed particles”, i.e., the number of 
particles that have a longer transit time as compared to a certain 
reference. As reference, we used the transit time of the slowest 
released particle in a control vessel without evagination. 
Accordingly, the transit time for each particle was determined and 
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 2 80 0.25 (0.20-0.31)
 3 25 0.28 (0.24-0.38)
 4 19 0.31 (0.23-0.39)
 5 10 0.37 (0.28-0.48)
 6 5 0.38 (0.32-0.60)
 7 1 0.24 (0.24-0.24)
 8 2 0.56 (0.36-0.76)
 9 3 0.46 (0.45-0.49)
 12 1 0.42 (0.42-0.42)
 13 1 0.63 (0.63-0.63)
Figure 3. We previously studied 254 lesions implanted with DES at a follow-up time of 1 year (117 lesions), 2 years (49 lesions) and 5 years 
(88 lesions). The maximum length of consecutive cross-sections containing evaginations was calculated and the maximum depth within that 
specific “cluster” of cross-sections with evaginations was analysed. A) shows the depth and length of each studied evagination; B) shows the 
median depth (and range) of evaginations of a certain length whereas the table in C specifically shows the number and depth of evaginations 
of a certain length.
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used as surrogate for the change in flow pattern and velocity in 
relation to the increase in evagination size by assessing the per-
centage of delayed particles.
Based on the results from the actual evagination, we concluded 
that particles located closer to the luminal centre are not affected by 
the evagination. We therefore released particles in six layers paral-
lel to the vessel surface where the first layer was placed at an offset 
of 20 μm from the vessel wall and the remaining ones at 100 μm 
increments (Figure 4A). The percentage of delayed particles was 
determined for each layer separately. Accordingly, a certain particle 
in a layer was considered delayed when its transit time was longer 
than the transit time of the slowest particle in the corresponding 
layer of the control vessel. To eliminate the arbitrariness in select-
ing the radial position of the different layers, we combined the 
results from each layer to one single value, namely delayed parti-
cles (DP):
where n denotes the index of the layer and rn its radius, and l and d 
denote the length and the depth of the simulated evagination, 
respectively. This can be understood as integrating the orange area 
in Figure 4B over one complete revolution around the vessel centre-
line. Finally, we normalised DPl,d with the maximum DPl,d of all 
tested configurations: 
  
The particle tracing simulation was performed with the 
COMSOL Multiphysics software using the described flow veloc-
ity data. The total simulation time was set to four seconds, encom-
passing almost five cardiac cycles. The first cycle was used as 
a run-in period, after which sets of particles were released 100 
times at a constant rate during the second cardiac cycle. The total 
simulation time of four seconds was chosen to allow sufficient 
time for all the released particles to reach the outlet in the control 
vessel. Time stepping in the time-dependent simulation was a crit-
ical issue since we had to deal with particles sticking to the wall 
due to numerical inaccuracy. By enforcing a maximal time step of 
five milliseconds, we ensured that the number of sticking particles 
did not exceed 0.5% for any layer. Sticking particles were 
excluded from the analysis.
Results
ASSESSMENT OF HAEMODYNAMICS IN THE ACTUAL 
EVAGINATION
The actual evagination measured (length×width×depth) 3.2 mm×-
1.5 mm×0.65 mm. Computational modelling of blood flow in terms 
of the particle tracing test revealed a local affection of flow through 
the vessel with evagination as compared to a control vessel without 
(Moving image 1). The flow closer to the luminal centre of the ves-
sel appeared not to be affected by the evagination (Moving image 1). 
The change in flow consisted mainly of recirculation within the 
evagination, which occurred during the period in the cardiac cycle 
encompassing maximum speed and maximum flow deceleration 
Figure 4. Set-up for the particle tracing test. The cylinder in panel A represents a modelled vessel (evagination omitted for simplicity) in which 
the vessel centreline is added as an x-axis. Along the y-axis, representing the vessel radius (1.5 mm), the distance from the centreline and the 
radial position (r) of various particle layers (n) is indicated. Accordingly, the layer closest to the vessel wall (n=1) is positioned 1.48 mm from 
the centreline, i.e., 20 µm from the vessel wall, with subsequent layers placed at 100 µm increments from the vessel wall towards the centreline 
(dr denotes the distance between two adjacent layers). Since particles closer to the centre of the vessel were not affected by the actual 
evagination, we included only layers 1-6 in the simulation of flow in modelled evaginations (B). To eliminate the arbitrariness in selecting the 
radial position of the different layers, we combined the results from each layer (% delayed particles) to one single value, namely delayed 
particles, DP (light orange volume), represented by the integration of the dark orange area over one revolution around the vessel centreline. 
The DP of each evagination size was then normalised to the maximum DP in the entire sample.
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(Figure 2C, Figure 5). The testing of a modelled evagination with 
dimensions comparable with the actual evagination (3.0 mm×-
1.2 mm×0.6 mm), but in a 3 mm vessel, showed qualitatively a sim-
ilar flow behaviour with regard to the occurrence of recirculation 
(Figure 5), confirming that the model assumptions of vessels with 
evaginations were appropriate. Taken together, these findings moti-
vated the further exploration of the impact of varying evagination 
size on local flow behaviour.
ASSESSMENT OF HAEMODYNAMICS IN MODELLED 
EVAGINATIONS
A total of 81 vessels with modelled evaginations of different sizes 
were assessed. The particle tracing test showed that the num-
ber of particles being delayed on their passage through the ves-
sel segment with evagination as compared to the control segment 
– expressed as the normalised DP – increased with increasing 
evagination size (Figure 6A). In addition, there was a tendency 
towards depth playing a greater role in local affection of flow in 
certain shorter evaginations compared to some longer evagina-
tions, as evidenced by the asymmetrical change in DP (Figure 
6A). To evaluate this more closely, we selected the simulated 
depth where this effect was most pronounced, namely 1 mm, 
and plotted the magnitude of normalised DP against the evagi-
nation length (Figure 6B, solid line). This showed more clearly 
the slight increase in the number of delayed particles in shorter 
evaginations at this depth followed by a small decrease and then 
an almost linear increase with increasing evagination length. By 
inspection of the animated particle trajectories of the individual 
particle tracing tests, we observed that recirculation prevailed in 
shorter evaginations (1-3 mm), whereas the flow deceleration and 
deflection increased with evagination length and depth (Moving 
image 2). Based on these qualitative findings, the course of the 
solid curve in Figure 6B may be explained by two components, 
namely deceleration due to larger lumen, which increases the 
Figure 5. Change in flow induced by the actual and corresponding modelled evagination. The normalised flow velocity (Qnorm) is expressed 
in colour where red represents the maximum velocity of forward flow; green, flow stagnation (velocity=0); and dark blue, maximum velocity 
of backward flow. The vessel with an actual evagination is shown in the upper panels and the corresponding vessel with modelled evagination 
is shown in the lower panels, at different times in the cardiac cycle (in Figure 2C: peak deceleration=0.048 sec; minimum speed=0.198 sec; 
peak acceleration=0.41 sec; maximum speed=0.52 sec). The inlet is located closest to the viewer. For orientation purposes, zoomed-out 
images of the respective vessels are shown in the right corners of the upper and lower left panels. The flow velocity is shown in three 
dimensions by transsection of the evagination longitudinally (along the length of the vessel axis), cross-sectionally, and horizontally (at half 
the depth of the evagination). Accordingly, flow velocity is highest at the centre of the vessel and zero close to the vessel wall. Backward flow 
and thus recirculation is evident close to the luminal surface at the proximal half of both evaginations. As seen by the black mesh, the actual 
evagination displays an irregular surface.
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transit time linearly with evagination length and depth, and recir-
culation, which is most pronounced at lengths below 4 mm. The 
solid curve in Figure 6B can thus be decomposed into two curves: 
a flow deceleration curve (dotted line), obtained by setting the 
intercept at zero and adjusting the slope to obtain a tangential con-
tact to the more linear part of the original normalised DP curve, 
and a recirculation curve (dashed line), obtained by subtracting 
the deceleration curve from the original normalised DP curve. By 
comparison of Figure 6A and Figure 6B we observed that the dip 
in DP in the colour plot is the point where recirculation becomes 
irrelevant based on the graph in Figure 6B (at evagination length 
4 mm, where the decrease in overall DP [solid line] has stagnated 
and where the DP caused by recirculation [dashed line] approxi-
mates 0). This specific point was determined for various evagina-
tion depths, as shown by the crosses in Figure 6A, which could 
be more or less approximated by a straight line. Accordingly, for 
evaginations located to the left of this line, recirculation is the 
predominant mechanism to explain the increase in number of 
delayed particles, whereas the asymptotic dashed curve represents 
the cut-off for evagination sizes above which recirculation can be 
observed for at least one particle once during one cardiac cycle.
Discussion
In the present study, we assessed the potential influence of coronary 
evaginations on blood flow with the following main findings. 
1) Computational modelling of flow in a 3-D reconstructed vessel 
with an actual evagination showed that the presence of the evagina-
tion affects flow locally by inducing both a general flow decelera-
tion due to a larger lumen, seen as a deflection of flow towards the 
evagination, as well as recirculation of flow within the evagination. 
2) The use of a modelled ellipsoid evagination of similar dimension 
to an actual evagination demonstrated similar changes in flow. 
3) The affection of flow as measured by the number of “delayed 
simulated particles” appeared to increase with increasing evagina-
tion size.
THE EFFECT OF EVAGINATIONS ON BIOMECHANICAL 
CONDITIONS
It is generally accepted that biomechanical conditions play an 
important role in the genesis and development of vascular dis-
ease17-19. As expressed by the triad of Virchow, disturbances in 
blood flow may lead to stasis and thereby thrombosis20. This is the 
first computational flow study to describe the magnitude of stasis 
Figure 6. Results of the particle tracing test. A) shows the normalised number of delayed particles (DPnorm) in modelled vessels with 
evaginations of varying sizes as compared to a control vessel without evagination. The increase in DPnorm generally increases with 
increasing evagination size; however, there is a tendency towards a relatively greater increase for deep evaginations (0.7-1.0 mm) even at 
smaller lengths (2-4 mm). This is most pronounced at 1 mm depth. B) shows the result after plotting DPnorm for depth 1 mm against the 
evagination length (solid line) showing more clearly the increase in DP followed by a decrease and then again an increase. According to 
particle trajectory lines (Moving image 2), the initial increase is represented by recirculation, whereas the subsequent increase is more related 
to the flow deceleration due to the larger lumen at the evagination, seen as a deflection of flow towards the evagination. The solid line can 
thus be decomposed into a deceleration (dotted line) and a recirculation component (dashed line). Determination of the point where the 
recirculation component becomes irrelevant for various evagination sizes (crosses in A) yields the linear solid curve in A, whereas the 
asymptotic dashed curve represents the cut-off for evagination sizes above which recirculation can be observed for at least one particle at 
least once in the cardiac cycle (dashed curve determined by inspection of the animated particle trajectories).
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by particle tracing within the newly described morphological find-
ing of coronary evaginations. Compared to previous reports on 
haemodynamic investigations of vascular aneurysms13,21,22, we 
observed similar flow disturbances in the region of evaginations in 
terms of stagnation and flow reversal, suggesting that, although rel-
atively small compared to true aneurysms, coronary evaginations 
have the potential to affect blood flow and may thus be of clinical 
relevance. As compared to the study of haemodynamics in aortic 
aneurysms, which is typically performed in selected individual 
cases15,21, we estimated more broadly how the magnitude of flow 
disturbance varies with incremental changes in evagination lengths 
and depths, based on data obtained from an in vivo study employing 
OCT. The flow disturbance appeared to increase with increasing 
evagination sizes. Specifically, we observed a non-linearity in flow 
alteration with a transient relatively larger increase for short evagi-
nations at greater depths as compared to longer evaginations 
(Figure 6), apparently due to an inconsistent variation in the magni-
tude of flow reversal and deceleration at different evagination sizes. 
The cause of this non-linearity can only be speculated, and one pos-
sibility may relate to the geometrical shape of the evaginations. The 
gradual increase in depth in short evaginations is relatively larger in 
relation to the length as compared to longer evaginations. Thus, the 
former acquire a somewhat “saccular” shape sooner than the latter, 
which remain “fusiform” until the depth is increased relatively 
more. Although a specific relationship between the severity of flow 
disturbance and ectasia size and shape had not been established pre-
viously, haemodynamic simulations of individual aortic aneurysms 
suggest that saccular aneurysms generally affect flow relatively 
more than those that are fusiform21. However, there is a suggestion 
that the magnitude of flow disturbance depends not only on the 
maximum cross-sectional area of the aneurysm but also on the total 
size of the recirculation zone, which can be considerable in fusi-
form vessel dilations21.
POTENTIAL CLINICAL IMPLICATIONS
In the setting of vascular aneurysms, the main purpose of fluid-
dynamic simulations is to assess the risk of rupture in order to initi-
ate timely intervention23. In this regard, focus has mainly been on 
wall shear stresses and oscillatory shear indices with data indicating 
that high oscillations in shear stresses during the cardiac cycle cor-
relate with a risk of rupture22. As compared to large aneurysms of 
native vessels, it may be postulated that rupture of coronary evagi-
nations is rather unlikely due to an assumedly stabilising effect of 
the stent. Instead, there may be a risk of thrombosis considering the 
presence of stasis and recirculation. Based on this, our aim was to 
study flow behaviour within lesions with evaginations, and there-
fore analysis of wall shear stress was omitted. We previously 
reported the occurrence of very late thrombosis in stented segments 
exhibiting evaginations9. Although the mechanisms leading to 
thrombosis in lesions with evaginations are unclear, above all two 
particular possibilities are attractive. Firstly, evaginations may 
induce thrombosis directly by promoting the convection of platelets 
towards the vessel wall where stasis and recirculation contribute to 
their aggregation. Secondly, thrombosis may occur following a co-
action of evaginations with other risk factors to increase the risk for 
thrombosis. In a recent study of 254 lesions treated with DES and 
imaged with OCT at one to five years, we found a significantly 
higher frequency of malapposed and uncovered struts in lesions 
with evaginations as compared to those without24, both features 
associated with stent thrombosis1,3. In addition, non-occlusive (sub-
clinical) thrombus was more common in lesions with evaginations. 
On further analysis, IVUS suggested positive remodelling to be the 
mechanism of evaginations. It is conceivable that, with continuing 
outward remodelling of the vessel, it may at some point detach 
from the rigid stent exposing not only tissue factor but also stent 
struts which consequently become malapposed. These features in 
combination with the flow disturbances caused by evaginations ful-
fil all the criteria of the triad of Virchow (Figure 7A), suggesting a 
high propensity of thrombosis. Accordingly, in the presence of 
evaginations, malapposed and uncovered struts may be more prone 
to serve as a nidus for thrombus formation (Figure 7B).
Assuming the proposed coaction of various risk factors, it seems 
logical that the clinically relevant threshold of evagination depth 
and length would also depend on the relative extent of the other risk 
factors and vice versa. Nevertheless, it is tempting to speculate on a 
threshold above which evaginations may induce clinically relevant 
flow disturbances. Imai and colleagues previously assessed the 
clinical importance of peri-stent contrast staining (PSS) – an angio-
graphic phenomenon observed in previously stented segments, sug-
gested to be due to vessel ectasias at these sites25. In lesions with 
PSS, per definition extending >20% and >100% of the stent diam-
eter, in the depth and length, respectively (e.g., in a 3 mm stent this 
would mean a cut-off for ectasia/evagination depth >0.6 mm and 
length >3 mm), they found an increased risk of target lesion revas-
cularisation and stent thrombosis as compared to lesions without 
PSS. Since evaginations and PSS reflect the same phenomenon 
(Figure 7B), it is interesting that PSS dimensions above the defined 
cut-off occur in Figure 6A in the region with increased flow distur-
bance, suggesting that this cut-off might be clinically relevant. 
Considering the above, it is possible that the pattern of flow distur-
bance (flow recirculation vs. deceleration) at the site of evagination 
is less important than the size of evagination. Although it is 
unknown whether increasing evagination size with/without other 
risk factors indeed translates into clinical events, the findings of the 
present study will hopefully stimulate further investigations to 
assess the impact of evaginations on clinical outcomes.
Limitations
For simplicity, we omitted the modelling of the stent, which might 
alter haemodynamics, as this would have required consideration 
of different stent designs and strut thicknesses, yielding an unsur-
passably large number of combinations to test. The tested regular 
ellipsoid shape of our modelled evaginations in conjunction with 
a “healthy” straight cylindrical vessel of only one size may not 
reflect in vivo evaginations correctly, with their complex luminal 
configurations. Furthermore, the tested vessel segment assumed 
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Figure 7. Factors associated with late stent thrombosis. A) shows a number of factors associated with late stent thrombosis and classified 
according to the triad of Virchow. B) and C) show the angiographic and OCT findings in a case of late stent thrombosis. This 54-year-old male 
had a sirolimus-eluting stent implanted in the right coronary artery in the setting of a STEMI. Seventeen months later, clopidogrel was 
discontinued and, 27 months following stent implantation, the patient presented with an inferior STEMI. One week following thrombolysis, 
angiography showed peri-stent contrast staining in the previously stented segment (dashed line). OCT demonstrated evaginations (E), 
malapposed (M), and uncovered (*) struts, as shown in C and D. Please note that OCT was performed without a guidewire, which is 
a differential diagnosis for the malapposed strut in C. ACS: acute coronary syndrome; DAPT: dual antiplatelet therapy; DES: drug-eluting 
stent; TF: tissue factor
only one single evagination per cross-section, and thus the assess-
ment of interplay in case of several evaginations was omitted. 
Additionally, a side effect of the compensation of vessel rotation 
around the catheter may be an excessive straightening of the shape 
of the evagination that may further affect haemodynamics. With 
respect to the fluid-dynamic simulation conditions, our simula-
tion model used massless particles, which together with the par-
ticle layer approach may not precisely reflect the in vivo blood 
flow. Furthermore, due to the lack of published data relating the 
exposure time to stagnating and recirculating flow with the rate 
of thrombocyte adhesion, we could not use the derived metric DP 
to predict thrombus formation in an evagination. The results were 
therefore normalised.
Conclusion
OCT-detected coronary evaginations in stented segments represent 
an outward bulging of the luminal contour between struts. Following 
computational modelling of 3-D evaginations and blood flow, we 
found that evaginations affect flow locally, and that the flow distur-
bance increases with increasing evagination size. The clinical 
implications of these findings need to be evaluated further.
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Online data supplement
Moving image 1. Panels A and B show the particle trajectories 
during the particle tracing test of the 3-D reconstructed actual 
evagination. In panel A, the particles are released in a ran-
dom fashion, where it is evident that particles located closer to 
the lumen were not affected by the evagination, whereas parti-
cles closer to the vessel wall were both deflected towards the 
evagination and recirculating within the evagination. For reasons 
of simplicity, the simulation was therefore performed with 6 lay-
ers of particles, as shown in panels B and C, the latter showing 
the results within a control vessel without evagination. The par-
ticle colour indicates the release time (blue=first set of particles; 
red=last set of particles).
Moving image 2. This image shows the results of the particle trac-
ing test in a control vessel and in modelled vessels with evagina-
tions of varying depths (ED) and lengths (EL). Recirculation is 
most prominent in shorter evaginations, whereas the overall flow 
deceleration due to the larger lumen at the evagination, seen as a 
deflection of flow towards the evagination, increased steadily with 
increasing evagination length. The particle colour indicates the 
release time (blue=first set of particles; red=last set of particles).
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Abstract
Aims: Angiographic evidence of edge dissections has been associated with a risk of early stent thrombosis. 
Optical coherence tomography (OCT) is a high-resolution technology detecting a greater number of edge 
dissections – particularly non-flow-limiting – compared to angiography. Their natural history and clinical 
implications remain unclear. The objectives of the present study were to assess the morphology, healing 
response, and clinical outcomes of OCT-detected edge dissections using serial OCT imaging at baseline and 
at one year following drug-eluting stent (DES) implantation.
Methods and results: Edge dissections were defined as disruptions of the luminal surface in the 5 mm seg-
ments proximal and distal to the stent, and categorised as flaps, cavities, double-lumen dissections or fissures. 
Qualitative and quantitative OCT analyses were performed every 0.5 mm at baseline and one year, and clini-
cal outcomes were assessed. Sixty-three lesions (57 patients) were studied with OCT at baseline and one-year 
follow-up. Twenty-two non-flow-limiting edge dissections in 21 lesions (20 patients) were identified by 
OCT; only two (9%) were angiographically visible. Flaps were found in 96% of cases. The median longitu-
dinal dissection length was 2.9 mm (interquartile range [IQR] 1.6-4.2 mm), whereas the circumferential and 
axial extensions amounted to 1.2 mm (IQR: 0.9-1.7 mm) and 0.6 mm (IQR: 0.4-0.7 mm), respectively. Dis-
sections extended into the media and adventitia in seven (33%) and four (20%) cases, respectively. Eighteen 
(82%) OCT-detected edge dissections were also evaluated with intravascular ultrasound which identified nine 
(50%) of these OCT-detected dissections. No stent thrombosis or target lesion revascularisation occurred up 
to one year. At follow-up, 20 (90%) edge dissections were completely healed on OCT. The two cases exhibit-
ing persistent dissection had the longest flaps (2.81 mm and 2.42 mm) at baseline. 
Conclusions: OCT-detected edge dissections which are angiographically silent in the majority of cases are 
not associated with acute stent thrombosis or restenosis up to one-year follow-up.
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Introduction
Stent implantation is the preferred treatment for coronary artery ste-
nosis. As a consequence of vessel trauma during stent implantation, 
edge dissections occasionally occur and may lead to abrupt or 
threatened vessel closure due to obstruction from prolapsing tissue 
or thrombosis. Previous reports have suggested an association 
between angiographic as well as intravascular ultrasound (IVUS)-
detected edge dissections and early stent thrombosis (ST)1-5. At the 
same time, other studies evaluating the outcomes following stent 
implantation have shown that only a minority of patients with edge 
dissections experience clinical adverse events6-8. The impact of 
these findings and their management has therefore been debated.
Optical coherence tomography (OCT) is a high-resolution technol-
ogy allowing a detailed assessment of the coronary vessel wall and 
implanted devices9. Consequently, OCT detects a higher number of 
edge dissections as compared to angiography and IVUS9,10. The often 
dramatic appearance of these vessel disruptions, even when angio-
graphically silent, may generate concern for further complications and 
trigger additional stent implantation11,12. The question whether this is 
justifiable at a time where OCT is increasingly used during interven-
tions has thus resurfaced. At present, the natural history and clinical 
implications of these findings in the short and long term remain insuf-
ficiently described. The objectives of the present study were to assess 
the morphology, healing response, and clinical outcomes of OCT-
detected edge dissections using serial OCT imaging at baseline and at 
one year following drug-eluting stent (DES) implantation.
Methods
STUDY POPULATION
The study included serial data from the Copenhagen OCT registry 
and from the OCT substudy of the RESOLUTE all-comers trial13. 
The Copenhagen OCT registry was a single-centre prospective non-
randomised evaluation of strut coverage and apposition at 12-month 
(average) follow-up in relation to apposition at baseline, using the 
following DES: CYPHER SELECT® Plus (Cordis, Johnson & John-
son, Warren, NJ, USA), TAXUS® Express™ (Boston Scientific, 
Natick, MA, USA), and Resolute® (Medtronic Inc., Santa Rosa, CA, 
USA). Patients were included between June 2008 and November 
2010, and were eligible if they had ≥1 lesion with >50% diameter 
stenosis in a native coronary artery, with a reference vessel diameter 
between 2.25 and 4.0 mm. Exclusion criteria were ST-segment eleva-
tion myocardial infarction (MI), left ventricular ejection fraction 
<30%, renal insufficiency (creatinine >133 µmol/L), and lesion loca-
tion in the left main stem or bypass graft. OCT as well as IVUS were 
performed after a satisfactory angiographic result, defined as a resid-
ual diameter stenosis <20% and Thrombolysis In Myocardial Infarc-
tion (TIMI) flow grade 3. It was prespecified that angiographically 
visible edge dissections occurring during the procedure would only 
be treated in case they were obstructive and flow-limiting (defined as 
dissections at least type C with a residual diameter stenosis >50% 
and a TIMI flow ≤2). Specifically, treatment of edge dissections vis-
ible by OCT was not permitted unless they fulfilled the angiographic 
criteria. Administration of glycoprotein (GP) IIb/IIIa inhibitors 
was left to the discretion of the operator. Whether this was a conse-
quence of the dissection or not was noted. Imaging with both OCT 
and IVUS was repeated at 12-month (average) follow-up. Of note, 
six patients (out of a total 49 patients) imaged at baseline in the 
Copenhagen cohort were excluded due to withdrawal of consent for 
follow-up.
The RESOLUTE trial was a randomised multicentre all-comers 
non-inferiority trial comparing the Resolute and XIENCE V® (Abbott 
Vascular, Santa Rosa, CA, USA) stents14. Inclusion criteria were broad, 
including patients with chronic stable angina as well as acute coronary 
syndromes, having ≥1 lesion with >50% diameter stenosis with a refer-
ence vessel diameter between 2.25 and 4.0 mm. Exclusion criteria 
were known intolerance to any of the stent components, and planned 
surgery within six months of the index procedure. Administration of 
GP IIb/IIIa inhibitors was left to the discretion of the operator. The 
OCT substudy included patients randomly selected for angiographic 
follow-up at 13 months from centres where OCT was available. The 
principal endpoint was strut coverage at follow-up13. A limited number 
of patients, included between May and November 2008, also had 
a baseline evaluation. There were no per protocol prespecified instruc-
tions regarding the management of edge dissections; however, for the 
purpose of this study, the occurrence of angiographic edge dissections 
after stent implantation was noted and, if present, also whether these 
were treated with additional stent implantation.
From the serial data available, we included lesions exhibiting edge 
dissections as assessed by OCT after stent implantation. Both studies 
were approved by the local ethics committees and written informed 
consent was obtained from all patients prior to enrolment.
OCT AND IVUS ACQUISITIONS
OCT acquisitions were performed with commercially available sys-
tems (time-domain M2 and M3 systems; frequency-domain C7 sys-
tem) from LightLab/St. Jude (Westford, MA, USA). OCT images 
were acquired at a frame rate of 15.6, 20, and 100 frames/s at a pull-
back speed of 1, 3 and 10 mm/s with the M2, M3 and C7, respec-
tively. Acquisition with occlusive (M2) and non-occlusive (M3 and 
C7) techniques has been described previously15. IVUS images were 
acquired with the Atlantis SR Pro 40 MHz catheter and iLab system 
(Boston Scientific, Natick, MA, USA) at a frame rate of 30 frames/s 
and pullback speed of 0.5 mm/s, according to accepted standards16.
ANGIOGRAPHIC ANALYSIS
All angiograms were assessed by three independent cardiologists with 
regard to the presence of edge dissections. In case of disagreement, 
a consensus diagnosis was obtained. If present, the dissection was 
graded according to the National Heart, Lung, and Blood Institute 
classification17.
OCT IMAGE ANALYSIS
OCT pullbacks were analysed off-line using proprietary software 
from LightLab/St. Jude. The region of interest included reference 
vessel segments (RVS) 5 mm proximal and distal to the stent, which 
were analysed systematically at 0.5 mm intervals. Edge dissections 
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were defined as disruptions in the luminal vessel surface in the 
RVS, with or without involvement of the stented segment.
Dissections were classified as flaps, cavities, double-lumen dissec-
tions or fissures (Figure 1A-Figure 1D), and their longitudinal exten-
sions along the stented segment were measured. For flaps, the flap root 
thickness was assessed semi-automatically from the joint point with 
the vessel wall to the luminal surface along a line projected through the 
gravitational centre of the lumen. The flap length was measured from 
the joint point with the vessel wall to the tip of the flap. The flap area 
was measured as the area bounded by the flap root thickness trace and 
the luminal contours of the flap. For cavities, the cavity depth was 
measured along a line projected through the gravitational centre of the 
lumen, from the deepest point in the cavity to a virtual line extrapolated 
between the luminal vessel contours on each side of the cavity. The 
cavity width was quantified at its widest point as parallel to the virtual 
line as possible, and the cavity area was assessed as the area bounded 
by the luminal contour of the cavity and the help line extrapolated 
between the luminal vessel contour on each side of the cavity. Double-
lumen dissections were those having a false lumen separated from the 
true lumen by a cap. The cap thickness was quantified semi-automati-
cally from the joint point with the vessel wall to the luminal vessel con-
tour along a line projected through the gravitational centre of the 
lumen, and the largest of the two cap thicknesses was used. The cap 
length was measured as the distance between the two joint points con-
nected by a straight line, while the cap area was defined as the area 
bounded luminally by the vessel surface to the sides by the cap thickness 
traces, and in the depth by the false lumen. Fissures were present when 
a split was visible delineating a flap-like structure not lifted from the 
vessel wall, which otherwise displayed an uninterrupted luminal con-
tour. Due to a poor demarcation of the root of the flap-like structure, no 
measurements were performed on the fissures at the cross-sectional 
level; however, they were included in the assessment of longitudinal 
extension as it was hypothesised that they were consistent with injury. 
The circumferential extension of the dissection was expressed as the 
number of quadrants involved. The axial injury of the dissection was 
described as intimal involvement when only the intima was affected 
and media was still intact, as medial involvement when the dissection 
extended into the media without disruption of the entire medial layer, 
and as adventitial involvement when the media was dissected through-
out its thickness (Figure 1E-Figure 1G). In case the media was not dis-
cernible, the dissection was classified as involving only the intima. The 
lumen area was assessed in each selected frame of the RVS as the area 
bounded by the luminal vessel contour. The kappa value for inter-
observer reproducibility of the classification of edge dissections at the 
lesion level was 1.0.
We also assessed the underlying tissue at the site of the dissec-
tions (at the lesion level) with respect to plaque type, which was 
classified as fibrous (>500 µm thick in at least one quadrant), fibro-
calcific, or thin-cap (TCFA) fibroatheroma according to the interna-
tional consensus (the two latter plaque types considered to be 
present when the calcified or lipid regions extended >1 quadrant)18. 
We also noted whether the extension was eccentric or concentric.
Figure 1. Classification of edge dissections. A) shows a dissection flap with indication of the flap root thickness (1), flap length (2), and flap 
area (white shading). B) shows a dissection cavity with the cavity depth (3), cavity width (4) and cavity area (white shading) displayed. The 
white arrow points to an artefact caused by non-uniform rotational distortion, and should not be misinterpreted as a dissection. The diagnosis 
was made by inspecting adjacent frames (not shown). C) shows a double-lumen dissection with indication of the largest cap thickness (5), cap 
width (6), and cap area (white shading). D) the arrows point to a fissure. Panels E-G show dissections involving only the intima (i) (E), the 
media (m) (F), and the adventitia (a) (G). F) the double arrows demarcate the only intact portion of the disrupted media. G) the arrow 
indicates the point where the media is lifted from the adventitia.
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also involved the stented segments. None of the six patients from 
the Copenhagen cohort who withdrew consent for follow-up exhib-
ited dissections at baseline examination.
Twenty (90%) out of 22 dissections were completely healed at 
follow-up (Figure 3). The two dissections that did not heal 
(Figure 4) exhibited the longest circumferential extension (2.81 and 
2.42 mm), and in one case the longest longitudinal extension 
(6.0 mm) at baseline, and both were combinations of flaps and dou-
ble-lumen dissections.
The morphometric results are presented in Table 3. Luminal dimen-
sions in the reference vessel segment remained stable at follow-up.
The plaque type at the site of dissection was: an eccentric fibrous 
plaque in 17 (77.3%) lesions; concentric fibrous plaque in one 
(4.5%) lesion; eccentric fibrocalcific plaque in four (18.2%) lesions; 
and an eccentric TCFA in one (4.5%) lesion. In all cases of eccen-
tric plaque, the point of dissection was at the transition site between 
the normal intima/thinnest point of plaque and the point where the 
plaque increases in thickness (Figure 2 and Figure 3). The two 
cases exhibiting signs of incomplete healing at follow-up had both 
underlying eccentric fibrous plaques.
RESULTS OF IVUS ANALYSIS
IVUS imaging at baseline was available for 18 (82%) lesions, of 
which nine (50%) exhibited edge dissections. The results of serial 
morphometric analyses from 17 (77%) lesions are presented in 
Table 3. The lumen and EEM areas of the RVS increased slightly at 
follow-up; however, the plaque and media area remained stable.
CLINICAL OUTCOMES
All patients but one received dual antiplatelet therapy with aspirin 
and clopidogrel during the entire one-year follow-up period. One 
patient received clopidogrel alone. There were no deaths, MIs, 
IVUS IMAGE ANALYSIS
IVUS pullbacks were analysed off-line using the QCU-CMS soft-
ware (Medis, Leiden, The Netherlands) at standard 1 mm intervals in 
the described region of interest. Dissections were defined as tears in 
the intima-media with visualisation of blood speckle behind a flap or 
within a cavity or double lumen. The presence of dissections was 
assessed at the lesion level. The lumen area was measured in the RVS 
as the area bounded by the luminal vessel contour, whereas the exter-
nal elastic membrane (EEM) area encompassed the area bounded by 
the interface between the intima-media layer and the adventitia. The 
plaque and media area was calculated as the EEM area minus the 
lumen area. The kappa value for inter-observer reproducibility of the 
presence or not of edge dissection by IVUS was 1.0.
CLINICAL OUTCOMES
Clinical outcomes in terms of death, MI, target lesion revascularisa-
tion (TLR) and target vessel revascularisation (TVR) were assessed 
for the Copenhagen OCT registry by two independent observers 
blinded to the imaging results, and for the RESOLUTE trial by 
a clinical events adjudication committee. The overall rate of stent 
thrombosis at one year was assessed according to the Academic 
Research Consortium definitions19.
STATISTICAL ANALYSIS
Continuous data were presented as means±standard deviations or 
median and interquartile ranges (IQR), depending on their distribution, 
which was assessed using the Kolmogorov-Smirnov test. Categorical 
data were presented as frequencies and percentages. The morphometric 
data at baseline and follow-up were compared using a paired t-test, and 
a two-sided  p≤0.05 was considered statistically significant.
Results
CLINICAL AND PROCEDURAL CHARACTERISTICS
Out of a total of 57 patients with 63 lesions, 20 patients with 
21 lesions and 22 OCT-defined edge dissections were included in 
the final analysis (Figure 2). Table 1 shows the baseline demo-
graphics. The average age was 63 years, 15 (75%) patients were 
males, and 14 (70%) patients presented with acute coronary syn-
drome. All lesions had a final TIMI 3 flow. Out of the 22 OCT-
defined edge dissections, two (9%) were angiographically visible 
as type A haziness, and both were located within the same vessel 
(distal lesion with proximal dissection and proximal lesion with 
distal dissection), separated by only 2 mm. Of note, none of the 63 
lesions was treated with additional stents, whereas five (25%) of 20 
patients received treatment with GP IIb/IIIa inhibitors directly as 
a consequence of the OCT findings.
Results of OCT analysis
Out of the 62 assessable lesions with 58 distal and 30 proximal vis-
ible edges, 21 (34%) lesions with 16 (28%) distal and six (30%) 
proximal edges showed dissections, respectively. One of these 
lesions had both a proximal and distal dissection. Table 2 shows the 
characteristics of these dissections at baseline. Six (27%) dissections 
Study population
– 57 patients
– 63 lesions
Cases with ≥1 analysable stent
edge by OCT at BL and FUP
– 56 patients
– 62 lesions
   (58 distal/30 proximal edges visible)
Cases with visible edge dissections by
OCT included for analysis
– 20 patients
– 21 lesions
   (20 distal/12 proximal edges visible)
– 22 dissections
   (16 distal/6 proximal)
Cases with no serially
analysable edge
– 1 patient
– 1 lesion
Cases without edge
dissections
– 36 patients
– 41 lesions
Figure 2. Flow chart.
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Table 1. Baseline demographics.
Patient characteristics, N=20 N (%)
Age, years* 63.0 (56.5-67.5)
Male gender 15 (75.0)
Hypertension 11 (55.0)
Hyperlipidaemia 16 (80.0)
Diabetes mellitus 5 (25.0)
Current/previous smoker 4 (20.0)
Family history 14 (82.4)
Previous MI 3 (15.0)
LVEF 60 (55-60)
Clinical presentation ACS 14 (70.0)
SAP 6 (30.0)
Multivessel disease 9 (45.9)
Lesion and procedural characteristics, N=21
Target vessel LAD 6 (28.6)
LCX 4 (19.0)
RCA 11 (52.4)
Target segment Proximal 9 (42.9)
Mid 8 (38.1)
Distal 4 (19.0)
Stent type CYPHER Select Plus 9 (42.9)
Resolute 5 (23.8)
XIENCE V 4 (19.9)
TAXUS Express 3 (14.3)
Stent diameter, mm* 3.0 (3.0-3.5)
Total stented length, mm* 23 (18-28)
Stents per lesion, n* 1.0 (1.0-2.0)
Overlap 5 (23.8)
TIMI pre <3 5 (23.8)
3 16 (76.2)
TIMI post 3 21 (100.0)
Predilatation 15 (71.4)
Post-dilatation 10 (47.6)
Maximum implantation/dilation diameter, mm* 3.0 (3.0-3.5)
Maximum implantation/dilation pressure, atm* 16 (14-20)
GP IIb/IIIa use 5 (25)¶
*Values are median (interquartile range). ACS: acute coronary syndrome; 
atm: atmospheres; LAD: left anterior descending artery; LCX: left 
circumflex artery; LVEF: left ventricular ejection fraction; MI: myocardial 
infarction; N: number; RCA: right coronary artery; SAP: stable angina 
pectoris; TIMI: Thrombolysis In Myocardial Infarction. ¶denominator 
equals n=20 patients.
TLRs or stent thromboses during the entire follow-up for any of the 
patients. However, at the one-year imaging procedure one patient 
had a clinically driven TVR. The two patients with lesions exhibit-
ing signs of persistent edge dissections at one-year follow-up were 
free of any major adverse cardiac events up to three years after the 
index procedure. None of the six patients from the Copenhagen 
cohort who had withdrawn consent for a follow-up OCT examina-
tion experienced any events at follow-up.
Discussion
Percutaneous coronary interventions are inevitably associated 
with vascular injury, including intimal tears and medial disrup-
tion20,21. Using a systematic classification and quantification of 
the extent of injury in three dimensions, we studied the natural 
history of OCT-detected non-flow-limiting edge dissections and 
found the following: 1) edge dissections were in principle consti-
tuted by dissection flaps, although cavity, double lumen and fis-
sure formation were also seen; 2) the majority of OCT-detected 
edge dissections healed uneventfully without excessive tissue 
formation; and 3) OCT-detected edge dissections, most of which 
were angiographically silent, were in this series of patients associ-
ated with favourable procedural outcomes and mid-term 
prognosis.
INCIDENCE OF EDGE DISSECTIONS AND MECHANISM OF 
HEALING
The incidence of edge dissections following stent implantation 
ranges from 1.7-6.4%1,2 by angiography, increasing to 7.8-19.3% 
by IVUS7,8,22, and 26.3%10 up to 34% seen by OCT in the present 
study. This not only reflects differences in resolution, but also indi-
cates that the use of intracoronary imaging tools more often requires 
a decision regarding management of apparently “imperfect” results. 
Table 2. Dissection characteristics.
Dissection characteristics, N=22 N (%)
Exhibited 
features within 
dissections
Flap 21 (95.5)
Cavity 8 (36.4)
Double lumen cap 7 (31.8)
Fissure 3 (13.6)
Predominant 
dissection type 
within 
dissections
Flap 21 (95.5)
Cavity 1 (4.5)
Double lumen cap 0
Fissure 0
Total longitudinal dissection length, mm* 2.90 (1.60-4.20)
Maximal circumferential extension¶, mm* 1.20 (0.86-1.67)
Maximal axial extension‡, mm 0.61 (0.38-0.70)
Maximal dissection area, mm2* 0.58 (0.27-0.76)
Dissection volume, mm3* 0.65 (0.19-1.06)
Maximal 
circumferential 
extent
1 quadrant 18 (81.8)
2 quadrants 4 (18.2)
Maximal vessel 
injury
Intimal involvement 11 (50.0)
Medial involvement 7 (33.3)
Percent frames with medial 
involvement*#
52.8 (33.3-80.0)
Adventitial involvement 4 (19.5)
Percent frames with medial 
involvement*#
60.4 (22.2-89.2)
Values are median (interquartile range); N: number; *values are median 
(interquartile range); ¶circumferential extension refers to the flap length, 
cavity width and cap length; ‡axial extension refers to flap root 
thickness, cavity depth and cap thickness; #in the respective lesions
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Published evidence, as well as the notable (25%) dissection-triggered 
use of GP IIb/IIIa inhibitors in the present study, confirm that OCT-
detected edge dissections may cause concern for further events11,12, 
although their sequelae up until now have not been sufficiently 
explored. Our data show that the majority of edge dissections 
healed completely during follow-up with only two out of 22 lesions 
showing residual signs of injury at one year. As indirectly suggested 
by the absence of an increase in plaque area by IVUS, the mechanism 
of healing was previously proposed to be a “layering” or “tacking 
down” rather than filling in of the gap with plaque material7 –
something which OCT in our study provided direct evidence for. It 
may be hypothesised that this is the consequence of the normal phys-
iological response to injury, where fibrin deposition at the disrupted 
surfaces of exposed tissues contributes to “gluing” the dissected 
layers together following the approximation of fluttering tissue 
flaps against the vessel wall by the flowing blood. It therefore 
Figure 3. Examples of healed dissections. The figure shows three dissection sites (A-C) at baseline and follow-up. Of note, there were no 
changes in signal intensity from baseline to follow-up at any of the dissection sites in the study. SB: side branch; i: intima; m: media; 
a: adventitia; white arrows in C1 and C2 point to residual blood in the vessel lumen, which should not be mistaken for dissections (diagnosis 
made by inspecting adjacent frames (not shown)); red arrow in C2 points to a seam line artefact, which should not be mistaken for 
a dissection.
Table 3. Morphometric results by OCT and IVUS.
Parameter Baseline Follow-up Absolute change Relative change p-value
Optical coherence tomography, N=22 – Reference vessel segment
Lumen area, mm2 5.35±1.73 5.58±1.72 0.21±0.81 6.7±18.4% 0.203
Lumen diameter, mm 2.58±0.42 2.64±0.38 0.06±0.20 3.1±8.8% 0.174
Intravascular ultrasound, N=17 – Reference vessel segment
Lumen area, mm2 5.95±2.29 6.84±1.98 0.89±1.51 22.6±34.6% 0.027
Lumen diameter, mm 2.70±0.50 2.92±0.39 0.22±0.35 9.9±15.1% 0.021
EEM area, mm2 11.20±2.38 12.40±2.58 1.21±1.92 12.9±20.3% 0.020
EEM diameter, mm 3.75±0.40 3.95±0.39 0.20±0.32 5.9±9.4% 0.020
P&M area, mm2 5.25±1.27 5.56±1.61 0.32±1.09 6.5±20.1% 0.251
Values are mean±standard deviation.
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Figure 4. Incompletely healed dissections. The figure shows the serial appearance of the two incompletely healed edge dissections (A-B). 
Of note is that the flap length in both cases was reduced at follow-up, although the dissection in panel A extended slightly longer longitudinally.
seems reasonable to assume that large flaps, in particular in the cir-
cumferential direction, are more mobile than smaller ones, and may 
not only increase the risk of obstruction and thrombosis, but also 
predispose to delayed vessel healing if continuously being sepa-
rated from the vessel wall by blood, somewhat analogous to obser-
vations from wound healing23. In fact, the two edge dissections 
which healed incompletely at follow-up in the present study exhibited 
the largest flap length (2.81 and 2.42 mm) at baseline and thus the 
longest circumferential extension in the entire cohort. Due to the 
low incidence of incomplete healing, we can only speculate that 
the maximum flap length may be more important for predicting 
healing than the extension in the axial and longitudinal direction, 
since the former is perpendicular to the blood flow. However, the 
combination with a double-lumen formation, kept open by the 
blood stream, may also play a role and could possibly have been 
the cause of the slight progression in longitudinal length in one of 
these cases at follow-up (from 1.8-2.0 mm). Although the sample 
size was relatively low, as were the frequencies of TCFA and 
fibrocalcific plaques at the stent edges, there seemed to be no par-
ticular association between the underlying plaque type and pro-
pensity of healing.
In terms of healing of edge dissections, our data are in line with 
a recent report by Kume et al24 who observed, in a total of 36 patients 
(39 lesions) with 12 edge dissections, that all but one were fully 
healed at follow-up. However, the following differences should 
be noted: data in the present study were collected prospectively 
(vs. retrospectively); with prespecified instructions on the interven-
tional strategy in 45/63 (71%) lesions (vs. strategy left to the discre-
tion of the operator); with similar follow-up time in all patients (vs. 
median (range) follow-up of 188 (98-461) days); solely with the use 
of DES (vs. DES+bare metal stents [BMS]); with a methodology 
comprising all types of edge dissections including cavities and dou-
ble-lumen dissections which occurred in 13.6% to 36.4% of cases 
(vs. flaps alone). Although the number of non-healed dissections at 
one year was very low, the present study provides details on the char-
acteristics that may have contributed to the lack of complete healing, 
and which may be regarded as hypothesis-generating for the further 
understanding of factors of importance for vessel healing.
CLINICAL IMPORTANCE OF EDGE DISSECTIONS
The absence of early events in our study is in line with previous 
IVUS reports and the OCT report by Kume et al, indicating that there 
appears to be no increased risk of early stent thrombosis in lesions 
with residual edge dissections as compared to those without8,24-26. In 
the present study, this may be attributed to several factors: 1) the 
small injury defect; 2) an early “tacking down” limiting the risk of 
obstruction and thrombosis; and 3) a potent antithrombotic and anti-
platelet therapy. However, the fact that the vast majority of dissec-
tions were angiographically silent and half were unidentified by 
IVUS indicates that they were relatively smaller in comparison to 
those previously associated with early stent thrombosis, including 
angiographic type B-F dissections1-3. Most importantly, however, 
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these and other studies unanimously showed that, in addition to edge 
dissections, other “abnormal findings” were concurrently present by 
angiography and IVUS, most consistently a low final minimal lumen 
diameter/area and poor stent expansion, but also a reduced final TIMI 
flow <34,5,27,28, suggesting that stent edge dissections may not per se 
cause acute events.
EDGE DISSECTIONS AND RESTENOSIS
In the long term, our morphometric analysis showed an absence of 
restenosis at the site of previous dissection despite the presence in 
several cases of deep vessel injury involving the media and/or 
adventitia, something otherwise known to be associated with 
a hyperproliferative response29. Our results confirm previous find-
ings by Sheris et al who similarly observed that the plaque and 
media area in the RVS by IVUS remained stable over a period of 
six months, even in the presence of submedial dissections7. It could 
be speculated that the antiproliferative drug from the DES in our 
study could have had a beneficial effect in preventing restenosis 
even in the RVS. However, considering that Sheris et al found the 
same in patients with BMS, together with other data showing that 
non-occlusive type A-D dissections following balloon angioplasty 
were associated with a reduced risk of restenosis compared to 
lesions without dissections6, it is likely that the process of “tacking 
down” by the flowing blood was more important, as it is well 
known that wounds with separated edges often heal with extensive 
scar formation, compared with wounds with approximated edges 
which heal with hairline scars23.
As it relates to the differences in lumen areas between the various 
imaging techniques used, it is well known that areas as measured by 
IVUS tend to be larger than by OCT30-32 (with the old as well as the 
new OCT systems), and our measurements are fully in line with 
this. The differences have occasionally been shown to be very large 
(25-72% difference)31. This can be caused by the use of an occlu-
sion balloon; however, another possible cause is the relatively 
greater degree of cardiac motion by IVUS due to a very slow pull-
back (0.5 mm/s) as compared to OCT (1-20 mm/s), resulting in 
a relatively larger “imprecise” matching between baseline and fol-
low-up. In addition, with the resolution of OCT being 10-20 µm, 
and that of IVUS 100-150 µm, “inaccuracies” within the resolution 
window are relatively larger by IVUS (±100-150 µm) than by OCT 
(±10-20 µm) which may result in significant differences32.
MANAGEMENT OF OCT-DETECTED RESIDUAL EDGE 
DISSECTIONS
Due to the absence of adverse events in the present cohort, we cannot 
provide any quantitative directives on which dissections will cause 
events and which will not. However, longitudinal extensions up to an 
average of 7.8 mm in previous IVUS studies25, and a circumferential 
extension up to 2.81 mm by OCT as seen in our study, were both asso-
ciated with an uneventful mid-term clinical course. The additional 
mechanical treatment of OCT-detected residual edge dissections being 
mainly angiographically silent should therefore be carefully evaluated, 
not least when considering that additional IVUS-guided stent implan-
tation for residual edge dissections has not been shown to entail any 
benefits in terms of reducing the rate of restenosis and stent thrombosis 
when compared to an angiographically guided group without treatment 
of these injuries24, but was rather associated with complications in 
terms of TLR8. Considering that GP IIb/IIIa inhibitors seem to exert 
a protective effect against early stent thrombosis3,33, these may be a rea-
sonable alternative to stent implantation in the presence of large 
non-flow-limiting OCT-detected edge dissections.
Limitations
The number of patients in this observational study was relatively small, 
mainly related to the requirement of serial assessment with OCT and 
IVUS. Furthermore, the inability of OCT to image proximally/ostially 
located regions, due to the need for blood clearance during acquisition, 
precluded visualisation of all proximal reference vessel segments. 
Together with a certain selection of patients, the dissection incidence of 
34% may not reflect that in the real world, although it may be assumed 
that they are fairly representative for OCT-detected edge dissections 
which are for the most part angiographically silent. The low number of 
patients further limited our ability to detect rare adverse events and thus 
to provide recommendations on when a residual dissection imposes an 
increased risk of, e.g., acute stent thrombosis. Finally, we did not assess 
the predictors of edge dissections as our focus was on their natural his-
tory, and as predictors had previously been evaluated8. Furthermore, 
considering that the majority of these dissections underwent complete 
healing, this may seem redundant.
Conclusion
OCT-detected edge dissections, which are angiographically silent 
in the majority of cases, constitute a relatively frequent and benign 
finding after DES implantation, and are not associated with acute 
stent thrombosis or restenosis up to one-year follow-up.
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Introduction
Fully bioresorbable everolimus-eluting vascular scaffolds (BVS;
Abbott Vascular, Santa Clara, CA, USA) are a novel approach to
treating coronary lesions. The ABSORB cohort A and cohort B trials
investigated the implantation of 3 mm BVS, up to a maximum
length of 18 mm, in simple lesions only.1,2 The implantation of
overlapping BVS in longer lesions has not previously been reported.
Although the initial results in ABSORB cohort A were very
promising, it was found that the main limitation of the BVS (BVS
1.0) was a premature reduction in radial strength.3-7 Through
several design modifications, primarily aimed at maintaining the
structural integrity of the BVS for longer, excellent results were
obtained in ABSORB cohort B at six months.8-10 This second
generation BVS (BVS 1.1) is now the subject of a large, international,
multicentre, ABSORB EXTEND Single Arm Study with the aim of
recruiting over 1,000 patients from over 50 centres worldwide. As
part of this study, a 50 patient sub-study will be conducted to assess
the outcomes of overlapping BVS in the treatment of long lesions,
with the use of optical coherence tomography (OCT) at both baseline
and follow-up.
Firstly, we report our initial experiences of the different types of
overlap achievable with the BVS through implantation in an in vitro
phantom model followed by 2-dimensional (2D) and 3-dimensional
(3D) OCT imaging (frequency domain OCT [FD-OCT]). Secondly,
we report our experiences of some of these overlap methodologies
in a healthy porcine coronary artery model at 28 and 90 days to
assess the neointimal response and strut coverage. Thirdly, we
report our initial findings in humans from four of the first five
patients to have had implantation of overlapping BVS from the
ABSORB EXTEND Single Arm Study. Baseline angiographic,
intravascular ultrasound (IVUS), 2D and 3D FD-OCT reconstructions
of the varying types of overlapping BVS will be demonstrated. Lastly
we report our revised OCT methodology protocol for the assessment
of the overlapping BVS at baseline and subsequent angiographic
and OCT follow-up, in order to assess the coverage of the
overlapping BVS. Since the overlapping BVS segment area is highly
complex, the standard OCT assessment of the BVS, which has
previously been performed in the ABSORB cohort A and B trials,3,7,10
is not possible and a new methodology is therefore required.
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BVS
The BVS revision 1.1 (Figure 1) is a balloon expandable device
consisting of a polymer backbone of Poly-L (racemic)-lactide
(PLLA) coated with a thin layer of a 1:1 mixture of an amorphous
matrix of Poly-D, L (racemic)-lactide (PDLLA) polymer, and
100 micrograms/cm2 of the anti-proliferative drug everolimus. The
PDLLA allows for the controlled release of everolimus, 80% of which
is eluted within the first 30-days. The elution rate, tissue
concentration and dose density of everolimus are similar for both
the BVS and the XIENCE V everolimus eluting stent (EES). Both
PLLA and PDLLA are fully bioresorbable. The polymer is degraded
via hydrolysis of the ester bonds in the backbone. The resulting
poly-lactide low molecular weight oligomers eventually leave the
polymer matrix and are hydrolysed and metabolised through the
pyruvate and Kreb energy cycles in the surrounding tissues and
blood. Small particles, less than 2 µm in diameter, are
phagocytosed by macrophages. According to preclinical studies,
the time for complete bioresorption of the polymer backbone is
approximately two years.9
Two platinum markers (Figure 1) located at each BVS edge allows
for the accurate visualisation of the radiolucent BVS during coronary
angiography and OCT. The cell area in the pattern of the BVS was
reduced in size during the design modification from BVS 1.0 to 1.1
in order to give maximum and more uniform support to the vessel
wall (Figure 1)8.
imaging core was subsequently directly inserted into the guidewire
lumen of the BVS deployment catheter. This helped to maintain the
near perfect central position of the imaging core within the phantom
model, with the consequential benefits of avoiding potential imaging
artefacts.
A perspex (Plexiglas®) tube with an internal diameter of 3.5 mm
and filled with contrast, kept at a temperature of 37 degrees Celsius
to approximate human body conditions, was used as the phantom
model to bench test the overlapping BVS. The transparent nature of
the phantom model allowed us to directly visualise the longitudinal
position of the imaging core of the OCT probe relative to the overlap
of the BVS struts, thereby allowing the acquisition of cross-sectional
2D OCT images of the entire overlap region (Online moving image).
The cross-sectional images of the overlapping BVS struts were
acquired at 15.4 frames/sec, with the fibreoptic imaging core being
pulled back at a speed of 0.1 mm/sec.
Overlapping 3.0 mm diameter BVS, 18 mm in length, were
implanted in the phantom model in three different overlapping
configurations (described below) to best replicate the types of
overlap that could potentially be achieved in human implantation.
“Interdigitating or adjacent positioning struts without overlap” of two
adjacent BVS (Figures 2a-2d): this involved the near perfect
positioning of the two BVS devices adjacent to each other, through
very careful positioning of the platinum markers so that they were
sited side by side, with each BVS virtually “slotting” into the other.
As illustrated, 2D and 3D OCT imaging showed the uniform
distribution of struts without gap or “stacking” of struts.
“Complete overlap with multiple numbers of stacked struts” of two
adjacent BVS (Figures 2e-2h): OCT imaging shows struts clearly
overlapped and completely superimposed on each other (“stacked
struts”) thereby forming a total strut thickness of at least 300
microns in these stacked strut regions. In the phantom model, this
kind of overlap was achieved through the overlapping of the
platinum markers as demonstrated (Figures 2e and 2g).
“Complete overlap with reduced numbers of stacked struts” of two
adjacent BVS (Figures 2i-2l): this was a standard overlap with
rotation of the BVS platinum markers so that they were positioned
90 degrees to each other. This allowed an overlap, but reduced the
number of stacked struts, as many of the would-be overlapping
struts in one BVS tended to slot into the cell space between the strut
of the other BVS. Using this approach, most of the BVS strut
thicknesses at the overlap were maintained at 150 microns, with
fewer areas with stacked struts. In the phantom model, this kind of
overlap was achieved through the positioning of each of the BVS
markers at right angles to each other.
Implantation in an animal model
From the bench-work experimentations, we elected to test in a non-
diseased porcine coronary artery model the two types of complete
overlap achievable that best represented single or stacked strut
appearances.
Overlapping BVS were implanted in the coronary arteries of healthy
swine. After 28 and 90, days the segments implanted with
overlapped BVS were harvested and scanning electron microscopy
undertaken. Results indicated that in the complete overlap with
Figure 1. The BVS 1.1 device. Two platinum markers can be seen clearly
on the left side, the corresponding platinum markers on the other side
of the BVS 1.1 are located posteriorly. The green zone represents the cell
area which was reduced in size during the design modification from BVS
1.0 to 1.1.
Bench testing (in vitro phantom model) and
implantation in a porcine model
Bench testing
A commercially available OCT M2 system (ImageWire™ ; LightLab
Imaging Inc., Westford, MA, USA) was used for imaging. The OCT
probe was stripped down with the removal of the fibreoptic imaging
core (150 microns in diameter) from the OCT probe. The fibreoptic
The Contribution of Optical Coherence Tomography to Interventional Cardiology 121
- 3 -
multiple stacked struts, each with a thickness of at least 300 microns,
(Figure 3a) there was a somewhat delayed endothelialisation at
28 days. Conversely, in the complete overlap with reduced number
of stacked struts, thereby minimising the thickness of struts with a
thickness of 300 microns with most struts having a thickness of
150 microns, endothelialisation appeared to be almost complete at
28 days (Figure 3b). At 90 days however, all forms of the overlap
tested in the porcine model were fully covered and endothelialised
(Figure 3c).
Replicating the forms of bench-tested
overlapping BVS in humans
Trying to intentionally achieve any of the three overlapping BVS we
have bench-tested during conventional percutaneous coronary
intervention (PCI) is highly difficult and is more likely to occur by
chance. With the “interdigitating” or adjacent positioning of BVS
during conventional PCI, the main risk is leaving a gap
(“geographical miss”)11 between the BVS with the consequential
risk of restenosis. With the other two techniques, either type of
complete overlap will occur only by chance as the markers need to
be positioned at 90 degrees to each other in order to reduce the
number of stacked struts, something that would be practically
unachievable during conventional PCI.
Implantation in humans - case examples
from the ABSORB EXTEND Single Arm Study
Case 1: “complete overlap with multiple number of stacked struts”
(Figure 4)
A 66-year-old gentleman presented with stable angina (Canadian
Cardiovascular Society angina Class II), he was an ex-smoker and
had no other comorbidities. Coronary angiography demonstrated
a significant long lesion, of at least 24 mm in length, in the proximal
LAD, with quantitative coronary angiography (QCA) revealing an
interpolated reference vessel diameter (RVD) at the minimal lumen
diameter (MLD) of 2.33 mm. Proximal and distal Dmax of the
intended implantation site were 2.50 mm each, which made this
vessel suitable for implantation with two overlapping 3×18 mm BVS
devices.12 Pre-dilatation was undertaken with a 2.5 mm balloon and
Technical report
Figure 2. Outer appearances of the overlapping BVS in a phantom model (A, E and I), 3D reconstruction of OCT (B, F, J), magnified image of outer
appearances (C, G and K) and corresponding cross-sectional OCT images (D, H and L) are presented. Yellow arrows indicate platinum marker
positions. The upper panel represents “inter-digitating” or “adjacent positioning” of the BVS without overlap. The middle and lower panels represent
the two differing forms of “complete overlap” that can be achieved. Note in the lower panel, there are a reduced number of stacked struts as
compared to the middle panel – this is because in the lower panel, the platinum markers are positioned at 90 degrees to each other, this causes the
majority of the overlapped struts to be positioned in the cell area between the struts rather than being stacked on top of each other.
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two overlapping 3×18 mm BVS were implanted with at least 4 mm
of overlap. Mild under-deployment of the BVS at the overlap was
noted (Dmin 2.35 mm of deploying balloon) which required post-
dilatation with the BVS deploying balloon to higher pressures. Post-
implantation, IVUS and OCT imaging were carried out. Off-line 3D
reconstruction and volume rendering of the OCT images were
undertaken (INTAGE Realia; KGT, Tokyo, Japan), the methodology
of which has previously been described.13 As illustrated, the IVUS
and OCT imaging clearly shows the complete overlap with multiple
stacked struts as previously demonstrated in the bench and animal
model.
A further example of complete overlap with multiple stacked struts
is illustrated online (Online Appendix).
Case 2: “Combination of interdigitating and complete overlap”
(Figure 5)
A 78-year-old male presented with stable angina (Canadian
Cardiovascular Society angina Class III). He was an ex-smoker with
no other risk factors. Coronary angiography demonstrated a single
lesion in the obtuse marginal vessel, 14 mm in length with a 90%
diameter stenosis (RVD 2.5 mm). Predilatation with a 2×15 mm
balloon was performed without complication and a 3.0×18 mm BVS
was deployed. Because of incomplete lesion coverage after initial
BVS deployment, a second 3.0×18 mm BVS was deployed more
distally overlapping with the first. No post-dilatation was performed
and the patient made an uneventful recovery.
The area of overlap was calculated to be 2.7 mm by 2D OCT and
when visualised on 3D OCT, the upper portion of the overlap
appeared to be “interdigitating” and the lower part appeared to be
completely overlapping with the struts of one BVS positioned within
the cells of the other BVS (Figure 5b), thereby reducing the number
of stacked struts.
Case 3: “Adjacent positioning of the BVS with minimal overlap”
(Figure 6)
A 74-year-old female, with a history of hypertension and a previous
myocardial infarction four months previously, presented with
unstable angina (Braunwald Classification Class II). Coronary
angiography identified a single lesion in the proximal RCA, 27 mm
in length with a maximum of 90% diameter stenosis (RVD 2.8 mm)
and TIMI 1 flow. Pre-dilatation was successfully performed with a
2×20 mm balloon and two overlapping BVS (3.0×18 mm) were
subsequently deployed in the proximal RCA (maximum pressure
14 atm). No post-dilatation was performed.
2D and 3D OCT appeared to show an example of adjacent
positioning of both BVS with a very minimal (0.5 mm) overlap
between the two adjacent BVS in the proximal RCA.
2D OCT assessment of the overlap in humans
The 2D assessment of the non-overlapping BVS at baseline and
follow-up has previously been conducted in the ABSORB cohort A
and B studies.3,7,10 As part of the OCT substudy in the ABSORB
EXTEND Single Arm Study, OCT assessment of the overlapping BVS
will be performed by an independent core laboratory. However, given
the complexities of the overlapping struts as shown in the case
examples, with the varying and unique patterns of strut distribution
and stacking seen from frame to frame (Figure 7), the standard OCT
methodology for assessing simple lesions cannot be applied to the
overlap. It is therefore necessary to include all the frames in the
overlap to allow for the accurate baseline and follow up assessment.
This is in contrast to the assessment of non-overlapping segments
from the ABSORB cohort A and B trials, where frames occurring
every 1 mm were routinely analysed. Dependent on the length of the
overlap, this will proportionately increase or decrease the number of
frames for analysis.
The nomenclature and principles of analysis of OCT frames,
previously applied to the shorter lesions in ABSORB cohort A and B,
will be maintained for the overlap frames at both baseline and follow
Figure 3. Scanning electron microscopic images acquired from healthy
porcine coronary models representing the two forms of complete overlap
of BVS. Delayed endothelialisation at 28 days is seen with multiple
numbers of stacked struts at the overlap (corresponds to Figure 2e-2h)
(a). Almost complete endothelialisation at 28 days is seen with reduced
numbers of stacked struts at the overlap (corresponds to figure 2i-2l)
(b). However at 90 days complete endothelialisation was seen with both
overlapping types (c). Yellow arrows indicate overlapped segments.
A
B
C
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Figure 4. Case 1: “Complete overlap with multiple stacked struts” Coronary angiography revealed a long lesion in the proximal-mid LAD (A),
interpolated RVD at MLD of 2.3 mm (B) and the final angiographic result post overlapping BVS implantation (C). OCT and IVUS identified the
proximal, overlapping and distal platinum markers (D) - black arrows indicate the position of the markers seen on coronary angiography and white
arrows the position of the markers seen on OCT and IVUS imaging. Consecutive OCT images across the overlap (pullback speed 20 mm/sec)
(E) reveals multiple configurations of struts with numerous stacked struts seen. 
A
D
E
B C
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up (Table 1). However, in most cases, the methodology will vary
slightly to reflect the complexities in strut distribution seen at the
overlap. The study investigators will be aware that the frames
analysed are from the overlap and that these frames will be
investigated separately, as compared to the non-overlapped
segments.
The following OCT parameters, with a brief description of the
methodology, will be analysed for the overlap.
1. Lumen area (Figure 8)
This is calculated in the conventional way as with a simple, non-
overlapping lesion. The internal vessel contour is drawn around with
multiple correction points using the OCT software which then, through
a process of “splining,” automatically draws in the lumen which the
operator can adjust so that it corresponds to the lumen contour. Of
note is that the lumen contour on baseline OCT images will always be
drawn behind (i.e., abluminally) the struts, even if they are embedded
Figure 4 (cont). Three-dimensional volume rendered images of OCT images of the vessel, with guide-wire shadow (F), internal longitudinal view of
the vessel showing the 4 mm overlap (G), a fly-through view (proximal-distal) of the vessel at the overlap (H) and a close up view of the vessel wall
at the area of overlap (I). White arrows (G) represents the edge of each respective overlapping BVS, note the side-branch (septal branch) which
marks the location of one end of the overlap in all views. Black arrows (H, I) represents the overlap in the fly-through view.
F
G
H I
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Figure 5. Case 2: Combination of “complete overlap” and “interdigitating struts without overlap.” Consecutive OCT images across the overlap
(pullback speed 20 mm/sec) (A) showing overlapping BVS struts with a small number of stacked struts. Longitudinal view of the vessel in 3D OCT
(B). White arrows show the edge of each BVS with “interdigitating struts” at the upper margin and “complete overlap” at the lower end with the
struts positioned in the cell area of the other BVS thereby reducing the number of stacked struts. Virtual fly-through view (proximal-distal) (C) with
black arrow indicating overlapped segment and a close up view of the overlap (D) with black arrow indicating same position of overlap. The
guidewire can clearly be seen (B). Note the “drop out” in the strut resolution to the left of the overlap (B) – this is an artefact due to a premature
cardiac beat, this is a potential problem when slower pullback speeds of the FD-OCT probe are used.
A
B
C D
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(Figure 8b – see struts in 12 o’clock position) on follow-up OCT, the lumen
contour will be drawn behind the struts if they are uncovered only.
2. Scaffold area (Figure 11)
The scaffold area, as the name suggests, is the area contained
within the BVS frame and in non-overlapping lesions, is usually
a circular area drawn around all the abluminal sides (“back side”)
of the BVS struts. The scaffold area is an important concept for
bioresorbable scaffolds, as changes can signal losses in material
radial strength or structural integrity. Unfortunately drawing the
scaffold area at the overlap can potentially be difficult, given that
- 8 -
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Figure 6. Case 3: BVS with minimal (0.5 mm) overlap. Consecutive OCT images across the overlap (pullback speed 20 mm/sec) (A). The OCT
images show a few stacked struts in 4-5 OCT frames only. Longitudinal section of the vessel (B), white arrows show the edge of each BVS positioned
with approximately 0.5 mm of overlap. Fly-through view (proximal-distal) (C) with black arrow indicating the minimal overlapped segments.
A
B
C
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there are multiple stacked struts clusters (collections of struts all
apposed to each other) and the operator potentially not knowing
around which struts to draw the scaffold area.
The OCT image of a BVS 1.1 strut consists of a “black core” area
surrounded by a “white frame” (Figure 9). The white frame is
interpreted to comprise an area of backscatter from the surfaces of
the BVS strut, whereas the black core is interpreted as
representing the completely radiolucent bulk material. The BVS
strut thickness is approximately 150 microns. When the strut
becomes covered at follow-up (Figure 9), the black core area
Technical report
Figure 7. Illustration to demonstrate the varying appearances of the
stacked BVS struts seen on OCT analysis. Stacked struts and stacked
strut clusters (collections of struts all apposed to each other) are shown.
Figure 8. Lumen area in an overlapping BVS segment. The lumen area
is drawn in the conventional way by following the contours of the lumen
in non-bifurcating (A) and bifurcating (B) vessels.
Figure 9. Characteristics of BVS 1.1 strut at baseline and six month
follow-up (case example form ABSORB Cohort B). At baseline, each
strut consists of a black core surrounded by a white frame (A). At six
month follow-up (b) the black core remains intact, however when the
strut becomes covered, trying to identify the white frame is not
possible with reliability as demonstrated (B).
remains translucent. However, trying to identify the white frame
with reliability is difficult and subjective. In the overlap situation,
where the struts are either apposing each other or even embedded
in the vessel wall, trying to again identify the white frame with
reliability is also difficult (see case examples). Conversely, long-
term animal studies have shown that the black core area seen on
OCT, although replaced by proteoglycans upon bioresorption of the
polymer, retains its shape and translucency on OCT at up to two
years follow-up;9 the black core area is therefore a constant point of
reference to measure from.
We therefore recommend that the scaffold area be measured from
the abluminal side of the black core area. Wherever the struts
(either single strut of part of a stacked strut cluster) appose the
vessel wall, the contour line of the scaffold area is drawn around the
abluminal side of the black core for those particular struts, with a
correction point marked at the halfway position of the abluminal
black core border (Figure 10). The computer software can then use
these correction points to create the scaffold area through the
splining process as previously described. The rationale being that
the BVS delivers its radial strength through areas of the scaffold in
apposition to the vessel wall, and any overlapping struts not
apposing the vessel wall will deliver their radial strength to the vessel
wall through their apposition to struts which already appose the
vessel wall.
In situations where a strut or strut cluster is seen to be not apposing
the vessel wall, the scaffold area is drawn around the abluminal side
of the black core of the struts that are the nearest to the vessel wall
(Figure 11). Struts not apposing the vessel wall at the overlap do not
necessarily imply incomplete scaffold apposition (ISA); this is more
likely to be related to either the strut being located at a side branch,
or it being part of a stacked strut cluster that typically is apposing
the wall on the next few OCT frames.
It should be noted that only one correction point per strut is required
for the computer software to create, through the process of splining,
the scaffold area when performing the OCT analysis of the overlap.
(Figure 11). Whilst placing two correction points per strut may make
the scaffold area more agreeable to the eye, i.e., it being more
circular, we have found that the actual differences in terms of the
scaffold area appears to be insignificant as illustrated (Figure 12).
3. Black core area (Figure 13)
The black core area for each frame is calculated as illustrated. This
is used for calculating the “flow area” as described below.
Table 1. OCT parameters for measurement at the overlap.
OCT Parameters to be measured at the overlap
Lumen area
Scaffold area
Black core area
Flow area
Thickness of struts to assess strut coverage
– thickness of single strut, thickness of single strut at side branch
– thickness of stacked struts, thickness of stacked struts at the
side branch
Incomplete scaffold apposition (ISA)
Black core ISA
Thickness ISA
A B
A B
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4. Flow area (Figure 14)
Effectively the flow area is the area of the vessel where blood flows
through. This is calculated as the lumen area minus the black core
area. Theoretically, the area occupied by the white frame of the BVS
strut should also be subtracted from the flow area; however, because
of the unreliability of measuring the white frame area as previously
described, this has been omitted from the flow area calculation. As
the flow area will be calculated at baseline and follow up, the white
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Figure 10. Methodology of drawing the scaffold area around the single strut, the stacked struts and stacked strut clusters of the BVS. The scaffold
area is drawn around the abluminal side of the black core area in a single strut. In a stacked strut cluster (A), the scaffold area is drawn around
the abluminal side of the black core area (black arrow) at each strut that apposes the vessel endothelium (A, B), as these are points of scaffolding
to the vessel. White boundaries indicate a stacked strut cluster.
Figure 11. Scaffold area in the overlapping BVS in the main-branch (A) and side-branch (B). (A) This is drawn from the “backside” (i.e., abluminal
side) of the black core area of the outermost strut or stacked strut cluster (at the point of all the struts apposing the vessel endothelium) apposing
the vessel wall. Where there does not appear to be any apposition of a single strut or stacked strut cluster to the vessel endothelium, the contour
of the scaffold area continues to follow the outermost (most abluminal) scaffold strut or stacked strut cluster.
Figure 12. Scaffold area requires one correction point per black-core area to allow the computer software to create the scaffold area through
a process of “splining.” One (A) or two correction points (B) can be placed for each black-core area. Although a more smoother and visual appealing
scaffold area is seen with two markers per black core area – the actual difference in terms of scaffold area is not significant.
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Figure 13. Black core area. Each single strut or stacked strut cluster
has its individual black core area measured to calculate the strut area
for each OCT image at the overlap.
Figure 14. Flow area. As illustrated – this is the lumen area minus the
strut area.
Figure 15. Thickness of single struts and thickness of stacked struts in a non-bifurcating (A) and bifurcating (B) vessel. Green area represents the
lumen area boundary.
frame area in both the baseline and follow up flow areas will effectively
cancel each other out when the difference in flow area is calculated.
At follow up, if all the struts are covered, the flow area will equal the
lumen area. If, however, all the struts are not covered, the flow area
will equal lumen area minus uncovered black core/white frame areas.
5. Thickness of single struts and thickness of stacked struts to assess
strut coverage (Figure 15)
The thickness of struts is taken from the midpoint of the
endoluminal side of the black core area in single struts to the lumen
area boundary (thickness of single strut), from the midpoint of the
most endoluminal strut in stacked strut clusters to the lumen area
boundary (thickness of stacked struts) and also from the
endoluminal side of a stacked strut cluster to the lumen area
boundary, when more than 50% of the more abluminal strut is not
covered by the more endoluminal strut.
In side branches this principle is maintained for both single struts
(thickness of single strut at side branch) and stacked strut clusters
(thickness of stacked struts at side branch) with the thickness
measured to the presumed lumen area boundary.
At follow-up OCT, the thickness of the covered single or stacked
struts will have a positive value in covered struts, whilst uncovered
struts will continue to have a negative value as was seen at baseline.
6. Black core ISA and thickness ISA (Figure 16)
Incomplete scaffold apposition (ISA) is measured both at baseline and
follow-up to assess for procedural or late acquired ISA. As the black
core area is constant, all ISA measurements will be made from here.
The “thickness ISA” is measured from the abluminal side of the white
frame zone to the lumen area boundary. The black core ISA is measured
from the abluminal side of the black core area, where the margin is very
clear (Figure 16), to the lumen area boundary as illustrated.
Discussion
Based on the bench-work and subsequent data from the animal
model, it would appear that either the “interdigitating position” or
complete overlap with reduced number of stacked struts would be
A B
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BVS i.e., minimal overlap as shown in case 3. This would potentially
minimise the numbers of stacked struts, limit the risk of a gap
occurring between the BVS and theoretically increase the rate
towards complete endothelialisation. The outcomes from the OCT
substudy in the ABSORB EXTEND Single Arm Study investigating
the overlap are therefore awaited with interest.
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the ideal solutions in order to ensure more rapid endothelialisation
at the overlap. By using these methods, the number of stacked
struts would be minimised, remembering that each stacked strut
has a minimum thickness of 300 microns as opposed to a single
strut thickness of 150 microns, and that the evidence from the
animal model suggests that these stacked struts would potentially
be at risk of delayed endothelialisation. However, both of these
overlapping techniques cannot be performed angiographically with
reliability, and are more likely to occur by chance rather than by
procedural technique as previously described.
The occurrences of reduced endothelialisation at the overlap has
previously been described with overlapping metallic drug eluting
stents (DES).14,15 Finn et al 200514 showed in a rabbit iliac artery
model that both overlapping sirolimus (SES) and paclitaxel (PES)
eluting stents demonstrated evidence of a persistent inflammatory
response, fibrin deposition and delayed endothelialisation. With
overlapping metallic DES, damage or cracking of the polymer16,17
can potentially occur at the overlap with the consequent risk being
persistent foreign body inflammation. In clinical practice however,
the evidence for a lack of endothelialisation at the overlap with
metallic DES is more controversial. Some studies have suggested an
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adverse events18,19 and other studies have failed to make this
association20,21 or even suggested differences in coverage pattern
(but not in the number of uncovered struts) dependent on the type
of DES implanted.21
With the BVS 1.1, the polymer is both bioresorbable and biocompatible,
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24 months and the inflammatory response to the polymer should be
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theoretically eliminating the risk of late stent (“scaffold”) thrombosis.
Based on the results of the bench-work and animal models,
perhaps the more practical and pragmatic solution in implanting
overlapping BVS is positioning each BVS very close to each other
and ensuring only a small territory of overlap occurs between each
Figure 16. Black core ISA and thickness ISA. The “black core ISA” (B,
D) and the “thickness ISA” (C, E) are clearly demonstrated. Note the
black core ISA is taken from the abluminal side of black core ISA
where the border is very clear – the red arrow indicates a zone from the
abluminal white frame to the black core area where the margin of the
black core cannot be clearly be defined. The black core area should
therefore not be measured from within this zone.
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Online data supplement
Moving image. Demonstration of the phantom model used to assess
the overlapping BVS. The recording on the right shows the pullback
of the OCT fibreoptic imaging core and the recording on the left
demonstrates the corresponding OCT images obtained during the
pullback.
Figure M. 3D OCT demonstrating a virtual fly-through (proximal-
distal) of the vessel (pullback speed of FD-OCT probe 10 mm/sec).
The treated lesion was 28 mm in length with a maximum of 60%
diameter stenosis (RVD 2.5 mm) and TIMI 3 flow; two overlapping
BVS (3.0×18 mm) were successfully deployed (maximum
pressure 14 atm). No post-dilatation was performed. The overlap
in the mid RCA can clearly be visualised (6 mm) with multiple
stacked struts.
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CHAPTER 4 METHODOLOGICAL 
CONSIDERATIONS IN THE 
APPLICATION OF OPTICAL 
COHERENCE TOMOGRAPHY 
FOR THE EVALUATION OF 
BIORESORBABLE SCAFFOLDS
4.2 Spatial distribution and temporal 
evolution of optical coherence 
tomography “white dots” in the 
poly-L-lactide backbone of an 
intracoronary bioresorbable 
scaffold: association to polymer 
crazes during crimping of the 
device. 
Gutierrez-Chico JL, Radu MD, Diletti R, Sheehy A, 
Glauser T, Harrington J, Rapoza R, Onuma Y, Serruys 
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he Abbott Vascular bioresorbable vascular scaffold 
(BVS) (Santa Clara, CA, USA) consists of a semi-
crystalline poly(L-lactide) (PLLA) backbone and con-
formal coating of amorphous poly(D,L-lactide) (PDLLA) and 
the antiproliferative agent, everolimus. The molecular weight 
of the BVS polymers is degraded primarily through hydrolysis 
of the ester bonds present in each monomer subunit. Crystal-
line residues with a characteristic dimension less than 2 μm are 
phagocytosed by macrophages. Ultimately, PLLA and PDLLA 
degrade to lactate, which is metabolised via the Krebs’ cycle 
and other metabolic pathways,1 similarly to other biodegrad-
able polymers.2 Complete polymer resorption occurs approxi-
mately 2 years after implantation.3,4 The BVS is laser-cut from 
a single piece of polymer tubing and then crimped onto a bal-
loon. The structural design of the BVS consists of 19 W-shaped 
rings connected longitudinally by straight links (Figure 1). The 
BVS has delivered acceptable and durable clinical and angio-
graphic results up to 2 years post-procedure when the scaffold 
has been completely resorbed.5,6
Unlike metallic stents,2,7–11 the translucency of the processed 
polylactide used in the Abbott Vascular BVS makes it particu-
larly suitable for optical coherence tomography (OCT) imag-
ing. The optical radiation can penetrate the translucent poly-
mer, with significant backscattering occurring only at the 
borders of struts where the refractive index of the medium 
changes. Alternatively, the strut core has been characterized as 
a “black box”,3,5,6 signifying the absence of refractive index 
changes within the material (Figure 2). However, some OCT 
images show a focal hyperintense signal in the strut core with-
out apparent contact with either the axial or transversal strut 
T
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Spatial Distribution and Temporal Evolution of Scattering  
Centers by Optical Coherence Tomography  
in the Poly(L-Lactide) Backbone of a  
Bioresorbable Vascular Scaffold
Juan Luis Gutiérrez-Chico, MD, PhD; Maria D. Radu, MD; Roberto Diletti, MD; Alexander Sheehy, PhD; 
Mary Beth Kossuth, PhD; James P. Oberhauser, PhD; Thierry Glauser, PhD; Joel Harrington, PhD;  
Richard J. Rapoza, PhD; Yoshinobu Onuma, MD; Patrick W. Serruys, MD, PhD
Background: Scattering centers (SC) are often observed with optical coherence tomography (OCT) in some struts 
of bioresorbable vascular scaffolds (BVS). These SC might be caused by crazes in the polymer during crimp-
deployment (more frequent at inflection points) or by other processes, such as physiological loading or hydrolysis 
(eventually increasing with time). The spatial distribution and temporal evolution of SC in BVS might help to under-
stand their meaning.
Methods and Results: Three patients were randomly selected from 12 imaged with Fourier-domain OCT at both 
baseline and 6 months in the ABSORB cohort B study (NCT00856856). Frame-by-frame analysis of the SC distribu-
tion was performed using spread-out vessel charts, and the results from baseline and 6 months were compared. A 
total of 4,328 struts were analyzed. At baseline and follow-up all SC appeared at inflection points. No significant dif-
ference was observed between baseline and 6 months in the number of SC struts (14.9 vs. 14.5%, P=0.754) or in the 
distribution of SC. The proportion and distribution of SC did not vary substantially among the patients analyzed.
Conclusions: The SC observed in OCT imaging of the BVS are located exclusively at inflection points and do not 
increase with time. These findings strongly suggest that SC are caused by crazes in the polymer during crimp-deploy-
ment, ruling out any major role of hydrolysis or other time-dependent processes.
Key Words: Coronary stenosis; Drug-eluting stents; Optical coherence; Poly(lactide); Tomography
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Figure 1.  Structure of the Abbott 
Vascular bioresorbable vascular scaf-
fold revision 1.1. An 18-mm length 
scaffold consists of 19 W-shaped 
rings (white arrows), connected with 
the adjacent rings by 3 straight longi-
tudinal units (red arrows).
Figure 2.  Definition of scattering centers (SC). The struts classified as having SC present a focal hyperintense backscattering 
signal in the core of the strut, which typically does not reach either the axial or the transversal strut edges, thus taking the appear-
ance of a “dot” inside a box (Left). Notice the difference with the typical “black box” appearance of the BVS struts (Right upper). 
It is important to differentiate between SC from the optical appearance of confluent or bifurcating struts, where there is also a 
hyperintense signal in the core of the strut; however, in this case, it reaches its axial edges (Right lower).
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edges (Figure 2). The cause of this backscattering signal re-
mains to be elucidated: it might reflect a change in the poly-
mer’s optical properties induced by the hydrolysis process or it 
might correspond to deformation-induced crazes in the back-
bone of the PLLA polymer, the latter preferentially located at 
hinge points of the BVS structure. The existence of regions 
with accelerated hydrolysis in humans or the presence of poly-
mer crazes, eventually growing under continuous physiologic 
load, could both jeopardize the structural integrity of the BVS 
required to be functional.
This study explored the hypothesis that scattering centers 
(SC) observed in strut cores at baseline OCT imaging are 
derived from polymer crazing caused by the mechanical defor-
mation of scaffold crimping and deployment, analyzing whether 
the spatial distribution of the SC at baseline is consistent with 
that hypothesis. The temporal evolution of these SC at 6 months 
permits assessment of the eventual influence of physiological 
loading, polymer degradation, or tissue integration in the gen-
esis of the SC.
Methods
Study Sample
The ABSORB Cohort B registry (NCT00856856) design has 
been published elsewhere.3 The study enrolled patients older 
than 18 years, with diagnosis of stable or unstable angina pec-
toris or silent ischemia, and de novo lesions in native coronary 
arteries amenable for percutaneous treatment with the BVS 
(percent diameter stenosis ≥50% by visual estimation, reference 
vessel diameter 2.5–3.5 mm). Exclusion criteria included: acute 
myocardial infarction, unstable arrhythmias, left ventricular 
ejection fraction ≤30%, restenotic lesions, lesions located in the 
left main coronary artery or in bifurcations involving a side 
branch >2 mm, a second clinically or hemodynamically signifi-
cant lesion in the target vessel, documentation of intracoronary 
thrombus, or initial TIMI 0 flow. For invasive follow-up pur-
poses, the cohort was subdivided into 2 groups: cohort B1, 
undergoing multimodality invasive imaging (QCA, intravascu-
lar ultrasound, virtual histology, palpography, and OCT) at 6 
and 24 months; and cohort B2, with an identical imaging fol-
low-up protocol scheduled at 12 and 36 months. All of the 
study lesions were treated with the BVS Revision 1.1 design 
Figure 3.  Patient 3: spread-out vessel chart showing the spatial distribution of the struts with scattering centers in the scaffolded 
vessel immediately post-implantation (baseline) and at the 6-month follow-up. The x-axis represents the distance from the distal 
edge of the stent to the strut; the y-axis represents the angle where the strut is located in the circular cross-section respect to the 
center of gravity of the vessel, taking as reference 0° the position at 3 o’clock. The result is a graphic representation of the spatial 
distribution of the struts along the scaffolded vessel as if it had been cut along the reference angle (0°) and spread out on a flat 
surface.
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3.0×18 mm (Figure 1). The registry was approved by the ethics 
committee at each participating institution, and each patient 
gave written informed consent before inclusion.
For the present pilot study, a random sample of 3 patients in 
cohort B1 was selected among those patients who had under-
gone OCT imaging with a Fourier-domain C7 system (Light-
lab Imaging, Westford, MA, USA) at baseline and at the 6-
month follow-up.
OCT Study
OCT pullbacks were obtained at baseline and follow-up with 
a Fourier-domain C7 system using a Dragonfly catheter (Light-
lab Imaging) at a rotation speed of 100 frames/s with a non-
occlusive technique.12 After infusion of intracoronary nitro-
glycerine, the imaging wire was withdrawn by a motorized 
pullback at a constant speed of 20 mm/s, while Iodixanol 320 
contrast (VisipaqueTM, GE Health Care, Cork, Ireland) was 
infused through the guiding catheter at a continuous rate of 
2–6 ml/min.
Two independent operators analyzed the selected OCT pull-
backs offline using proprietary software (Lightlab Imaging). 
The region of interest was defined as that between the most 
distal and most proximal frames in which struts could be 
detected by OCT. In this region of interest, a frame-by-frame 
analysis (0.2-mm longitudinal intervals) was performed. In 
every cross-section the lumen contour was drawn and a marker 
set at the mid-point of the adluminal leading edge of each 
strut. The markers defined the circumferential position of the 
strut with respect to the center of gravity of the vessel as an 
angle, taking the position at 3 o’clock as the 0° reference.
Struts were labeled as containing SC if one or more focal 
hyperintense regions could be seen in the core of the strut, 
separated from the axial and transverse strut border interfaces. 
Struts with hyperintense central regions extending to the lumen 
border were considered to be related to the optical appearance 
of bifurcating/confluent struts but not classified as SC. In some 
of these cases, an indentation between the 2 bifurcating/con-
fluent struts could be identified (Figure 2). Two investigators 
classified the struts independently, and the discrepancies were 
resolved by consensus.
Spread-Out Vessel Charts
The spatial distribution of the struts along the scaffolded 
vessel was analyzed through spread-out vessel charts. These 
Figure 4.  Schematic representation of the 3 types of hinges in the scaffold structure and their locations in the spread-out vessel 
diagram. The longitudinal connectors between the rings define inflection points that include ψ- and Υ-hinges (see schematic). 
Angulations in the zig-zag ring at a point where there is no longitudinal connector are denominated “crown peaks”. The scaffold 
has 19 rings; each ring contains 3 ψ-hinges, 3 Υ-hinges and 6 crown peaks, except the most distal ring (3 ψ-hinges and 9 crown 
peaks) and the most proximal ring (3 Υ-hinges and 9 crown peaks).
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graphics were obtained by correlating the longitudinal distance 
of each strut from the distal edge of the scaffold (abscises) 
with the angle defining its circumferential position with respect 
to the center of gravity of the vessel (ordinates) in each OCT 
pullback.13,14 The resulting charts represent the scaffolded ves-
sel as if it had been cut longitudinally along the reference 
angle 0° and spread out on a flat surface (Figure 3).
Inflection Points (Hinges) Analysis
The results displayed on the spread-out vessel charts permit 
visual identification of the different inflection points15 in the 
scaffold structure. The inflection points were classified into 3 
types (Figure 4): (1) ψ-hinges (psi-hinges) at the distal part of 
a longitudinal connector, where the angle between the connec-
tor and the W-shaped ring is acute; (2) Υ-hinges (ipsilon-
hinges) at the proximal part of a longitudinal connector, where 
the angle between the connector and the W-shaped ring is 
obtuse; (3) crown peaks: hinges in the W-shaped rings at inflec-
tion points with no longitudinal connector. A 3.0×18 mm BVS 
consists of 19 W-shaped rings, 54 longitudinal connectors and 
120 crown peaks. In each BVS ring 3 ψ-hinges, 3 Υ-hinges, 
and 6 crown peaks can be identified, except in the most distal 
(3 ψ-hinges and 9 crown peaks) and the most proximal (3 Υ-
hinges and 9 crown peaks).
At least 4 points are required to define the shape of ψ or Υ, 
whereas 3 points are sufficient to define the shape of a crown 
peak. A hinge was considered associated with SC if SC appeared 
in any of the struts minimally required to define the hinge shape 
around the inflection point.
Individual tracking of the temporal evolution of each hinge 
was performed by matching the hinges in the spread-out vessel 
charts at baseline and 6-month follow-up.
Bench Analysis
 Devices with the same design as the BVS in cohort B were 
used for a bench evaluation. Scaffolds were analyzed under 
light microscopy for the presence of enhanced opacity caused 
by scattering. Three uncrimped and 3 deployed devices were 
examined with optical microscopy (Keyence VHX-600) with 
incident light to maximize scattering within the bulk of the 
polymer and minimize surface reflection. SC were defined as 
areas of whitening greater than 20 μm in diameter (Figure 5). 
The spatial distribution of SC along the scaffolded vessel was 
recorded using the spread-out vessel charts.
Statistical Analysis
The fraction of struts and hinge points with SC was calculated 
and the results compared with Pearson’s chi-square test. The 
ability of OCT to track SC hinges between the baseline and 
follow-up pullbacks of the same patient was tested with a 
weighted κ coefficient for the number count of white-dotted 
hinges per ring. Interobserver variability for the count of struts 
and of struts containing SC was calculated per cross-section 
by Kendall’s tau-b and Spearman correlations. All the analyses 
and graphics were performed with the PASW 17.0.2 statistical 
package (SPSS Inc, Chicago, IL, USA).
Results
The 24 patients in the ABSORB cohort B1 underwent OCT at 
baseline and at 6-month follow-up; in 12 of these cases, the 
images were acquired with a Fourier-domain C7 system. No 
case was excluded from the analysis because of image quality 
issues. From these 12 cases, 3 were randomly selected for the 
spatial and temporal analysis of the SC. In all cases but one 
(patient 1, baseline OCT), the operator removed the guidewire 
before starting the OCT pullback to improve the image quality.
A total of 4,328 struts were analyzed: 1,502 in patient 1 
(718 at baseline, 784 at 6 months), 1,403 in patient 2 (700 at 
baseline, 703 at 6 months) and 1,423 in patient 3 (728 at base-
line, 695 at 6 months). The interobserver agreement was excel-
lent for the count of struts per cross-section (Kendall’s tau-
b=0.872, Spearman rho=0.932 at baseline, P<0.001; Kendall’s 
tau-b=0.851, Spearman rho=0.912 at follow-up, P<0.001), and 
for the count of struts containing SC (Kendall’s tau-b=0.936, 
Spearman rho=0.959 at baseline, P<0.001; Kendall’s tau-
b=0.954, Spearman rho=0.971 at follow-up, P<0.001). Ana-
lyst 1 tended to count on average 0.18 struts more per cross-
section than analyst 2 at baseline (P=0.014), and 0.22 struts 
more at follow-up (P=0.04). No significant interobserver bias 
was detected in the count of struts with SC.
Analysis of the proportion of SC with respect to the total 
number of struts showed no significant difference between 
baseline and follow-up in any of the patients (Table 1). No 
significant difference was found between patients for the pro-
portion of SC at any time point.
Figures 4, S1 and S2 present the spread-out vessel charts at 
baseline and 6-month follow-up of the 3 patients. All of the SC 
were located around hinges; no SC were detected in straight 
segments. Some hinges were sliced in different cross-sections 
because of the coincidence with systolic cardiac motion; in 
those cases it can be seen that the SC are located in the inner 
curvature of the bending (acute angle), without corresponding 
Figure 5.  Representative images from the bench analysis of 
pre-crimp (Upper) and post-deployment (Lower), showing the 
stress-whitening at hinge points. Before crimp/deployment, 
scaffolds appeared transparent under optical microscopy. 
After deployment, scattering evidenced by increased opacity 
was observed at all hinge regions of the device.
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SC in the outer curvature (obtuse angle) (Figure 6).
A comparison of the proportion of SC hinges did not show 
any significant difference between baseline and follow-up or 
between patients (Table 2).
Visual analysis of Figures 4–6 highlights the difficulty of 
tracking specific SC between baseline and the 6-month fol-
low-up. The spatial distribution of the SC did not match 
exactly, suggesting that different features are revealed with 
any given pullback. To assess the ability to match the SC loca-
tion at the 2 time points, the agreement in the number count of 
white-dotted hinges per ring between baseline and follow-up 
was tested with a weighted κ, which showed very poor agree-
ment between the different hinges: best agreement for ψ-
hinges (weighted κ range 0.23–0.62), for the rest of hinges, 
Figure 6.  Hinges sliced in different 
cross-sections because of the coinci-
dence with systolic cardiac motion 
(vessel and catheter moving in the 
same direction). The image shows 2 
crown peaks with scattering centers 
and illustrates how the scattering is 
located in the inner curvature of the 
hinge (right side, red arrows; A), with 
no scattering in the slices correspond-
ing to the outer curvature (B–E).
Table 1. Proportion of Struts With Scattering Centers Immediately Post-Implantation and at the 6-Month 
Follow-up
Post-implant 6 months P value
Patient 1
  No. of struts    718    784 0.919
  SC   91 (12.7%)   98 (12.5%)
Patient 2
  No. of struts    700    703 0.586
  SC 116 (16.6%) 109 (15.5%)
Patient 3
  No. of struts    728    695 0.818
  SC 112 (15.4%) 110 (15.8%)
Total
  No. of struts 2,146 2,182 0.754
  SC 319 (14.9%) 317 (14.5%)
Patient 1 vs. Patient 2 (P value) 0.106 0.130
SC, scattering centers. Data are n (%)
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weighted κ<0.34 (Table S1).
In the bench study, a total of 684 hinge regions in each 
group of uncrimped and deployed devices were evaluated by 
optical microscopy. Analysis revealed the complete absence 
of SC in all regions of the uncrimped devices. In contrast, after 
deployment there were SC in all hinge regions (Figure 3).
Discussion
In this study we used a novel methodology for analyzing mor-
phological changes in the polymeric scaffold of a BVS using 
OCT. Spread-out vessel charts have been previously described 
in trials comparing the performance of intracoronary devices 
using OCT per strut analysis.13,14,16 They are simple and intui-
tive graphic representations of the spatial distribution and 
clustering of the studied phenomenon, in this case of the SC 
along the BVS, providing insight into how the scaffold mate-
rial may be changing over time post-implantation. This study 
is the first to use spread-out vessel charts as the primary tool 
for detailed spatial analysis, and the results presented here 
prove its potential and motivate future development of the 
technique. This methodology may complement 3D-rendering 
technologies, which are appealing imaging tools but limited in 
analytical capability.
The spread-out vessel charts presented here also illustrate 
another unanticipated phenomenon, namely, the effect of car-
diac motion on the images obtained during the OCT pullback. 
One can see the elongation of the segments imaged in systole 
(when the vessel moves in the same direction as the pullback 
catheter) and the compression of the segments imaged in dias-
tole (when vessel and pullback move in opposite directions).
Visual analysis of the struts displayed in the spread-out ves-
sel charts showed that all of the SC were located at hinge 
points. OCT relies upon changes in refractive index on a length 
scale greater than that of the wavelength of light used in the 
instrument to create signal intensity.17,18 Thus, the presence of 
SC within the strut core is suggestive of the creation of new 
interfaces in the polymeric material, leading to microscopic 
changes in the refractive index. In vivo, mechanical deforma-
tion, polymer molecular weight degradation, and tissue inte-
gration are all potential causes of refractive index changes. The 
exclusive location of the SC at hinge points strongly suggests 
that they represent micro-crazes in the polymer. Deformation-
induced crazing has long been demonstrated in both amor-
phous and semicrystalline polymers.19 In semicrystalline poly-
mers, crazes are typically microvoids traversed by fibrils in the 
direction of the applied stress, a combination that preserves 
the strength of the material while creating a discontinuity in 
the index of refraction.19–21 The BVS undergoes varying mag-
nitudes of mechanical deformation during crimping and de-
ployment, depending on the location on the scaffold, but the 
highest strain (and stress) is experienced at the hinge points, 
the points about which the scaffold collapses and expands dur-
ing crimping and deployment, respectively. Optically, this 
deformation manifests in the deployed device as stress-whiten-
ing at the hinge points (Figure 3), which is also evidence of 
crazing. The spatial distribution of the SC in OCT parallels 
that of the crazing observed in optical microscopy, clustering 
around the hinge points and leaving the scaffold areas that 
experience little or no mechanical deformation as unblem-
ished “black boxes”.
Though hydrolysis is a natural part of PLLA degradation, 
the presence of SC immediately post-implantation in a propor-
tion comparable to that at the 6-month follow-up, likely rules 
out the involvement of hydrolysis in the genesis of these images 
during the first 6 months. Likewise, the similar proportion of 
SC at baseline and at the 6-month follow-up suggests that other 
processes, such as physiological loading, induce minimal craz-
ing of the polymer after deployment. Therefore, the structural 
integrity of the scaffold is not jeopardized by hydrolysis or 
Table 2. Number and Percentage of Struts Characterized by the Presence of Scattering Centers Immediately 
Post-Implantation and at the 6-Month Follow-up
Post-implant 6 months P value
Patient 1*
  ψ-hinges (n=54)   27 (54.0%)   33 (61.1%) 0.463
  Υ-hinges (n=54)   25 (49.0%)   27 (50.0%) 0.920
  Crown peaks (n=120)   36 (31.6%)   37 (30.8%) 0.902
  All inflection points (n=228)   88 (40.9%)   97 (42.5%) 0.731
Patient 2
  ψ-hinges (n=54)   34 (63.0%)   36 (66.7%) 0.687
  Υ-hinges (n=54)   25 (46.3%)   25 (46.3%) 1.000
  Crown peaks (n=120)   53 (44.2%)   45 (37.5%) 0.293
  All hinges (n=228) 112 (49.1%) 106 (46.5%) 0.574
Patient 3
  ψ-hinges (n=54)   38 (70.4%)   41 (75.9%) 0.515
  Υ-hinges (n=54)   21 (38.9%)   27 (50.0%) 0.245
  Crown peaks (n=120)   53 (43.3%)   42 (35.0%) 0.186
  All hinges (n=228) 111 (48.7%) 110 (48.2%) 0.925
Between patients (P value)
  ψ-hinges 0.226 0.250
  Υ-hinges 0.555 0.906
  Crown peaks 0.091 0.547
  All hinges 0.154 0.457
Data are n (%)
*In patient 1 only 50 ψ-hinges, 51 Υ-hinges and 114 crown peaks were analyzable at baseline, because of the presence 
of a guidewire in the pullback (Table presents corrected %).
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crazing up to 6 months. The preservation of structural integrity, 
especially in the first 3 months after implantation (the so-called 
“revascularization phase”) is of the utmost importance to coun-
teract vessel recoil and adverse remodeling, hence maintaining 
the initial luminal gain.1 Our finding is consistent with the 
excellent clinical outcomes reported for the BVS to date.3,5,6
Previous studies from our group unsuccessfully attempted 
to track the individual SC between baseline and follow-up 
using 3D-rendering technologies (unpublished data). The cur-
rent approach offers a clearer and more visual representation 
of the spatial location of the SC, but still fails to track them 
individually between 2 time points. Furthermore, the poor 
agreement between baseline and follow-up regarding the SC 
count per ring discourages any further attempt of matching. At 
a rotation speed of 100 Hz and a pullback speed of 20 mm/s, 
any feature smaller than 200 μm will be difficult to capture in 
multiple pullbacks, and the OCT study should be rather con-
sidered a random sampling of the study phenomenon. This 
might explain the failure to match individual SC, and also why 
OCT detected SC in only 43–49% of the hinges, even though 
light microscopy had shown stress-whitening in 100%. Con-
sistent with this, OCT had the highest sensitivity for SC detec-
tion in the largest hinges (ψ-hinges: 61–76%) and the lowest 
sensitivity in the smallest hinges (crown peaks: 31–44%).
Study Limitations
The OCT longitudinal image co-registration is limited in this 
study because of the pullback and rotation speeds used in the 
acquisition, which are the standard for clinical applications 
with a Fourier-domain C7 system. This study is a retrospec-
tive analysis from patients included in a clinical study, aimed 
at interpreting intriguing imaging observations; therefore, the 
pullback speed could not be altered to examine the factors that 
may govern longitudinal co-registration. For in vitro, pre-
clinical, or prospective designs, a slower pullback speed (eg, 
10 mm/s) would improve the ability to reproducibly observe 
features smaller than 200 μm and improve co-registration 
accuracy.
The presence of a guidewire in one of the pullbacks might 
affect the comparability of these OCT studies, because the 
projected shadow hides a random sector of the cross-section. 
We minimized this problem by analyzing the proportion of 
SC with respect to the number of visible struts/hinges in the 
pullback.
The similarity between anomalous SC and the images gener-
ated by confluent or bifurcating struts might have affected the 
results. Although the defined analysis methodology attempted 
to differentiate between these essentially different images and 
showed excellent reproducibility, classification imprecision 
cannot be totally excluded.
 The compression of the images during diastole made the 
reconstruction of the BVS structure difficult in some segments. 
Although the reconstruction was possible in all cases, follow-
ing the pattern of the device, the accuracy of the analysis is 
hampered in those segments.
Conclusions
The SC observed in the Abbott Vascular BVS are located 
exclusively at hinge points and present at baseline and 6-month 
follow-up in similar proportions, suggesting that these images 
may represent polymer crazing caused by mechanical defor-
mation during the crimping and deployment processes, likely 
ruling out any role of hydrolysis in their genesis. The consis-
tent number and location of the SC between baseline and the 
6-month follow-up suggests that physiological loading is not 
inducing further crazing on length scales greater than the spa-
tial resolution capability of OCT.
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Abstract To quantify with in vivo OCT and histol-
ogy, the device/vessel interaction after implantation of
the bioresorbable vascular scaffold (BVS). We eval-
uated the area and thickness of the strut voids
previously occupied by the polymeric struts, and the
neointimal hyperplasia (NIH) area covering the end-
oluminal surface of the strut voids (NIHEV), as well as
the NIH area occupying the space between the strut
voids (NIHBV), in healthy porcine coronary arteries at
2, 3 and 4 years after implantation of the device.
Twenty-two polymeric BVS were implanted in the
coronary arteries of 11 healthy Yucatan minipigs that
underwent OCT at 2, 3 and 4 years after implantation,
immediately followed by euthanasia. The areas and
thicknesses of 60 corresponding strut voids previously
occupied by the polymeric struts and the size of 60
corresponding NIHEV and 49 NIHBV were evaluated
with both OCT and histology by 2 independent
observers, using a single quantitative analysis software
for both techniques. At 3 and 4 years after implanta-
tion, the strut voids were no longer detectable by OCT
or histology due to complete polymer resorption.
However, analysis performed at 2 years still provided
clear delineation of these structures, by both tech-
niques. The median [ranges] areas of these strut voids
were 0.04 [0.03–0.16] and 0.02 [0.01–0.07] mm2 by
histology and OCT, respectively. The mean (±SD)
thickness by histology and OCT was 220 ± 40 and
120 ± 20 lm, respectively. The median [ranges]
NIHEV by histology and OCT was 0.07 [0.04–0.20]
and 0.03 [0.01–0.08] mm2, while the mean (±SD)
NIHBV by histology and OCT was 0.13 ± 0.07 and
0.10 ± 0.06 mm2. Our study indicates that in vivo
OCT of the BVS provides correlated measurements of
the same order of magnitude as histomorphometry,
and is reproducible for the evaluation of certain
vascular and device-related characteristics. However,
histology systematically gives larger values for all the
measured structures compared to OCT, at 2 years post
implantation.
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Introduction
Bioresorbable coronary scaffolds are a novel
approach to the percutaneous treatment of coronary
artery disease. Recently, the everolimus-eluting bior-
esorbable vascular scaffold (BVS) (Abbott Vascular,
Santa Clara, Santa Clara, USA) has been studied in
the first-in-man ABSORB cohort A trial, which
demonstrated the feasibility and safety of this device,
with a rate of major adverse cardiac events of 3.4%
up to 3 years [1–3]. The BVS is composed of a
backbone of poly-L-lactide (PLLA), covered with the
polymer poly-D, L-lactide (PDLLA), containing and
controlling the release of the drug, everolimus
(Novartis, Basel, Switzerland). PLLA and PDLLA
degrade to lactic acid which is metabolized via the
Krebs’ cycle during the bioresorption process. The
radiolucent device is visualized on angiography by
radio-opaque platinum markers located at each end
[4]. The introduction of these new devices prompts us
to refine our methods of evaluation, using state-of-
the-art imaging modalities, such as optical coherence
tomography (OCT). This imaging technique has a
near-histological resolution (*15 lm), which makes
it ideal for studying the device/vessel interaction in
detail [5]. As the polymeric struts are translucent,
light-based imaging modalities are particularly suit-
able for this purpose. Up to now, histological
morphometry has been crucial in the evaluation of
the performance of new devices [6]. As histology is
limited to animal and human post-mortem studies, in
vivo assessment using OCT is highly desirable. This
porcine study was set up in 2006 with the goal to
evaluate the device/vessel interaction after implanta-
tion of the BVS at 2, 3 and 4 years, using OCT and
histology. The qualitative strut-related characteristics
with regards to the process of biodegradation were
published recently [7]. In this part of the study, we
sought to evaluate whether mimicking the histolog-
ical morphometric approach using OCT is feasible
and reproducible for the evaluation of the vascular
healing following implantation with the BVS.
Specifically, we sought to compare a number of
quantitative parameters assessed by ex vivo/‘‘post
processed’’ histology and in vivo/‘‘non-processed’’
OCT, in order to assess the agreement between these
techniques. These parameters include: the number
and size of the structures resembling struts, and
quantification of the tissue growth covering the
endoluminal surface and the tissue growth between
these structures.
Methods
Study sample and OCT imaging
Twenty two polymeric devices, BVS revision 1.0
(3 9 12 mm) were implanted in 11 healthy Yucatan
minipig coronary arteries, with a balloon: artery ratio
of 1.2:1. The BVS revision 1.0 has three main
components: the polymeric backbone, the polymeric
drug reservoir, and the antiproliferative drug, everol-
imus. The polymeric scaffold is balloon-expandable,
and is composed of a high molecular weight PLLA
with serpentine rings interconnected by links. The
scaffold body design is coated with a matrix of
PDLLA and everolimus in a 1:1 ratio. The device is
laser cut from an extruded tube and has two radio-
opaque platinum markers at both ends [8]. Since OCT
at 3 and 4 years following implantation displayed no
signal at the site where struts were expected to have
been previously implanted, we evaluated only the
devices available at 2 years follow-up. At this time
point, the PLLA backbone is almost completely
resorbed, as evidenced by gel permeation chroma-
tography, and histology shows accumulations of
proteoglycans (stained positively with Alcian blue)
at corresponding sites. By OCT, however, these
‘‘strut voids’’ appear as well delineated hyporeflective
foci. Since it is known that by OCT, immediately
after implantation, BVS polymeric struts appear as
black boxes with bright borders [1], these findings
indicate that OCT does not distinguish between the
BVS strut polymeric material and the provisional
matrix that replaces the strut after full bioresorption
[7]. Throughout the entire length of this manuscript,
we will use the term ‘‘strut void’’ to describe these
strut-like structures, previously occupied by the
polymeric material.
OCT was performed in vivo using the M2 CV
imaging system (LightLab Imaging, Westford, MA,
USA). In brief, the low-pressure HeliosTM occlusion
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balloon catheter was advanced distally to the region
of interest over a conventional 0.014 inch angioplasty
wire, which was then exchanged with the OCT
ImageWireTM. After calibration of the image wire by
correction of the Z-offset [9], the occlusion balloon
catheter was withdrawn proximally to the region of
interest, and inflated to 0.5–0.7 atmospheres. During
image acquisition, blood clearance was achieved by
manual continuous flushing with lactated Ringer’s
solution. Cross-sectional images were acquired at
15.6 frames/s, with an automatic pullback speed of
1 mm/s. Images were stored digitally for off-line
analysis.
Processing for histology and selection
of corresponding OCT and histology images
Animal sacrifice was performed immediately after
OCT imaging by intravenous sodium pentobarbital
infusion. The heart was explanted from the thoracic
cavity, the aorta clamped, and the coronary arteries
were pressure perfused at 100–120 mm Hg: first with
0.9% saline, followed by 10% neutral buffered
formalin for approximately 30 min. Hearts were then
immersed in formalin for complete fixation. Follow-
ing this, arteries were carefully dissected off the
heart. The location of the scaffolds was confirmed by
high-contrast film-based radiographs (Faxitron X-ray
Corp., Lincolnshire, IL, USA) and the specimens
were dehydrated in a graded series of ethanol. The
scaffolded segments were then embedded in methyl
methacrylate (MMA) for polymerization [4]. The
MMA block was sawed into three 4 mm segments,
and three cross-sections were cut using a rotary
microtome with a tungsten carbide blade: one at the
proximal scaffold segment, 2 mm distal to the
proximal metallic marker; one at the middle segment,
6 mm distal to the proximal marker; and one at the
distal scaffold segment, 2 mm proximal to the distal
marker. Finally, the samples were mounted and
stained with hematoxylin and eosin (HE) and/or
elastic Van Gieson (EVG).
Corresponding OCT cross-sections were selected
by one observer (YO), using the distances from the
platinum markers and anatomical landmarks, such as
side branches, as references. Two observers (BG,
MR) identified the corresponding structures of inter-
est. The quantitative analysis was performed with the
observers blinded to each other’s results, as well as to
the correspondence between the OCT and histology
images. We assumed that the sharp boundary of the
strut voids by histology corresponded to the sharply
delineated bright borders of the ‘‘black boxes’’ by
OCT.
Quantitative analysis of OCT and histology
images
OCT and histology images were analyzed with the
QCU-CMS software version 4.64 (Laboratory of
Clinical and Experimental Image processing, Leiden,
The Netherlands), which has previously been shown
to provide correlated quantitative measurements as
compared to the LightLab software [20]. Once images
were uploaded, calibration was performed: for OCT,
the diameter (0.36 mm) of the image wire was used,
whilst histology images were calibrated using the
scale bar provided by the pathologist. After calibra-
tion of the images, the following parameters were
quantified: (1) the number of strut voids previously
occupied by the polymeric struts (2) the lumen area
and the area encompassing the abluminal surfaces of
these strut voids; (3) the area and thickness of these
strut voids and (4) the neointimal hyperplasia (NIH)
area covering the endoluminal surface (NIHEV) and
the NIH area between the strut voids (NIHBV)
(Fig. 1). To be more specific, the measurements were
performed in the following way (Figs. 1 and 2): 1.
‘‘Scaffold’’ area: after manual localization of the strut
voids by setting a green circle at the mid point of their
abluminal surfaces, these points were connected
automatically by a trace line placed by the software.
In addition, the center of gravity of the scaffold area
was determined automatically by the software. 2.
Lumen area: the lumen contour was automatically
traced by the software; 3. The area of the strut void:
this was manually demarcated by following the
contour of these structures; 4. NIHBV: in order to
demarcate the NIH areas laterally, we used the angle
tool of the software, which takes the center of gravity
of the scaffold as reference.
The rays of the angle tool were placed as help
lines, at the edges of every strut void creating an area
between these which was limited axially by the
scaffold line and the lumen contour and laterally by
the help lines (Fig. 1 and 2); 5. NIHEV: was defined
as the area limited by the ‘‘help lines’’ placed at the
edges of the strut voids, their endoluminal surfaces,
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and the lumen area contour; 6. Neointimal thickness:
this was measured from the mid point of the
endoluminal surface of the strut voids to the lumen
contour, along a line projected through the center of
gravity of the scaffold; 7: Strut void thickness: this
was assessed by measuring the distance between the
mid points of the endoluminal and abluminal surfaces
of the strut voids.
Statistical analysis
Statistical analyses were performed with SPSS,
version 16 (SPSS Inc.,Chicago, IL, USA). Discrete
variables are presented as counts and percentages,
and continuous variables as mean ± standard
deviations, or medians and interquartile ranges or
ranges (minimum–maximum). The Pearson’s corre-
lation coefficient (r2) was computed to compare OCT
and histological measurements. Bland–Altman plots,
displaying the systematic (mean absolute difference)
and random (95% limits of agreement) errors, and the
interclass correlation coefficient for absolute agree-
ment (ICCa) and consistency (ICCc) were used to
assess the agreement between techniques. Inter-
observer variability was assessed using the correla-
tion coefficient (r2). A two-sided p-value B 0.05 was
considered significant.
Results
A total of six corresponding cross-sections were
available for the purpose of this study (Fig. 3).
Histology displayed 75 strut voids previously occu-
pied by the polymeric struts whilst OCT showed only
60. Fifteen of these strut voids by histology could not
be identified in the OCT images due to non-uniform
rotational distortion, marginalization of the image
wire into a side branch and a long distance to the
image wire, together with a low light incidence angle
resulting in a high light attenuation (Fig. 4). Thus, a
total of 60 corresponding strut voids were included in
the analysis. In only 1 of 6 frames were all
corresponding strut remnants visualised by both
OCT and histology with the consequence that the
lumen and scaffold area was only accurately assessed
in this frame (OCT: 2.78 and 5.14 mm2; histology:
1.02 and 4.40 mm2, for lumen and scaffold area,
respectively). The ratio between the lumen area and
stent area for the OCT was 0.54 while for histology
was 0.23 and the % area obstruction of the scaffold
for OCT was 45% while for histology 76%. Apart
from the strut voids that were not adequately
visualized, all images were successfully analysed
using the histomorphometrical methodology with the
dedicated off-line software. Table 1 and Fig. 5 show
the descriptive statistics and Bland–Altman plots for
the different parameters measured with OCT and
histology. The average difference and 95% limits of
agreement were: for the strut area: 0.03 [0.07;
-0.01], for the strut thickness: 0.10 [0.18; 0.02], for
the NIHEV: 0.04 [0.10; -0.02] and for the NIHBV:
0.03 [0.21; 0.15]. In general, histomorphometry
provided larger values for all parameters compared
Fig. 1 Schematic representation of the quantitative analysis.
Panel a The thick red line represents the vessel wall; the black
continuous line, the lumen contour; black squares strut voids
previously occupied by the polymeric struts; and the blue
dotted line the abluminal ‘‘scaffold’’ area. The red cross
indicates the center of gravity of the remnants of the scaffold,
which was provided automatically by the software after manual
indication of the mid point of the abluminal surfaces of the
strut-like structures. The center of gravity point was used to
place ‘‘the help lines’’ (black dotted lines) for the measurement
of the neointimal hyperplasia area covering the endoluminal
surface of these structures (red area), and the neointimal
hyperplasia area between these structures (green area). The
neointimal thickness (red arrow) was measured from the
endoluminal surface of the strut voids to the lumen contour,
along a line projected through the center of gravity of the
scaffold and the mid point of the abluminal surface of these
structures. The strut void thickness (white arrow) was
measured in a similar way
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to OCT. Interobserver variability was evaluated for
all variables assessed with histology and OCT
(Fig. 6). The mean (SD) differences between observ-
ers were negligible for the parameters measured in
the histological sections (area and thickness of strut
voids 0.00 (0.00) mm2 and 0 (30) lm, repcetively;
NIHEV 0.00 (0.00) mm
2, and NIH BV 0.00 (0.01)
mm2), as well as for those assessed in the OCT cross-
sections (for area and thickness of strut voids: 0.00
(0.00) mm2 and 0 [10] lm, respectively; for NIHEV
0.00 (0.01) mm2, and NIHBV -0.03 (0.01) mm
2).
The Lin’s correlation coefficient interpreted by the
ICCc and ICCa for the area of strut voids were: 0.34
[95% confidence interval (CI): 0.10–0.55], P\ 0.004
and 0.18 [95% CI: -0.08 to 0.43], P\ 0.004; for the
thickness of these structures: 0.08 [95% CI: -0.18 to
0.33], P = 0.271 and 0.01 [95% CI: -0.03 to 0.07],
P = 0.271; for NIHEV: 0.39 [95% CI: 0.15–0.59],
P\ 0.001 and 0.19 [95% CI: -0.09 to 0.46], P\
0.001; and for NIHBS: -0.03 [95% CI: -0.29 to
0.29], P = 0.50 and -0.03 [95% CI: -0.27 to 0.28],
P = 0.50.
The Pearson’s correlation coefficient (r2) for the
interobserver variability for the histology assessment
was: for the thickness and area of the strut voids
thickness: r2 = 0.89 and r2 = 0.78, respectively; for
NIHEV: r
2 = 0.87; and for NIHBV: r
2 = 0.86 (P\
0.001 for all analyses). Corresponding results for the
OCT measurements were: for thickness and area of
strut voids: r2 = 0.70 and r2 = 0.57, respectively; for
NIHEV: r
2 = 0.67; and for NIHBV: r
2 = 0.66 (P\
0.001 for all analyses).
Fig. 2 Demonstration of quantitative measurements by histol-
ogy and OCT. Panels A and B show the inverted grey scale and
color histology images, respectively, with superimposed
quantitative measurements (green lines in A), and panels
C and D, the corresponding grey scale and sepia OCT, with the
respective measurements (only C). The red lines are provided
by the software, and are projected from the center of gravity of
the scaffold through the mid points of the abluminal surfaces of
the struts
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Fig. 3 Cross-sections of corresponding OCT and histology of the left anterior descending artery (A/G, B/H, C/I), and the right
coronary artery (D/J, E/K, F/L). Histology specimens are stained with elastic Van Gieson
Fig. 4 Factors precluding identification of some of the strut
voids in corresponding OCT and histology images. Panels A–
C demonstrate how non-uniform rotational distortion (A),
marginalisation of the image wire into a side branch (B), and a
long distance between the image wire and black boxes preclude
visualisation of these strut voids by OCT, as compared to
corresponding histology (D–F). Due to the lack of visualization
of these structures, abluminal scaffold areas could not be
accurately assessed. In order to obtain reproducible measure-
ments, it was before the analysis decided to trace the scaffold
area only at the sites of black boxes that are visualized, with the
consequence of an underestimation of the ‘‘true’’ OCT scaffold
area
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Discussion
In the present study, we performed a quantitative
analysis of in vivo OCT images of the remnants of
bioresorbable vascular scaffolds at 2 years following
implantation, using a methodology similar to the
morphometric approach used with histology. The
main findings of this pilot study are: 1. Histology
appears to systematically give larger values, when
compared with OCT; 2. the approach similar to
histomorphometry for quantitative analysis of OCT
images is feasible and reproducible for the evaluation
Table 1 Descriptive statistics of all parameters measured by
OCT and histology
OCT Histology
Area of the strut voids,
mm2
0.02 (0.01–0.07) 0.04 (0.03–0.16)
Thickness of the strut
voids
120 (70–180) 220 (120–350)
NIHBV, mm
2 0.03 (0.01–0.08) 0.07 (0.04–0.20)
NIHEV, mm
2 0.09 (0.01–0.27) 0.13 (0.01–0.31)
NIH neointimal hyperplasia, BV between the voids, EV
endoluminal surfaces of the voids, values are median (range)
Fig. 5 Bland-Altman plots depicting the agreement between
techniques for the evaluation of the area (panel A) and
thickness (panel B) of the strut voids previously occupied by
the polymeric struts, the neointimal hyperplasia area covering
the endoluminal surface of these voids (panel C), and the
neointimal hyperplasia area between the voids (panel D), with
histology and OCT
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at follow up after implantation of the BVS; and 3.
despite the use of anatomical landmarks and intra-
scaffold radiopaque markers to identify correspond-
ing cross-sections, higher numbers of strut voids were
visualized by histology than by OCT.
Differences in quantitative measurements
between OCT and histology
The observation that quantitative measurements by
histology and OCT may differ is not new, as previous
studies have suggested that histological processing
may induce a certain degree of artifacts related to
formalin fixation and dehydration [10]. Surprisingly
however, our study showed that all morphological
characteristics analyzed were systematically larger by
histology as compared to OCT. More specifically, the
strut void area, strut void thickness, NIHEV and
NIHBV were 100%, 83%, 130% and 44% larger by
histology compared to OCT, respectively. Several
factors may have contributed to this difference. The
first involves the calibration of the OCT image wire
by adjustment of the Z-offset before image acquisi-
tion, as well as calibration of the scaling of OCT and
histology images before analysis, which are crucial
for any quantitative measurement. In the present
study, these were all performed according to current
standards [9]. Secondly, differences can potentially
be related to the application of different analysis
softwares for different techniques. We tried to
circumvent this by utilizing the same software, as
well as by using semi-automatic approaches, for all
analyses, which was evidenced in the good interob-
server reproducibility seen. Nevertheless, the quanti-
tative results by histology were systematically larger
than by OCT, as compared to previous studies, even
if these applied different softwares for the different
techniques [11, 12]. Other interfering factors are
therefore likely to be involved. For the NIH areas, our
results resemble those reported by Murata et al. and
Templin et al., who found that histology estimated
the NIH areas covering metallic stents slightly higher
than OCT, at 28 and 90 days, and at 10, 14 and
28 days, respectively [13, 14]. However, in our study,
the overestimation by histology was greater. This
may be related to the combined differences in: the
mechanical constraints imparted on the tissue
between the bioresorbable vascular scaffold as
compared to metallic stents; in the tissue composition
at time point of examination (2 years), which
includes a higher proportion of collagen and smooth
muscle cells as compared to time points less than
90 days [15]; and in the composition of the strut
voids which, as shown by Onuma et al., are replaced
by highly water-containing acid mucopolysacharides
material, which stains positively with Alcian Blue, at
this time point [7]. Further, previous studies have
indicated that formaldehyde, which we used for tissue
fixation, can cause dimensional changes that are
dependent on the composition of the tissue (for
example causing swelling in liver tissue and shrink-
age in muscle tissue), the pH of the tissue, and the
temperature and concentration of the fixative [10]. In
addition to tissue fixation, dehydration with ethanol,
embedding and polymerization in MMA, and sub-
sequent deplastization likely further impacted the
tissue dimensions obtained histologically. Consider-
ing the contrasting nature of the tissues at late follow-
up of the BVS, namely the proteoglycan-rich tissue
replacing pre-existing struts compared to the sur-
rounding smooth muscle cell and collagen-dense
tissue of the arterial wall, these tissue-specific
dimensional changes are especially notable at fol-
low-up after implantation of the BVS. This is
supported by the qualitative results regarding the
histological appearance of the strut-like structures at
2 and 3 years. At 2 years, the strut voids appear more
spherical, having a highly water-containing proteo-
glycan, while they are contracted and almost com-
pletely coalesced into the arterial wall at 3 years
(Fig. 6) [7]. Considering this, it is likely that the
proteoglycan-based nature of strut foci at 2 years
resulted in their swelling as an artifact of histological
processing.
The fact that OCT was performed in vivo, when
the vessel has a tonus and is naturally pressurized,
may also explain some of the discrepancies, although
efforts were made to pressurize vessels during
histology preparation. However, the most plausible
explanation involves the attempt to correspond OCT
and histology cross-sections, which depends on the
orientation of the OCT image wire relative to the
vessel curvature and relative to the location in the
vessel lumen, which in turn influence how the OCT
‘‘biotome’’ cross-sects the tissue and the scaffold.
The difficulty finding completely corresponding
cross-sections may be further affected by the
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differences in slice thicknesses of the samples
provided by the different techniques. For histology,
the minimum slice thickness possible to obtain, is in
the range of 4–5 lm with a sampling interval of
100 lm [16], and depends on the microtome, while
the minimum frame thickness available with the OCT
system used in the present study is 60 lm and
depends on the longitudinal sampling distance, which
is in turn related to the frame rate (15.6 frames/s) and
the pullback speed (1 mm/s). Nevertheless, it should
be stressed that wherever possible, efforts were made
to secure corresponding cross-sections by histology
and OCT using the scaffold platinum markers and
anatomical structures, as landmarks. Thus, our report
highlights some of the difficulties that may be
encountered in this type of study, which are important
to acknowledge (Fig. 7).
Consideration of technical aspects with OCT
imaging
Although efforts were made to obtain matched cross-
sections between OCT and histology using land-
marks, we found a higher density of strut voids by
histology than by OCT. In addition to the factors
mentioned above, we noticed that the intrinsic
properties of the OCT technology related to the use
of light also influenced our analysis. By marginali-
zation of the light source, causing an acute incidence
angle of the light on the vessel wall, as well as by the
relatively low scan diameter of the employed time
domain-OCT system (7 mm) compared to newer
generation frequency domain (FD)-OCT systems
(10 mm), visualisation of the strut voids along the
entire 360 degree vessel circumference was hindered
Fig. 6 Linear regression analysis plots depicting the interob-
server variability for the evaluation of the area and thickness of
the strut voids, the neointimal hyperplasia area covering the
endoluminal surface of these voids, and the neointimal
hyperplasia area between the voids, with histology (panels
A–D) and OCT (panels E–H), respectively
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(Fig. 3B, C), which prevented the identification of
these structures and the accurate delineation of the
abluminal scaffold area, as well as delineation of the
lumen area. Nevertheless, the only available accurate
corresponding lumen and scaffold areas by OCT and
histomorphometry showed that measurements by
OCT were larger than those by histology, which is
in line with previous studies [11–13]. Despite the
potential advantages of in vivo ‘‘non-processed’’
OCT, the presence of non-uniform rotational distor-
tion, which is related to vessel tortuosity, as well as
the presence of artefacts due to heart motion in
systole and diastole, further complicated the selec-
tion of perfectly corresponding frames. The new
generation FD-OCT which has a much higher frame
rate, allowing a higher pullback-speed without sig-
nificant loss in longitudinal sampling density [14, 17,
18], promises to overcome some of these issues,
together with recent advances allowing retrospective
reconstruction of gated OCT acquisitions [19]. How-
ever, these technologies were not available at the
time of data acquisition.
Histomorphometry-like analysis with OCT
Onuma et al. recently described a qualitative analysis
of OCT images of the polymeric struts of the BVS.
As opposed to that analysis, our study focused on the
evaluation of the quantitative tissue response around
the strut voids previously occupied by the polymeric
struts in terms of neointimal hyperplasia between and
on the endoluminal surface of these, which we found
to be feasible and reproducible, with a good interob-
server reproducibility. Despite the mentioned issues
regarding comparison between OCT and histology,
OCT represents at present the in vivo imaging
modality with the highest resolution, which enables
Fig. 6 continued
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us to evaluate fine details in the assessment of the
device/vessel interaction.
Study limitations
Our initial goal was to assess the morphometric
parameters of the remnants of the device implanted
with OCT at 2, 3, and 4 years following implanta-
tion. As part of the degradation process, the number
of bioresorbable struts identified by OCT decreased
with time. We now know that the polymeric struts
are completely resorbed and replaced by proteogly-
cans by 2 years. However, this respective time point
could not be foreseen at the time of planning of the
study. For the comparison of different measurements
by OCT and histology, it was necessary to select a
time point where strut-like structures (strut voids) are
fully visible with OCT. Consequently, specimens at
3 and 4 years could not be included in this study,
wherefore the sample size was relatively small. We
cannot dismiss the possibility that the low sample
size could, to some extent, explain the relatively
large distribution of individual parameters. Never-
theless, we believe that the findings of this pilot
study are interesting as they represent our initial
quantitative experience with the novel bioresorbable
technology, and may serve as a guide to the planning
of future trials with corresponding OCT and histo-
morphometry to evaluate bioresorbable vascular
scaffolds.
Fig. 7 Histological examples of the appearance of strut voids
at 2 and 3 years following implantation of the bioresorbable
vascular scaffold. Panels A–D show strut voids at 2 and 3 years
follow-up, respectively. At 2 years, the proteoglycan-rich
matrix appears to collapse in the middle of the void upon
histological preparation, giving a spherical appearance, while
the matrix at 3 years is coalesced with the neointima of the
vessel wall, giving the impression that the borders of the
contents of the void are better held together with the neointima.
Panels A and C are stained with hematoxylin and eosin, while
panels B and D are stained with Alcian blue. Reproduced from
Onuma et al. Circulation 2010
Int J Cardiovasc Imaging
123
158  Chapter 4.2
Conclusion
The present pilot study showed that an approach for
quantitative analysis of OCT images akin to histo-
morphometry is feasible and reproducible for the
evaluation of the vascular healing at follow up after
implantation of the BVS and that corresponding OCT
and histomorphometry provide results of the same
order of magnitude. Despite the use of landmarks to
identify corresponding cross-sections, histology sys-
tematically provided larger measurements for all
studied parameters. Whether this is related to factors
influencing acquisition and processing of images, or
the bioresorbable nature of the device, requires
further investigation, for example using the new-
generation FD-OCT, and a larger sample analysed
with a higher sampling density.
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CHAPTER 5 THE APPLICATION OF OPTICAL 
COHERENCE TOMOGRAPHY IN 
THE CLINICAL EVALUATION OF 
BIORESORBABLE SCAFFOLDS
5.1 Head to head comparison of 
optical coherence tomography, 
intravascular ultrasound 
echogenicity and virtual histology 
for the detection of changes in 
polymeric struts over time: insights 
from the ABSORB trial.
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Abstract
Aims: To analyse and to compare the changes in the various optical coherence tomography (OCT), echo-
genicity and intravascular ultrasound virtual histology (VH) of the everolimus-eluting bioresorbable scaffold 
(ABSORB) degradation parameters during the first 12 months after ABSORB implantation. In the ABSORB 
study, changes in the appearance of the ABSORB scaffold were monitored over time using various intracoro-
nary imaging modalities. The scaffold struts exhibited a progressive change in their black core area by OCT, 
in their ultrasound derived grey level intensity quantified by echogenicity, and in their backscattering ultra-
sound signal, identified as “pseudo dense-calcium” (DC) by VH.
Methods and results: From the ABSORB Cohort B trial 35 patients had paired OCT, echogenicity and VH 
assessment at baseline and at six- (n=18) or 12-months follow-up (n=17). Changes in OCT strut core area, 
hyperechogenicity and VH-derived DC were analysed and compared at the various time points. At six months, 
the change (median[IQR]) in OCT strut core area was –7.2% (–14.0–+0.9) (p=0.053), in hyperechogenicity 
–12.7% (–33.7–+1.4) (p=0.048) and VH-DC 22.1% (–10.8–+48.8) (p=0.102). At 12 months, all the imaging 
modalities showed a decrease in the various parameters considered (OCT: –12.2% [–17.5– –1.9], p=0.093; 
hyperechogenicity –24.64% [–36.6– –16.5], p=0.001; VH-DC: –24.66% [–32.0– –7.0], p=0.071). However, 
the correlation between the relative changes in these parameters was statistically poor (Spearman’s rho <0.4).
Conclusions: OCT, echogenicity and VH were able to detect changes in the ABSORB scaffold struts, 
although the correlation between those changes was poor. This is likely due to the fact that each imaging 
modality interrogates different material properties on different length scales. Further studies are needed to 
explore these hypotheses.
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Abbreviations
IVUS intravascular ultrasound
LLI LightLab Imaging
OCT optical coherence tomography
PDLLA poly(D,L-lactide)
PLA polylactide
PLLA poly(L-lactide)
VH virtual histology
Introduction
The everolimus-eluting bioresorbable ABSORB scaffold (Abbott 
Vascular, Santa Clara, CA, USA) represents a novel approach for 
the treatment of coronary lesions, providing transient luminal sup-
port and vessel wall drug delivery without the long-term limitations 
of conventional metallic drug-eluting stents1-3.
In the ABSORB trials, multi-modality imaging techniques were 
applied, including optical coherence tomography (OCT), intravas-
cular ultrasound (IVUS) greyscale and virtual histology (VH). 
These modalities have been extensively used, primarily to investi-
gate geometric changes to the vessel wall and lumen and secondar-
ily to assess changes in the appearance of the struts, as surrogate for 
changes in polymer microstructure caused by hydrolytic degrada-
tion of the polymer over time. OCT, for example, monitored the 
progressive integration of the scaffold into the vessel wall, with 
modification in the reflectivity of the strut core area and in the size 
of the black strut core area3,4; IVUS showed a progressive reduction 
in the grey level intensity of the polymeric struts over time, detected 
by change in hyperechogenicity5, and VH reported changes in 
dense calcium areas (DC) as the struts are detected by the software 
as “pseudo dense-calcium”2,3,6,7.
However, no systematic and serial comparison between these 
three intracoronary imaging modalities and their derived parame-
ters, detecting the polymer microstructural changes, has been made. 
With this “pilot-study”, we tried to quantitatively compare the 
material property changes of the scaffold as detected by OCT, echo-
genicity and VH in vivo at six and 12 months after ABSORB 
implantation.
Methods
STUDY POPULATION
The ABSORB Cohort B study enrolled 101 patients older than 18 
years of age with a diagnosis of stable/unstable angina or silent 
ischaemia (Trial number: NCT00856856). Those patients were 
divided into two groups: the first group (Cohort B1) underwent 
invasive imaging including greyscale IVUS, IVUS-VH and OCT at 
six-month follow-up; the second group (Cohort B2) had the same 
invasive imaging at 12 months3. All lesions were de novo, in a 
native coronary artery with a reference vessel diameter of 3.0 mm, 
a percentage diameter stenosis ≥50% and <100%, a thrombolysis in 
myocardial infarction flow grade of ≥1, and were treated with 
implantation of an ABSORB scaffold (3.0×18 mm). Major exclu-
sion criteria were: patients with an acute myocardial infarction, 
unstable arrhythmias or who had a left ventricular ejection fraction 
<30%, restenotic lesions, lesions located in the left main coronary 
artery, lesions involving a side branch ≥2 mm in diameter, and the 
presence of thrombus or other clinically significant stenoses in the 
target vessel. The local ethics committee at each participating insti-
tution approved the trial and each patient gave written informed 
consent before inclusion.
Only patients with paired IVUS-VH, echogenicity and OCT data 
were included in the present analysis.
ABSORB SCAFFOLD
The ABSORB scaffold is a fully bioresorbable intracoronary device 
made from semi-crystalline poly(L-lactide) (PLLA) coated with an 
amorphous poly(D,L-lactide) (PDLLA) copolymer that contains and 
controls the release of the antiproliferative drug everolimus. The pri-
mary mechanism for molecular weight degradation of both polylac-
tide (PLA) materials is hydrolysis, a process in which the ester bonds 
present in the monomeric subunit of PLA molecules are progres-
sively cleaved. Ultimately, PLLA and PDLLA degrade to lactic acid, 
which is readily converted to lactate and processed via both the 
Kreb’s cycle (for L-lactate) and methylglycoxal metabolism (for 
D-lactate1,2,8). Based on preclinical studies, the time for complete 
resorption is assumed to be approximately two years9.
The ABSORB Cohort A and Cohort B trials evaluated the 
ABSORB scaffold generation 1.0 and 1.1, respectively1,2. There are 
no differences in polymeric material, drug dose, drug release rate or 
strut thickness between the two generations. Of note, the ABSORB 
1.1 has a smaller maximum circular unsupported surface area than 
the ABSORB 1.010. Controls implemented in the manufacturing of 
ABSORB 1.1 have resulted in more prolonged luminal support 
post-implantation3.
IVUS ACQUISITION
Treated vessels were examined post-procedure and at follow-up 
with 20 MHz phased array intravascular ultrasound (IVUS) Eagle-eye® 
catheters (Volcano Corporation, Rancho Cordova, CA, USA), using 
automated pullback at 0.5 mm per second after administration of 
0.2 mg intracoronary nitroglycerine. IVUS analyses were performed 
by an independent core laboratory (Cardialysis BV, Rotterdam, The 
Netherlands).
IVUS-VH ANALYSIS
Backscattering of radiofrequency signals provides information on 
vessel wall tissue composition11. All IVUS-VH analyses were per-
formed offline using the pcVH 2.1 software (Volcano Corporation, 
Rancho Cordova, CA, USA). Four tissue components (necrotic 
core: red; dense calcium: white; fibrous: green; and fibrofatty: light 
green) were identified with autoregressive classification sys-
tems11,12. Each individual tissue component was quantified, colour 
coded in all IVUS cross-sections and reported as absolute and rela-
tive areas11. As previously shown, the polymeric struts are normally 
classified as areas of “pseudo dense calcium” (DC)2,3,6,7,13. For this 
reason, we assessed the change in DC areas between post-implanta-
tion and follow-up as previously reported1,2,6.
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IVUS ECHOGENICITY ANALYSIS
Fully-automated quantitative echogenicity analysis software, previ-
ously developed in-house and validated, was used to quantify the 
hyperechogenicity in the treated segment5,14. Briefly, the mean grey 
value of the adventitia is used to classify tissue components as either 
hypo- or hyperechogenic. The adventitia circumscribing the coronary 
artery is defined as a layer extending from 0.2 to 0.5 mm outside the 
external elastic membrane. To minimise artefacts, tissue within acous-
tic shadowed areas is excluded and very high grey level pixels are iden-
tified as upper tissue14. After the tissue identification process, the 
relative fraction of hypo- versus hyperechogenic tissue volumes are 
calculated for the entire scaffold segment5. As the polymeric struts, due 
to a high grey value intensity, are identified as hyperechogenic tissue 
and show a continuous decrease of their grey level intensity during the 
degradation process, we therefore used changes in hyperechogenicity 
as a surrogate for scaffold degradation, as previously described5,15,16.
OCT ACQUISITION AND ANALYSIS
OCT imaging was performed as an optional investigation in 
selected centres, using either time domain (M3 system; LightLab 
Imaging [LLI], Westford, MA, USA) or frequency domain OCT 
systems (C7XR system, LLI) at baseline and follow-up10,17-21. The 
OCT measurements were performed with proprietary software for 
offline analysis (LightLab Imaging). Adjusting for the pullback 
speed, the analysis of continuous cross-sections was performed at 
1 mm longitudinal intervals within the treated segment.
The ABSORB scaffold shows important differences with respect to 
metallic stents when imaged by OCT. The optically translucent poly-
mer allows imaging of both luminal and abluminal boundaries of the 
strut, which appears as a box with a black central core (strut core area) 
framed by highly reflective borders3. The second generation ABSORB 
1.1 shows, up to 12 months, a progressive decrease in strut core area, 
and none of the changes in morphological strut appearance that were 
seen with the first generation ABSORB 1.01,2. In this analysis, we 
therefore focus on the changes in the strut core area between post-
implantation and follow-up, as a surrogate for scaffold degradation3,4.
STATISTICAL ANALYSIS
Categorical variables are expressed as counts and percentages. 
Continuous variables are presented as mean±standard deviation or 
median and interquartile range, according to their normal or not 
normal distribution. Normality of the data was evaluated using the 
Kolmogorov-Smirnov test. The correlation between various param-
eters across all time points was performed with the Spearman’s test, 
as the data were not normally distributed.
The percentage changes for VH-derived dense calcium, hyper-
echogenicity and strut core area by OCT were calculated for each 
scaffolded coronary segment as follows:
 (Follow-up - post ABSORB scaffold implantation)
 post ABSORB scaffold implantation 
×100%
A two-tailed value of p<0.05 was considered statistically signifi-
cant. Statistical analyses were performed with SPSS 16.0 software 
(SPSS Inc., Chicago, IL, USA).
Table 1. Clinical and angiographic baseline characteristics.
Cohort B1 
(n=17)
Cohort B2 
(n=18)
Age (years) mean±SD (n) 61.0±9.0 60.0±9.1
Men, n (%) 13 (76) 13 (72)
Smokers, n (%) 4 (23) 5 (27)
Diabetes, n (%) 2 (12) 2 (11)
Hypertension requiring medication, n (%) 8 (47) 11 (61)
Hyperlipidaemia requiring medication, n (%) 15 (88) 11 (61)
Previous target vessel intervention, n (%) 4 (23) 3 (16)
Previous myocardial infarction, n (%) 8 (47) 2 (11)
Clinical presentation, n (%)
Stable angina 14 (82) 13 (72)
Unstable angina 2 (12) 3 (16)
Silent ischaemia 0 (0) 2 (12)
Target vessel, n (%)
Left anterior descending 6 (35) 11 (61)
Left circumflex 5 (30) 4 (22)
Right coronary artery 6 (35) 3 (17)
SD: standard deviation
Results
BASELINE CLINICAL AND ANGIOGRAPHIC 
CHARACTERISTICS
Overall, 35 patients had paired multi-modality imaging analyses 
post-implantation and at follow-up. Of these, 17 patients were fol-
lowed up at six months, and the remaining 18 were followed up at 
12 months. Clinical and angiographic characteristics are shown in 
Table 1.
MULTI-IMAGING ANALYSES FROM OCT, IVUS-VH AND 
ECHOGENICITY AT SIX AND 12 MONTHS
Table 2 shows the mean strut core area, mean absolute and relative 
VH-DC area, mean absolute and relative hyperechogenicity values 
immediately after ABSORB implantation and at six and 12-month 
follow-up.
At six months, the change in strut core area by OCT was –7.25% 
(–14.07–+0.98) (p=0.053), in VH-DC 22.13% (–10.82–+48.85) 
(p=0.102) and in hyperechogenicity –12.71% (–33.70–+1.41) 
(p=0.048). At 12 months, the change in strut core area was –12.20% 
(–17.55– –1.98) (p=0.093), in VH-DC –24.66% (–32.07– –7.01) 
(p=0.071) and in hyperechogenicity –24.64% (–36.63– –16.51) 
(p=0.001) (Figure 1).
CORRELATION BETWEEN OCT, IVUS-VH AND ECHOGENICITY
There was a poor correlation between the changes in the evaluated 
parameters both at six and at 12 months (six months: OCT vs. 
hyperechogenicity Spearman’s rho= –0.361, p=0.141; OCT vs. 
VH-DC Spearman’s rho=0.362, p=0.139; hyperechogenicity vs. 
VH-DC Spearman’s rho=-0.218, p=0.385; 12 months: OCT vs. 
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hyperechogenicity Spearman’s rho=0.262, p=0.309; OCT vs. 
VH-DC Spearman’s rho=0.233, p=0.368; hyperechogenicity vs. 
VH-DC Spearman’s rho=0.368, p=0.233). The correlation did not 
improve when considering the data from six and 12 months together 
(OCT vs. hyperechogenicity Spearman’s rho= –0.038, p=0.830; 
OCT vs. VH-DC Spearman’s rho=0.281, p=0.102; hyperecho-
genicity vs. VH-DC Spearman’s rho=0.071, p=0.683) (Figure 2).
Discussion
The main findings of the analysis are: 1) there appears to be a reduc-
tion in strut core area by OCT and in hyperechogenicity values both 
at six and 12-month follow-up; 2) VH detects contrasting changes 
in dense-calcium between six and 12 months; 3) at the patient level, 
the correlation between the various parameters detected by the 
three imaging modalities is poor.
One of the most interesting concepts of the ABSORB scaffold is 
the temporary lumen scaffolding: in contrast with metallic stents, 
the polymeric scaffold does not involve a permanent caging of the 
vessel, as it is bioresorbed over time22,23. In keeping with this con-
cept, much interest has been focused on the use of intracoronary 
imaging techniques and their capabilities in detecting in vivo 
changes in scaffold material properties.
Figure 1. Relative reduction in strut core area, hyperechogenicity 
and DC content between baseline and 6/12 months follow-up. DC: 
dense calcium
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Table 2. Multi-imaging data from both cohorts.
Cohort B1 (n=17) Cohort B2 (n=18)
Baseline 6-month p-value Baseline 12-month p-value
Mean strut core area (mm2) 0.21±0.03 0.20±0.05 0.053 0.19±0.03 0.17±0.06 0.093
Mean DC area (mm2) 1.15±0.90 1.39±0.82 0.050 1.47±0.72 1.23±0.49 0.029
Mean DC (%) 14.10±7.08 16.27±6.67 0.102 17.38±5.62 13.75±3.92 0.071
Mean hyperechogenicity volume (mm3) 36.6±13.7 34.5±19.0 0.446 38.2±14.3 33.2±41.0 0.093
Mean hyperechogenicity (%) 23.1±9.4 19.2±8.9 0.048 24.4±10.5 18.2±8.9 0.001
DC: dense calcium
Figure 2. Examples of OCT, IVUS, VH and echogenicity findings of corresponding cross-sectional images with a side branch (*) selected as 
an anatomical landmark. The white arrows indicate a hyperechogenic tissue in echogenicity analysis, hidden by the grey media stripe in the 
VH analysis. OCT: optical coherence tomography; IVUS: intravascular ultrasound; VH: virtual histology
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With regard to OCT, it is sensitive to refractive index changes on 
a length scale greater than the wavelength of the light emitted from 
the catheter. For this reason, it detects the polymeric struts as being 
highly reflective compared to the lumen and the vessel wall. 
Conversely, the black strut core area, despite the heterogeneity of 
the semi-crystalline polymer structure, has a light-poor signal after 
ABSORB implantation, indicating that changes in refractive index 
occur on a length scale less than that of the wavelength of the OCT 
light. However, as hydrolytic degradation progresses, it is reasona-
ble to expect that this polymer microstructural heterogeneity coars-
ens, leading eventually to an increase in OCT reflectivity. For 
example, in the ABSORB Cohort A trial, testing the first generation 
ABSORB device, OCT showed that at six months, only 3% of the 
strut boxes kept the so-called “preserved box” appearance seen at 
post-implantation, whereas the remaining 97% changed their 
reflectivity, becoming “open box, dissolved bright box or dissolved 
black box2”. Each of these OCT appearances was related to differ-
ent histological characteristics in an animal study, where it was 
shown that reduction in strut core area and transition from pre-
served to open/dissolved box may represent indirect signs of scaf-
fold degradation (e.g., polymer microstructural heterogeneity) and 
integration into the vessel wall9. Conversely, in the ABSORB 
Cohort B trial, using the second generation ABSORB device, the 
scaffold struts maintained the OCT-defined “preserved box” 
appearance both at six and at 12-month follow-up exhibiting a pro-
gressive reduction in black strut core area by OCT3,24. Concomitantly, 
IVUS greyscale showed a progressive reduction in the grey level 
intensity of the struts; this phenomenon was quantified by echo-
genic analysis, demonstrating a reduction in the hyperechogenicity 
values of the polymeric struts over time5. In the ABSORB Cohort A 
study, quantitative differential echogenicity was already applied to 
monitor in vivo changes of the scaffold by means of the acoustic 
property changes, showing an increase of hyperechogenic tissue 
immediately after the ABSORB implantation, which was back to 
pre-implantation values at the time of expected degradation and 
bioresorption (approximately two years2,5). At six months, the dif-
ferences in hyperechogenic reduction between the ABSORB 
Cohort A and Cohort B (50% vs. 17%) were in line with the differ-
ences in the struts’ OCT appearance and in the late loss (0.43 mm 
vs. 0.19 mm), further supporting differences in hydrolytic degrada-
tion rate characteristics between the two ABSORB devices3.
At variance with these findings, a slight increase in the backscat-
tering signal of the struts interpreted as dense calcium by VH was 
detected at six months with a subsequent decrease at 12 months. It 
should be kept in mind that not only the polymeric scaffold –with 
its presence and degradation– but also the tissue surrounding the 
struts contributes to the VH-derived dense calcium quantification, 
which may explain this contrasting finding6,25. In particular, our 
global evaluation of the area comprised between the lumen and the 
medial stripe integrates into our quantification of dense calcium 
also the backscattering signal not related to the sole struts, but, for 
instance, to the plaque behind the scaffold. Changes in composition 
of this plaque are therefore also detected by VH. In a porcine model 
some inflammatory cells, such as granuloma and giant cells, were 
found surrounding the polymeric struts in the early stages after 
implantation, before decreasing over time9. At six months, focusing 
on the VH appearance of the plaque behind the scaffold, we con-
firmed this observation in humans, finding a progression in the NC 
content25. Of note is that dense calcium is a frequent finding within 
the necrotic core region; in this case it is frequently “speckled” and 
can be due to calcification of a “nidus” of macrophages26. Changes 
over time in strut core area and in hyperechogenicity are instead 
probably less related to the plaque changes.
It is important to highlight that despite an overall agreement 
between hyperechogenicity and strut core area in terms of reduction 
of both parameters during the first 12 months, analysis at the patient 
level revealed that the correlation between these imaging parame-
ters is poor. This is not surprising, since the optical and ultrasonic 
parameters reflect different aspects of scaffold degradation. From 
our animal experience, we learnt that the polymer is first hydro-
lysed into small oligomers digested by macrophages and that the 
strut voids initially occupied by the polymeric struts are then filled 
with proteoglycan and eventually integrated into the vessel wall. 
Hence, the changes in black strut core area by OCT do not reflect 
the molecular dissolution of the polylactide, as the polymer and the 
proteoglycan material have the same optical properties, but rather 
the filling of the strut voids by connective tissue ultimately making 
the struts undetectable by OCT and in histology9. Conversely, 
changes in the material properties of polylactide (e.g., crystallinity, 
molecular weight, stiffness, etc.) have previously been demon-
strated to predominantly affect the acoustic properties of the mate-
rial over time, and these can be detected by ultrasonic waves15,16.
Although both echogenicity and VH data are based on the appli-
cation of ultrasound, the correlation between them was also poor. 
This lack of correlation may be explained by the differences of 
methodologies used in these two techniques. Whilst the echogenic-
ity software analyses the complete image and the echo intensity 
(envelope amplitude), which is normally used in the formation of 
the greyscale-IVUS image, the VH software analyses the frequency 
of the signal underlying the amplitude (radiofrequency backscatter-
ing). As the classification tree of VH was not validated for recogni-
tion of metallic/polymeric struts, the backscattering signal, derived 
from a stent/scaffold, was usually interpreted by the software as 
dense calcium, such as found in heavily calcified coronary seg-
ments6,27. Conversely, echogenicity analysis excluded from its tis-
sue quantification the acoustically shadowed areas, resulting in a 
likely better discrimination between polymeric struts and calcified 
coronary segments. Another important point to consider in the VH 
detection of the polymeric struts is that some scaffold strut informa-
tion may be missed because of the presence of the medial grey 
stripe and it is extremely dependent on the contours drawing28,29 
(Figure 2). In addition no data are available to date correlating the 
backscattering signal changes with the physical and mechanical 
properties of polylactide.
Finally, it is important to note the difference in variability of the 
various changes explored by these techniques, with OCT exhibiting 
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the least variability (Figure 1). The fundamental differences in the 
principles and spatial resolution of each technique should be taken 
into account in the interpretation of this variability and also of their 
poor correlation30,31.
Limitations
A major limitation of our analysis is the small number of patients 
compared to the total number of patients enrolled in the trial. For 
this reason the p-values of the modification over time in the various 
parameters investigated have to be considered as exploratory. Nev-
ertheless, limiting the analysis to only patients receiving all three 
imaging modalities allows a more accurate comparison between the 
various parameters investigated. Lack of data about the polylactide 
degradation has also to be taken into account as a possible limita-
tion of our comparison. An in vitro or ex vivo study would be 
required to correlate these parameters with the scaffold/polymer 
degradation.
Conclusions
Our analysis showed that during the first 12 months after ABSORB 
scaffold implantation there is a reduction in black strut core area, as 
measured by OCT, and in the hyperechogenicity of the scaffold, 
representing independent signs of scaffold/polymer degradation. In 
contrast, VH only showed a reduction in “pseudo dense-calcium” at 
12 months indicating some limitations in monitoring scaffold prop-
erty changes.
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Objectives The aim of this study is to assess the serial changes in strut apposition and coverage of
the bioresorbable vascular scaffolds (BVS) and to relate this with the presence of intraluminal
masses at 6 months with optical coherence tomography (OCT).
Background Incomplete strut/scaffold apposition (ISA) and uncovered struts are related to a higher
risk of scaffold thrombosis. Bioresorbable vascular scaffolds can potentially avoid the risk of scaffold
thrombosis because of its complete resorption. However, during the resorption period, the risk of
scaffold thrombosis is unknown.
Methods OCT was performed in 25 patients at baseline and 6 months. Struts were classified according to
apposition, coverage, and presence of intraluminal masses. Persistent ISA was defined as malapposed struts
present at baseline and follow-up, and late acquired ISA as ISA developing at follow-up, and scaffold pattern
irregularities when the strut distribution suggested scaffold fracture.
Results At baseline, 3,686 struts were analyzed: 128 (4%) were ISA, and 53 (1%) were located over side-
branches (SB). At 6 months, 3,905 struts were analyzed: 32 (1%) ISA, and 35 (1%) at the SB. Persistent ISA was
observed more frequently than late acquired-ISA (81% vs. 16%, respectively; 3% were unmatchable). Late ac-
quired ISA was associated with scaffold pattern irregularities, which were related to overstretching of the scaf-
fold. Uncovered struts (63 struts, 2%) were more frequently observed in ISA and SB struts, compared with ap-
posed struts (29% vs. 1%; p  0.01). Intraluminal masses (14 cross-sections, 3%; in 6 patients, 24%) were more
frequently located at the site of ISA and/or uncovered struts (39% vs. 2% and 13% vs. 2%, respectively;
p  0.01).
Conclusions The lack of strut apposition at baseline is related to the presence of uncovered struts and in-
traluminal masses at 6 month. An appropriate balloon/artery ratio respecting the actual vessel size and avoid-
ing the overstretching of the scaffold can potentially decrease the risk of scaffold thrombosis. (ABSORB Clinical
Investigation, Cohort B [ABSORB B]; NCT00856856) (J Am Coll Cardiol Intv 2011;4:992–1001) © 2011 by the
American College of Cardiology Foundation
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Serial intravascular ultrasound (IVUS) imaging of metallic
drug-eluting stents (DES) has shown that incomplete
stent/strut apposition (ISA) at follow-up can be caused by
the persistence of ISA observed at baseline or by the new
appearance of late acquired incomplete scaffold/strut appo-
sition (LAISA) (1,2). Recent reports suggest that strut
apposition is important for the development of strut cover-
age, because malapposed struts are more frequently uncov-
ered at follow-up, as compared with apposed struts (3,4).
Furthermore, the absence of neointimal coverage as well as
the presence of malapposed struts have been related to late
stent thrombosis, even in patients treated with dual anti-
platelet therapy (5,6).
The novel everolimus-eluting bioresorbable vascular
scaffolds (BVS) are promising intravascular devices that
can potentially circumvent the risk of malapposed and
uncovered struts at follow-up. Notably, at 2 years after
implantation, the polymeric material has been shown
to be resorbed with the disappearance of struts that were
initially malapposed or at side branches (SBs) (7). The
first-generation BVS (version 1.0) demonstrated a high
rate of malapposed struts before complete resorption,
with a rate of malapposed struts at 6 months higher than
at baseline (6% vs. 5%, respectively; p  0.01). This
uncommon phenomenon was caused by a low rate of
resolved malapposed struts and by the occurrence of
LAISA at 6-month follow-up (8). The late scaffold area
reduction (shrinkage) observed at 6 months was the most
plausible explanation for the higher rate of ISA obser-
ved at follow-up compared with baseline. Despite this,
only 1% of struts remained uncovered at 6-month
follow-up (8).
The new-generation BVS (version 1.1) uses a new platform
design and a different processing of the polymer, as compared
with the previous generation of BVS (version 1.0), resulting in
an increased radial force and longer retention of mechanical
integrity (9). Consequently, there is now no detectable loss in
scaffold area at 6 months (10,11). Nevertheless, ISA and
uncovered struts can still be detected with the new generation
of BVS, but the fate of these struts is unknown.
The aim of our study is to describe the serial changes of
ISA and uncovered struts at baseline and at 6-month
follow-up of the new generation of BVS (version 1.1), as
assessed by optical coherence tomography (OCT).
Methods
Population. The ABSORB Cohort B (A Clinical Evalua-
tion of the Bioabsorbable Everolimus Eluting Coronary
Stent System [BVS EECSS] in the Treatment of Patients
With de Novo Native Coronary Artery Lesions) trial is a
nonrandomized, multicenter, single-arm, efficacy-safety
study (12). The study included 101 patients that were
allocated to 6-month angiographic and intravascular imag-
ing control (cohort B1) or 12-month angiographic and
intravascular imaging control (cohort B2). All lesions were
treated with a single-size device (3  18 mm) of the new
generation of BVS (version 1.1). The OCT imaging was an
optional investigation performed in selected participating
centers. In brief, the common inclusion criteria were pa-
tients 18 years of age or older, with a diagnosis of stable,
unstable, or silent ischemia that presented with a de novo
lesion in a native coronary artery between 50% and 99% of
the luminal diameter and a Thrombolysis In Myocardial
Infarction flow grade of 1 or
more. Exclusion criteria in-
cluded patients with an evolving
myocardial infarction, stenosis
of the left main or ostial right
coronary artery, presence of in-
tracoronary thrombus, or heavy
calcification.
The present study is a post
hoc analysis of those patients
included in the ABSORB co-
hort B1 that were serially im-
aged with OCT at baseline and
at 6-month follow-up.
BVS. The BVS version 1.1 revi-
sion is a balloon-expandable de-
vice, consisting of a polymer
backbone of poly-L-lactide coated with a thin layer of a 1:1
mixture of an amorphous matrix of poly-D,L-lactide polymer
containing 100 g/cm2 of the antiproliferative drug everoli-
mus. The implant is radiolucent but has 2 platinum markers
at each edge, which allows visualization on angiography and
other imaging modalities. Physically, the scaffold has struts
with an approximate thickness of 150 m arranged as
in-phase zigzag hoops linked together by 3 longitudinal
bridges.
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Abbreviations
and Acronyms
BVS  bioresorbable
vascular scaffolds
DES  drug-eluting stents
ISA  incomplete scaffold/
strut apposition
IVUS  intravascular
ultrasound
LAISA  late acquired
incomplete scaffold/
strut apposition
OCT  optical coherence
tomography
SB  side branch
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Treatment procedure. Lesions were treated with routine
interventional techniques. As per protocol, pre-dilation with
conventional balloons was mandatory. Pre-dilation balloons
should be shorter than the length of the scaffold and
0.5-mm smaller in diameter than the reference vessel. The
BVS implantation should not exceed the burst pressure as
indicated by the product chart (16 atm). Post-dilation with
a balloon shorter than the implanted device was allowed at
the discretion of the operator but, when performed, should
only be done with balloons sized to fit within the boundaries
of the scaffold. Intravascular imaging techniques were per-
formed when optimal BVS placement was obtained accord-
ing to the judgment of the physician on the basis of
angiographic results. In case of suboptimal deployment as
assessed by intravascular imaging techniques, post-dilations
were allowed at discretion of the operator until optimal stent
placement was achieved (on the basis of angiography). After
the last post-dilation, a new intravascular imaging acquisi-
tion was performed and was used for the study analysis.
OCT acquisition. The OCT imaging was performed with 2
different OCT systems (M3 Time-Domain System and
C7XR Fourier-Domain System; LightLab Imaging, West-
ford, Massachusetts). The M3 OCT system used a standard
intracoronary guidewire to cross the target lesion, and then
a single-lumen (e.g., Transit, Cordis, Johnson and Johnson,
Miami, Florida, or ProGreat, Terumo, Tokyo, Japan) or
double-lumen catheter (0.023-inch TwinPass, Vascular So-
lutions, Inc., Minneapolis, Minnesota) was required to
exchange the conventional wire with the LightLab Imaging
ImageWire. Pullback was performed during continuous
injection of contrast medium (1 to 3 ml/s, iodixanol 370;
Visipaque, GE Healthcare, Cork, Ireland) through the
guide catheter with an injection pump. The automated
pullback was performed at 3 mm/s with a frame rate of 20
images/s.
The C7XR system used a conventional wire to cross the
segment of interest. The OCT imaging catheter (Dragon-
fly, LightLab Imaging) was then advanced distally to the
treated region. Pullback was performed during continuous
injection of contrast medium (3 ml/s, iodixanol 370; Visi-
paque) through the guide catheter with an injection pump.
The automated pullback rate was 20 mm/s, and the frame
rate was 100 images/s.
OCT analysis. Offline OCT qualitative data analysis was car-
ried out by 2 expert analysts with the proprietary software for
offline analysis (LightLab Imaging). Both investigators were
blinded to the patient, procedural, and clinical characteristics as
well as to the clinical outcomes. Adjusting for the pullback
speed, the analysis of contiguous cross-sections was performed
at 1-mm longitudinal intervals within the treated segment (7
cross-sections/mm in case of M3 OCT system and 5 cross-
sections/mm in case of C7 OCT system).
At baseline, embedded struts were defined as present
when more than one-half thickness of the strut was im-
pacted into the vessel wall; protruding struts were defined as
struts being in contact with the vessel wall but with less than
one-half strut thickness impacted into the vessel wall. Both
embedded and protruding struts presented with different
degrees of apposed struts at follow-up, but we made no
distinction. At baseline and follow-up, malapposed struts
were defined as struts where the abluminal surfaces were
separated from the vessel wall by flush; and SB struts were
defined as struts overlying the ostium of an SB (Fig. 1). It
is noteworthy that, in contrast with metallic stents, the BVS
allows the assessment of the structures located behind the
struts without the usual shadowing of metallic struts.
Therefore, strut malapposition can be easily assessed when
the polymeric strut is separated from the vessel wall. At
follow-up, the absence of strut coverage was defined when 1
of the strut corners preserved the right angle shape without
signs of neointimal tissue (Fig. 1). Although strut apposi-
tion and coverage was measured as a consensus between 2
analysts, a total of 100 random images of 10 different
patients were analyzed separately by 2 analysts to ensure the
agreement of the qualitative assessments. Scaffold pattern
irregularities were defined when struts were found in loca-
tions incongruent with the scaffold pattern. They were
classified into 2 categories: 1) 2 struts overhanging each
other in the same angular sector of the lumen perimeter,
with or without malapposition; and/or 2) isolated struts
located more or less at the center of the vessel without
obvious connection to the expected adjacent strut pattern.
At follow-up, protruding masses attached to the vessel wall
or floating masses without contact with the vessel wall have
been suggested to be thrombi (3). However, the distinction
between thrombi and neointimal protrusions into the lumen
is not always possible. Therefore, any irregular mass at-
tached to the polymeric struts or floating into the lumen has
been classified as intraluminal mass without distinction
between thrombus and neointima.
With clear landmarks in the longitudinal OCT images,
all cross-sections with at least 1 ISA or SB strut at baseline
were matched with the corresponding image of all the
possible cross-sections of the entire recording at follow-up
(every 7 cross-sections/mm in case of M3 OCT system and
every 5 cross-sections/mm in case of C7 OCT system).
Every single ISA or SB strut at baseline was investigated at
follow-up, to assess its apposition and the state of neointi-
mal coverage. Similarly, those images with at least 1 ISA
and/or uncovered struts at follow-up were matched to the
corresponding image at baseline of all possible cross-
sections of the entire recording at baseline and investigated
to assess the original state of strut apposition.
Statistical analysis. Statistical analysis was performed with
the SPSS software (version 15.0, SPSS, Inc., Chicago,
Illinois). Discrete variables are presented as counts and
percentages and continuous variables as mean  SD.
Comparisons of continuous variables between baseline and
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follow-up have been estimated with the nonparametric
Wilcoxon signed-rank test. Comparison of percentages of
uncovered struts between apposed and nonapposed struts
has been performed with the Mann-Whitney U test at strut
level analysis. Adjustments for clustering data at the patient
and frame level analysis have not been performed. A 2-sided
p value 0.05 was considered statistically significant.
The interobserver agreement for qualitative measure-
ments was quantified by the Cohen’s kappa test for concor-
dance (13). In accordance with previous publications, a
value0 indicates poor agreement, 0 to 0.20 indicates slight
agreement, 0.21 to 0.40 indicates fair agreement, 0.41 to
0.60 indicates moderate agreement, 0.61 to 0.80 indicates
good agreement, and 0.81 to 1.0 indicates excellent agree-
ment (14).
Results
Population. The ABSORB Cohort B1 study included 45
patients, 28 of whom were imaged with OCT at baseline.
Two patients were excluded due to suboptimal quality of the
OCT recording (lack of imaging of the full length and/or
perimeter of the implant); and 1 asymptomatic patient
withdrew consent to invasive control at 6-month follow-up.
The remaining 25 patients, all of whom were serially imaged
with OCT at baseline and 6-month follow-up, were in-
cluded in the present study. A total of 11 and 9 patients
were imaged with the M3 OCT system at baseline and
follow-up, respectively; whereas 14 and 16 patients were
imaged with the C7 OCT system at baseline and follow-up,
respectively. Only 2 patients were imaged with different
OCT systems at baseline and follow-up.
Table 1. Baseline Clinical and Angiographic Characteristics (n  25)
Male 20 (80.0)
Age (yrs) 62.4 10.0
Hypertension 14 (56.0)
Hypercholesterolemia 24 (96.0)
Diabetes 2 (8.0)
Smokers 5 (20.0)
Prior MI 11 (44.0)
Prior PCI 6 (24.0)
Clinical indication
Stable angina 21 (84.0)
Unstable angina 4 (16.0)
Number of vessel disease
1 21 (84.0)
2 3 (12.0)
3 1 (4.0)
Target vessel
Left anterior descending 11 (44.0)
Left circumflex 6 (24.0)
Right coronary artery 8 (32.0)
Values are count (%) or mean SD.
MImyocardial infarction; PCI percutaneous coronary intervention.
Figure 1. Strut Apposition and Coverage Assessment
Apposition assessment at baseline: (A) protruding struts: less than one-half thickness of the strut is impacted into the vessel wall; (B) embedded strut: more than
one-half thickness of the strut is impacted into the vessel wall; (C) incomplete strut/scaffold apposition (ISA): the back-side of the strut is separated from the ves-
sel wall; (D) side-branches (SB) strut: the strut is located in the take-off of an SB without any contact with the vessel wall. Strut coverage assessment at follow-
up: (E) apposed and covered strut: the 4 corners of the polymeric strut have lost the right angle shape with signs of tissue coverage; (F) apposed and
uncovered strut: 1 of the 2 endoluminal strut corners preserves the right angle shape without signs of tissue coverage; (G) ISA/SB and covered strut: the 4 strut
corners have lost the right angle shape with signs of tissue coverage; (H) ISA/SB and uncovered: 1 of the 4 strut corners preserves the right angle shape without
signs of tissue coverage.
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Baseline clinical and angiographic characteristics are
shown in Table 1. Mean age was 62.4 years; 80% were men,
and 8% were diabetic. The clinical indication of the index
procedure was stable angina in 84% of patients. A total of
85% of patients had single-vessel disease.
Qualitative OCT findings at baseline. Qualitative OCT find-
ings at baseline are shown in Table 2. At baseline, 3,686
struts in 424 frames were analyzed: 2,554 were classified as
protruding (69.3%), 951 as embedded (25.8%), 128 as ISA
(3.5%), and 53 struts were overlying an SB (1.4%). Figure 2
shows the distribution of malapposed and SB struts
throughout the length of the BVS.
Matched cross-sections. A total of 80 of 90 baseline images
with ISA and/or SB struts were properly matched with the
corresponding frame at 6-month follow-up. Therefore,
95.3% of malapposed and 84.9% of SB struts were properly
matched between time points. At follow-up, the fate of the
malapposed struts observed at baseline was: 80.5% resolved
into apposed struts, and 14.8% persisted as ISA (4.7% were
unmatchable).
Qualitative OCT findings at 6-month follow-up. At 6
months, all polymeric struts were visible, remaining with the
preserved box appearance. Qualitative OCT findings are
shown in Table 3. At follow-up, 3,905 struts in 433 frames
were analyzed: 3,838 were apposed (98.3%), 32 were malap-
posed (0.8%), and 35 were located over an SB (0.9%). Lack
of tissue coverage was detected in 63 struts (1.6%). Distri-
bution of ISA, SB, and uncovered struts throughout the
length of the BVS is shown in Figure 2.
Strut coverage. A total of 43 of 3,838 apposed struts (1.1%)
were uncovered, whereas 10 of 32 ISA struts (31.3%) and 10
of 35 SB struts (28.6%) were uncovered. The comparison of
the rate of uncovered plus apposed struts (1.1%) with the
rate of uncovered plus ISA or SB struts (29.0%) was
statistically significant (p  0.01) (Fig. 3).
Intraluminal masses. At 6 months, intraluminal masses were
observed in 14 cross-sections (2.9%) in 6 patients (24.0%).
Table 2. Qualitative OCT Findings at Baseline (n  25)
Number of struts 3,686
Protruding 2,554 (69.3%)
Embedded 951 (25.8%)
ISA 128 (3.5%)
SB 53 (1.4%)
Matched ISA at baseline that at 6 months became 128
Apposed  covered 97 (75.8%)
Apposed  uncovered 6 (4.7%)
Persistent ISA  covered 15 (11.7%)
Persistent ISA  uncovered 4 (3.1%)
Unmatchable 6 (4.7%)
Matched SB struts at baseline that at 6 months became 53
Apposed  covered 12 (22.7%)
Apposed  uncovered 1 (1.9%)
SB  covered 27 (50.9%)
SB  uncovered 5 (9.4%)
Unmatchable 8 (15.1%)
ISA incomplete scaffold/strut apposition; OCT optical coherence tomography;
SB side branch.
Figure 2. Distribution of Malapposed and Uncovered Struts
Strut distribution with respect to the optical coherence tomography (OCT) catheter (degrees) and location throughout the bioresorbable vascular scaffold (BVS)
length (from distal to proximal) of malapposed, side-branch (SB), and uncovered struts. ISA  incomplete strut/scaffold apposition.
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Notably, intraluminal masses were more often associated with
malapposed and/or uncovered struts rather than apposed and
covered struts. Of struts with attached intraluminal masses, 40.0%
of struts were malapposed and uncovered, 18.2% were malap-
posed and covered, 9.3% were apposed and uncovered, and 0.9%
were apposed and covered (p  0.01).
Matched cross-sections. A total of 51 of 53 cross-sections
with ISA or uncovered struts were properly matched with
the corresponding image at baseline. Likewise, 97.1% of
malapposed and 95.2% of uncovered struts were properly
matched. The ISA was more frequently caused by persistent
ISA (81.3%) rather than LAISA (15.6%); 3.1% of the struts
were unmatchable. Late acquired ISA was only found in 2
patients (8.0%). Serial analysis of uncovered struts showed
that, at baseline, 36 matched struts were classified as
protruding (57.1%), 4 as embedded (6.3%), and 10 as ISA
(15.9%), and 10 struts were overlying an SB (15.9%); 4.8%
were unmatchable.
Clinical outcomes. At 6-month follow-up, no death, spon-
taneous acute myocardial infarction, scaffold thrombosis, or
target lesion revascularization of the 25 patients included in
the present study were documented. One patient experi-
enced a periprocedural acute myocardial infarction at the
time of the index procedure without any further complica-
tions. Another patient with suboptimal OCT imaging at
baseline (and excluded from our study) presented with
nonclinically driven target lesion revascularization at day 33.
At that time, OCT imaging showed scaffold pattern irreg-
ularities demonstrating substantial structural distortion,
with intraluminal masses attached to the malapposed struts.
At the time of the index procedure, this patient was also
treated with a post-dilation balloon that achieved a larger
predicted diameter than the maximum limit recommended
for the BVS.
Qualitative coverage agreement between the 2 analysts.
Two analysts investigated, in separate analyses, 100
selected cross-sections of 10 different patients with 767
struts. Both analysts agreed in 710 and 35 covered and
uncovered struts, respectively. The Kappa index was 0.75
(good agreement).
Discussion
The main findings of our study are: 1) with the BVS version
1.1, the number of malapposed struts decreased from
baseline to 6-month follow-up; 2) 80% of the malapposed
struts observed at baseline resolved into apposed struts at
follow-up, with a relatively low rate of LAISA at 6 months;
3) as at baseline and follow-up, ISA and SB struts were
associated with a lack of strut coverage at 6 months; and
4) intraluminal masses were rarely observed but were more
frequently associated with ISA and uncovered struts.
Acute ISA. With metallic-DES, acute ISA ranged from
3.7% to 11.6% of the total amount of struts in patients
without ST-segment elevation myocardial infarction
Figure 3. Strut Coverage at Follow-Up With Respect to Strut Apposition
Blue bars  covered; red bars  uncovered. ISA  incomplete scaffold/
strut apposition; SB  side-branch strut.
Table 3. Qualitative OCT Findings at 6-Month Follow-Up
Number of struts at 6 months 3,905
Apposed  covered 3,795 (97.2%)
Apposed  uncovered 43 (1.1%)
ISA  covered 22 (0.5%)
ISA  uncovered 10 (0.3%)
SB  covered 25 (0.6%)
SB  uncovered 10 (0.3%)
Number of struts with attached intraluminal masses at 6 months* 21 (0.5%)
Apposed  covered 9 (0.2%)
Apposed  uncovered 4 (9.3%)
ISA  covered 4 (18.2%)
ISA  uncovered 4 (40%)
SB  covered 0
SB  uncovered 0
Matched ISA struts at follow-up that at baseline were: 32 (0.8%)
ISA 26 (81.3%)
Protruding 5 (15.6%)
Embedded 0
Unmatchable 1 (3.1%)
Matched uncovered struts at follow-up that at baseline were: 63 (1.6%)
Protruding 36 (57.1%)
Embedded 4 (6.3%)
ISA 10 (15.9%)
SB 10 (15.9%)
Unmatchable 3 (4.8%)
Matched ISA  uncovered struts at follow-up that at baseline were: 10 (0.3%)
Protruding 5 (50.0%)
ISA 5 (50.0%)
N 25. *Percentages are estimated according the total amount of each strut type.
Abbreviations as in Table 2.
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(15,16). Patients with at least 1 malapposed strut ranged
from 32% to 88% in the same clinical setting (17,18). Our
study observed a rate of acute ISA of 3.5%; and 17 patients
(68%) presented with at least 1 malapposed strut. These
findings suggest that the BVS might have a similar rate of
acute ISA, as compared with metallic-DES.
Figure 2 shows the distribution of the malapposed struts
throughout the BVS length. According to this figure,
malapposed struts were distributed with a particular pattern
and were more frequently located at the 2 edges (especially
at the proximal edge), with few malapposed struts being
located in the central segments of the BVS. This is probably
caused by the placement of the central segment of the BVS
at the site of the minimal lumen area and by the use of
post-dilation balloons (in 56% of patients), shorter than the
length of the scaffold, applied at the central segment of the
BVS. At baseline, 2 of 25 patients presented with scaffold
pattern irregularities resulting in acute strut malapposition.
Both patients were treated with post-dilation balloons
immediately after the BVS implantation. In both cases,
post-dilation balloons were inflated at pressures that re-
sulted in predicted device diameters (according to the
manufacturer’s chart) larger than the recommended limits
for the BVS implantation (3.3 mm for a 3.0-mm nominal
diameter BVS). Scaffold pattern irregularities were located
at the proximal edges and extended over 2 to 4 mm of the
scaffold length. In these images, the number of ISAs were 2
and 5 struts, respectively. Additionally, no intraluminal
mass was observed in these frames.
ISA at 6 months. Malapposed struts of different metallic-
DES ranged from 0% to 15% of the total amount of struts
at 6 months in non–ST-segment elevation myocardial
infarction patients (19–21). In a single study comparing
different metallic-DES, zotarolimus DES presented with
lower rates of malapposed struts (0.0%), as compared with
paclitaxel (0.7%) or sirolimus DES (1.9%) (19). All serial
OCT imaging studies performed with metallic-DES have
found a progressively decreasing amount of malapposed
struts over time (21,22). Unfortunately, at the time of the
present study, no OCT data were available for the everoli-
mus DES at 6-month follow-up.
The healing process of the different metallic-DES is
extremely heterogeneous, with little data being available
with regard to the healing process of malapposed struts.
Serial OCT imaging of sirolimus DES at baseline and
10-month follow-up showed a high rate of persistent
malapposed struts, with 65% of ISA struts observed at
baseline remaining malapposed at follow-up. Late acquired
ISA was observed in 7.3% of malapposed struts at follow-up
(3). Although there are many IVUS studies with serial strut
analysis at baseline and at follow-up, the low sensitivity of
IVUS to assess ISA—when compared with OCT—
challenges the comparability of the results (23). Neverthe-
less, IVUS was able to identify some of the mechanisms
involved in the appearance of LAISA with metallic-DES.
Some patients experienced positive remodeling due to vessel
and lumen enlargement without increasing the plaque area.
In these cases, the vessel wall separated from the apposed
strut causing LAISA. This mechanism was more frequently
related to sirolimus DES (24,25) rather than paclitaxel DES
(1,25), everolimus DES (26), or zotarolimus DES (27).
The first generation of the everolimus-eluting BVS (ver-
sion 1.0) presented with more malapposed struts at 6
months than at baseline. A total of 78% of malapposed
struts observed at baseline persisted at 6 months. Late
acquired ISA was observed in 1.0% of the total amount of
struts and represented 16% of the total amount of ISA at
follow-up (8). The most plausible explanation for this
phenomenon was the loss in scaffold area observed during
the first 6 months, when the BVS version 1.0 had a
premature loss of its radial force and structural continuity
(10). This phenomenon caused the displacement of the
scaffold into the lumen and probably delayed the healing of
previously (baseline) malapposed struts. Likewise, this prob-
ably caused the appearance of new malapposed struts at
follow-up that were apposed at baseline (LAISA). As
assessed by IVUS (8), positive remodeling was not observed
with the BVS (version 1.0), unlike what was previously
reported in DES.
In our study, with the new generation of BVS (version
1.1), the percentage of malapposed struts at 6-month
follow-up was inferior to that at baseline (0.8% vs. 3.5%,
respectively; p  0.01). Only 15% of the malapposed struts
at baseline persisted at follow-up. Late acquired ISA was
observed in 5 struts (1.0%) in 2 patients and represented
16% of malapposed struts at follow-up. The mechanism
owing to LAISA in these 2 patients was the emergence of
scaffold pattern irregularities not observed at baseline. Scaf-
fold pattern irregularities were extended over 4 mm
throughout the length of the BVS and were mainly located
at the proximal edge. The IVUS analysis showed the
absence of positive remodeling at the site of the external
elastic membrane in those patients (data not shown).
Figures 4 and 5 show matched OCT images from baseline
to 6-month follow-up of the 2 patients with LAISA caused
by the emergence of scaffold pattern irregularities. Al-
though scaffold pattern irregularities were not observed in
any of those patients at baseline, it is remarkable that the
respective patients had been treated with post-dilation
with balloons that over-stretched the BVS to larger
diameters than the recommended maximum device di-
ameter of 3.3 mm.
The matched images of the 7 struts with acute ISA due
to acute scaffold pattern irregularities (at baseline) evolved to
ISA  covered (3 struts) and to ISA  uncovered (4 struts)
at 6 months. None of the cases were related to LAISA.
Strut coverage at 6-month follow-up. Strut coverage of
different metallic-DES is extremely heterogeneous. At 6
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months, sirolimus DES presented with a rate of uncovered
struts from 8.7% to 15.0% (19–22). Uncovered struts with
paclitaxel DES ranged from 2.7% to 5.0% (19,20), and
zotarolimus DES presented with 0% of uncovered struts in
a single report (19).
In our study, with the new generation of BVS (version
1.1), a total of 1.6% of struts were uncovered at 6-month
follow-up. The distribution of uncovered struts throughout
the BVS length did not show any particular pattern (Fig. 2).
However, uncovered struts at follow-up were relatively more
frequently found in struts that at baseline were ISA and SB
struts rather than apposed struts. Similar results have been
obtained with serial OCT imaging of sirolimus DES. Ozaki
et al. (3) found a higher percentage of uncovered struts, at
10-month follow-up, in struts that were malapposed at
baseline (65.4%) as compared with struts that were apposed
(8.6%). The first generation of everolimus-eluting BVS
(version 1.0) presented with 1.0% of uncovered struts at
6-month follow-up (8). Although the rate of ISA at 6
months was relatively high, uncovered struts were not
commonly found. Moreover, the mean neointimal hyper-
plasia area was statistically higher with the BVS version 1.0
than with the BVS version 1.1 (10). There is no clear
explanation for these findings. One hypothesis is that the
advanced resorption state and the strut appearance changes
observed with the BVS version 1.0 at 6 months as compared
Figure 4. Late Acquired ISA
Consecutive, matched OCT images at baseline (A to E) and 6 months (A‘ to E‘) of 1 patient treated with excessive post-dilation (3.4 mm). At baseline, the scaf-
fold pattern is regular. B, C, and D show 1 apposed strut at baseline (arrows) that at follow-up evolved to acquired malapposed strut (arrows) due to scaffold
pattern irregularities. Abbreviations as in Figure 2.
Figure 5. Late Acquired ISA With Attached IntraLuminal Masses
Consecutive, matched OCT images at baseline (A to F) and 6-month follow-up (A‘ to F‘). At baseline, the scaffold was post-dilated up to 3.4 mm of predicted
device diameter. The OCT images show all struts are apposed to the vessel wall without scaffold pattern irregularities. At 6 months, the scaffold presents with
pattern irregularities resulting in strut malapposition and lack of tissue coverage (*). Irregular intraluminal masses (arrows) with mild shadowing behind are
attached to the malapposed and uncovered struts. Abbreviations as in Figure 2.
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with the BVS 1.1 could trigger a higher neointimal response
and strut coverage.
intraluminal masses at 6-month follow-up. Lack of neointi-
mal coverage of different DES was proposed as the best
predictor of late stent thrombosis in pathological studies (6).
However, although sirolimus DES presented with a higher
percentage of uncovered struts compared with paclitaxel
DES, thrombi were more frequently found with paclitaxel
DES (20). This observation supports the concept of a
multicausal pathogenesis of late stent thrombosis, including
malapposition, expansive vessel remodeling, and other fac-
tors that can initiate thrombus formation (28,29). Due to its
high resolution, OCT is able to visualize, with great detail,
many of the proposed predictors of late stent thrombosis in
vivo (3,30). With sirolimus DES, Ozaki et al. (3) found
4.1% of frames with thrombi at 10-month follow-up;
thrombi were more frequently observed in frames with ISA
than in those without this feature (21% vs. 2%, respectively,
p  0.01). Our study found 14 cross-sections (2.9%) in 6
patients (24%) containing intraluminal masses at 6-month
follow-up. Intraluminal masses were more frequently ob-
served in cross-sections with ISA than without (39% vs. 2%;
p  0.01) and in cross-sections with uncovered struts than
without (13% vs. 2%; p  0.01), supporting that malappo-
sition and absence of coverage can initiate thrombosis.
However, whether this is of clinical importance needs to be
further investigated. Figure 5 shows intraluminal masses
attached to malapposed and uncovered struts in 1 patient
with acquired scaffold pattern irregularities and LAISA at 6
months.
Clinical implications. In our study, the new generation of
BVS presented with a lower rate of ISA, uncovered struts,
and intraluminal masses as compared with sirolimus DES at
6-month follow-up. The polymeric nature of this new
technology, however, could render it susceptible to iatro-
genically induced scaffold pattern irregularities. These can
lead to ISA and lack of strut coverage at 6-month follow-up.
The 5 cases reported in our study were treated with
aggressive post-dilations, probably resulting in overstretch-
ing of the scaffold at the time of the implantation. A third
generation of the device is intended to raise the limit of
deployment of the 3.0-mm nominal diameter device to 3.8
mm. Nevertheless, the previous generation of the BVS
(version 1.0) showed a complete resorption of its compo-
nents at 2-year follow-up without any malapposed or
uncovered struts (7). Therefore, in this case, the treatment
with dual antiplatelet therapy can become unnecessary. It is,
however, currently uncertain whether the new generation of
the BVS (version 1.1) will exhibit similar resorption char-
acteristics at 2 years.
Study limitations. The first limitation of the present study is
the limited number of patients. However, our report is 1 of
the largest OCT studies with serial imaging of the same
intracoronary device at baseline and at follow-up. The
second limitation is the lack of statistical adjustment for
clinical and anatomic covariables. The clustering essence of
the OCT data (patient level, stent level, frame level, and
strut level) needs a multilevel regression analysis not applied
in our study. Moreover, the different OCT pullback speed,
frame/rate, and quality of the image of the 2 OCT systems
used in the present study hamper the matching of cross-
sections between baseline and follow-up. A total of 12
cross-sections were unmatchable from baseline to follow-up
or vice versa: 8 cross-sections were imaged with the M3
OCT system and 4 cross-sections were imaged with the C7
OCT system in both baseline and follow-up. Finally, the
last limitation is the lack of results at very-long-term
follow-up. The extrapolation of the 2-year follow-up results
observed with the first generation of BVS (version 1.0) with
the new generation of BVS (version 1.1) is purely specula-
tive. However, all patients included in the ABSORB cohort
B study will be reinvestigated at 2-year follow-up with
invasive imaging techniques.
Conclusions
The new generation of BVS exhibited a low rate of acute,
persistent, and late acquired incomplete strut/scaffold
malapposition as well as uncovered struts. At baseline and
follow-up, malapposed and SB struts were related to a lack
of tissue coverage at 6 months. Scaffold pattern irregularities
were the only cause observed in our study of late acquired
malapposed struts and were also related to a lack of tissue
coverage. Attached intraluminal masses occurred more fre-
quently in malapposed and uncovered struts at 6 months. A
more careful device implantation, with appropriate sizing of
the vessel and respecting the deployment limits of inflation,
will reduce the rates of acute ISA and scaffold pattern
irregularities and, therefore, could circumvent most of the
ISA, uncovered struts, and intraluminal masses observed at
midterm follow-up.
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Objective: To quantify the circumferential healing process at 6 and 12 months following scaffold implan-
tation.
Background: The healing process following stent implantation consists of tissue growing on the top of
and in the space between each strut. With the ABSORB bioresorbable vascular scaffold (BVS), the outer
circumference of the scaffold is detectable by optical coherence tomography (OCT), allowing a more
accurate and complete evaluation of the intra-scaffold neointima.
Methods: A total of 58 patients (59 lesions), who received an ABSORB BVS 1.1 implantation and a sub-
sequent OCT investigation at 6 (n=28 patients/lesions) or 12 (n=30 patients with 31 lesions) months
follow-upwere included in the analysis. The thickness of the neointimawas calculated circumferentially
in the area between the abluminal side of the scaffold and the lumen by means of an automated detec-
tion algorithm. The symmetry of the neointima thickness in each cross section was evaluated as the ratio
between minimum and maximum thickness.
Results: The neointima area was not different between 6 and 12 months follow-up (1.57±0.42mm2 vs.
1.64±0.77mm2; p=0.691). No differencewas also found in themean thickness of the neointima (median
[IQR]) between the two follow-up time points (210m [180–260]) vs. 220m [150–260]; p=0.904).
However, the symmetry of the neointima thickness was higher at 12 than at 6 months follow-up (0.23
[0.13–0.28] vs. 0.16 [0.08–0.21], p=0.019).
Conclusions: A circumferential evaluation of the healing process following ABSORB implantation is fea-
sible, showing the formation of a neointima layer, that resembles a thick fibrous cap, known for its
contribution to plaque stability.
© 2011 Elsevier Ireland Ltd. All rights reserved.
∗ Corresponding author at: Interventional Cardiology Department Erasmus MC,
Thoraxcenter, ‘s Gravendijkwal 230,3015 CE Rotterdam, The Netherlands.
Tel.: +31 10 4635260; fax: +31 10 4369154.
E-mail address: p.w.j.c.serruys@erasmusmc.nl (P.W. Serruys).
1. Introduction
The aim of percutaneous treatment of a coronary lesion with an
intracoronary scaffolding device is to acutely restore the geome-
try of the coronary lumen, alleviating its flow-limiting character.
Thereafter, the reaction of the vessel wall to the implanted stent
initiates a healing process resulting in the growth of intra-scaffold
0021-9150/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.atherosclerosis.2011.12.008
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neointima [1,2]. Growth of this neo-tissue on top of a vulnerable
thin-cap fibroatheroma may generate a new “fibrous cap” which
may potentially increase the thickness of the cap [3–5]. This bio-
logical processmaybeofparticular interest in caseswhere scaffolds
have been implanted on top of a necrotic core, abutting the lumen.
Nevertheless, autopsy studies have suggested that metallic
struts embedded in necrotic core may remain uncovered even at
long-term, and thus be potentially a trigger for stent thrombosis
[4].
The bioresorbable vascular scaffolds, which in the long-term are
completely replaced by connective tissue and smooth muscle cells
– overcoming the problem of metal persistence into the coronary
vessel wall – can ensure the formation of a neointima layer [6,7]. In
additionas thepolymeric struts are translucent anddonot create an
optical shadow, an optical coherence tomography (OCT) evaluation
of the neointima growth can be performed in a more refined way
in the scaffold than in the metallic stents [8].
The aimof this analysiswas to assess and toquantify the circum-
ferential distribution of the intra-scaffold neo-intima tissue during
the first year after ABSORB implantation.
2. Methods
2.1. Study population
The ABSORB Cohort B trial (NCT00856856) is a multicen-
tre single-arm trial assessing the safety and performance of the
ABSORB BVS (Abbott Vascular, Santa Clara, USA). The details of this
trial have been previously reported [8,9].
In total, 101 patients were enrolled in the ABSORB Cohort B
trial, subdivided in two subgroups of patients: the first group of 45
patients (Cohort B1) randomized to invasive imaging at 6 and 24
months; the second group of the remaining 56 patients (Cohort B2)
randomized to the same invasive imaging at 12 and36months. OCT
was realized as an optional investigation in some of these patients
without any inclusion/exclusion criteria.
The present study is a post hoc analysis of the patients receiving
an OCT investigation at the various follow-up time points.
2.2. ABSORB BVS
The ABSORB BVS is a fully bioresorbable intra-coronary device
made of semi-crystalline poly (l-lactide) (PLLA) coated with an
amorphous poly (d,l-lactide) (PDLLA) copolymer that contains and
controls the release of the anti-proliferative drug everolimus. At
the time of implantation, the total strut thickness is 156m. The
primary mechanism for molecular weight degradation of both
polylactide (PLA) materials is hydrolysis, a process in which the
ester bonds between repeating lactide molecules are progres-
sively cleaved by water. Ultimately, PLLA and PDLLA degrade into
lactic acid, which is readily converted to lactate and processed via
both theKreb’s cycle (for l-lactate) andmethylglycoxalmetabolism
(for d-lactate) [7,10,11]. Based on preclinical studies, the time for
complete bioresorption is assumed to be approximately 2 years [6].
2.3. OCT acquisition and analysis
OCT imaging was performed as an optional investigation at
selected centers, using either time domain [M3 system, Light Lab
Imaging (LLI), Westford, MA, USA] or frequency domain OCT sys-
tems (C7XR system, LLI) at baseline and follow-up [12–17]. TheOCT
measurements were performed with proprietary software for off-
line analysis (Light Lab Imaging, Westford, MA, USA). Adjusting for
the pullback speed, the cross-sectional analysis was performed at
1mm longitudinal intervals within the treated segment.
When imaged with OCT, the ABSORB BVS presents important
differences compared to the metallic stents. The optically translu-
cent polymeric struts appear as blackboxes (strut core area) framed
by light-scattering borders that do not produce dorsal shadows,
thus allowing for a complete imaging of the strut thickness [8].
As the strut is entirely visible throughout its entire thickness, the
main quantitativemeasurements (strut core area, strut area, lumen
area, scaffold area, incomplete scaffold apposition area and neoin-
tima area) required different analysis rules than with the metallic
stents, as previously described [8,9]. In particular, the neointima
area has been previously calculated as [scaffold area – lumen area
– strut core area] and the thickness of the coverage has been mea-
sured for every strut between the abluminal side of the strut core
and the lumen [8,9].
At variance with this previous analysis, the strut core area is
now included in the neointima area assessment, in order to per-
form a circumferential measurement of the neointima thickness
by means of an automated contour detection algorithm available
in the Light Lab proprietary software. The size and the thickness
of the neo-intima area, delimitated by the scaffold (as outer ref-
erence, drawn at the abluminal side of the struts) and the lumen
contours (as inner reference), weremeasured in each frame (Fig. 1).
Frames containingmalapposed strutswere excluded fromthe anal-
ysis, as the area included between the scaffold and the lumen does
not contain in these cases any neointimal tissue, but represents
incomplete scaffold apposition (ISA) area. The neointima area was
estimated as scaffold area – lumen area. The neointima area was
normalized per scaffold size as “in-scaffold area obstruction” and
estimated as: [neointima area/scaffold area]×100. The symmetry
of the neointima thickness in each cross-section was evaluated
as a ratio between the minimum and the maximum thickness of
neointima in that cross-section [18,19].
Fig. 1. Circumferential assessment of neointima for ABSORB BVS. Panel A shows the circumferential distribution of the polymeric struts (*) in a cross-section. After drawing
the lumen and scaffold contours (Panel B), the neointima thickness is calculated (Panel C). Theminimum andmaximumdiameters of lumen and scaffold areas are also drawn.
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2.4. Statistical analysis
Continuous variables are expressed as mean± standard devia-
tion (SD) or median and interquartile range, depending on their
distribution. The distribution normality of the variables was tested
using the Kolgomorov–Smirnov test. Dichotomous variables are
reportedasnumbers andpercentages. Comparisonbetweengroups
was done by means of the non-parametric Mann–Whitney test.
Adjustment for clustering data at cross section level was per-
formed using a generalized estimating equations approach [20].
A two-tailed p-value <0.05 was considered statistically significant.
Statistical analyses were performed with SPSS statistical package,
version 17.0 (SPSS Inc., Chicago IL, USA).
3. Results
3.1. Patient population
A total of 58 patients (59 lesions) received an OCT investigation
at 6 (n=28 patients/lesions) or 12 (n=30 patients with 31 lesions)
months follow-up after ABSORB BVS implantation, and all were
included in the present analysis. (see Supplementary material for
baseline clinical characteristics).
3.2. OCT analysis of neointimal area at 6 and 12 months
follow-up
A total of 1083 cross sections were analyzed (531 and 552 at
6 and 12 months, respectively). Forty-nine cross sections were
excluded from the analysis due to the presence of ISA (23 and 26 at
6 and 12 months follow-up, respectively).
At a cross-section level, lumen and scaffold areas tended to
be smaller, while the minimum neointima thickness tended to be
larger at 12 as compared to 6 months. However, the mean neoin-
tima area was not different between the two time points (Table 1).
Fig. 2A shows the bimodal distribution histogram of the mean
neointima thicknesses, pooling the 6 and the 12 months follow-
up data. There was a significant relationship between the mean
neointima thickness measured at the minimum lumen area frame
and the angiographic late loss (r=0.624, p=0.003) (Fig. 2B).
At a lesion level, lumen and scaffold area also tended to be
smaller at 12months follow-up and theminimumneointima thick-
ness tended to be larger at 12 than at 6months follow-up (Table 1).
The symmetry of the neointima thickness (more homogeneous
distribution of neointima) was significantly higher at 12 than at 6
months follow-up both at cross-section and at lesion level (Fig. 3).
4. Discussion
The main findings of the present analysis are: (1) the method-
ology for measuring the neointima thickness circumferentially by
OCT is feasible with translucent bioresorbable scaffolds and allows
for the measurement of the neointima on top and between the
struts; (2) the neointima at 6 and 12 months does not differ in
terms of thickness but appears to be more symmetric at 12 than
at 6 months.
It is known that in the pathogenesis of acute coronary syn-
dromes a major role is played by coronary plaque rupture and
erosionwith subsequent local thrombosis [21]. In particular, patho-
logical studies have documented that these plaques are mostly
represented by thin-cap fibroatheromas (TCFA), which are lipid
core plaques covered by a thin fibrous cap (<65m) [22,23]. The
PROSPECT study has further demonstrated that IVUS-VH derived
TCFA are independent predictors of coronary events in patients
after an acute coronary syndrome at a median follow-up of 3.4
Fig. 2. Neointima thickness: histogram distribution and correlation with angio-
graphic late loss. Panel A: Histogram distribution of the neointima thickness at
cross-sectional level (1034 cross-section). The ABSORB BVS scaffold has a median
(interquartile range) of 210m (160–270m)with a bimodal distribution. Panel B:
the mean neointima thickness at the site of minimum lumen area (MLA) is signifi-
cantly correlated with the angiographic late loss.
years [24]. Nevertheless, it has not been yet demonstrated which
of these plaques are going to be the cause of events. Of note is that
themajority of the events in the PROSPECT study were progressive
angina, caused probably by plaque growth and not acute coronary
syndromes that could be attributed to the rupture of a vulnerable
plaque. In addition to this, TCFA were identified in the PROSPECT
study by IVUS-VH, which has a limited resolution to measure the
thickness of the cap. For these reasons, more natural history stud-
ies with more precise techniques for the detection of TCFAs are
needed before the interventional treatment of these lesions can be
recommended.
Pharmacological and mechanical treatments aimed to stabilize
TCFA are, however, a current topic of research. Takarada et al. [25]
showed that pharmacological treatment, such as statins, enables
to significantly increase the fibrous-cap thickness of coronary
plaques. The pilot SECRITT trial attempted to address for the first
time the question whether a mechanical preventive treatment of
such kind of plaques by means of self-expandable metallic stent
(“Shield”) may be feasible and safe [3]. The percutaneous treat-
ment of a TCFA by a metallic stent, especially bare-metal, triggers
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Table 1
Neointima thickness analysis by OCT.
Cross section level
6 month (508 cross sections) 12 months (526 cross sections) p-value
Mean lumen area (mm2) 6.26±1.72 5.63±1.48 0.071
Mean scaffold area (mm2) 7.86±1.63 7.31±1.38 0.095
Mean neointima thickness (m) 230 [190–280] 190 [150–270] 0.410
Minimum neointima thickness (m) 40 [10–105] 60 [30–120] 0.096
Maximum neointima thickness (m) 330 [280–410] 310 [240–410] 0.648
Neointima area (mm2) 1.60±0.62 1.68±0.77 0.517
In-scaffold area obstruction (%) 21.37±9.44 23.46±11.24 0.284
Symmetry of neointima thickness 0.10 [0.03–0.24] 0.20 [0.09–0.30] 0.005
Patient level
6 months (n=28) 12 months (n=31) p-value
Mean lumen area (mm2) 6.42±1.40 5.64±1.41 0.050
Mean scaffold area (mm2) 7.98±1.52 7.28±1.08 0.031
Mean neointima thickness (m) 210 [180–260] 220 [150–260] 0.904
Minimum neointima thickness (m) 50 [30–80] 80 [40–120] 0.071
Maximum neointima thickness (m) 335 [300–410] 340 [280–420] 0.912
Neointima area (mm2) 1.57±0.42 1.64±0.77 0.691
In-scaffold area obstruction (%) 20.66±7.47 23.38±11.73 0.322
Symmetry of neointima thickness 0.16 [0.08–0.21] 0.23 [0.13–0.28] 0.019
Data are reported as median and interquartile range or mean± standard deviation, according to their distribution.
Fig. 3. Symmetry of the neointima. Examples of non-symmetric (6 months follow-up) and symmetric (12 months follow-up) neointima thickness. The minimum and
maximum diameter of the lumen and scaffold contours are drawn.
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Fig. 4. Neointima layer covering coronary plaques. Examples of the formation of a neointima layer over two coronary plaques (indicated as § and *), scaffolded by an ABSORB
BVS device. At follow-up a neo-tissue is visible not only on the top of the polymeric struts, but also in the space between two adjacent struts (white arrows), thickening the
cap of the plaque originally treated (see the enlargement on the bottom). GW=shadow of the guidewire. M= shadow of the radio-opaque marker, present at the scaffold
edge (note: the shadow of the marker at follow-up is hidden by the guidewire shadow).
the formation of a fibrotic layer (more or less thick) on the top of
the thin cap covering the lipid pool, potentially reducing therefore
theprobabilityof plaque rupture/erosion.However, thepersistence
of metal and/or non-degradable polymers into the vessel wall can
have some detrimental effects (e.g., permanent presence of foreign
body, etc.) [26]. With regards to ABSORB bioresorbable vascular
scaffold, it has been established that at approximately 2 years the
polymeric material has been fully degraded and replaced by pro-
teoglycans. At 4 years, the initial location of the struts in the vessel
wall is no longer identifiable by histology or OCT and the neointi-
mal layer built up on the scaffolding structure becomes thereby a
“de novo” cap, which cannot be distinguished from a fibrotic cap,
normally seen in fibroatheroma [6,10,27] (Fig. 4). The formation of
a symmetric neo-tissue with a mean thickness of 220mwithout
remnants of polymeric struts, when the device is completely biore-
sorbed,may therefore favor theuseof a bioresorbable device for the
treatment of thin-cap fibroatheromas [10]. Based on the findings of
our previous pre-clinical studies,wehave established that themain
component of the neointima following ABSORB BVS implantation
is fibrous tissue, whereas fibrin and granulomatous cells are scarce
at long-term follow-up [6].
Of note is that in our analysis the thickness of the neointimawas
on average not different between 6 and 12months follow-up. Only
the minimum neointima thickness exhibited some tendency to be
larger at 12 than at 6 months follow-up. This observation suggests
that the healing process following an ABSORB BVS implantation is
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almost completed 6months after the device implantation, without
further increase of neointima overtime. Conversely, the symme-
try of the neointima, although far away from the value of 1, which
potentially represents a highly symmetric neointima, significantly
increases from 6 to 12months follow-up, reflecting amore circum-
ferentially homogenous distribution of tissue capping the original
plaque. A symmetric distribution of neointima thickness ensures
more likely the presence of a “thick cap” on the top of the plaque
originally treated, regardless of its circumferential location in the
vessel wall.
It is noteworthy that the comparison between 6 and 12 months
represents an unpaired comparison so that the tendency toward
a reduction in lumen and scaffold areas should be carefully inter-
preted. In the paired comparison, previously reported, there was
not reduction in scaffold area by OCT at 6 and 12 months [8,9]. The
histogram distribution of the neointima thickness seems to have a
bimodal distribution, which is consistentwith the DES late loss dis-
tribution, previously observed [28]. Of note is that the angiographic
late loss appeared to be significantly correlated with the thickness
of the neointima at the site ofMLA [29,30]. The difference in resolu-
tion between the two imaging techniques and other factors, such as
remodeling of the vessel, should be taken into account for explain-
ing this relationship. It is also known that the level of neointima
proliferation may affect the correlation between late loss by QCA
and neointima thickness by OCT that is high in presence of a high
late loss [30]. The small number of patients did not allow us this
kind of sub-analysis and will require further studies.
5. Limitations
Our analysis may have some limitations. The first is that the
assessment of the intra-scaffold neointima area incorporates the
area of the strut core in the quantification of the neointima area,
at variance with the method previously described [8,9]. However,
fromanimal studies, itmaybeargued that that eachpolymeric strut
is ultimately replaced by proteoglycan and connective tissue: for
this reason, the inclusion of the strut core area into the neointima
areamore correctly reflects the thickness of the tissue covering the
plaque originally treated [6] (See Fig. 1 in Supplementarymaterial).
Another important consideration is about the small sample size
at the two time points. Nevertheless, these patients represent the
unique cohort of patients received an ABSORB implantation and an
OCT analysis.
The presence of ISA is another limitation of ourmethodology, as
the automatic detection software algorithm of the software recog-
nizes this area as neointima. However, the segments with ISA can
be excluded and analyzed using conventional methodology.
6. Conclusions
An accurate and circumferential quantification of the heal-
ing process following implantation of bioresorbable scaffolds is
allowed. The formation of a thick neointimal layer, without rem-
nants of polymeric struts, creates a “de novo” cap, which may be
used to seal a thin-cap fibroatheroma.
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In search of vulnerable features of coronary
plaques with optical coherence tomography: is it
time to rethink the current methodological
concepts?
Maria D. Radu1* and Erling Falk2
1Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark; and 2Aarhus University Hospital Skejby, Aarhus, Denmark
This editorial refers to ‘Thin-cap fibroatheroma and
microchannel findings in optical coherence tomography
correlate with subsequent progression of coronary
atheromatous plaques’, by S. Uemura et al., doi:10.1093/
eurheartj/ehr284
Intravascular optical coherence tomography (OCT) is increasingly
being used to assess coronary vessel pathology in vivo due to its
unrivalled high resolution of 10–20 mm. Previous reports have
shown that OCT is capable of visualizing thin-cap fibroatheromas
(TCFAs),1 which are thought to be the precursor lesions of rup-
tured plaques responsible for the majority of thrombosis-mediated
sudden death.2 In addition, OCT is able to identify features that
have been related to the advancement of atherosclerotic lesions,
including neovascularization3,4 and macrophage infiltration.5,6 It is
against this background that Uemura and colleagues describe the
baseline OCT morphological characteristics of angiographically
non-significant, non-culprit coronary lesions exhibiting rapid pro-
gression over a period of 6–9 months.7 At a median follow-up
of 7 months, 13 (19%) of the 69 studied lesions showed
angiographic progression from a mean diameter stenosis of
28.8–61.4%, compared with 28.9–29.3% in the remaining
lesions. Progression was clinically silent in all but three patients.
OCT at baseline suggested a higher incidence of TCFAs, intrapla-
que microchannels, lipid pools, macrophages, intimal lacerations,
and intraluminal thrombi in the progressed lesions, thus being in
line with pathology-driven hypotheses of the role of these features
in the progression of coronary atherosclerosis.7
The study is intriguing in that it reports for the first time the inno-
vative concept of using OCT to evaluate potential markers of rapid
plaque progression. Nevertheless, the results should be interpreted
with caution: first due to the small size and possible selection bias in
the evaluated cohort; and secondly, in view of the current methodo-
logical concepts. Concerning the former, lesions were selected from
the angiogram by the identification of a focal discrete non-significant
stenosis (,50% diameter stenosis), thus disregarding important
information about the plaque (total burden) at baseline, as this
can be visualized neither by the angiographic lumenogram nor by
OCT in view of its limited tissue penetration. By the selection of
only a very short segment (10 mm of length), other non-significant
regions were excluded, thus making it somewhat difficult to gener-
alize the results. In relation to the latter, the study indirectly draws
attention to the challenges of developing amethodological approach
that accounts for the limitations of present OCT embodiments in
characterizing plaque-related features—in particular those of
TCFAs. These challenges merit further consideration and will be
the focus of this editorial.
Pitfalls in the OCT interpretation
of TCFAs
Given the assumed importance of TCFAs in causing clinical events,
there is a strong desire in the interventional community to identify
and treat these lesions before they cause harm. TCFAs, with their
lipid-rich/necrotic cores and thin fibrous caps,8 visualized by OCT
as diffusely demarcated signal-poor regions with overlying thin
signal-rich layers (Figure 1A and C ),1 are often diagnosed with con-
fidence, although there is emerging evidence of several factors that
may obscure a correct diagnosis.
First is the intrinsic capability of OCT to distinguish lipid from
non-lipid plaques. This capability was shown to be very high in
the landmark validation study from 2002 where Yabushita et al.
observed an excellent sensitivity and specificity (90–94% and
90–92%, respectively) of OCT for detecting lipid plaques.1
However, subsequent reports have shown conflicting results,
which can in part be attributed to the heterogeneity between
studies in terms of vessel types (coronary vs. carotid vs. aortic),
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sample sizes, previous experience of OCT observers, and plaque
dimensions (small vs. large; superficial vs. deep).9–11 Nevertheless,
most studies showed a varying degree of misclassification of
fibrous plaques into lipid-rich as well as fibrocalcific plaques.
Recent data have proposed that the accuracy of plaque character-
ization with OCT, and then in particular the detection of
lipid pools and necrotic cores, may be increased by combining
OCT with other intracoronary modalities, such as intravascular
ultrasound-virtual histology (IVUS-VH).11 Additional improvement
in tissue characterization by OCT may also be expected from the
application of quantitative analysis techniques involving the
measurement of signal attenuation and backscatter intensity.12
A second factor to be considered as differential diagnosis of the
TCFA is the presence of macrophages. OCT displays macrophages
as punctate, highly backscattering (i.e. signal-rich) structures with
significant signal attenuation.6 Given the similarities in optical prop-
erties, thin bands of accumulated macrophages close to the luminal
surface can mimic the appearance of TCFAs (Figure 1D–F).13 Recent
studies, including the one by Uemura et al.,7 point to the fact that
macrophage infiltrations are becoming a target of interest in the
search for markers of vulnerability. For the time being, the incidence
of macrophage accumulations, and to what extent they affect the
TCFA diagnosis, remains unknown. However, considering that
they are being assessed in parallel with TCFAs, it is highly desirable
to identify means that can aid in the differentiation of the two, as well
as to assess the reproducibility. The latter would in particular have
been interesting to know in the study by Uemura and colleagues.7
Artefacts represent a third issue that may complicate the
correct diagnosis of a TCFA. The most relevant artefacts include
those related to the luminal marginalization of the imaging light
source, namely ‘attenuation in the line-of-sight’ and tangential
signal drop-out, which typically occur when the light beam
travels more or less parallel to the vessel wall.11 Insights into the
technical background of OCT image display is crucial for identifying
these features. Their occurrence and, more importantly, how often
they cause misinterpretation are presently unknown but certainly
deserve further investigation.
Challenges in the quantification
of the fibrous cap
An additional concern related to the diagnosis of a TCFA is the
partly quantitative aspect of the assessment. On the one hand
Figure 1 (A–C) AnOCT cross-section from a non-culprit vessel of a patient with ST-elevationmyocardial infarction. (A) From 1 to 11 o’clock, a
relatively signal-rich layer is seen covering a signal-poor region. This layer becomes thinner from 4 up to 8 o’clock. Of note, the underlying signal-
poor region is diffusely demarcated at 4–6 o’clock but slightly marked at 6–8 o’clock (white shaded area in the magnification in B), suggestive of a
lipid pool and calcific pool, respectively (according to criteria by Yabushita et al.1). (C) Amagnification of the diffusely demarcated signal-poor region
in A, illustrating the difficulty in manually measuring the thickness of the overlying fibrous cap (white traces). The results of the measurements from
left to right are 60, 80, 70, and 130 mm.Given that the firstmeasurement has been placed correctly, the lesion can be diagnosed as a TCFA using the
current criteria. (D–F) Three consecutive frames with findings consistent with luminal macrophage accumulation. In D, there is a signal-rich band
from7 to 9 o’clock, with strong light attenuation creating an underlying signal-poor region, which is relatively sharply demarcated laterally (arrows).
The appearance as awhole is reminiscent of a TCFA; however, inspection of adjacent frames (E and F, 0.4 mm apart) suggests that there is no typical
lipid pool/necrotic core aswould be expected in a TCFAhaving a large necrotic core. Instead, the attenuated area becomes somewhat ‘transparent’,
with even sharper borders in E, and disappears in F, revealing a relatively homogeneous, bright tissue composition, consistent with a fibrous plaque.
The high light attenuation in D can thus be attributed to shadowing from the luminal signal-rich band, which in conclusion probably represents
macrophage infiltration. The images are derived from the imaging substudyof theCOMFORTABLE-AMI trial. Courtesyof Professor StephanWind-
ecker and Dr Lorenz Ra¨ber, Bern University Hospital, Bern, Switzerland.
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there is the cut-off value of the thin fibrous cap, which continues to
be a matter of dispute; and on the other hand there is the subjec-
tive, manual delineation of this layer. The often used cut-off to indi-
cate a thin cap and thus vulnerability is based on autopsy reports
and is 65 mm, as 95% of ruptured fibrous caps causing sudden cor-
onary death were below this threshold.2 It could be argued that
this value may be inappropriate for non-ruptured TCFAs consider-
ing that they have less necrotic core, cholesterol clefts, and macro-
phage infiltration than ruptured plaques,8 but also because
histological processing techniques may cause up to 20% tissue
shrinkage. Recent in vivo OCT data from Yonetsu and colleagues
support the latter, as they found that 95% of ruptured fibrous
caps (visualized as thin signal-rich flaps in relation to cavities) had
a minimum thickness of 80 mm,14 suggesting that this may be a
more appropriate value for ruptured plaques. However, a suitable
cut-off for non-ruptured plaques still needs to be defined. In this
regard, we need first to scrutinize the methods for quantifying
the thickness of intact caps.
The current approach is to measure the distance from the arter-
ial lumen to the inner border of the lipid pool at the point where
the fibrous cap thickness is considered minimal.7,14,15 To the best
of our knowledge, the only available validation study of cap thick-
ness measurement is the one from 2006 by Kume et al. who found
a good agreement (mean difference –24+44 mm) between OCT
and histology in 35 lipid-rich plaques with histology-derived cap
thicknesses between 10 and 450 mm (mean: 138 mm), out of
which  7–8 were histology-defined TCFAs according to the cor-
relation plot.15 The interobserver variability was low, with a mean
difference of 20+ 59 mm. However low, this difference may be of
crucial importance for classifying a lesion as a TCFA or not, in par-
ticular for cap thicknesses in the range 45–100 mm, depending on
the cut-off value used (65 vs. 80 mm).2,14
Further, the process of delineating the cap also deserves some
attention: This involves initially the identification by eye-balling of
the ‘thinnest point’ selected from ‘TCFA-looking’ areas within the
longitudinal and circumferential direction, followed by the manual
measurement, where a line is traced from the relatively well demar-
cated lumen contour to the lipid border, which by definition is
diffuse.1 The subjectivity of both steps suggests that this may not
be as straightforward as previously anticipated—something that is
illustrated in Figure 1C. The additional challenge to assess the same
location in a blinded fashion at a later time point, in order to
assess progression or regression of the cap thickness, needs no
further mention. Bearing in mind that Uemura et al. found TCFAs
to be highly correlated with subsequent disease progression, it
would have been interesting to know the reproducibility and distri-
bution of cap thickness measurements in the two assessed groups,
as well as to what extent a consideration of different cut-off values
would have influenced the results.7
Rethinking the current
methodological concepts
With the above inmind,we can conclude that the issues complicating
the TCFA diagnosis require attention; both because prior studies
need to be interpreted with caution, and because a number of
OCT studies involving the assessment of TCFAs are underway. Con-
sidering thementioned points, the diagnosis of TCFAs could possibly
be made more reliable by implementing a phenomenological
approach consisting of a number of inclusion as well as exclusion cri-
teria. These could be complemented by semi-automatic techniques
tomeasure cap thicknesses in order to, on the one hand, increase the
reproducibility, and, on the other hand, to take full advantage of the
large amount of data provided by OCT. For the latter, this could
involve the extension of cap thickness measurement to larger
areas of the lesion rather than only one specific point, which
would provide interesting information about the lesion in general.
This information may, together with other assessed features, help
us to better understand why some TCFAs cause events while
others do not.16 Moreover, validation of the specific entity of OCT-
defined TCFA as well as that of the necrotic core needs to be con-
sidered, as this has not yet been performed.
Additional refinements of our methodological concepts should
suggestively involve a revision of the manner in which the qualitat-
ive findings are reported. In this regard, it may be argued that a
semi-quantitative expression of the data may reflect the effect of
a certain feature more accurately than a mere binary approach—
something that may be important for the further interpretation
of the results, as well as for the comparison with other studies.
Accordingly, it would have been interesting to know the percen-
tage of frames with TCFA in the two groups studied by Uemura
et al., and whether a semi-quantitative rather than a binary report-
ing of the data could have influenced the final results.
Taken together, an awareness of the limitations of current meth-
odological concepts will allow us to develop ways to circumvent
these in order to be able to use the large amount of information
provided by OCT more accurately. This may eventually allow us
to take full advantage of what OCT can offer in order to
better understand the diagnostic benefits of this wonderful high-
resolution modality.
Conflict of interest: none declared.
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Abstract
Aims: To demonstrate the feasibility and potential usefulness of an offline fusion of matched optical coher-
ence tomography (OCT) and intravascular ultrasound (IVUS)/virtual histology (IVUS-VH) images.
Methods and results: A total of nine matched OCT, IVUS, and IVUS-VH cross-sections were fused 
according to a methodology described in this report. On the basis of the fused images, an OCT-IVUS-VH 
tissue classification algorithm is proposed taking into account the individual strength of both techniques.
Conclusions: Offline fusion of co-registered IVUS and OCT is feasible and combines the strengths of both 
imaging modalities, potentially improving the diagnostic accuracy of plaque characterisation.
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Introduction
The gold standard for the assessment of human coronary atheroscle-
rosis is histology. By nature, histology remains restricted to post-
mortem studies and animal models, which do not reflect anatomy 
under pressurised conditions in vivo and does not provide longitudi-
nal information as it relates to disease progression or regression 
within the same individual and lacks transferability of animal data to 
humans1. Therefore, in vivo imaging modalities that allow a diagnos-
tic accuracy similar to histology are in demand. Intravascular imag-
ing techniques currently provide the highest resolution of all available 
coronary imaging modalities2 and can contribute to the understand-
ing of mechanisms underlying the progression of coronary artery 
disease; evaluate pharmaceutical effects on progression and regres-
sion of atherosclerosis3; and can potentially guide interventional 
therapy with the aim of improving outcomes4.
Editorial, see page 19
Two intracoronary technologies are predominantly used for research 
and clinical application, namely intravascular ultrasound (IVUS) and 
optical coherence tomography (OCT), both of which have previously 
been validated against histology5-11. The applied imaging physics differ 
fundamentally: IVUS, which has been available since the early 1990s, is 
based on the backscattering of ultrasound waves at a frequency of mil-
lions of cycles per second. When extracting information from the ultra-
sonic signal, two physical characteristics can be utilised: first, the 
amplitude of the reflected ultrasound wave, which is used to create the 
greyscale (GS) image; and second, the radio-frequency signal, which is 
the basis for virtual histology (IVUS-VH), a technique that aims to assess 
plaque composition, also validated in previous studies7. The axial resolu-
tion of IVUS is in the range of 80-200 µm depending on the sound fre-
quency, and the penetration depth amounts to 8-10 mm. As opposed to 
IVUS, OCT is a relatively novel technique, available for clinical use 
since 2005 (CE approval of time-domain OCT). It is based on the use of 
near-infrared light, with a wavelength specifically chosen of around 
1,300 nm in order to reduce the light absorption of different tissues to a 
minimum. The axial resolution of OCT is in the range of 10 µm, an order 
of magnitude higher than IVUS, allowing for the identification of certain 
features shown to be related to plaque vulnerability. The high resolution, 
however, comes at the cost of a limited tissue penetration, which amounts 
to 1-2 mm11,12. Consequently, OCT provides a detailed assessment of fea-
tures close to the lumen surface, whereas IVUS offers a cross-section of 
the entire vessel wall. In view of the fundamental differences in imaging 
physics resulting in different information gained by IVUS and OCT, a 
combination of these techniques may improve the assessment of coro-
nary atherosclerosis in a synergistic manner. As the sensitivity and speci-
ficity for assessing the tissue composition of atherosclerotic lesions 
varies for the two technologies, a combined approach may further 
enhance the diagnostic precision. At present, there is neither a dedicated 
imaging probe that would allow a simultaneous in vivo IVUS-OCT 
assessment, nor specific software enabling an offline fusion of matched 
IVUS and OCT images. It is against this background that we describe 
here our methodological approach to fuse co-registered IVUS and OCT 
images, in order to achieve a comprehensive in vivo assessment of 
human atherosclerosis.
Methods
DEFINITIONS
CO-REGISTRATION  Co-registration refers to the recording of an 
identical region of interest (ROI) within a coronary artery by two 
different imaging technologies. To date, a simultaneous co-registra-
tion of IVUS and OCT images, using a single bimodal imaging 
catheter, cannot be obtained in vivo. Consequently, separate acqui-
sition of IVUS and OCT images in a serial fashion is necessary. 
Serial imaging, however, impacts importantly on the matching pro-
cess, as common landmarks have to predefined and identified.
MATCHING  Matching relies on the identification of corresponding 
frames from two separately acquired pullbacks. Matching is initi-
ated by the identification of common landmarks, such as side 
branches, bifurcations or large calcifications, and the precision of 
the matching increases with the number of common landmarks 
identified. Matching can be achieved manually, or semi-automati-
cally using dedicated software13.
FUSION  Fusion refers to the offline merging of two fully matched 
cross-sections that were acquired using two different imaging tech-
niques. In this report we describe the methodological procedures 
and feasibility of manual matching and fusion of IVUS (IVUS-GS 
or IVUS-VH) and OCT images to create combined tissue maps, 
which in the future may lead to the development of dedicated fusion 
software to analyse co-registered images.
 
IMAGE ACQUISITION
OCT images were acquired using the C7 frequency domain OCT 
system (LightLab Imaging/St. Jude Medical, Westford, MA, USA). 
The Dragonfly™ OCT catheter (LightLab Imaging/St. Jude Medi-
cal) was advanced over a conventional guidewire, distal to the dis-
tal landmark of interest (typically a side branch), and care was 
taken to document the catheter position angiographically. After 
intracoronary administration of 100 µg nitroglycerine, blood was 
displaced using a non-ionic contrast agent (Xenetics®; Guerbet 
S.A., Villepinte, France) at 4-6 ml/sec. When sufficient blood clear-
ance was achieved, imaging pullback was initiated at a rate of 
20 mm/sec. After successful OCT imaging and verification of tar-
get landmarks on the OCT pullback, the Eagle-Eye® Gold 20 MHz 
IVUS probe (Volcano Corp., San Diego, CA, USA) was positioned 
at the same starting point, which was documented angiographically. 
After another administration of 100 µg nitroglycerine, catheter 
pullback was initiated at a standard rate of 0.5 mm/sec, and contin-
ued beyond the proximal landmark. Images were stored for later 
offline analysis.
POST-ACQUISITION IMAGE PROCESSING
MATCHING OF PULLBACKS AND DEFINITION OF ROI  The 
OCT data was loaded into a dedicated offline workstation with pro-
prietary software from LightLab Imaging/St. Jude, whereas IVUS 
data was loaded into the QCU-CMSTM software (Medis, Leiden, 
The Netherlands) on a separate computer next to the OCT worksta-
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tion. As a first step, the most proximal side branch was identified in 
both OCT and IVUS pullbacks, and the cross-sectional rotation of 
the OCT pullback was adapted according to the orientation of the 
IVUS pullback. Subsequently, as many common side branches as 
possible were identified, and the most proximal and distal common 
side branches were used to define the matched ROI.
MATCHING OF CROSS-SECTIONS  Within the matched ROI, 
a subsegment of interest (coronary artery plaque) was identified by 
OCT, and side branches within or adjacent to this segment were 
located in both OCT and IVUS pullbacks. Subsequently, matched 
cross-sections of interest were identified, again using common 
landmarks such as: small side branches; a certain position and con-
figuration of calcifications; and/or a characteristic lumen shape and 
circumferential profile of the plaque thickness. Finally, a 1 mm 
calibration line was inserted in order to allow for size adaptation 
prior to the fusion, and the selected cross-sections were exported in 
JPEG format.
FUSION OF CROSS-SECTIONS  Cross-sections were uploaded in 
Adobe® Photoshop® (Adobe Systems Incorporated, San Jose, CA, 
USA) and the matched IVUS-GS, IVUS-VH and OCT images 
placed next to each other. Thereafter, the following steps were 
undertaken:
1.  The size of OCT and IVUS images was adjusted by matching the 
calibration line of 1 mm.
2.  The two-dimensional orientation of the cross-sections was fine-
tuned by rotating the images using cross-sectional landmarks 
according to the following hierarchy: a) side branch; b) calcifica-
tion; c) lumen shape; d) circumferential plaque configuration 
(distance between lumen and external elastic membrane).
3.  To optimise the overlay of IVUS on top of OCT images, the 
transparency function of Adobe Photoshop was used to allow the 
simultaneous visibility of the structures in the underlying OCT 
image. As a suitable default setting for overlaying IVUS on top 
of OCT images, a transparency of 60-70% for the IVUS-GS 
images, and 70-80% for the IVUS-VH images, was used 
(Figure 1, Figure 3 and Figure 5).
4.  Using information from the matched original OCT and IVUS-
VH images (Figure 2A, Figure 4A and Figure 6A), the contours 
of all visible tissue compartments as well as the external elastic 
membrane (EEM) were delineated and coloured using the fol-
lowing colour codes: white=calcific tissue by OCT/dense cal-
cium by IVUS-VH; green=fibrous tissue by OCT/fibrous and 
fibro-fatty tissue by IVUS-VH; red=necrotic/lipid tissue by 
OCT/necrotic core by IVUS-VH; and grey=media by OCT/
media stripe, i.e., EEM, by IVUS-VH (Figure 2B, Figure 4B and 
Figure 6B). The tissue composition in OCT images was assessed 
using previously validated criteria14.
5.  The delineated compartments derived from the two technologies 
were then superimposed and displayed simultaneously in a fused 
schematic image (Figure 2C, Figure 4C and Figure 6C).
6.  For the final presentation of the schematic fused cross-sections, 
the information from the technology having a “superior” accu-
racy for a respective feature outweighed the information from the 
technology with the “inferior” accuracy, and was placed on top 
of it. The algorithm considered is outlined in Table 1.
Results
We selected in total three matched coronary artery cross-sections 
showing various plaque morphologies from co-registered IVUS 
and OCT pullbacks obtained from patients undergoing a study 
Figure 1. In panels A1-3 matched cross-sections obtained by IVUS-GS (A1), OCT (A2) and IVUS-VH (A3) depict fibrocalcific plaque in the left 
half of the vessel, and a necrotic core/lipid pool at the opposite side of the calcification. Superimposition of IVUS-GS on top of OCT and 
IVUS-VH on top of OCT is presented in panels B1 and B2, respectively.
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Figure 2. Panels A1 and A2 show the same matched OCT and IVUS-VH images as in Figure 1. Panels B1 and B2 show the resulting tissue maps 
after delineation of the visible tissue compartments according to validated criteria. Green indicates fibrous/fibro-fatty tissue; white, calcific 
tissue; red, lipid tissue/necrotic core; and grey, media/EEM. The dotted lines in the OCT image in panel B1 indicate that the deep contours of 
the lipid/necrotic region at 1-5 o’clock and the calcific pool at 6-9 o’clock cannot be accurately delineated. Of note, the necrotic tissue 
displayed by the software behind the calcifications in panel A2 has been excluded in the tissue map in panel B2, as it is known that this 
information is not reliable. Panel C shows the superimposed tissue maps from panels B1-2 in which many features coincide; however, they have 
different sizes and shapes due to different imaging physics. Of note, the IVUS-VH displays a necrotic core with direct contact to the lumen 
suggestive of an IVUS-VH TCFA, which is in contradiction with the OCT that displays a thick fibrous cap, suggesting an OCT ThCFA. As OCT 
is considered to be superior in terms of superficially-located tissue, the final diagnosis using a fused approach is a calcified ThCFA. The final 
fused result after weighting of the individual components in the tissue maps, according to the algorithm in Table 1, is shown in panel D.
Table 1. Algorithm for fusion of manually delineated tissue contours based on OCT and IVUS-VH.
OCT-defined contours are followed: IVUS-VH-defined contours are followed:
Calcification
 
Has to be confirmed by both technologies, 
otherwise, re-evaluation* is needed.
–  When borders of calcifications are 
clearly demarcated
Fibrous tissue 
In case of disagreement between 
technologies within the same quadrant, 
re-evaluation* is needed.
–  As long as fibrous tissue is visible, 
which is typically when it is located 
superficially
–  When fibrous tissue lies deep and thus is not 
visible by OCT (>300-400 micrometre)
Lipid pool/necrotic core 
In case of disagreement between 
technologies within the same quadrant, 
re-evaluation* is needed.
–  When border of lipid pool/necrotic core 
is superficially located
–  When luminal border of necrotic core lies deep and 
thus is not visible by OCT (>300-400 µm)
 
–  When delineating the abluminal border of lipid 
pool/necrotic core, as this is seldom visible by OCT
Fibrous cap – Always to delineate the fibrous cap
Cap rupture and erosion –  Always to delineate ruptures and 
OCT-defined erosions
EEM – When tunica media is visible – When tunica media is not visible by OCT
EEM: external elastic membrane; * A review of the correctness of the matching process, of consistency between consecutive frames, as well as 
evaluation of potential artefacts
including both IVUS and OCT (NCT00962416). Below follows an 
explanation of the findings from the isolated and fused images.
EXAMPLE 1. CALCIFIED THICK-CAP FIBROATHEROMA
UNFUSED MATCHED IMAGES  The OCT cross-section in Figure 
1A2 shows two sharply delineated signal-poor, low-attenuation foci 
at 6-9 and 9-11 o’clock, suggestive of calcific pools. The cores of 
these calcifications exhibit a homogeneous appearance and are cov-
ered by a relatively thin (80 µm) homogeneous signal-rich layer of 
even thickness, consistent with fibrous tissue. Opposite the calcifi-
cation, a diffusely demarcated signal-poor zone with high light 
attenuation is seen, indicative of a lipid pool. This is covered by 
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Figure 3. In panels A1-3, matched cross-sections obtained by IVUS-GS (A1), OCT (A2) and IVUS-VH (A3) show a thin-cap fibroatheroma 
(TCFA) with a large necrotic core/lipid pool abutting to the lumen in panel A3, and rupture of the thin fibrous plaque at 6 o’clock in panel A2. 
Superimposition of IVUS-GS on top of OCT and IVUS-VH on top of OCT is presented in panels B1 and B2, respectively.
Figure 4. Panels A1 and A2 show the same matched OCT and IVUS-VH images as in Figure 3. Panels B1 and B2 show the resulting tissue maps 
after manual delineation of the visible tissue compartments according to validated criteria. Green indicates fibrous/fibro-fatty tissue; red, lipid 
tissue/necrotic core; and grey, media/EEM. The dotted line in the OCT image in panel B1 indicates that the deep contour of the lipid/necrotic 
region cannot be accurately delineated. Panel C shows the superimposed tissue maps from panel B1-2 in which the necrotic core and parts of 
fibrous features coincide. The final fused result after weighting of the individual components and contours in the tissue maps, according to the 
algorithm in Table 1, is shown in panel D.
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Figure 6. Panels A1 and A2 show the same matched OCT and IVUS-VH images as in Figure 5. Panels B1 and B2 show the resulting tissue maps 
after manual delineation of the visible tissue compartments according to validated criteria. Green indicates fibrous/fibro-fatty tissue; red, lipid 
tissue/necrotic core; and grey, media/EEM. The dotted line in the OCT image in panel B1 indicates that the deep contour of the lipid/necrotic 
region cannot be reliably traced. Panel C shows the superimposed tissue maps from panels B1-2 in which the necrotic core and parts of fibrous 
features coincide. The final fused result after weighting of the individual components and contours in the tissue maps, according to the 
algorithm in Table 1, is shown in panel D. Similar cross-sections as in Figure 5 are shown (OCT and IVUS-VH). A colour-coded tissue map 
was derived from the original OCT image. (B1 ). The dotted line indicates that the abluminal border zone of the necrotic core/lipid pool is not 
precisely traceable. In panel C, the tissue maps of OCT and IVUS-VH are fused and in panel D the final fusion is executed under the 
assumptions made in Table 1.
Figure 5. In panels A1-3, matched cross-sections obtained by IVUS-GS (A1), OCT (A2) and IVUS-VH (A3) display a thick-cap fibroatheroma 
(ThCFA) with a necrotic core/lipid pool covered by a thick cap (>200 µm by OCT) at 4 o’clock. Superimposition of IVUS-GS on top of OCT 
and IVUS-VH on top of OCT is shown in panels B1 and B2, respectively.
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a signal-rich fibrous cap that measures >200 µm, defining this part 
of the cross-section as an OCT-derived calcified thick-cap 
fibroatheroma.
Figure 1A1 shows the matched IVUS-GS image depicting two 
hypoechoic pools suggesting calcific areas. Of note, the calcific 
pool at 6-9 o’clock is inducing an acoustic shadowing which pre-
vents visualisation of the deep contour of the calcification. With the 
exception of the region with acoustic shadowing, the external elas-
tic membrane delineating the plaque border is clearly visible 
throughout the circumference.
Based on the radio-frequency signal, the corresponding 
IVUS-VH cross-section in Figure 1A3 displays the two calcific 
pools in white. Depending on the extent of acoustic shadowing, tis-
sue characterisation using radio-frequency data from behind the 
calcifications is less reliable8. The zone at the opposite side of the 
calcification is displayed as necrotic core with direct contact to the 
lumen, indicative of an IVUS-VH derived calcified thin-cap 
fibroatheroma, which challenges the findings by OCT.
FUSED IMAGES  In this example, matching and fusion was 
facilitated by the presence of the two calcific pools as well as the 
specific lumen shape and characteristic plaque thickness profile 
(thin intima from 11-1 o’clock). Superimposition of IVUS-GS/
VH on top of OCT is shown in Figure 1B1-2. Of note, both the 
lumen shape and size, and the calcific pools overlay each other 
with a high agreement. The information that is added by OCT as 
compared to IVUS includes the following: firstly, the fibrous cap 
overlying the calcific pools cannot be visualised using IVUS as 
the thickness is below the resolution of the technique; secondly, 
the abluminal border of the calcific pools and therefore the area of 
the calcification is not assessable using IVUS due to the acoustic 
shadowing, which is however in part possible with OCT. Con-
versely, the limited penetration of the optical signal does not 
allow for the visualisation of the EEM, when it is in the far-field 
of the source of light (Figure 1A2, 7-8 o’clock) or concealed 
behind highly attenuating tissue (Figure 1A2, 1-6 o’clock). OCT 
therefore precludes the determination of the total plaque volume 
and of the remodelling index (information that is available by 
IVUS). Figure 2 shows how the schematic tissue information can 
be combined and fused by individual weighting of the information 
obtained by OCT and IVUS-VH according to the steps described 
above and the algorithm presented in Table 1. IVUS-VH displays 
a thin-cap fibroatheroma with necrotic core in contact to the 
lumen, whereas a thick fibrous cap (>200 µm) is depicted by 
OCT, suggesting an OCT-derived thin-cap fibroatheroma (TCFA). 
According to a combined algorithm (see also discussion section), 
the final diagnosis corresponds to a VH-OCT derived calcified 
thick-cap fibroatheroma.
EXAMPLE 2. THIN-CAP FIBROATHEROMA (TCFA)
UNFUSED MATCHED IMAGES  Figure 3A2 shows an OCT cross-
section displaying a circumferential signal-poor region, diffusely 
demarcated luminally, with a fast signal drop-off, suggestive of 
lipid/necrotic tissue. The region is covered by a highly reflective 
thin layer (minimal thickness 40 µm) – a thin fibrous cap – which is 
fissured at 6 o’clock and lifted from the underlying tissue from 
5-8 o’clock. Taken together, the findings suggest a ruptured TCFA. 
IVUS-GS in Figure 3A1 shows concentric plaque with a zone of 
relatively high echogenicity from 6-12 o’clock. The corresponding 
IVUS-VH confirms a large area of confluent necrotic core from 
6-1 o’clock, abutting the lumen at >30 degrees, thus corresponding 
to a VH-derived TCFA.
FUSED IMAGES  In this case, cross-sectional fusion was facili-
tated by the presence of the small side branch at 11 o’clock, together 
with the oval lumen shape. The superimposed OCT and IVUS 
images are shown in Figure 3B1,2. This example illustrates the limi-
tation of OCT in visualising the EEM behind a thick highly light-
attenuating lipid/necrotic core. At the same time, however, the 
figures demonstrate that the combination of OCT with IVUS allows 
for delineation of the EEM and thus assessment of the total plaque 
volume. IVUS, on the other hand, is limited by its resolution, which 
is clearly evident in this example by the inability to visualise the 
thin fibrous cap and, specifically, the site of plaque rupture. Never-
theless, the superimposed image demonstrates that the IVUS-VH 
derived necrotic core is in contact with the lumen at the localisation 
of the ruptured plaque, indicating that the technology has the capa-
bility to recognise a TCFA although a detailed surface assessment is 
not possible. In the OCT image at three o’clock, there is a disconti-
nuity in the fibrous cap, which is partially obscured by the shadow-
ing of the guidewire. Figure 4 shows the delineation of tissue 
compartments in OCT creating a schematic tissue map, which is 
then fused with that provided by IVUS-VH. Of note, the deep bor-
der of the lipid/necrotic core cannot be delineated by OCT, which is 
highlighted with a dotted line. For the final fused image in Fig-
ure 4D, the delineation of lipid/necrotic core features was based on 
OCT for the luminal contour and on IVUS-VH for the abluminal 
border, while the information on deeply located fibrous tissue and 
EEM border was derived from IVUS-VH, all according to the algo-
rithm presented in Table 1.
EXAMPLE 3. THICK-CAP FIBROATHEROMA (ThCFA)
UNFUSED MATCHED IMAGES  The OCT cross-section in Fig-
ure 5A2 reveals a deeply located low-signal area at 2-6 o’clock cov-
ered by a thick homogeneous signal-rich layer, suggestive of an 
OCT-derived ThCFA. Due to the limited tissue penetration, the 
media can only be appreciated at the site of the discrete intimal 
thickening from 9-1 o’clock. IVUS-GS, however (Figure 5A1), pro-
vides a well-defined overview of the deeper parts of the vessel wall 
allowing for the assessment of the EEM area. IVUS-VH indicates 
plaque composed of >10% confluent necrotic core without contact 
with the lumen, suggesting an IVUS-VH derived ThCFA.15 Of note, 
the intimal thickening as seen by OCT between 9-1 o’clock is not 
displayed by IVUS-VH, as the thickness of the intima (~200 µm by 
OCT) does not exceed the default setting of the thickness of the 
medial stripe on IVUS-VH (250 µm)16.
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FUSED IMAGES Cross-sectional matching, superimposition (Fig-
ure 5B1,2) and fusion (Figure 6) were, in this example, facilitated by 
the presence of a large side branch at 7-9 o’clock in conjunction with 
the eccentric profile of the plaque. The information added by IVUS-
GS in this example mainly includes the delineation of the EEM, but 
also the indication of necrotic core/lipid pool at the site correspond-
ing to the signal-poor region in OCT, thus further supporting the 
diagnosis of a ThCFA. This is of importance as, whether the signal-
poor region in the OCT image is mainly caused by light attenuation 
by the thick fibrotic layer, or is rather due to the attenuating effects of 
deep lipid/necrotic core, can be discussed. Both may play a role in 
this case, the argument for the latter being that a slight increase in the 
signal can be appreciated deep in the vessel wall around 3-4 o’clock, 
indicating that light still reaches this part of the vessel wall and that 
attenuation is thus caused by both. Figure 6 shows schematically how 
tissue compartments were delineated by OCT, and how the combined 
OCT and IVUS-VH information was weighed to create a fused tissue 
map, based on the algorithm shown in Table 1.
Discussion
To our knowledge, this is the first report demonstrating the feasibility 
of an offline fusion of co-registered OCT and IVUS-GS/VH images. 
A few studies have been published on the combined use of IVUS and 
OCT for the assessment of coronary atherosclerosis, yet none of them 
used an offline fusion approach17-19. The examples presented here 
illustrate the advantages of combining complementary information 
from two technologies with differing physical properties, resulting in 
an optimised assessment of volumetric and structural characteristics 
of human atherosclerosis. Consequently, fusing co-registered 
matched IVUS and OCT images offers the following advantages.
IDENTIFICATION OF TUNICA MEDIA AND ASSESSMENT OF 
PLAQUE VOLUME
The identification of the medial layer by OCT relies on the penetra-
tion of light through the entire intima, which is determined by sev-
eral factors. First, tissue penetration in general relates to the intrinsic 
properties of the OCT light such that increasing the wavelength 
would increase the penetration depth; however, this would come at 
the cost of resolution. Second, the penetration depth of OCT 
depends on the optical properties of the tissues, namely absorption 
and backscatter, which determine to what degree light is attenuated 
along the scan line. Accordingly, lipid and necrotic tissue attenuate 
the light significantly, whereas fibrous and calcified tissues allow a 
deeper penetration. However, the extent of the vessel wall finally 
visualised also depends on the thickness of the plaque. Third, the 
imaging depth is to some extent also affected by the position of the 
imaging catheter in the lumen, which is related to vessel tortuosity. 
Consequently, marginalisation of the catheter results in a poorer 
delivery of light to the part of the vessel circumference located far-
thest away20.
As opposed to OCT, IVUS technology uses longer wavelengths, 
which, in the absence of large calcifications, enables it to detect the 
interface (i.e., the external elastic membrane) between the media 
and adventitia. In this way, IVUS permits assessment of the total 
plaque volume as well as vessel remodelling, which is of particular 
importance in the study of plaque progression and regression21. In 
Figure 3 and Figure 5 we demonstrated how the overlay of IVUS 
on top of OCT facilitates the location of the EEM behind highly 
attenuating tissue in the OCT cross-section.
LIPID POOLS AND NECROTIC CORES
Lipid pools and necrotic cores are recognised by OCT as diffusely 
demarcated signal-poor regions. In addition to precluding delinea-
tion of the media, they also prevent the evaluation of other poten-
tially present tissues types. This is illustrated in Figure 5 where 
evaluation of the deep tissue at 1-7 o’clock is not possible by OCT 
(Figure 5A2). However, IVUS-VH (Figure 5A3) suggests that 
fibrous tissue is present behind the necrotic core at 2 o’clock. 
Fusion of OCT and IVUS-VH information in this example offers 
a more accurate characterisation of the vessel wall composition. 
Notwithstanding, we wish to emphasise that additional studies need 
to compare directly a fused analysis of co-registered IVUS and 
OCT images against histology in order to determine whether this 
technique results in higher diagnostic precision, and whether it can 
eliminate misinterpretations of OCT related to the limited penetra-
tion depth. We would also like to mention that, for the fusion of 
OCT and IVUS-VH images showing lipid/necrotic content, a gen-
eral requirement should include the co-localisation of this feature to 
some extent in both technologies. In case of disagreement, potential 
causes, such as imaging artefacts or insufficient matching, should 
be excluded prior to fusion of the images.
CALCIFICATIONS
IVUS has a high sensitivity and specificity for the detection of cal-
cifications8. However, as calcium is a potent ultrasound reflector, 
calcific deposits produce an acoustic shadowing, preventing the 
assessment of the configuration as well as the thickness and volume 
of calcific pools22. Occasionally, dense fibrous tissue may, by 
IVUS, produce an echo-dense signal and mimic a calcification. By 
OCT, calcific pools are in general well-defined and not associated 
with shadowing. This allows an accurate delineation and volumet-
ric assessment, as long as they are not located too deep, as demon-
strated in Figure 1 and Figure 2. In addition, the differentiation 
between dense fibrous tissue and calcifications is readily possible, 
as the attenuation and backscattering signal of the two tissue types 
are quite different10. However, when deeply located, calcifications 
may be confused with lipid pools and vice versa, as suggested by 
Manfrini and co-workers23 and, in these cases, IVUS may poten-
tially aid in differentiation of the two. Taken together, fusion of the 
complementary information added by IVUS and OCT may improve 
the accuracy for the detection and quantification of calcium.
ASSESSMENT OF VULNERABILITY
One of the major objectives in cardiovascular medicine is the pro-
spective identification of lesions that may later cause myocardial 
infarction or cardiac death. The histological lesion type suggested 
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to be responsible for the majority of thrombosis-related cardiac 
deaths is the ruptured TCFA, composed of a necrotic core with an 
overlying thin fibrous cap, measuring <65 µm in 95% of these 
TCFA21. While the detection of lipid and necrotic tissue is unrelia-
ble with IVUS-GS due to a high inter- and intra-observer variabil-
ity22, analysis of radio-frequency data (IVUS-VH) has proved to 
be useful for the identification of necrotic core8. As visualisation 
of the fibrous cap is not possible due to a limited resolution, a con-
sensus was reached, stating that a TCFA can be diagnosed by 
IVUS-VH when the amount of confluent necrotic core exceeds 
10% and is in direct contact with the lumen for >30 degrees of the 
circumference15,24.
As compared to IVUS, OCT has sufficient axial resolution to 
assess directly the cap thickness overlying signal-poor diffusely 
demarcated lipid pools/necrotic cores14,25, as well as to allow the 
evaluation of the structural integrity of the cap, as illustrated in 
Figure 3. Nevertheless, it should not be neglected that several fea-
tures can obscure a correct TCFA diagnosis, including plaque-
related components (e.g., macrophage accumulation) and various 
artefacts, which can mimic the appearance of a TCFA.
The fused approach in the setting of detecting TCFA potentially 
permits a more specific identification of this vulnerable plaque type, 
and may therefore increase the prognostic accuracy for future events. 
In this regard, the following criteria may be requested for the com-
bined diagnosis of a vulnerable TCFA following fusion of OCT and 
IVUS: 1) IVUS-VH – presence of >10% confluent necrotic core; 
2) OCT – presence of a diffusely demarcated signal-poor region, 
covered by a signal-rich fibrous cap <65 µm thick; 3) the findings of 
necrotic core by VH and lipid pool/necrotic core by OCT should 
naturally coincide within the same quadrant. It remains to be defined 
whether a summary of additional vulnerability criteria within the 
fused image (e.g., IVUS: remodelling index26, calcific nodules27; 
OCT: micro-channels28, calcific nodules, intra-plaque haemor-
rhages29, plaque rupture and erosions30) could further increase the 
accuracy to predict future events.
COMBINED OCT-IVUS PROBES
The major limitation of the methodology applied for fusion of 
IVUS and OCT is related to the sequential assessment of OCT and 
IVUS using two separate probes, as this necessitates a laborious 
matching procedure prior to offline fusion. Simultaneous assess-
ment with the use of a combined IVUS-OCT catheter has recently 
been reported by Yin et al31,32. This group of engineers have demon-
strated the feasibility of a simultaneous IVUS-OCT assessment, a 
“true” co-registration, in pathology specimens free of blood. To 
date, the need for full blood clearance during the OCT image acqui-
sition constitutes the main limiting step for in vivo application of a 
combined IVUS-OCT probe for simultaneous acquisition. While 
blood prevents light transmission, it serves as an ideal medium to 
transmit ultrasound waves. Consequently, as blood clearance dur-
ing the OCT pullback requires a short pullback time (to date 20 mm/
sec) in order to reduce ischaemia, IVUS necessitates a much slower 
pullback speed (0.5-1.0 mm/sec).
Limitations
The images presented in this report were selected on the basis of 
their illustrative and didactic character, and it remains to be shown 
whether fusion is feasible in a broad spectrum of co-registered, 
matched cross-sections. As the imaging was performed in vivo, we 
were unable to investigate the diagnostic accuracy of a fused 
approach in comparison with histology. Finally, we have not used 
any imaging software specifically validated to create fused images. 
Therefore, the display of the presented images is purely explora-
tory, but may serve as a preamble for the further development of 
a dedicated software application. The distinction between necrotic 
core and lipid pool using OCT has not yet been validated. For this 
reason, we do not attempt to differentiate between the two tissue 
types, accepting that the fusion of VH necrotic core and OCT lipid 
pool/necrotic core cannot entirely correspond.
Conclusion
Offline fusion of co-registered IVUS and OCT is feasible and com-
bines the strengths of both imaging modalities, potentially improv-
ing the diagnostic accuracy of plaque characterisation and offering 
an ideal platform to elaborate on new diagnostic algorithms that 
consider the individual strengths of both technologies. Offline 
fusion demonstrates the potential usefulness of a combined IVUS-
OCT device that would allow for a simultaneous image acquisition 
and an online fusion.
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SUMMARY
Without doubt, optical coherence tomography (OCT) has brought us closer than any 
other imaging modality to a histology-like visualisation of the coronary vessel wall. 
By enabling the identification in vivo of features thought to be the main causes of 
athero- and stent thrombosis, namely thin-cap fibroatheromas (TCFA) and incompletely 
covered and malapposed struts, OCT offers a prerequisite to study these lesions and 
determine ways to prevent and modify them, potentially impacting on patient morbid-
ity and mortality. The fruitful use of the powerful capabilities of OCT demands from the 
interventional cardiologist knowledge about the pathophysiology of atherothrombosis 
and stent failure; as well as the understanding of the principles and methods of OCT 
imaging. This thesis offers significant insights into these, and provides important data 
regarding the safety of OCT and the vascular healing of metallic and bioresorbable 
vascular scaffolds.
UNDERSTANDING OPTICAL COHERENCE TOMOGRAPHY
In chapter 1.1, we described the technical principles of OCT, with emphasis on the dif-
ferent factors that may influence the image resolution as well as the limitations related 
to the need to clear the vessel of blood during image acquisition. Although the latter 
is inevitable, we showed in chapter 1.2 that this does not constitute a major clinical 
challenge since three-vessel imaging with both OCT and intravascular ultrasound-
virtual histology (IVUS-VH) can be performed at the same occasion even in high-risk 
ST-elevation myocardial infarction patients, with a high success-rate and safely in both 
the short and long term. 
When it comes to understanding the OCT image, we have seen in chapter 1.3 that the 
signal intensity in the final output image and concurrently the penetration depth of 
the technique, depends on how the OCT light is attenuated, absorbed and scattered 
on its way from the catheter through the vessel wall – to an extent that depends on the 
composition of the scanned tissue. The various artefacts that can influence the correct 
representation of the targeted lesion can be divided into: those related to disturbances 
in the OCT signal – notably suboptimal vessel flushing, thrombi and macrophage infil-
trations; artefacts that are caused by catheter marginalisation and cardiac motion; and 
artefacts associated with the preparation of the catheter.
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METHODOLOGICAL CONSIDERATIONS FOR EVALUATING METALLIC STENTS
As described in chapter 2.1, a limitation of OCT in the evaluation of strut apposition is 
the inability of the infrared light to penetrate the metal platforms of conventional stents. 
Therefore, OCT visualises only the endoluminal surfaces of metallic struts, which appear 
as bright spots with dorsal shadowing. When the actual strut thickness is known, apposi-
tion can be assessed either by reconstructing the true strut thickness and comparing it 
with the luminal vessel boundary; or by measuring the distance from the endoluminal 
surface of the strut to the luminal vessel contour and comparing it with the actual strut 
thickness. In either case, the high resolution of OCT allows the classification of strut ap-
position into categories previously not assessable with IVUS. 
The stent area is measured by connecting the endoluminal or abluminal surfaces of 
struts with a trace line. Although the former is more straightforward, it was the latter 
that brought our attention to a morphological configuration of the vessel wall not previ-
ously described (chapter 2.2). By reconstructing the abluminal boundary of the stent 
such that it allows the assessment of the outer boundary of the stent circumference 
similar to what is customary with translucent polymeric scaffolds 1, the abluminal stent 
area represents the circumferential “point of contact” between the stent and the vessel 
wall when the stent is completely apposed. By using this method, we noted that the 
luminal contour between struts in some stents was located outside this abluminal stent 
contour although these struts were not malapposed. These were termed pseudoapposed 
in order not to confuse them with the protruding struts which at that time (2007) referred 
to apposed struts that were not completely embedded in the vessel wall at baseline. 2 
These pseudoapposed struts, which we later renamed “protruding” (chapter 2.3), often 
co-located with malapposed struts. By an initial exploratory analysis we found that 
malapposed and protruding struts were more frequently associated with acute coronary 
syndrome and angiographically visible dissections at stent implantation; and that these 
types of struts tended to have lesser strut coverage compared to apposed struts. From 
these results we hypothesised that the protruding struts and their associated vessel 
bulgings were a manifestation of an abnormal vessel response to the respective stents.
CORONARY EVAGINATIONS AND EDGE DISSECTIONS
We continued to study the abovementioned morphological features in chapter 3.1, with 
particular attention to the vessel bulgings which were termed coronary evaginations. Per 
definition, these were present when the depth of the outward bulge between struts ex-
ceeded the actual strut thickness. Since evaginations sometimes extended over several 
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consecutive cross-sections, creating an ectatic vessel appearance by 3D reconstruction, 
we assessed the presence of major evaginations (ME) which were at least 3 mm of length 
with a minimal depth of 10% of the nominal stent diameter. We studied 254 lesions 
treated with five different drug-eluting stents (DES) assessed with OCT at one, two and 
five years following implantation. OCT-detected ME were specifically related to early-
generation sirolimus-eluting stents (SES), being smaller and generally less frequent in 
newer-generation DES. Malapposed and uncovered struts were significantly more com-
mon in lesions with vs. without ME, as was subclinical thrombus. One of the cohorts 
offered serial data with both OCT and IVUS at baseline and one-year follow-up, showing 
that intra-stent dissections and tissue protrusions present after stent implantation were 
associated with an increased risk of evaginations at follow-up. The paired IVUS-analyses 
suggested positive remodeling as the mechanism of coronary evaginations. 
It is remarkable that positive vessel remodeling in SES has been associated with chronic 
eosinophilic inflammation deep in the vessel wall – in animal studies as well as in hu-
man autopsy material from cases of late stent thrombosis. 3-5 Similarly, IVUS-assessed 
vessel remodeling, predominantly after implantation of SES, has been correlated with 
eosinophils in thrombus aspirates from patients with very late stent thrombosis. 6 The 
similarity in patterns between our findings and those of previous studies altogether 
support the notion that OCT-detected ME represent a pathological vessel reaction 
particularly related to SES. 
Even though our study included one of the largest OCT cohorts to date, it was too small 
for an evaluation of the clinical impact of ME in terms of the rare event very late stent 
thrombosis. We therefore used fluid dynamic simulations to assess the haemodynamics 
of these lesions and found that the presence of evaginations caused local flow distur-
bances with a change in flow which increased with the evagination size (chapter 3.2). 
Whether this may be one of the mechanisms of the subclinical thrombi found in the 
above study, and part of the pathophysiology of clinical stent thrombosis would be 
interesting to assess further.
In chapter 3.3, we revisited a highly debated topic, namely the natural history of 
OCT-detected non-flow-limiting edge dissections following DES-implantation. A total 
of 22 edge dissections (flaps in most cases) were studied at baseline and one year af-
ter implantation. The median (IQR) longitudinal length was 2.9 (1.6-4.2) mm, and the 
circumferential extension, 1.2 (0.9-1.7) mm. The dissections extended into the media 
and adventitia in around half the lesions, and were angiographically visible in only two 
cases. At follow-up, 90% of edge dissections were completely healed by OCT. The two 
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cases with persistent dissection had the longest flaps at baseline. Altogether, there were 
no clinical events up to one year. Together with results from other studies, OCT-detected 
non-flow-limiting edge dissections seem to constitute a benign phenomenon that can 
be left untreated. 7-9
METHODOLOGICAL CONSIDERATIONS FOR EVALUATING BIORESORBABLE 
VASCULAR SCAFFOLDS
Due to the polymeric composition, bioresorbable vascular scaffolds (BVS) have unique 
characteristics when imaged with OCT in that the optically translucent polymer 
allows complete imaging of the strut thickness without shadowing of the underly-
ing vessel wall, such that the BVS struts appear as boxes with black cores framed by 
light-scattering borders. How this unique appearance by OCT affects the methods for 
assessing main quantitative measurements as compared to metallic stents, has previ-
ously been described for lesions implanted with a single scaffold. 1 In chapter 4.1, we 
focused on lesions in which multiple BVS were implanted in an overlap fashion and saw 
that endothelialisation in porcine coronaries was delayed at these sites – notably in the 
presence of multiple stacked struts (each 300 µm thick). Due to the potential clinical 
importance of these findings, and due to the complex appearance by OCT of these re-
gions, we first explored the different types of overlap that can potentially be achieved in 
human implantation with two scaffolds as assessed in phantom models. Of note, these 
same patterns were found in human clinical case examples. Subsequently, we defined 
methods for assessing in a constant manner relevant quantitative OCT parameters at 
the overlap, taking into account the type of overlap, scaffold apposition, and the time 
point of implantation.
Even though BVS struts by OCT per definition appear as boxes with black cores framed 
by light-scattering borders, the translucency can be seen altered in some instances, 
namely as focal intense signals in the black core without apparent contact with the strut 
borders. In chapter 4.2 we found that these “white dots” by OCT at baseline as well as at 
six months follow-up were located exclusively at hinge points of the scaffold, strongly 
suggesting that these are caused by crazing of the polymer during the manufacturing 
process when the scaffold is crimped onto a delivery balloon, rather than induced by the 
degradation process.
In chapter 4.3, we compared various quantitative measures obtained with OCT and 
histology from the BVS at two years after implantation in porcine coronary arteries. 
Even though the measurements correlated somehow by being in the same order of 
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magnitude, histology systematically overestimated all measurements. As discussed, 
there are several potential explanations for this, with the most plausible involving an 
unsatisfactory correspondence of cross-sections. This report not only illustrates the 
challenges with validation studies where histology is used as gold standard, but also 
highlights important differences between in vivo OCT and post mortem histology which 
are relevant to consider when using extrapolated results and hypotheses from autopsy 
studies to clinical examinations with OCT.
OCT TO ASSESS VASCULAR HEALING IN BIORESORBABLE SCAFFOLDS 
By definition, the polymeric structure of the BVS changes with degradation as opposed 
to the non-erodible platform of metallic stents. OCT, IVUS and IVUS-VH can be used to 
assess not only the geometrical changes in BVS with time but also changes in the ap-
pearance of the struts as surrogate for changes in polymer microstructure caused by 
hydrolytic degradation. In chapter 5.1, we compared quantitative changes in BVS struts 
of the scaffold revision 1.1 evaluated with OCT, IVUS and IVUS-VH at baseline, six and 
twelve months. We found a trend for a reduction in strut core area by OCT, and decrease 
in hyperechogenicity by IVUS, at both six and twelve months. IVUS-VH showed incon-
clusive changes in dense calcium. The correlation between techniques was poor, which 
is not surprising considering that each technique is fundamentally different and inter-
rogates material- and tissue composition based on different properties (optical- (OCT), 
echogenic- (IVUS echogenicity) and radiofrequency (IVUS-VH)) – each at individual scale 
lengths.
Considering the thick struts of the BVS together with the relative fragility of the scaffold 
structure, requiring caution during implantation and post-dilatation, it is of interest to 
evaluate the occurrence and natural history of incompletely apposed struts. Chapter 
5.2 showed by serial analysis at baseline and 6 months that incompletely apposed struts 
were rare (128 struts, 3.5%) immediately after implantation, and healed within 6 months 
into apposed struts in the majority of cases (75.8%) by means of tissue coverage. Among 
the incompletely apposed struts seen at follow-up (32 struts, 0.8%), only 5 were late 
acquired, and displayed scaffold pattern irregularities suggestive of scaffold fracture, 
which was not detectable at baseline. Interestingly, the respective two patients were 
at baseline treated with post-dilatation up to higher diameters than recommended. 
The few (2%) uncovered struts and the rare presence of intra-luminal masses (3% of 
cross-sections) at follow-up were more frequently observed in incompletely apposed 
compared to completely apposed struts. 
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A closer investigation of the strut coverage at the frame level showed in chapter 5.3 that 
the thickness of the coverage was well-developed at six months and remained stable 
up to twelve months follow-up. The circumferential distribution expressed as the ratio 
of the minimum and maximum thickness of coverage in the respective cross-section, 
was more symmetric at twelve months. Considering the homogeneous and bright ap-
pearance of the coverage, suggestive of a fibrous neointima, it is exciting to speculate 
whether this can, once the scaffold is resorbed, fulfil the function of a de novo fibrous cap 
to stabilise vulnerable thin-cap fibroatheromas by increasing the fibrous cap thickness. 
METHODOLOGICAL CONSIDERATIONS FOR USING OCT TO EVALUATE 
ATHEROSCLEROSIS
In addition to the assessment of coronary devices by means of quantitative parameters, 
OCT enables the qualitative evaluation of coronary atherosclerosis. As emphasised in 
chapter 6.1, the histological diagnosis of atherosclerosis is based on the direct visualisa-
tion of microstructural composition. In contrast to this, OCT characterises atheroscle-
rosis based on the optical properties of the three main tissue types. Although a similar 
nomenclature is being used with the two modalities, the simplified classification offered 
by OCT means that the same term used with OCT not necessarily reflects the exact same 
histopathological lesion. The subject is further complicated by the occasional utilisation 
of contrasting nomenclature between OCT and histology for the same type of lesion, for 
example fibrous plaque by OCT, which corresponds to pathological intimal thickening 
by histology. Although these issues have not been previously highlighted, they should 
be considered because they not only cause confusion but may also lead to important 
misinterpretation of results and incorrect extrapolation of conclusions between non-
corresponding pathology- and OCT studies. We have reviewed the current histological 
classification of atherosclerotic plaques, and in the best possible way corresponded 
terminology and plaque definitions between histology, OCT and IVUS-VH, based on 
qualitative criteria combined with arbitrary quantitative criteria, where necessary.
The thin-cap fibroatheroma (TCFA), thought to be the precursor lesion of ruptured 
plaques responsible for the majority of thrombosis-mediated sudden deaths 10, repre-
sents the main motive for using OCT in the clinical evaluation of coronary atherosclerosis. 
In chapter 6.2 we focused on the various factors that may influence a correct OCT-diag-
nosis of TCFAs comprising those related to the intrinsic capabilities of OCT to distinguish 
qualitatively lipid from non-lipid plaques and other structures; different artefacts related 
to light phenomena; as well as factors related to the quantitative aspect of the assess-
ment. Based on the previous proposition that the accuracy of plaque characterisation 
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with OCT may be increased by combining OCT with IVUS-VH data, we demonstrated in 
chapter 6.3 the feasibility of the off-line fusion of co-registered OCT, IVUS-greyscale and 
IVUS-VH following the definition of an algorithm that takes into account the individual 
strengths of both techniques. The presented examples illustrate how the combination 
of these modalities can optimise the structural and volumetric assessment of human 
atherosclerosis. Whether this combined information can in addition reduce the rate of 
misclassification of different plaques remains to be settled.
CONCLUSIONS
This thesis comprehensively reflects the many considerations related to the research 
and clinical use of OCT, as well as the diverse contributions of OCT to interventional 
cardiology. I believe this thesis is of value as it has particularly:
•  Offered a comprehensive guide to a systematic OCT image interpretation related to 
coronary stents and atherosclerosis, through the elaboration of The Clinical Atlas of 
OCT;
•  Provided important insights into the methodological considerations behind the OCT 
evaluation of metallic stents, bioresorbable scaffolds, and atherosclerosis; and
•  Presented new data on the feature coronary evagination; the clinical impact of edge 
dissections; and the vascular responses to the implantation of bioresorbable scaf-
folds.
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SAMENVATTING
Optische coherentie tomografie (OCT) heeft ons, zonder twijfel, dichter bij gebracht naar 
een op  histologie-gelijkende visualisatie van de kransvatwand dan andere beeldvor-
mende technieken. OCT kan in vivo de belangrijkste karakteristieken van de hoofdoor-
zaken van atherosclerose en stent trombose identificeren zoals “thin-cap fibroatheroma” 
(TCFA) en niet complete weefsel bekleding van de stent “struts” en malappositie van 
de stent “struts”. Zodoende kan men met behulp van OCT deze laesies bestuderen en 
kunnen we mogelijke maatregelen worden ontdekt die modificatie of zelfs preventie 
toelaten, en die dientengevolge een verbetering kunnen geven van de morbiditeit en 
mortaliteit. Echter het nuttige gebruik van OCT vereist van de interventie cardioloog 
niet alleen kennis van de pathofysiologie van atherosclerose en stent disfunctie, maar 
ook begrip van de principes en methodes van OCT. Dit proefschrift draagt bij aan het 
verkrijgen van belangrijke inzichten. Bovendien worden belangrijke gegevens verschaft 
betreffende veiligheid van OCT, het vaatwand genees proces na implantatie van met-
alen stent of BVS.
DE PRINCIPES VAN OPTISCHE COHERENTIE TOMOGRAFIE
In hoofdstuk 1.1 beschrijven we de technische principes van OCT met de nadruk op 
verschillende factoren die de beeld resolutie kunnen be-invloeden en de beperkingen 
ten gevolge van de noodzaak om het bloedvat vrij te maken van stromend bloed ge-
durende de acquisitie van de beelden. Dit laatste is echter geen majeur probleem en het 
is mogelijk om zowel OCT als IVUS-VH onderzoek te doen in alle drie de kransvaten in 
een zitting zelfs bij patienten met een STEMI (hoofdstuk 1.2). Dit blijkt veilig te zijn met 
geen nadelige gevolgen op korte of langere termijn.
In hoofdstuk 1.3 beschrijven we dat de OCT signaal intensiteit en de penetratie diepte 
afhankelijk zijn hoe het OCT lichtsignaal door absorptie, attenuatie en spreiding wordt 
veranderd gedurende de reis van de katheter en door de vaatwand afhankelijk van de 
weefsel compositie van de onderzochte vaatwand. Verschillende  artefacten kunnen de 
correcte representatie van de te onderzoeken laesie in de weg staan zoals: verstoringen 
van het OCT signaal door b.v. niet optimale vaat schoonspoeling, trombus, en macrofa-
gen infiltratie; marginalisatie van de katheter en cardiale contractie; en onzorgvuldige 
voorbereiding van de katheter.
EVALUATIE METALEN STENTS
In hoofdstuk 2.1 worden de tekortkomingen van OCT besproken met betrekking tot 
de evaluatie van stent appositie omdat infrarood licht niet penetreert door het metaal 
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van de conventionele stent. Daardoor kan OCT alleen maar het endoluminale oppervlak 
van de stent “struts” afbeelden, die er uit zien als heldere stippen met daarachter een 
schaduw. Indien de actuele dikte van de “strut” bekend is kan de appositie bepaald 
worden door enerzijds reconstructie van de echte “strut”dikte en deze vergelijken ten 
opzichte van de vaatwand grens of anderzijds door het meten van de afstand tussen 
het endoluminale oppervlak van de “struts” en de luminale vaatwand contour en dit te 
vergelijken met de actuele “strut” dikte. Door de grote resolutie van OCT is het mogelijk 
de stent appositie nauwkeurig te classificeren hetgeen niet mogelijk was met IVUS. 
Het stent oppervlak kan worden gemeten door een lijn te trekken door ofwel de endo-
luminale ofwel de abluminale kant van de stent. De endoluminale meting is recht toe 
recht aan, maar door de abluminale metingen kregen we een totaal nieuw, niet eerder 
beschreven inzicht betreffende de morfologische configuratie van de vaatwand (hoofd-
stuk 2.2). Reconstructie van de abluminale grens van de stent betekent vaststelling van 
de buitengrens van de stent omtrek hetgeen lijkt op de situatie met een translucente 
polymeer “scaffold”. 1 Dit betekent dat de stent in complete appositie is wanneer het 
abluminale stent oppervlak (de buitengrens) gelijk is aan het endoluminale vaatwand 
grens oppervlak. Zo ontdekten we dat de luminale vaatwand contour tussen de “struts” 
van sommige stents gelokaliseerd was buiten de abluminale stent contour, alhoewel 
deze “struts” geen malappositie hadden. Dit noemden we “pseudo apposition”, niet te 
verwarren met “protruding stents” die toentertijd refereerden naar appositie van  stents 
die niet volledig waren ingebed in de vaatwand na implantatie. 2 Deze “pseudo apposed 
struts” werden herbenoemd tot “protruding struts” (hoofdstuk 2.3). Het bleek dat de 
stents met goede appositie en “protruding struts” vaker geassocieerd waren met ACS en 
angiografisch zichtbare dissectie na stent implantatie. Dit type stent “struts” neigt naar 
een mindere “strut” bekleding vergeleken met stents met goede appositie. Op basis van 
deze resultaten concludeerden we dat “protruding struts” en de samengaande uitstul-
pingen een uiting zijn van een abnormale vaatwand reactie op deze stents.
CORONARY EVAGINATIONS EN STENT RAND DISSECTIES
In hoofdstuk 3.1 worden “protruding struts“ kenmerken verder bestudeerd met spe-
ciale aandacht voor de vaatwand uitstulpingen die we “coronary evaginations” hebben 
genoemd. Coronaire uitstulpingen zijn aanwezig indien de grootte van de uitstulping 
naar buiten tussen de stent “struts” meer is dan de actuele dikte van de “struts”. Deze 
uitstulpingen strekken zich soms uit over verschillende dwarsdoorsneden, waardoor 
de vaatwand met een 3D reconstructie lijkt op een “ectatic“ vat. We onderzochten de 
frequentie van grote uitstulpingen (GU) die gedefinieerd waren als tenminste 3 mm lang 
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en met minimale diepte van 10% van de nominale stent diameter. We onderzochten 
254 laesies die werden behandeld met 5 verschillende DES en die werden onderzocht 
met OCT 1, 2 en 5 jaar na implantatie. OCT GU kwamen vaker voor bij eerste generatie 
“sirolimus-eluting stent” (SES) en ze waren kleiner en minder vaak voorkomend bij 
nieuwe generatie DES. Malappositie en niet beklede stent “struts” en subklinische 
trombus kwamen significant vaker voor bij laesies met GU, vergeleken met laesie zonder 
deze uitstulpingen. In een cohort patienten die serieel onderzocht werden met OCT en 
IVUS onmiddellijk na implantatie en 1 jaar later zagen we dat de “intrastent dissecties” 
en weefsel uitstulpingen na stent implantatie samengingen met een verhoogd risico 
op uitstulpingen 1 jaar later. De gepaarde IVUS analyse suggereert dat de positieve 
vaatwand remodelering de oorzaak kan zijn van deze uitstulpingen.
Het is opvallend dat positieve vaatwand remodelering met SES samengaat met chro-
nische eosinofiele ontsteking van de diepe delen van de vaatwand zoals kan worden 
vastgesteld in dier studies en autopsie materiaal van patienten met late stent trombose. 
3-5 Ditzelfde fenomeen werd ook gezien in patienten met zeer late stent trombose die 
een positieve vaatwand remodelering hadden met IVUS waar ook eosinofiele cellen 
werden gevonden in trombus aspiraten. 6 De overeenkomsten tussen onze bevindingen 
en die gemeld in de bovenstaande studies onderschrijven het idee dat met OCT gede-
tecteerde GU kunnen worden toe geschreven aan een pathologische vaatwand reactie 
voornamelijk voorkomend na SES implantatie. 
Onze studie was te klein, alhoewel het een van de grootste OCT cohort was, om te kun-
nen vaststellen dat deze uitstulpingen gepaard gaan met een klinisch waarneembare 
complicatie zoals b.v. de zelden voorkomende zeer late stent trombose. Daarom heb-
ben we een ander studie opzet gekozen. In een stroom dynamisch model hebben we 
de hemodynamische effecten van deze uitstulpingen bestudeerd. We zagen dat deze 
uitstulpingen lokale stroom verstoringen veroorzaakten en dat hoe groter deze uitstul-
pingen waren des te groter was de verstoring van de stroom (hoofdstuk 3.2). Verdere 
studies moeten uitwijzen of het ontstaan van subklinische trombus vorming onderdeel 
is van de pathofysiologie van stent trombose.
In hoofdstuk 3.3  bespreken we een heet hangijzer, namelijk wat is het natuurlijke 
beloop van OCT gedetecteerde niet stroom belemmerende rand dissectie na DES 
implantatie. Twee en twintig rand dissecties (flappen in de meeste gevallen) ontstaan 
onmiddellijk na implantatie en na 1 jaar later werden onderzocht. De mediane (IQR) lon-
gitudinale lengte was 2.9 (1.6-4.2) mm en de grootte van de circumferentie 1.2 (0.9-1.7) 
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mm. Deze dissecties liepen door tot in de media of adventitia in 50% van de gevallen en 
in 2 gevallen waren deze ook angiografisch zichtbaar. Na 1 jaar vervolg onderzoek bleek 
90% volledig genezen te zijn bij OCT. Twee gevallen met persisterende scheur hadden 
de grootste scheur na implantatie. Er traden geen klinische complicaties op gedurende 
het 1 jaar vervolg onderzoek. We kunnen dan ook concluderen op basis van onze en 
andere onderzoeken dat de met OCT vastgestelde niet doorstroming belemmerende 
rand dissecties een goedaardig fenomeen zijn die geen behandeling behoeven. 7-9
EVALUATIE VAN BIORESORBEERBARE VASCULAIRE “SCAFFOLDS”
De BVS zijn samengesteld uit polymeren met unieke karakteristieken. Met OCT kun-
nen we, doordat de polymeren optische doorlaatbaar zijn, de hele “strut” dikte zonder 
schaduw van de onderliggende vaatwand  afbeelden. De BVS ziet er met OCT uit als 
een doosje met een zwarte kern in een lijst met lichte rand. De unieke afbeelding met 
OCT van de BVS vereist andere kwantitatieve metingen dan die met metalen stents. 1 
In hoodstuk 4.1 concentreerden we ons op laesies in varkens die werden behandeld 
met multipele overlappende BVS en we constateerden dat de endothelialisatie  was 
vetraagd – met name op de plaatsen met “strut” overlap (BVS stent “strut” 300 µm dik). 
Dit kan potentieel klinische consequenties hebben indien BVS overlappend in patienten 
worden ge-implanteerd. Daarom hebben we eerst in een fantoom de potentieel ver-
schillende overlap types bestudeerd die met OCT complexe beelden weergeven. Deze 
types werden ook gevonden bij overlappende BVS implantatie in patienten. Vervolgens 
hebben we methodes ontwikkeld die op een constante manier relevante kwantitatieve 
OCT parameters meten, ook op het niveau van de overlap, daarbij rekening houdend 
met het type overlap, “scaffold” appositie en tijdstip van implantatie. 
We zagen dat met OCT de overlappende “scaffolds”  andere beelden gaven dan de vrij 
liggende “struts”, doordat de doorlaatbaarheid in sommige gevallen veranderde waar-
door focale intense signalen, de “white dots”, ontstonden in de zwarte kern van de “strut” 
zonder dat er een duidelijk contact was met de grenzen van de “struts”. In hoofdstuk 4.2 
beschrijven we dat deze “white dots” met OCT zowel bij implantatie als na 6 maanden 
vervolg uitsluitend waren gelokaliseerd op de scharnier punten van de “scaffolds”  daar-
mee suggererend dat dit eerder wordt veroorzaakt door beschadiging van de polymeer 
ten tijde van het maken van de “scaffold” wanneer deze geklemd wordt op de ballon en 
niet door het intrinsieke degradatie proces van de “scaffolds”.
In hoofdstuk 4.3 beschrijven we de resultaten van de verschillende kwantitatieve met-
ingen met OCT in vergelijking met histologie van de BVS 2 jaar na implantatie in varkens. 
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Alhoewel de metingen met beide methoden min of meer hetzelfde waren, bleek het 
dat de metingen met histologie systematisch hoger waren. Hiervoor zijn verschillende 
redenen aan te geven, maar de meest plausibele lijkt een onbevredigende correspon-
dentie van de dwarsdoorsneden te zijn. Dit illustreert niet alleen de uitdagingen met 
validatie studies met histologie als referentie standaard, maar belicht ook de belangrijke 
verschillen tussen in vivo OCT en post mortem histologie. Dit is met name relevant indien 
resultaten en hypothesen van autopsie studies worden geextrapoleerd naar klinisch 
onderzoek met OCT.
EVALUATIE MET OCT VAN VASCULAIRE GENEZING NA BVS IMPLANTATIE
Met behulp van OCT, IVUS en IVUS-VH kunnen we de degradatie in de tijd van de poly-
meren van de BVS volgen door de optredende geometrische veranderingen en de OCT 
beeld veranderingen van de “struts”. Deze dienen als surrogaat voor de veranderingen 
in de polymeer microstructuur die veroorzaakt wordt door degradatie ten gevolge van 
hydrolyse. In hoofdstuk 5.1 beschrijven we de kwantitatieve veranderingen van de BVS 
“struts” van de BVS revisie 1.1 gemeten met OCT, IVUS en IVUS-VH, zowel onmiddellijk na 
implantatie en na 6 en 12 maanden. Met OCT zagen we een reductie van het oppervlak 
van de kern van de “strut” en een afname van de hyper-echoreflectie met IVUS zowel na 
6 en 12 maanden. Met IVUS-VH werden niet overtuigende veranderingen gezien van 
de calcium neerslagen. De correlatie tussen de verschillende technieken was niet goed 
maar dat was te verwachten gezien de fundamentele verschillen van de onderzoek 
technieken die gebruikt werden voor het onderzoek van het “scaffold” materiaal en 
weefsel compositie: OCT – licht, IVUS – geluidsreflectie, en IVUS-VH – radiofrequentie.
We vonden het interessant om het voorkomen van en het natuurlijk beloop van incom-
plete appositie van de BVS “struts” te bestuderen vanwege het gegeven dat de BVS een 
relatief fragiele structuur heeft. In hoofdstuk 5.2 toonden we aan met serieel analyse 
onmiddellijk na implantatie en 6 maanden later dat incomplete appositie van “struts” 
zeldzaam is (128 “struts”, 3.5%) onmiddellijk na implantatie, terwijl na 6 maanden de 
meerderheid van deze “struts” nu in een goede appositie (75.8%) verkeerd door genez-
ing met weefselbekleding. Van de “struts” met incomplete appositie na 6 maanden (32 
“struts”, 0.8%) waren 5 later ontstaan. Deze toonden onregelmatige patronen van de 
“scaffold” die verdacht waren voor fractuur, die niet aanwezig was bij implantatie. Bij 
2 van de patienten kan dit verklaard worden doordat de “scaffold” ten tijde van de bal-
lon dilatatie een grotere diameter heeft gekregen dan wordt aanbevolen. De weinige 
“struts” (2%) die niet met weefsel bekleed zijn en de zeldzame aanwezigheid van intra-
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luminale massa (3% dwarsdoorsnede) na 6 maanden kwamen vaker voor bij incomplete 
appositie van de “struts” in vergelijking met complete appositie.
In hoofdstuk 5.3 worden de resultaten weergegeven van een nauwkeurig onderzoek 
naar de bekleding van de “struts”. Na 6 maanden is de dikte van de bekleding goed 
ontwikkeld en dit blijft stabiel tot na 12 maanden. De circumferentiele distributie van de 
bekleding uitgedrukt als de verhouding tussen minimale en maximale dikte was meer 
symmetrisch na 12 maanden. De bekleding is homogeen en helder en daarmee sug-
gestief dat er een fibreuse neointima is ontstaan. Het is interessant om te speculeren dat 
deze neointima, nadat de BVS volledig is geresorbeerd, kan fungeren als een de novo 
fibreuse kap die de dunne kap van een TCFA kan stabiliseren doordat de dikte van de 
kap toeneemt.
EVALUATIE VAN ATHEROSCLEROSE MET OCT
Met OCT kan ook coronaire atherosclerose kwalitatief beoordeeld worden. De histolo-
gische diagnose van atherosclerose is gebaseerd op de directe visualisatie van de micro 
structurele samenstelling (hoofdstuk 6.1). Dit contrasteert met OCT die atherosclerose 
baseert op de optische eigenschappen van de 3 voornaamste weefsel types. Alhoewel 
een identieke nomenclatuur wordt gebezigd door de 2 modaliteiten, betekent het niet 
dat de gesimplificeerde classificatie met OCT noodzakelijkerwijs dezelfde histologische 
typering geeft. Dit alles wordt nog versterkt doordat soms niet dezelfde nomenclatuur 
wordt gehanteerd tussen OCT en histologie. Zo is b.v. een fibreuse plaque met OCT 
een intima verdikking met histologie. Deze problemen werden in het verleden niet 
benoemd, maar toch is het van belang hier aandacht aan te besteden omdat anders 
verwarring kan optreden dat kan resulteren in belangrijke misinterpretatie en onjuiste 
extrapolatie van conclusies. We hebben de huidige classificatie van atherosclerotische 
plaques opnieuw beoordeeld en op de best mogelijke manier gebruik gemaakt van 
dezelfde terminologie en plaque definities als OCT, histologie en IVUV-VH, waarbij we 
ons baseerden op kwalitatieve criteria gecombineerd waar nodig met arbitraire criteria. 
OCT is goed in de diagnose van TCFA de laesie die wordt beschouwd als zijnde de 
voorloper van een geruptureerde plaque die samen gaat met intracoronaire trombose 
en het optreden van  plotse dood. 10 In hoofdstuk 6.2 bespreken we verschillende 
factoren die kunnen leiden tot een onjuiste OCT diagnose van TCFA. OCT heeft prob-
lemen met het maken van een duidelijk onderscheid tussen een lipide en niet lipide 
plaque. Verschillende artefacten kunnen worden gerelateerd aan licht fenomenen, maar 
ook kwantitatieve aspecten van de beoordeling kunnen problemen geven. Echter de 
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correcte karakterisering van de plaque met OCT kan worden verbeterd door OCT te 
combineren met IVUS-VH.  In hoofdstuk 6.3 demonstreren we de mogelijkheid van “off-
line” fusie van coregistratie beelden met OCT, IVUS en IVUS-VH door gebruik te maken 
van een algoritme dat rekening houdt met de individuele sterkte van elke techniek. 
De gepresenteerde voorbeelden illustreren dat de combinatie van deze modaliteiten 
de structurele en volumetrische beoordeling van atherosclerose in vivo kan worden 
verbeterd. Verdere studies zijn nodig om aan te tonen dat de combinatie van informatie 
in staat is om de frequentie van misclassificatie van coronaire plaques terug te dringen.
CONCLUSIES
Het proefschrift biedt een overzichtelijk neerslag van de vele problemen die gepaard 
gaan met onderzoek en klinische toepassing van OCT, maar ook van de vele bijdragen 
van OCT aan de interventie cardiologie. Het proefschrift is waardevol omdat het:
•  Geeft een overzichtelijke handleiding om systematisch OCT beelden te interpret-
eren van coronaire stents en atherosclerose, zoals te zien is in met zorg uitgevoerde 
Clinical Atlas of OCT;
•  Verstrekt belangrijke inzichten in de methodologische beschouwingen omtrent OCT 
evaluatie van metalen stents, bioresorbeerbare “scaffolds” en atherosclerose; en
•  Verschaft nieuwe data betreffende een speciaal probleem de “coronary evagina-
tions”; en  bespreekt het klinisch belang van stent rand dissectie; en de vasculaire 
reacties na de implantatie van een bioresorbeerbare “scaffold”.
234 Sammenvatting & conclusies
REFERENCES
 1. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier 
B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-
Hebert K, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable 
everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 
six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301-2312.
 2. Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of 
image acquisition and quantitative assessment of stent strut apposition. EuroIntervention. 
2007;3(1):128-136.
 3. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, 
Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-
eluting stent: should we be cautious? Circulation. 2004;109(6):701-705.
 4. John MC, Wessely R, Kastrati A, Schomig A, Joner M, Uchihashi M, Crimins J, Lajoie S, Kolodgie FD, 
Gold HK, Virmani R, Finn AV. Differential healing responses in polymer- and nonpolymer-based 
sirolimus-eluting stents. JACC Cardiovasc Interv. 2008;1(5):535-544.
 5. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R. Com-
parison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in 
porcine coronary arteries. Circulation. 2009;120(2):141-149, 141-142.
 6. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger 
M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular 
ultrasound findings with histopathological analysis of thrombus aspirates in patients with very 
late drug-eluting stent thrombosis. Circulation. 2009;120(5):391-399.
 7. Kume T, Okura H, Miyamoto Y, Yamada R, Saito K, Tamada T, Koyama T, Neishi Y, Hayashida A, 
Kawamoto T, Yoshida K. Natural history of stent edge dissection, tissue protrusion and incomplete 
stent apposition detectable only on optical coherence tomography after stent implantation. Circ 
J. 2012.
 8. Chamie D, Bezerra HG, Attizzani GF, Yamamoto H, Kanaya T, Stefano GT, Fujino Y, Mehanna E, Wang 
W, Abdul-Aziz A, Dias M, Simon DI, Costa MA. Incidence, predictors, morphological characteristics, 
and clinical outcomes of stent edge dissections detected by optical coherence tomography. JACC 
Cardiovasc Interv. 2013;6(8):800-813.
 9. De Cock D, Bennett J, Ughi GJ, Dubois C, Sinnaeve P, Dhooge J, Desmet W, Belmans A, Adriaens-
sens T. Healing course of acute vessel wall injury after drug-eluting stent implantation assessed 
by optical coherence tomography. Eur Heart J Cardiovasc Imaging. 2014;15(7):800-809.
 10. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque 
morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336(18):1276-
1282.
Acknowledgements 235
ACKNOWLEDGEMENTS
This thesis for the degree of Philosophiae Doctor was carried out at the Thoraxcenter, 
Erasmus University Medical Centre in Rotterdam, between July 2010 and December 
2011. I am convinced that no part of it would have been achieved without the generous 
help of a lot of people. I am therefore deeply grateful to all my colleagues, friends and 
family for providing their experience and support, and for sharing both the good and 
challenging times. I wish in particular to thank:
Prof. Patrick Serruys, the promoter of this thesis. It has been a great honour and privi-
lege to work with one of the pioneers and shapers of interventional cardiology; to be 
able to personally experience your outstanding innovative mind which has enabled you 
to lead not one but four revolutions in interventional cardiology; your amazing ability 
to orchestrate a multitude of international projects simultaneously; your unbelievably 
hard work and your enthusiasm for new epic projects; your indefatigable energy; your 
incredible memory enabling you to retain an impressive amount of information far 
beyond your 1800 publications; your attentiveness to perfection and detail without 
losing the helicopter view; and your capability to continuously attract a large number 
of international fellows whom you generously accept into your successful team. Thank 
you for being a tremendous source of inspiration; for granting me invaluable insights 
into planning and performance of everything from clinical trials and manuscript writing, 
to fund raising, congresses and editorial work; for all the interesting studies I had the 
opportunity to work with you on, out of which the Clinical Atlas of OCT was surely one 
of the most pleasurable. I will always be proud of having been your fellow, and hope to 
be able to continue our collaboration. 
Dr. Henning Kelbæk, my co-promoter, for firmly believing in me and always encourag-
ing my development as a researcher and clinician, not only at home in Copenhagen 
but also during my entire stay in Rotterdam. Thank you for being a huge source of 
inspiration: for continuously helping me with my clinical studies and teaching me how 
to practically organise and manage my clinical projects at home, even when far away; 
for always providing me with good advice when needing it; for importantly showing 
me how research can be kept alive alongside clinics; for your continuous and generous 
support not least financially; for your much appreciated friendship; for showing me that 
humility and world reputation are indeed compatible; and for always making me feel 
welcome in the cath lab at Rigshospitalet. I am deeply grateful for the years I had the 
privilege to work with you thus far, and hope that there are many more to come.
236 Acknowledgements
Dr. Hector García-García, my co-promotor, with whom I had many interesting discus-
sions on intracoronary imaging, and with whom I had the pleasure to collaborate on the 
Clinical Atlas of OCT. Thank you for guiding me in lots of practical things, especially for 
swiftly helping me to make the necessary connections when being a newcomer in Rot-
terdam; for facilitating my collaboration with Cardialysis; and for being available during 
my acquaintance with the Medis software. Thank you also for the friendship I made with 
you and your lovely family, and for the unforgettable barbeques in the park.
Dr. Kari Saunamäki, my supervisor in Copenhagen. It was you who initially opened the 
door for me to the grand world of interventional cardiology. Thank you for stimulating 
my curiosity and staying there afterwards to guide me on the right paths; for helping 
to make our projects in Copenhagen financially and practically possible, not least for 
your invaluable help with the inclusion of patients into our studies. Thank you for your 
much appreciated friendship; for always being available for me, patiently listening to my 
concerns; and for helping me out with excellent advice. I admire you greatly for being 
such an interesting person, and for teaching me that life is more than just work. I hope 
to have the privilege to continue our eight-year-long collaboration, not least through 
your continued guidance in PCI procedures, and our enjoyable meetings in Snowmass.
Dr. Erik Jørgensen and Dr. Steffen Helqvist: Thank you for the appreciated collabora-
tion with our studies in Copenhagen; for your patient help and always good advice; for 
being such excellent examples in the art of PCI, and for encouraging me to follow my 
heart.
My fellow research colleagues and friends in Rotterdam: 
Lorenz: you have been and still are one of my most appreciated friends and colleagues. 
Thank you for teaching me a lot about research and life; for the many endless, exhausting 
yet still enjoyable hours spent to prepare the Atlas of OCT; for your always generous help 
and encouragement during my stay in Rotterdam, which I will never forget. I sincerely 
admire your intelligence, extremely hard work, unbelievably organisational mind, and 
how all this fits in a kind and humble person. I hope that our excellent collaboration and 
friendship will continue for many years.
Bill: I cannot tell you how much I have appreciated our friendship. You have felt practi-
cally like family to me during my time in Rotterdam. Thank you for all the happy mo-
ments we had together, our nice talks, the BVS histology paper we worked intensively 
Acknowledgements 237
on, and the unforgettable Sunday dinners after church. I am so happy for you that you 
have found the conditions you were seeking.
Vasim: I have really appreciated the many hours we spent together in the same working 
room, all the good laughs you have stimulated in me, our friendship, and for always 
being a caring person, not least when it came to fruit and delicious cookies and cakes. I 
will never forget the hilarious sushi-session we had together with Bill at my place.
Josep: thank you for your always polite manners, for our friendship, for the nice paper 
we did together, and for introducing me to delicious Catalan grilled onions.
Salvatore: you truly impressed me with your calmness, diplomacy and remarkably 
productivity. It felt like every time we turned our backs, you had written another paper. 
Thank you for your appreciated friendship and for always being ready for a nice dinner 
or a good party.
Yoshinobu-sensei: thank you for your kind friendship and good advice in various situa-
tions. I highly admire you for your hard work, incredible energy, and humility. I sincerely 
wish you success, should it be in Rotterdam or Japan.
Takashi-sensei: together with your wife Yuko, you have both been such honest and 
dear friends. I am truly grateful for your invaluable help with the IVUS analysis in the 
evagination paper, where you laid aside all your other projects just to help me – some-
thing I will never forget. I appreciate very much that our friendship still continues, and 
hope to be able to welcome you and Yuko again in Copenhagen.
Roberto: thank you for all the good talks we had during my stay in Rotterdam, and for 
allowing me to trick you into setting up a jogging team with me – it was great fun. To be 
more serious, I was very impressed by the incredible strength you showed during your 
father’s illness, and how you continued to cope with all the different projects in spite of 
this.
Jung Ho: Dr. Heo, we had so much fun together. Thank you for your appreciated friend-
ship, for introducing me to South Korean “kimchi”, and for demonstrating to us all the 
incredible art of powernap. I am happy for you that you are back home now with your 
wife and daughter that you missed so much.
238 Acknowledgements
Il Soo: Dr. Lee, you astonished us all when you and your wife invited us for an incredibly 
memorable and moving evening at your place with delicious food, words of wisdom, 
and ancient South Korean tea. I greatly admire your kindness, humility and always-calm-
disposition, and truly appreciate our warm friendship.
Juan-Luis: although our time in Rotterdam only overlapped for a short period of time, 
I am grateful for the good advice you gave me before coming to Rotterdam and at the 
beginning of my stay. I am convinced that with your intelligence, you will prosper in any 
department in Europe.
Alexander: although we didn’t have any common projects, it was interesting to hear 
about your work and to see your commitment within the field of nanotechnology. 
I wish importantly to thank Sylvie Lhoste who is also one of my paranimfs: you were and 
still are a one of my dearest friends. Thank you so much for always being there for me, 
for taking so good care of me, and for all the happy moments we shared not only in Rot-
terdam but also in San Francisco, Paris, Barcelona and Copenhagen. You have such a big 
heart and I sincerely wish you all the best, and that our friendship will continue to grow.
Paul Cummins: I am sincerely grateful for your always true and honest friendship, and for 
never hesitating to help me out in any situation, even at 10 pm. Thank you for still being 
there for me and for sharing memorable moments in Rotterdam as well as Copenhagen.
Nico Bruining: thank you for all the good discussions we had both in Rotterdam and 
abroad, and for all your appreciated advice. 
You were all my family during my stay in Rotterdam and it would never have been the 
same without you. I will never forget our happy time together.
Hanny Boutkan: as Professor’s secretary, you are overwhelmed not only with your du-
ties, but also with all kinds of requests from the fellows – yet, you always carry them out 
with excellence. Thank you so much for helping me out with all kinds of things, not least 
in tricky situations. I really appreciate your kind friendship and warm heart.
Marie-Angel Morel: thank you very much for your practical advice on many different 
things during my entire stay, and for the good moments we shared outside of work.
Acknowledgements 239
Prof. Stephan Windecker from Bern: thank you for granting me access to the SIRTAX-
LATE OCT data and for your appreciated help in manuscript writing. I truly admire the 
perfection of your hard work, and envy the excellent role model that Lorenz has in you. I 
look very much forward to continuing our collaboration on various projects.
Bindu Kalesan from Bern: thank you for your invaluable contribution to the evagination 
paper by performing the complex statistical analysis. During the numerous hours we 
spent together by skype and during my visits to Bern, I came to admire your amazing 
capability to work endlessly and without exhaustion – I do not understand how you do 
it. I appreciate your friendship and generous hospitality.
Prof. Peter Jüni from Bern: thank you very much for supporting the statistical analysis of 
the evagination paper and for the interesting discussions with had.
Aloïs Pfenniger from Bern: thank you for the good collaboration we had on the fluid 
dynamic simulation study; for your great patience with all my questions by skype and 
while in Bern; and for the many hours you spent on the time-consuming simulations.
Frédéric Doncieux and Véronique Deltort from PCR Publishing: thank you for an ex-
cellent and truly pleasant collaboration on the Atlas of OCT. I appreciate all our moments 
together, both with producing the Atlas and enjoying it, and look forward to future 
collaborations. Also thank you to your co-workers, and the iPad team lead by David 
Fairand. 
Company collaborations: thank you to Terumo, St. Jude, Biotronik and Stentys for mak-
ing the publication of the Atlas of OCT possible through their financial support; and 
thank you to Richard Rapoza from Abbott Vascular, for providing me with useful insights 
into various aspects of the BVS.
Giulio and Masanori-sensei from Bern: it has been a pleasure to get to know both of 
you and to spend nice moments in Bern and around the world. Thanks to Giulio for a 
nice collaboration on the Atlas of OCT, and to Masa for the collaboration on the IBIS-4 
safety paper.
I owe a special thank you to Prof. Pim de Feyter for kindly and swiftly translating into 
Dutch the introduction, summary and conclusion of my thesis.
240 Acknowledgements
I wish to thank all the committee members for kindly agreeing to evaluate my thesis.
Thank you to Nadia: my dear friend in Copenhagen who has during my entire fellowship 
abroad been a great support in soul and by skype.
Last but certainly not least, I am eternally indebted to my wonderful parents Mihai and 
Constanta Radu and my brothers Mikael and Dacius for their never-ending love and 
support, for always believing in me and making me feel special, and for faithfully sharing 
both joy and hardship. Thank you for having raised me with strong belief, hope and love, 
and for teaching me good values and work ethics from childhood. None of what I have 
in my life today would ever have been possible without your infinite support! I love you 
all very much!
The work of this thesis was financially supported by:
Dr. Henning Kelbæk
Dr. Kari Saunamäki
The Heart Centre Rigshospitalet Research Foundation
Copenhagen University Travel Grant
Astra Zeneca Travel Grant
Curriculum vitae 241
CURRICULUM VITAE
Name  Maria D. Radu
Date of birth 12th October 1978
Place of birth Stockholm, Sweden
Citizenship Swedish
E-mail  maria_d_radu@yahoo.com
EDUCATION  AND DEGREES
1997 – 2003 Master of Arts, solo piano
  Lund University
  Malmö Academy of Music
  Malmö, Sweden
1999 – 2006 Degree in Medicine and Surgery (MD)
  University of Copenhagen
  Faculty of Medicine
  Copenhagen, Denmark
2004 Clinical Fellowship in Otolaryngology, Dermatology and Ophthalmology
  Vanderbilt University
  Faculty of Medicine
  Nashville, Tennessee, USA
2007 – 2010 PhD Research Fellowship
  University of Copenhagen, Faculty of Medicine, and 
  Copenhagen University Hospital, Rigshospitalet
  Promotor: Dr. Kari Saunamäki
  Copenhagen, Denmark
2010 – 2012 PhD Research Fellowship
  Erasmus Medical Center
  Faculty of Medicine
  Promotor: Prof. Patrick W. Serruys
  Rotterdam, The Netherlands
242 Curriculum vitae
2006 – 2007 Clinical Internship in Internal medicine and Surgery
  Slagelse Hospital
  Slagelse, Denmark
2012 – (2017) Clinical Fellowship in Internal Medicine and Cardiology
  Herlev University Hospital, and 
  Copenhagen University Hospital, Rigshospitalet
  Copenhagen, Denmark
OTHER ACTIVITIES
Editor-in-Chief and author of the Clinical Atlas of OCT, together with editors Lorenz 
Räber, Hector Garcia-Garcia and Prof. Patrick W. Serruys (PCR Publishing): Dec 2010 – 
May 2012
Board member of the EAPCI Young interventionalists committee, under the European 
Association of Percutaneous Coronary Interventions: Aug 2011 – Aug 2014
Co-Chair of the EAPCI Young interventionalists committee, under the European Associa-
tion of Percutaneous Coronary Interventions: May 2014 – May 2016
Member of the International Working Group for Standardization of OCT: Dec 2009 – pres-
ent. Active participant of the Subgroup for Standardization of stent and atherosclerosis 
measurements: Nov 2012 – present
International Associate Editor of the Eurointervention Journal: Jun 2010 – present
Member of the Editorial Board of PCR online: May 2010 – present
Reviewer for the Eurointervention Journal; European Heart Journal; European Heart 
Journal Cardiovascular Imaging; Journal of the American College of Cardiology; Journal 
of the American College of Cardiology Cardiovascular Interventions; and Scandinavian 
Cardiovascular Journal: Feb 2010 – present
Abstract grader for the EuroPCR congress 2012 – 2014
Member of the EAPCI Women’s Committee: May 2014 – present
Curriculum vitae 243
Society memberships: 
Danish Society of Cardiology; Swedish Society of Cardiology; European Society of Car-
diology
Publication list 245
PUBLICATIONS
Radu MD, Kelbæk H, Jørgensen E, Helqvist S, Løjmand B, Engstrøm T, Saunamäki K. 
Intracoronary optical coherence tomography: Insights from clinical research – What do 
we need to learn? In press Curr Cardiov Imag Rep.
Murray SW, Cooper RM, Appleby C, McCann C, Binukrishnan S, Radu MD, Stables R. 
Double jeopardy: Multi-modality imaging of monozygotic “twin” and thick-cap fibroath-
eromas. In Press Atherosclerosis.
Dridi NP, Johansson PI, Lønborg JT, Clemmensen P, Radu MD, Qayyum A, Pedersen F, 
Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Tailored anti-
platelet therapy to improve prognosis in patients exhibiting clopidogrel low-response 
prior to percutaneous coronary intervention. Platelets. 2014 Aug 28:1-9. [Epub ahead of 
print]
Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, 
Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Prasugrel or 
double-dose clopidogrel to overcome clopidogrel low-response–the TAILOR (Throm-
bocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary 
intervention) trial. Platelets. 2013 Nov 18. [Epub ahead of print].
Radu MD, Räber L. Cautionary approach recommended when interpreting images 
obtained with optical coherence tomography. Lancet. 2014;383:1887.
Radu MD, Pfenniger A, Räber L, de Marchi S, Obrist D, Serruys PW, Vogel R. Flow distur-
bances in stent-related coronary evaginations – A computational fluid-dynamic simula-
tion study. EuroIntervention. 2014 May;10(1):113-23.
Radu MD, Räber L, Kalesan B, Muramatsu T, Kelbæk H, Heo J, Jørgensen E, Helqvist S, 
Farooq V, Brugaletta S, Garcia-Garcia HM, Jüni P, Saunamäki K, Windecker W, Serruys PW. 
Coronary evaginations are caused by positive vessel remodeling and are nearly absent 
following implantation of newer-generation drug-eluting stents: An optical coherence 
tomography and intravascular ultrasound study. Eur Heart J. 2014 Mar;35(12):795-807.
Radu MD, Räber L, Heo JH, Jørgensen E, Kelbæk H, Muramatsu T, Helqvist S, Gogas BD, 
Farooq V, Garcia-Garcia HM, Windecker S, Saunamäki K, Serruys PW. Natural history of 
246 Publication list
optical coherence tomography-detected edge dissections following drug-eluting stent 
implantation. EuroIntervention. EuroIntervention. 2014 Jan 22;9(9):1085-94.
Muramatsu T, García-García HM, Onuma Y, Zhang Y, Bourantas C, Diletti R, Radu MD, 
Ozaki Y, Serruys PW. Intimal flaps detected by optical frequency domain imaging in the 
proximal segments of native coronary arteries - An innocent bystander? Insights from 
the TROFI trial. Circ J. 2013;77(9):2327-33. 
Farooq V, Serruys PW, Heo JH, Gogas BD, Perkins LE, Onuma Y, Diletti R, Radu MD, Räber 
L, Bourantas CV, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom H, Garcìa-
Garcìa HM, Virmani R. Intracoronary Optical Coherence Tomography and Histology of 
Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary 
Artery Model: The Potential Implications for Clinical Practice. JACC Cardiovasc Interv. 
2013 May;6(5):523-32.
Dridi NP, Lønborg JT,  Radu MD, Clemmensen P, Engstrøm T, Kelbæk H, Jørgensen E, 
Helqvist S, Saunamäki K, Christensen TH, Baeres FM, Johansson PI, Holmvang L. Hyper-
coagulation Assessed by Thromboelastography is Neither Related to Infarct Size nor to 
Clinical Outcome After Primary Percutaneous Coronary Intervention. Clin Appl Thromb 
Hemost. 2013 Apr 23. Clin Appl Thromb Hemost. 2013 May 1. [Epub ahead of print]
Farooq V, Gogas BD, Okamura T, Heo JH, Magro M, Gomez-Lara J, Onuma Y, Radu MD, 
Brugaletta  S, van Bochove G, van Geuns RJ, Garcìa-Garcìa HM, Serruys PW. Three-
dimensional optical frequency domain imaging in conventional percutaneous coronary 
intervention: the potential for clinical application. Eur Heart J. 2013;34(12):875-85.
Brugaletta S, Garcia-Garcia HM, Gomez-Lara J, Radu MD, Pawar R, Khachabi J, Bruining 
N, Sabaté M, Serruys PW. Reproducibility of qualitative assessment of stent struts cover-
age by optical coherence tomography. Int J Cardiovasc Imaging. 2013;29(1):5-11. 
Räber L, Radu MD. Optimising cardiovascular outcomes using optical coherence tomog-
raphy-guided percutaneous coronary interventions. EuroIntervention 2012;8(7):765-
771.
Gogas BD, Serruys PW, Diletti R, Farooq V, Brugaletta S,  Radu MD, Heo JH, Onuma Y, 
van Geuns RJ, Regar E, De Bruyne B, Chevalier B, Thuesen L, Smits PC, Dudek D, Koolen 
J, Windecker S, Whitbourn R, Miquel-Hebert K, Dorange C, Rapoza R, Garcia-Garcia HM, 
Publication list 247
McClean D, Ormiston JA. Vascular response of the segments adjacent to the proximal and 
distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month 
and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from 
the first-in-man ABSORB cohort B trial. JACC Cardiovasc Interv. 2012;5(6):656-65.
Prati F, Guagliumi G, Mintz GS, Costa M, Regar E, Akasaka T, Barlis P, Tearney GJ, Jang IK, 
Arbustini E, Bezerra HG, Ozaki Y, Bruining N, Dudek D, Radu M, Erglis A, Motreff P, Alfonso 
F, Toutouzas K, Pinto F, Serruys PWJC, Di Mario C. Expert review document, part 2. Meth-
odology, terminology and clinical applications of OCT for assessment of interventional 
procedures. Eur Heart J. 2012;33(20):2513-20.
Radu MD, Räber L, van Soest G, Garcia-Garcia HM, Serruys PW. Chapter 1. Principles of 
intravascular optical coherence tomography. The Clinical Atlas of OCT. PCR Publishing. 
May 2012.
Radu MD, Räber L, Serruys PW. Chapter 2. Artefacts with intracoronary optical coher-
ence tomography. The Clinical Atlas of OCT. PCR Publishing. May 2012.
Räber L, Radu MD, Garcia-Garcia HM, Akasaka T, Banz Y, Kume T, Windecker S, Serruys 
PW. Chapter 3. Atherosclerosis visualised with optical coherence tomography. The Clini-
cal Atlas of OCT. PCR Publishing. May 2012.
Radu MD, Räber L, Gomez-Lara J, Kelbæk H, Stefanini G, Jørgensen E, Helqvist S, Tellez 
A, Granada J, Saunamäki K, Serruys PW, Windecker S. Chapter 4. Optical coherence 
tomography for the assessment of intracoronary stents. The Clinical Atlas of OCT. PCR 
Publishing. May 2012.
Gogas BD, Radu M, Onuma Y, Perkins L, Powers JC, Gomez-Lara J, Farooq V, Garcia-Garcia 
HM, Diletti R, Rapoza R, Virmani R, Serruys PW. Evaluation with in vivo optical coherence 
tomography and histology of the vascular effects of the everolimus-eluting bioresorb-
able vascular scaffold at two years following implantation in a healthy porcine coronary 
artery model: implications of pilot results for future pre-clinical studies. Int J Cardiovasc 
Imaging. 2012;28(3):499-511.
Räber L, Heo JH, Radu MD, Garcia-Garcia HM, Stefanini GG, Moschovitis A, Kelbaek H, 
Windecker S, Serruys PW. Off-line fusion of co-registered intravascular ultrasound and 
248 Publication list
frequency domain optical coherence tomography images for the analysis of human 
atherosclerotic plaques. EuroIntervention. 2012;8(1):98-108.
Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining 
N,  Cho JM,  Chowdhary S,  Costa MA,  de Silva R,  Dijkstra J,  Di Mario C,  Dudeck D,  Falk 
E,  Feldman MD,  Fitzgerald P,  Garcia H,  Gonzalo N,  Granada JF,  Guagliumi G,  Holm 
NR, Honda Y, Ikeno F, Kawasaki M, Kochman J,Koltowski L, Kubo T, Kume T, Kyono H, Lam 
CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel 
MA, Nadkarni S, Okura H,Otake H, Pietrasik A, Prati F, Räber L, Radu MD, Rieber J, Riga 
M,  Rollins A,  Rosenberg M,  Sirbu V,  Serruys PW,  Shimada K,  Shinke T,  Shite J,  Siegel 
E,Sonada S, Suter M, Takarada S, Tanaka A, Terashima M, Troels T, Uemura S, Ughi GJ, van 
Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman 
NJ, Weisz G. Consensus standards for acquisition, measurement, and reporting of intra-
vascular optical coherence tomography studies: a report from the international working 
group for intravascular optical coherence tomography standardization and validation. J 
Am Coll Cardiol. 2012;59(12):1058-72.
Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, 
Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, 
Ormiston J, Serruys PW. Circumferential evaluation of the neointima by optical coher-
ence tomography after ABSORB bioresorbable vascular scaffold implantation: can the 
scaffold cap the plaque? Atherosclerosis. 2012;221(1):106-12. 
Brugaletta S, Gomez-Lara J, Bruining N, Radu MD, van Geuns RJ, Thuesen L, McClean D, 
Koolen J, Windecker S, Whitbourn R, Oberhauser J, Rapoza R, Ormiston JA, Garcia-Garcia 
HM, Serruys PW. Head to head comparison of optical coherence tomography, intravas-
cular ultrasound echogenicity and virtual histology for the detection of changes in poly-
meric struts over time: insights from the ABSORB trial. EuroIntervention. 2012;8(3):352-8. 
Gutierrez-Chico JL, Radu MD, Diletti R, Sheehy A, Glauser T, Harrington J, Rapoza R, 
Onuma Y, Serruys PW. Spatial distribution and temporal evolution of optical coher-
ence tomography “white dots” in the poly-L-lactide backbone of an intracoronary 
bioresorbable scaffold: association to polymer crazes during crimping of the device. Circ 
J. 2012;76(2):342-50.
Radu MD, Onuma Y, Rapoza RJ, Diletti R, Serruys PW. In vivo visualisation by three-
dimensional optical coherence tomography of stress crazing of a bioresorbable vas-
Publication list 249
cular scaffold implanted for treatment of human coronary stenosis. EuroIntervention. 
2012;7(12):1461-3.
Radu MD, Falk E. In search of vulnerable features of coronary plaques with optical coher-
ence tomography: is it time to rethink the current methodological concepts? Eur Heart 
J. 2012;33(1):9-12.
Farooq V, Heo JH, Räber L, Brugaletta S, Radu MD, Gogas BD, Diletti R, Onuma Y, Garcia-
Garcia HM, Serruys PW. Tools & Techniques: Risk stratification and diagnostic tools in left 
main stem intervention. EuroIntervention. 2011;7(6):747-53.
Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen 
L, McClean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Regar E, Veldhof S, Rapoza 
R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Serial analysis of the malapposed and 
uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold 
with optical coherence tomography. JACC Cardiovasc Interv. 2011;4(9):992-1001.
Farooq V, Okamura T, Gogas BD, Heo JH, Magro M, Gomez-Lara J, Brugaletta S, Onuma 
Y, Radu M, Garcìa-Garcìa HM, Serruys PW. 3D Reconstructions of Optical Frequency Do-
main Imaging to Improve Understanding of Conventional PCI. JACC Cardiovasc Imaging. 
2011;4(9):1044-6. 
Gogas BD, Farooq V, Onuma Y, Magro M, Radu MD, van Geuns RJ, Regar E, Serruys PW. 
3-dimensional optical frequency domain imaging for the evaluation of primary per-
cutaneous coronary intervention in ST-segment elevation myocardial infarction. Int J 
Cardiol. 2011;151(1):103-5.
Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas BD, van 
Geuns RJ, Regar E, Schultz C, Windecker S, Lefèvre T, Brueren BR, Powers J, Perkins LL, 
Rapoza RJ, Virmani R, García-García HM, Serruys PW. Optical coherence tomography 
(OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. 
EuroIntervention. 2011;7(3):386-99.
Radu M, Jørgensen E, Kelbæk H, Helqvist S, Skovgaard L, Saunamäki K. Optical coher-
ence tomography at follow-up after percutaneous coronary intervention: relationship 
between procedural dissections, stent strut malapposition and stent healing. EuroInter-
vention. 2011;7(3):353-61.
250 Publication list
Radu MD, Räber L, Saunamäki KI, Serruys PW. How does optical coherence tomography 
visualize coronary atherosclerotic pool? Card Interv Today 2011, March/April.
Gogas BD, Parissis JT, Iliodromitis EK, Tsiodras S, Radu M, Paraskevaidis IA, Theodoro-
poulos SP, Kremastinos DT, Yacoub MH. Left ventricular assist device vegetation: “cure” 
without device explantation. Hellenic J Cardiol. 2010;51(6):549-51.
Radu M, Jørgensen E, Kelbaek H, Helqvist S, Skovgaard L, Saunamäki K. Strut apposi-
tion after coronary stent implantation visualised with optical coherence tomography. 
EuroIntervention. 2010 May;6(1):86-93.
Radu MD, Jørgensen E, Saunamäki K. [Optical coherence tomography for coronary 
visualisation]. Ugeskr Laeger. 2009 Aug 24;171(35):2466-7. Danish.
Th
e Co
n
Tr
ib
u
Tio
n
 o
f o
pTiC
a
l Co
h
er
en
C
e To
m
o
g
r
a
ph
y
 To
 in
Terv
en
Tio
n
a
l C
a
r
d
io
lo
g
y
 
m
a
r
ia
 d
. r
a
d
u
Th
e Co
n
Tr
ib
u
Tio
n
 o
f o
pTiC
a
l Co
h
er
en
C
e To
m
o
g
r
a
ph
y
 To
 in
Terv
en
Tio
n
a
l C
a
r
d
io
lo
g
y
 
m
a
r
ia
 d
. r
a
d
u
